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ABSTRACT	  
Antivenom	  is	  the	  only	  effective	  treatment	  against	  the	  systemic	  effects	  of	  snakebite	  and	  is	   currently	  developed	  by	   a	   century-­‐old	   immunisation	  protocol	   that	   aims	   to	   generate	  IgGs	  capable	  of	  binding	  and	  neutralizing	  most	  (if	  not	  all)	  of	  the	  venom	  toxins.	  However,	  snake	   venoms	   comprise	   more	   than	   a	   hundred	   proteins	   and	   peptides	   that	   exhibit	   a	  significant	   diversity	   in	   terms	   of	   isoform	   complexity,	   toxicity	   and	   immunogenicity.	  Therefore,	  antivenom	  doesn’t	  take	  into	  account	  the	  representation	  of	  venom	  toxins	  and	  contains	  therapeutically	  redundant	  IgGs	  to	  non-­‐toxic	  venom	  components,	  and	  a	  lack	  of	  high	   titre	   IgGs	   to	   highly	   toxic,	   but	   weakly	   immunogenic	   components.	   The	   usual	  consequence	  of	  the	  century	  old	  immunisation	  protocol	  is	  the	  need	  to	  administer	  large	  volumes	   to	   achieve	   venom-­‐neutralisation	   in	   an	   envenomed	   patient,	   which	   greatly	  increases	  the	  risk	  of	  antivenom-­‐induced	  adverse	  effects	  and	  reduces	  its	  affordability.	  	  The	   Alistair	   Reid	   Venom	   Research	   Unit	   has	   pioneered	   a	   new	   approach	   using	   the	  rationale	  of	  generating	  venom	  toxin-­‐specific	  antibodies	  on	  the	  basis	  that	  an	  antivenom	  that	   only	   targets	   the	  most	   pathogenic	   toxin	   groups	  would	   be	   predicted	   to	   overcome	  these	   issues	   by	   improving	   the	   clinical	   efficacy	   of	   the	   treatment.	   	   Based	   upon	  preliminary	  work	  illustrating	  extensive	  cross-­‐specific	  and	  cross-­‐generic	  reactivity	  of	  a	  toxin-­‐specific	  antibodies	  generated	  against	  some	  of	   the	  most	  pathogenic	   toxin	  groups	  of	   venoms	   from	   medically-­‐important	   species,	   the	   overarching	   aim	   of	   the	   work	  described	  in	  this	  thesis	  was	  to	  extended	  this	  toxin-­‐specific	  antivenom	  approach	  with	  a	  view	   to	   ultimately	   generating	   a	   therapy	   against	   all	   the	   African	   species	   of	   the	   Echis	  genus.	  	  In	  order	  to	  overcome	  the	  high	  isoform	  diversity	  known	  for	  most	  of	  the	  pathologically-­‐important	   venom	   toxin	   groups,	   we	   conducted	   a	   bioinformatic	   interrogation	   of	   the	  venom	   gland	   transcriptomes	   of	   Echis	   ocellatus,	   Echis	   pyramidum	   leakeyi	   and	   Echis	  
coloratus	  for	  five	  major	  target	  toxin	  groups:	  Phospholipases	  A2	  (PLA2),	  Serine	  proteases	  (SP)	  C-­‐type	  lectins	  (CTLs),	  Metalloproteinases	  (SVMPs)	  and	  Disintegrins	  that	  identified	  epitopes	  on	  the	  basis	  of	  i)	  sequence	  conservation,	  ii)	  antigenicity,	  (iii)	  surface	  exposure	  and	   (iv)	   coverage	   across	   the	   EST	   data.	   Resultant	   sequences	   were	   synthesised	   as	  epitope-­‐strings	   and	   subsequently	   delivered	   as	   DNA	   and	   recombinant	   proteins	  immunogens	   that	   in	   a	   proteic	   form	   successfully	   generated	   antibodies	   capable	   of	  binding	  to	  a	  number	  of	  reduced	  venom	  proteins	  in	  a	  cross-­‐reactive	  manner,	  suggesting	  the	  presence	  of	  specific	  and	  generic	  shared	  epitopes	  of	  importance.	  The	  results	  obtained	  in	  this	  study	  helped	  identifying	  key	  elements	  of	  the	  toxin-­‐specific	  approach	   for	   the	   design	   of	   antivenoms	   and	   highlighted	   the	   need	   to	   elucidate	   several	  aspects	  of	  the	  molecular	   interaction	  of	  the	  raised	  antibodies	  against	  the	  target	  venom	  proteins,	   in	   order	   to	   have	   an	   accurate	   approach	   to	   their	   binding	   in	   a	   native	   state.	   In	  addition,	  the	  study	  successfully	  approached	  venom	  glycosylation,	  and	  aspect	  that	  hasn’t	  been	   studied	   in	   detail	   and	   came	   apparent	   during	   the	   progress	   of	   the	   toxin	   specific	  antivenom	  gave	  light	  in	  the	  future	  stages	  of	  its	  development.	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   1	  
1. GENERAL	  INTRODUCTION	  
	  
1.1. Taxonomy	  and	  distribution	  of	  venomous	  snakes	  Snakes	   are	   complex	   limb-­‐less	   organisms	   that	   have	   evolved	   in	   a	   variety	   of	   different	  habitats	  around	  the	  world.	  More	  than	  2,800	  species	  have	  been	  found	  and	  classified	  in	  the	  suborder	  Serpentes	  (Ophidia),	  which	   itself	   is	  divided	   into	  three	  superfamilies	  and	  16-­‐20	   families.	   Snakes	   that	   have	   evolved	   venom	   as	   a	  mechanism	   to	   catch	   and	   digest	  different	   prey	   items	   have	   been	   classified	   into	   advanced	   snakes	   belonging	   to	   the	  Colubroidea	   (or	   Caenophidia)	   superfamily.	   Within	   the	   Colubroids,	   venomous	   snakes	  are	   grouped	   into	   four	   families;	   Colubridae,	   Atractaspididae,	   Elapidae	   and	   Viperidae	  (O'Shea	  2005).	  The	  Colubridae	  family	  is	  the	  largest	  with	  around	  290	  genera	  and	  1,700	  species	   distributed	   around	   the	   world	   and	   is	   known	   to	   group	   mostly	   non-­‐venomous	  snakes.	   With	   a	   wide	   variety	   of	   relative	   dentition,	   this	   group	   comprises	   species	   that	  range	   from	   an	   aglyph	  maxillary	   dentition,	  where	   a	   posterior	   fang	   is	   unspecialized	   or	  nonexistent;	  to	  an	  opistoglyph	  dentition,	  where	  a	  posterior	  fang	  is	  variably	  enlarged	  in	  relation	  to	  the	  rest	  of	  the	  teeth.	  While	  the	  enlarged	  posterior	  maxillary	  teeth	  can	  be	  or	  not	   be	   grooved,	   some	   colubrids	   also	   present	   a	   complex	   tubular	   gland	   (the	  Duvernoy	  gland)	  that	  produces	  secretions	  that	  can	  be	  toxic	  and	  of	  medical	  importance	  to	  humans	  (Minton	  1990;	  Weinstein	  and	  Kardong	  1994).	  The	  family	  Atractaspidae	  is	  a	  small	  group	  of	  unusual	  front-­‐fanged	  snakes	  with	  around	  4	  genera	  and	  65	  species	  distributed	  across	  Africa	  and	  Arabia.	  Known	  as	  'back-­‐stabbing	  vipers',	  their	  dentition	  is	  characterized	  by	  having	  a	  single,	  elongated	  maxillary	  fang	  at	  the	  front	  of	  the	  mouth	  that	  is	  elongated	  and	  hollow	   connected	   to	   the	   enclosed	   venom	   delivery	   system.	   The	   Elapidae	   family	   has	  around	   63	   genera	   272	   species,	   which	   are	   sub	   divided	   into	   the	   subfamilies	   Elapinae	  (corals,	  cobras,	  mambas	  and	  kraits)	  and	  Hydrophiinae	  (sea	  snakes)	  and	  are	  distributed	  across	  the	  Americas,	  Africa,	  Middle	  East,	  Asia	  and	  Australasia.	  Elapids	  are	  front-­‐fanged,	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proteroglyphous	   snakes	  with	   small,	   immobile	   fangs	  positioned	   at	   the	   anterior	   end	  of	  the	   maxilla.	   Species	   of	   this	   group	   are	   usually	   highly	   venomous	   and	   some	   are	  responsible	   for	   accidents	   of	   high	   medical	   importance.	   The	   Viperidae	   family,	   with	  around	  30	   genera	   and	  230	   species	   is	   categorized	   into	   the	   subfamilies	  Viperinae	   (pit-­‐less	   ‘old	  world’	  vipers)	  and	  Crotalinae	  (pit	  vipers)	  and	  is	  distributed	  across	  the	  world	  with	  the	  exception	  of	  Australasia.	  Vipers	  are	  one	  of	  the	  most	  medically	  important	  group	  of	  snakes;	  with	  a	  solenoglyph	  dentition,	  their	  maxilla	  is	  reduced	  and	  there	  are	  no	  other	  teeth	  than	  the	  venom-­‐conducting	  fangs	  (O'Shea	  2005).	  
	  
1.2. Snakebite	  as	  a	  medical	  problem	  Snakebite	   has	   been	   categorized	   by	   the	   World	   Health	   Organization	   (WHO)	   as	   a	  neglected	   tropical	   disease	   (NTD).	   With	   a	   considerable	   high	   mortality	   and	   morbidity	  worldwide,	   snakebite	   is	   estimated	   to	   cause	   up	   to	   1.8	  million	   incidences	   of	   per	   year,	  which	   lead	   up	   to	   approximately	   94,000	   deaths	   in	   sub-­‐Saharan	   Africa,	   South	   and	  Southeast	   Asia	   and	   Latin	   America	   (Kasturiratne	   et	   al.	   2008).	   Snakebite	   is	   known	   to	  occur	   in	   tropical	  and	  sub-­‐tropical	  areas;	   In	  Africa	   for	  example,	  a	  recent	  meta-­‐analysis	  approach	   indicated	   that	   95%	   of	   the	   accidents	   and	   97%	   of	   the	   deaths	   occur	   in	   rural	  environments	   (Chippaux	  2011)	  meaning	   that	   the	   affected	   target	   is	   usually	   subsisting	  farming	   communities	   as	   well	   as	   agricultural	   workers	   that	   have	   to	   deal	   with	   this	  problem	   as	   a	   daily	   occupational	   hazard	   (Harrison	   et	   al.	   2009;	   Chippaux	   2011).	  Although	   antivenom	   is	   effective	   against	   the	   systemic	   effects	   of	   snakebite	   (Lalloo	   and	  Theakston	   2003),	   the	   treatment	   of	   local	   effects	   and	   severe	   tissue	   necrosis	   caused	   in	  some	  envenomation	  cases	  requires	  another	  strategy,	  i.e.	  the	  application	  of	  inhibitors	  of	  the	  toxins	  responsible	  for	  the	  devastating	  activities.	  The	  high	  incidence	  of	  amputations	  in	  affected	  limbs	  (5,900-­‐14,600	  per	  year)	  that	  has	  been	  reported	  for	  patients	  treated	  in	  Africa	   reflects	   the	   problematic	   of	   snakebite	  morbidity,	  where	   surviving	   victims	   often	  end	   with	   permanent	   disabilities	   that	   are	   eventually	   linked	   to	   a	   significant	   economic	  
	   	   3	  
impact	  on	  rural	  agriculture	  (Warrell	  et	  al.	  1977;	  Hansdak	  et	  al.	  1998;	  Habib	  et	  al.	  2001;	  Kasturiratne	  et	  al.	  2008;	  Harrison	  et	  al.	  2009;	  Chippaux	  2011).	  
	  
Additionally,	  snake	  envenoming	  is	  a	  particularly	  important	  public	  health	  problem	  that	  usually	   affects	   countries	   that	   have	   the	   lowest	   gross	   domestic	   product	   (GDP)	   (Figure	  1.1)	  and	   that	  are	   subsequently	   the	   least	  able	   to	  afford	  or	  access	   treatment.	  Countries	  suffering	  from	  high	  rates	  of	  snakebite	  morbidity	  and	  mortality	  have	  commonly	  a	  very	  low	  governmental	  expenditure	  on	  health,	  and	  a	  subsequent	  suboptimal	  access	  to	  health	  services	  (Harrison	  et	  al.	  2009).	  Consequently,	  the	  limited	  availability	  of	  antivenom	  has	  eventually	   lead	   to	   a	   global	   crisis	   due	   to	   the	   lack	   of	   a	   coordinated	   and	   constructive	  strategy	  for	  the	  delivery	  of	  the	  treatment	  (Williams	  et	  al.	  2011).	  	  
	  
	  
Figure	  1.1:	  The	  global	  distribution	  of	  the	  annual	  estimates	  of	  snakebite-­‐induced	  deaths.	  Darker	  colours	  denote	  the	  highest	  numbers	  of	  snakebite	  mortality	  (Kasturiratne	  et	  al.	  2008).	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1.3. Envenomations	  by	  the	  Echis	  genus	  The	   genus	   Echis,	   also	   referred	   to	   as	   the	   saw	   scaled	   vipers	   (Spawls	   et	   al.	   2004),	   is	  thought	   to	   be	   responsible	   for	   the	  majority	   of	   the	   94,000	   deaths	   that	   occur	   per	   year	  worldwide	   than	   any	   other	   single	   genus	   of	   snakes	   (Bhat	   1974;	   Warrell	   et	   al.	   1977;	  Theakston	   and	  Warrell	   2000;	   Habib	   et	  al.	   2001;	   Chippaux	   2011).	   The	   high	  mortality	  rates	  account	  for	  a	  number	  of	  factors	  that	  include:	  (i)	  a	  high	  occurrence	  of	  Echis	  species	  throughout	  parts	  of	  a	  large	  geographical	  area	  (Figure	  1.2)	  that	  range	  from	  India	  and	  Sri	  Lanka	  in	  the	  east,	  across	  the	  Arabian	  peninsula	  to	  Mauritania	  and	  Senegal	  and	  up	  to	  the	  Mediterranean	   Sea	   in	   Africa	   reaching	   northern	   parts	   of	   Kenya	   (Spawls	   et	   al.	   2004;	  Arnold	  et	  al.	  2009),	  (ii)	  a	  highly	  hemorrhagic	  venom	  that	  typically	   induce	  local	  effects	  such	   as	   necrosis,	   swelling,	   blistering	   and	   oedema	   and	   systemic	   effects	   that	   involve	  extensive	  bleeding	  by	  methods	  such	  as;	  disseminated	  intravascular	  coagulation	  due	  to	  the	  activation	  of	  factor	  V	  and	  factor	  X,	  the	  continuous	  activation	  of	  fibrinogen	  and	  the	  breakdown	  of	  the	  vascular	  endothelium	  by	  haemorrhagins	  (Warrell	  et	  al.	  1977;	  Chugh	  1989;	  Gilon	   et	  al.	   1989;	   Porath	   et	  al.	   1992;	  Benbassat	   and	   Shalev	   1993;	  Kochar	   et	  al.	  2007)	   and	   (iii)	   a	   consistent	   lack	   of	   antivenom	   effectiveness	   and	   cross-­‐reactivity	  (Warrell	  and	  Arnett	  1976;	  Warrell	  et	  al.	  1977;	  Benbassat	  and	  Shalev	  1993;	  Visser	  et	  al.	  2008;	  Warrell	  2008)	  has	  been	  reported	  by	  the	  ineffectiveness	  of	  E.	  carinatus	  antivenom	  to	   treat	   patients	   envenomed	   by	  E.	   carinatus	   sochureki	   and	  E.	   ocellatus	   (Kochar	   et	   al.	  2007;	  Visser	  et	  al.	  2008)	  and	  antivenom	  raised	  against	  west	  and	  east	  African	  species	  to	  treat	  bites	  from	  members	  of	  the	  E.	  pyramidum	  complex	  (Gillissen	  et	  al.	  1994;	  Valenta	  et	  
al.	  2011).	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Figure	  1.2:	  Distribution	  map	  showing	  the	  range	  of	  the	  four	  main	  taxa	  of	  the	  genus	  
Echis:	  Echis	  ocellatus	  (blue),	  E.	  pyramidum	  (red),	  E.	  coloratus	  (green)	  E.	  carinatus	  (purple).	  From	  Casewell	  et	  al.	  (2010)	  	  
Historically,	   the	   availability	   of	   antivenoms	   in	   Africa	   has	   been	   marked	   by	   critical	  shortages,	  which	  does	  not	   fulfill	   the	  needs	  of	  patients.	   In	   the	  1970s	   there	  were	   three	  main	  manufactures:	  IPSER	  AFRIQUE	  (Institute	  Pasteur	  Paris)	  covering	  Bitis,	  Echis,	  Naja	  
Dendroaspis,	  North	   Africa	  behringwerke,	  Marburg	   covering	  Cerastes	   ,Bitis,	  Echis,	  Naja	  and	  for	  Central	  Africa	  excluding	  Echis	  but	  including	  Hemachatus	  and	  Dendroaspis	  ;	  and	  SAMIR	   from	   Johannesburg	   with	   a	   polyvalent	   and	   echis	   monovalent	   antivenom	  	  (Williams	   et	   al.	   2011).	   More	   recently	   constructive	   international	   efforts	   to	   provide	  antivenoms	   for	   Sub-­‐Saharan	   Africa	   have	   created	   a	   distinctive	   strategy	   to	   raise	  antibodies	   in	   sheep	   rather	   than	  horses	   and	   further	   redesign	   to	  deliver	   IgG	   in	   a	  more	  effective	  manner.	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1.4. Echis	  venom	  composition	  	  Venom	   gland	   transcriptomes,	   aiming	   to	   examine	   the	   expression	   levels	   of	   mRNAs	  encoding	  venom	  proteins	  in	  cells	  of	  the	  venom	  glandular	  epithelium	  at	  any	  given	  time,	  have	  been	  extensively	  interrogated	  for	  several	  medically	  important	  snake	  species	  that	  include	  members	  of	  the	  genus	  Bothrops	  (Kashima	  et	  al.	  2004;	  Cidade	  et	  al.	  2006;	  Neiva	  
et	  al.	  2009),	  Bitis	  gabonica	  (Francischetti	  et	  al.	  2004),	  Deinagkistrodon	  acutus	  (Zhong	  et	  
al.	  2006),	  Sistrurus	  catenatus	  edwardsii	  	  (Pahari	  et	  al.	  2007),	  E.	  ocellatus	  (Casewell	  et	  al.	  2009),	   Bungarus	   flaviceps	   (Siang	   et	   al.	   2010),	   Bungarus	   multicinctus	   and	   Naja	   atra	  (Jiang	   et	   al.	   2011),	   Micrurus	   altirostris	   and	   M.	   corallinus	   (Correa-­‐Netto	   et	   al.	   2011)	  (among	  others)	   .	  Together,	  they	  have	  successfully	  provided	  a	  comprehensive	  scenario	  of	  the	  diversity	  and	  abundance	  of	  all	  the	  transcripts	  encoding	  venom	  proteins.	  	  
	  
While	  a	  number	  of	   venom	  proteins	   from	   the	  genus	  Echis	  with	  varying	  activities	  have	  been	   described	   (Peng	   et	  al.	   1993;	   Jasti	   et	  al.	   2004a;	   b;	   Juarez	   et	  al.	   2006;	   Zhou	   et	  al.	  2008)	   an	   overview	   of	   the	   venom	   gland	   toxin	   composition	   of	   Echis	   ocellatus	   was	  determined	   by	   Wagstaff	   and	   Harrison	   (2006).	   They	   identified	   a	   number	   of	   toxin	  families	  that	  included	  include	  Phospholipases	  A2	  (PLA2s),	  C-­‐Type	  lectins	  (CTLs),	  Serine	  Proteases	  (SPs),	  L-­‐Aminoacid	  Oxidases	  (LAOs),	  growth	  factors	  among	  others	  present	  at	  relatively	   low	   levels	   of	   expression	   (1-­‐10%)	   when	   compared	   to	   the	   snake	   venom	  metalloproteinases	  (SVMPs)	  of	   the	  known	  subclasses	  (PI-­‐III)	  (Fox	  and	  Serrano	  2008),	  which	   were	   found	   to	   represent	   approximately	   60%	   of	   all	   the	   toxin	   transcripts	  (Wagstaff	  and	  Harrison	  2006).	  A	  further	  study	  by	  Wagstaff	  et	  al	  (2009)	  interrogated	  E.	  
ocellatus	  venom	  proteome	  revealing	  differences	  when	  compared	  to	  the	  transcriptome	  (Figure	  1.3).	  Consequently,	  although	  the	   transcriptome	  can	  be	  commonly	  viewed	  as	  a	  precursor	  of	  the	  proteome,	  transcriptomic	  data	  should	  be	  analysed	  in	  combination	  with	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the	  ‘venome’	  or	  venom	  proteome	  in	  order	  to	  account	  for	  small	  transcriptional	  and	  post-­‐translational	  modifications.	  	  
	  
Figure	  1.3:	  The	  composition	  of	  the	  E.	  ocellatus	  venom	  gland	  transcriptome	  and	  proteome	  DC-­‐fragment,	  disintegrin/cysteine-­‐rich	  fragment	  from	  PIII	  snake	  venom	  Zn2+-­‐metalloproteinase	  (SVMPs),	  CTL:	  C-­‐type	  lectin-­‐like	  protein,	  Ser-­‐Prot:	  serine	  proteinase,	  PLA2:	  phospholipase	  A2,	  LAO:	  L-­‐amino	  acid	  oxidase,	  CRISP:	  cysteine-­‐rich	  secretory	  protein,	  Asp-­‐Prot:	  aspartic	  proteinase,	  Hyal:	  hyaluronidase,	  SVMPi:	  snake	  venom	  metalloproteinase	  inhibitors	  (Modified	  from	  Wagstaff	  et	  al,	  2009).	  
	  
A	  further	  comparative	  transcriptomic	  analysis	  interrogating	  the	  venom	  gland	  of	  other	  members	  of	  the	  Echis	  genus	  by	  Casewell	  et	  al.	  2009	  revealed	  that	  the	  most	  numerically	  abundant	  venom	  toxin	  families	  in	  the	  four	  Echis	  species	  (Echis	  ocellatus,	  E.	  Pyramidum	  
Transcriptome-
Proteome-
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leakeyi	  and	  E.	  carinatus	  sochureki)	  were	  the	  SVMPs,	  CTLs,	  PLA2s,	  and	  SPs	  (Figure	  1.4).	  A	   description	   of	   the	   basic	   structure,	   biological	   function	   and	   pathological	   role	   of	   is	  outlined	  as	  follows.	  
	  
Figure	  1.4:	  The	  relative	  abundance	  and	  diversity	  of	  each	  Echis	  genus	  venom	  toxin	  family	  Phospholipase	  A2	  (PLA2),	  Serine-­‐proteases	  (SP),	  C-­‐type	  lectins	  (CTL),	  Snake	  venom	  Metalloproteinases	  (SVMPs)	  and	  Disintegrins	  (DIS)	  (Casewell	  et	  al.	  2009).	  
	  
1.4.1. Snake	  Venom	  Metalloproteinases	  (SVMPs)	  The	  SVMPs	  are	  the	  most	  abundant	  toxin	  transcripts	  found	  in	  the	  Echis	  genus	  (Casewell	  
et	  al.	  2009).	  The	  SVMPs	  (Snake	  Venom	  Metalloproteinases)	   together	  with	   the	  ADAMs	  (A	   Disintegrin	   and	   Metalloproteinase)	   are	   zinc-­‐dependant	   enzymes	   and	   belong	   to	   a	  subgroup	  of	  the	  reprolysins,	  a	  subfamily	  of	  the	  M12	  family	  of	  metalloproteinases	  (Fox	  and	   Serrano	   2005).	   The	   SVMPs	   and	   ADAMs	   share	   structural	   features	   such	   as	  homologous	  metalloproteinase	  domains	  and	  in	  some	  cases,	  domain	  structures	  located	  at	  the	  carboxyl	  end	  to	  the	  proteinase	  domain	  (Fox	  and	  Long	  1998).	  SVMPs	  have	  been	  classified	  according	  to	   the	  presence	  of	  additional	  non-­‐proteinase	  domains.	  Those	  that	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comprise	   only	   one	   domain,	   the	  metalloproteinase	   domain	   are	   referred	   to	   as	   P-­‐I	   and	  those	  subsequently	  extended	  by	  i)	  a	  disintegrin	  domain	  or	  a	  ii)	  disintegrin-­‐like	  together	  with	  a	  cysteine-­‐rich	  domain	  are	  referred	  to	  as	  P-­‐II	  and	  P-­‐III	  respectively.	  Some	  further	  classifications	  account	  for	  post-­‐translational	  modifications	  that	  have	  been	  found	  within	  the	  toxin	  group	  (Figure	  1.5)	  (Fox	  and	  Serrano	  2005;	  2008).	  All	  SVMPs	  share	  a	  catalytic	  zinc-­‐binding	  motif	   in	   their	  metalloproteinase	  domain	   (HEXXHXXGXXH)	   followed	  by	   a	  conserved	   a	   Met-­‐Turn	   sequence	   (CI/VM)	   from	   where	   the	   zinc	   atom	   locates	  tetrahedrally	  with	  the	  help	  of	  three	  histidines	  and	  a	  water	  molecule	  that	  is	  bound	  to	  an	  adjacent	  glutamate	   (Gomis-­‐Ruth	  et	  al.	  1994;	  Watanabe	  et	  al.	  2003).	  SVMPs	  also	  share	  an	  integrin	  binding	  RGD	  motif	  in	  that	  is	  located	  in	  the	  disintegrin	  domain	  (of	  the	  classes	  that	  contain	  it).	  	  
	  The	   P-­‐I	   class	   is	   the	   simplest	   isoform	   of	   this	   toxin	   group	   and	   contains	   only	   the	  metalloproteinase	  domain	  in	  the	  mature	  form	  (20-­‐30	  kDa),	  after	  the	  pro-­‐peptide	  and	  a	  spacer	   domain	   has	   been	   proteolytically	   processed	   in	   its	   nascent	   form	   (Figure	   1.5).	  Confirmation	   at	   cDNA	   sequence	   level	   needs	   to	   be	   undertaken	   in	   the	   classification	   of	  this	   class,	   taking	   into	   account	   that	   mature	   proteins	   comprising	   only	   the	  metalloproteinase	  domain	  can	  also	  be	  derived	   from	   the	  proteolytic	  processing	  of	  P-­‐II	  and	  P-­‐III	  SVMPs	  (Fox	  and	  Serrano	  2005;	  Gutiérrez	  et	  al.	  2009).	  	  	  
 
Figure	  1.5:	  The	  P-­‐Ia	  SVMP	  subclass.	  Modified	  from	  Fox	  and	  Serrano	  (2008)	  	  The	  P-­‐II	  class	  of	  SVMPs	  (30-­‐60	  kDa)	  comprises,	  additionally	  to	  the	  pro-­‐peptide	  domain,	  the	  metalloproteinase	  domain	  extended	  by	  a	  disintegrin	  domain,	  which	   is	  bound	  by	  a	  short	  spacer	  sequence	  (Figure	  1.6)	  (Bjarnason	  and	  Fox	  1995;	  Tsai	  et	  al.	  2000;	  Fox	  and	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Serrano	   2005;	   Gutiérrez	   et	   al.	   2009).	   Most	   of	   the	   times,	   the	   protein	   undergoes	   a	  proteolytic	  processing	   that	   results	   in	   the	   release	  of	   the	  disintegrin	  domain	  as	   a	  post-­‐translational	   modification,	   and	   as	   mentioned	   before,	   the	   resulting	   metalloproteinase	  domain	   could	   be	   mistakenly	   classified	   as	   a	   P-­‐I	   class	   SVMP.	   	   Only	   a	   few	  mature	   P-­‐II	  SVMPs	  have	  been	  found	  together	  with	  the	  disintegrin	  domain	  such	  as	   the	  monomeric	  SVMP	   jerdonitin,	   from	   the	  venom	  of	  Trimeresurus	  jerdonii	   and	   the	  dimeric	  bilitoxin-­‐I,	  from	  the	  venom	  of	  Agkistrodon	  bilineatus	  (Nikai	  et	  al.	  2000;	  Chen	  et	  al.	  2003).	  Fox	  and	  Serrano	   (2005)	   suggested	   a	   subclassification	   of	   this	   class	   by	   taking	   into	   account	   the	  absence	  (Figure	  1.6,	  P-­‐IIa)	  or	  presence	  (Figure	  1.6,	  P-­‐IIb)	  of	  the	  disintegrin	  domain,	  as	  well	   as	   the	  dimeric	   conformations	   that	   are	   formed	  by	   including	   (Figure	  1.6,	   P-­‐IIc)	   or	  excluding	  (Figure	  1.6,	  P-­‐IId,	  P-­‐IIe)	  the	  proteinase	  domain.	  	  	  
 
Figure	  1.6:	  The	  P-­‐II	  SVMP	  subclass.	  Modified	  from	  Fox	  and	  Serrano	  (2008)	  
	  The	   forms	   found	   in	   the	   P-­‐III	   class	   of	   SVMPs	   (60	   –	   100	   kDa)	   include	   a	   pro-­‐domain,	   a	  metalloproteinase	   domain,	   a	   disintegrin-­‐like	   domain	   (Dis-­‐like),	   and	   a	   cysteine-­‐rich	  (Cys-­‐rich)	  domain	   (Fox	  and	  Serrano	  2005).	  The	  Dis-­‐like	  domain	  of	  P-­‐IIIs	   is	   similar	   to	  the	  disintegrin	  domain	  of	  P-­‐IIs,	  with	  the	  exception	  that	  there’s	  an	  XCD	  sequence	  instead	  of	   the	   integrin-­‐binding	   sequence	   RGD	   (Calvete	   2013).	   P-­‐IIIs	   are	   usually	   found	   as	  monomers	   that	   belong	   to	   the	   subgroup	   P-­‐IIIa	   (Figure	   1.7)	   and	   as	   dimers	   to	   the	  subgroup	  P-­‐IIIc	  (Figure	  1.7).	  Evidence	  of	  proteolytic	  processing	  of	  the	  Dis-­‐like	  and	  Cys-­‐
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rich	  domains	  has	  been	  shown	  in	  the	  case	  of	  jararhagin	  C	  from	  B.	  jararaca	  (Usami	  et	  al.	  1994),	   alternagin	  C	   (B.	  alternatus)	   (Cominetti	  et	  al.	  2004)	  and	  catrocollastatin	  C	   from	  
Crotalus	   atrox	   (Shimokawa	   et	   al.	   1997)	   for	   which	   they	   have	   been	   classified	   into	   the	  subgroup	   P-­‐IIIb	   (Figure	   1.7).	   The	   subclass	   P-­‐IIId	   has	   the	   usual	   arrangement	   of	   the	  members	  of	  its	  class	  with	  the	  difference	  that	  additional	  C-­‐type	  lectin-­‐like	  domains	  are	  linked	   by	   disulphide	   bonds	   to	   the	   main	   proteinase	   domain	   (Fox	   and	   Serrano	   2005;	  2008).	  This	  subclass	  was	  previously	  classified	  as	  a	  separate	  class	  of	  SVMPs	  under	  the	  name	   of	   P-­‐IVs	   (Fox	   and	   Serrano	   2005;	   Gutiérrez	   et	   al.	   2009),	   but	   since	   no	   mRNA	  transcripts	  have	  been	  found	  for	  this	  form,	  a	  further	  classification	  was	  done	  accounting	  it	  as	  a	  post	  translational	  modification	  of	  the	  class	  P-­‐III	  (Fox	  and	  Serrano	  2005).	  	  	  
 
Figure	  1.7:	  The	  P-­‐III	  SVMP	  subclass.	  Modified	  from	  Fox	  and	  Serrano	  (2008)	  	  The	   variety	   of	   modifications	   in	   the	   domain	   structure	   from	   the	   SVMP	   subclasses	   are	  thought	  to	  account	  for	  the	  wide	  range	  of	  pathological	  activities	  reported	  up	  to	  date	  for	  this	   toxin	   group.	   One	   of	   the	   most	   prominent	   effects	   caused	   by	   this	   toxin	   group	   is	  haemorrhage,	   but	   other	   alterations	   such	   as	   coagulopathy,	   fibrinolysis,	   myonecrosis,	  apoptosis,	   blistering,	   proinflammatory	   activity	   and	   prothrombin	   activation	   have	   also	  been	   reported	   as	   important	   and	   highly	   dependant	   on	   the	   proteolytic	   processing	   of	  these	   enzymes	   (Kamiguti	   et	   al.	   1996;	   Gutierrez	   and	   Rucavado	   2000;	   Gutierrez	   et	   al.	  2005).	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1.4.2. C-­‐Type	  lectins	  C-­‐Type	   lectins	   are	   the	   second	   most	   abundant	   toxin	   group	   of	   the	   toxin-­‐encoding	  transcripts	  of	  the	  Echis	  genus.	  While	  C-­‐type	  lectins	  (CTLs)	  are	  non-­‐enzymatic	  proteins	  found	   in	   many	   animals	   which	   bind	   in	   a	   Ca2+-­‐dependent	   fashion	   to	   mono-­‐	   and	  oligosaccharides,	   those	   found	   in	   in	   snake	   venoms	   can	   be	   the	   classic	   sugar	   biding	  protein	   (which	   is	   not	   a	   highly	   toxic	   component	   of	   the	   venom)	   or	   another	   that	  structurally	  resembles	  classic	  lectins,	  but	  is	  unable	  to	  recognize	  carbohydrates	  because	  of	   the	   lack	   of	   Ca2+	  binding	   loop	   involve	   in	   sugar	   binding	   named	   (CLPs)	   (Ogawa	   et	  al.	  2005).	   CLPs	   are	   usually	   heterodimers	   formed	   by	   loop	   swapping	   composed	   of	  homologous	   α-­‐	   and	   β-­‐subunits	   that	   interacts	   through	   a	   loop	   linked	   by	   a	   disulphide	  bond.	  CLPs	  are	  an	   important	   component	  of	  Viperide	  venoms	  and	   can	  be	  divided	   into	  coagulant,	   platelet	   aggregation	   agonists	   based	   on	   their	   pharmacological	   activity	  (Morita	  2005;	  Ogawa	  et	  al.	  2005).	  	  	  
1.4.3. Phospholipases	  A2	  Phospholipases	   A2	   are	   estereolytic	   enzymes	   that	   hydrolyse	   glycerophospholipids	   at	  the	   sn-­‐2	  position	   of	   a	   glycerol	   backbone	   releasing	   lysophospholipids	   and	   fatty	   acids.	  	  Their	  mechanism	  of	  catalysis	  is	  commonly	  dependant	  upon	  the	  binding	  of	  a	  Ca2+	  ion	  in	  a	  consensus	  sequence	  located	  between	  the	  25th	  and	  33rd	  residue	  (Y25-­‐G-­‐C-­‐Y/F-­‐C-­‐G-­‐X-­‐G-­‐G33)	  (Scott	  1997).	  The	  members	  that	  belong	  to	  this	  toxin	  group	  for	  viperide	  species	  fall	  under	  the	  classification	  of	  group	  II,	  which	  differ	  from	  others	  by	  the	  lack	  of	  a	  pancreatic	  loop	  that	  is	  present	  in	  the	  members	  of	  group	  I.	  These	  enzymes	  contain	  120-­‐125	  amino	  acid	   residues	   and	   7	   disulfide	   bridges	   and	   can	   be	   divided	   into	   different	   subgroups	  according	  to	  the	  residue	  that	  is	  located	  in	  the	  49th	  position	  of	  the	  sequence,	  which	  can	  commonly	  be	  Asp49	  (important	  for	  catalysis)	  (Scott	  et	  al.	  1990).	  	  Substitution	  by	  lysine	  -­‐	  K49	  (Maraganore	  et	  al.	  1984),	  serine	  -­‐	  S49	  (Polgar	  et	  al.	  1996),	  asparagine	  -­‐	  N49	  (Tsai	  
et	  al.	  2004)	  or	  arginine	  -­‐	  R49	  (Tsai	  et	  al.	  2004)	  is	  known	  to	  interrupt	  the	  binding	  of	  the	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Ca2+	  cofactor,	   interfering	   in	   its	  hydrolytic	  activity	  (Maraganore	  and	  Heinrikson	  1985).	  In	  Echis,	   Phospholipases	   A2	   that	   exhibit	   both	   enzymatic	   (Asp49)	   and	   non-­‐enzymatic	  (Ser49)	   activities	   are	   found	  with	   a	   representation	   of	   5-­‐8%	  of	   toxin	   transcripts	   for	  E.	  
coloratus,	  E.	  ocellatus	  and	  E.	  c.	  sochureki	  (Casewell	  et	  al.	  2009).	  	  	  
1.4.4. Serine	  proteases	  The	  toxin	  group	  of	  Serine	  Proteases	  (SPs)	  is	  represented	  in	  2-­‐5%	  of	  the	  toxin	  encoding	  transcripts	   (Casewell	   et	   al.	   2009),	   which	   was	   thought	   to	   be	   relatively	   low	   when	  compared	   to	  other	  viperid	   species	   (Cidade	  et	  al.	   2006;	  Pahari	  et	  al.	   2007)	  and	  on	   the	  known	   severe	   coagulopathy	   reported	   for	   victims	   of	  Echis	  envenoming	   (Warrell	   et	  al.	  1977)	   that	   can	   	   easily	   be	   related	   to	   the	   direct	   effect	   of	   this	   toxin	   group	   on	   platelet	  aggregation,	   blood	   coagulation	   and	   fibrinolytic	   pathways	   (Kini	   2006).	   SPs	   can	   be	  categorised	  into	  thrombin-­‐like	  or	  kallikrein-­‐like	  proteases.	  The	  thrombin-­‐like	  subgroup	  contains	  enzymes	  that	  are	  functionally	  related	  to	  thrombin,	  and	  are	  therefore	  capable	  of	   converting	   fibrinogen	   to	   fibrin	   (Pirkle	   1998)	   as	   well	   as	   activating	   several	  components	   of	   the	   blood	   coagulation	   cascade	   involved	   in	   platelet	   aggregation	   (for	  example,	  factor	  V)	  (Siigur	  et	  al.	  1999).	  Kallikrein-­‐like	  SPs	  on	  the	  other	  hand,	  resemble	  the	   mammalian	   kallikrein	   enzymes,	   known	   for	   initiating	   the	   release	   of	   bradykinin	  through	  the	  proteolytic	  cleavage	  of	  kininogen	  (Matsui	  et	  al.	  2000).	  
	  
1.4.5. Disintegrins	  Disintegrins	  represent	  3	  –	  4	  %	  of	  Echis	  toxin	  transcripts	  (Casewell	  et	  al.	  2009)	  and	  are	  a	   non-­‐enzymatic	   toxin	   family	   from	   snake	   venoms	   and	   comprises	   small	   (40-­‐100	  aminoacids)	   cysteine-­‐rich	   proteins.	   Disintegrins	   are	   the	   result	   of	   the	   proteolytic	  processing	   of	   multi-­‐domain	   class	   II	   (P-­‐IIa,	   Figure	   1.6)	   or	   class	   III	   (P-­‐IIb,	   Figure	   1.7)	  SVMPs,	   or	   synthesised	   from	   short	   mRNAs	   (Okuda	   et	   al.	   2002).	   According	   to	   their	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polypeptide	   length	   and	   number	   of	   disulphide	   bonds,	   this	   toxin	   group	   is	   divided	   into	  five	   different	   subgroups	   (McLane	   et	   al.	   1998;	   Marcinkiewicz	   et	   al.	   1999a;	  Marcinkiewicz	   et	   al.	   1999b),	   with	   the	   first	   four	   groups	   comprising	   single-­‐chain	  molecules	   and	   the	   fifth	   subgroup	   containing	   only	   homo-­‐	   and	   hetero-­‐dimers.	  Disintegrins	   were	   initially	   shown	   to	   act	   by	   the	   selective	   blocking	   of	   the	   binding	   of	  fibrinogen	   to	   the	   integrin	   αIIbβ3	   receptor,	   being	   subsequently	   described	   as	   potent	  inhibitors	  of	  platelet	  aggregation	  (Huang	  et	  al.	  1987).	  The	  disintegrins	  are	  now	  known	  to	   have	   evolved	   a	   number	   of	   integrin-­‐binding	  motifs	   that	   includine	   RGD	   (blocks	   the	  integrins	   α8β1,	   α5β1,	   αvβ1,	   αvβ3	   and	   αIIbβ3),	  MLD	   (blocks	   the	   integrins	   α4β1,	   α4β7,	   α3β1,	  α6β1,	   α7β1	   and	   α9β1),	   VGD	   and	  MGD	   (block	   the	   α5β1	   integrin),	   KGD	   (blocks	   the	   αIIbβ3	  integrin),	   WGD	   (blocks	   the	   α5β1,	   αvβ3	   and	   αIIbβ3)	   and	   KTS/RTS,	   which	   block	   α1β1	  integrins	  (Calvete	  2005;	  Calvete	  et	  al.	  2005). 
	  
1.5. Current	  antivenom	  therapy	  	  An	   immunogen	   or	   antigen	   is	   an	   external	   substance	   that	   is	   capable	   of	   generating	   an	  immune	   response	   by	   interaction	   with	   relevant	   cells	   of	   the	   immune	   system	  (lymphocytes	   and	   various	   antigen-­‐presenting	   cells).	   On	   this	   basis,	   antivenom	   is	  formulated	   by	   injecting	   whole	   venom	   (from	   a	   single	   snake	   species:	   monospecific	   or	  from	   multiple	   snake	   species:	   polyspecific)	   to	   an	   animal	   host	   by	   following	   a	   specific	  immunisation	  schedule	  with	  the	  aim	  of	  generating	  neutralizing	  antibodies	  against	   the	  toxic	  effects	  of	  the	  venoms	  (Lalloo	  and	  Theakston	  2003).	  Horses	  or	  sheep	  are	  the	  usual	  candidates	  of	  choice	  for	  antivenom	  production	  due	  to	  the	  large	  serum	  volume	  that	  can	  be	   recovered	   after	   the	   immunisation,	   therefore	   allowing	   the	   formulation	   of	   the	  treatment	   as	   intact	   IgGs,	   or	   pepsin	   (F(ab/)2)/papain	   (Fab)	   cleaved	   fragments	   of	   IgGs	  (Mackessy	   2009a;	   Rucavado	   et	  al.	   2012).	   Antivenoms	   are	   currently	  manufactured	   by	  different	  purification	  protocols	  in	  at	  least	  45	  laboratories	  present	  in	  all	  continents	  (see	  http://apps.who.int/bloodproducts/snakeantivenoms/database/).	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Although	  antivenom	  is	  formulated	  with	  the	  objective	  of	  generating	  venom-­‐neutralising	  antibodies	  that	  will	  recognize	  and	  neutralize	  toxic	  properties	  of	  venom	  proteins	  (Lalloo	  and	  Theakston	  2003),	  snake	  venoms	  contain	  more	  than	  a	  hundred	  components	  which	  exhibit	   both	   immunogenic	   and	   non-­‐immunogenic	   components	   with	   a	   significant	  isoform	  diversity	   (Calvete	  et	  al.	   2007).	   98%	  of	   the	  venom	  dry	  weight	   is	   composed	  of	  proteins	   capable	  of	   inducing	   relevant	   toxic	   effects	   as	  well	   as	  non-­‐toxic	  proteins,	   both	  considered	  immunogenic.	  On	  the	  other	  hand,	  the	  remaining	  2%	  of	  the	  components	  are	  amino	  acids,	  nucleotides,	  carbohydrates,	   lipids	  and	  biogenic	  amines	  that	  are	  generally	  devoid	   of	   toxicity	   and	   considered	   to	   be	   non-­‐immunogenic	   (Leon	   et	   al.	   2011).	  Consequently,	   antivenom	   is	   neither	   directed	   towards	   the	   most	   pathogenic	   venom	  components	  nor	  takes	  into	  account	  some	  of	  the	  highly	  toxic,	  but	  weakly	  immunogenic	  components	  in	  venom	  (Visser	  et	  al.	  2008;	  Wagstaff	  et	  al.	  2009).	  In	  addition,	  the	  venom	  variation	  consequence	  of	  positive	  selection	  towards	  different	  prey	  items	  has	  been	  well	  studied	  in	  some	  groups	  and	  has	  been	  shown	  that	  it	  can	  significantly	  impact	  the	  clinical	  manifestations	   of	   envenomed	   patients	   (Warrell	   1989;	   Prasad	   et	   al.	   1999;	  Shashidharamurthy	  et	  al.	  2002)	  and	  the	  clinical	  efficacy	  of	  antivenom	  therapy	  (strictly	  dependant	  on	  the	  venom	  used	  in	  its	  manufacture)	  (Galan	  et	  al.	  2004;	  Visser	  et	  al.	  2008).	  The	  current	  immunization	  protocol	  leads	  to	  an	  antidote	  where	  only	  a	  fraction	  of	  IgGs	  is	  clinically	   relevant	   to	   the	   victim	   and	   consequently,	   large	   and	   life	   threatening	   volumes	  (60-­‐300ml	   of	   80+	   mg	   protein/ml)	   are	   generally	   required	   in	   order	   to	   achieve	   the	  reversal	  of	  envenoming	  (Malasit	  et	  al.	  1986).	  	  
	  
1.6. Improvement	  of	  antivenom	  therapy	  	  There	   are	   currently	   several	   strategies	   that	   aim	   to	   improve	   the	   safety	   issues	   (dose,	  purity	   and	  geographic/species	   efficacy)	  of	   current	   antivenoms	   (Harrison	  et	  al.	   2011).	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One	   of	   the	   most-­‐widely	   used	   in	   the	   current	   days	   is	   the	   successful	   approach	   of	  antivenomics,	   	  which	   is	   based	   in	   the	   immunodepletion	  of	   toxins	  by	   the	   incubation	  of	  antivenom	   with	   whole	   venom,	   which	   eventually	   leads	   to	   a	   reaction	   mixture	   that	  contains	   the	   toxins	   against	   which	   antibodies	   in	   the	   anti-­‐venom	   are	   directed	   and	  excludes	  those	  of	  low-­‐affinity	  that	  could	  be	  of	  a	  redundance	  for	  the	  therapy	  (Calvete	  et	  
al.	  2009;	  Gutierrez	  et	  al.	  2009;	  Gutierrez	  et	  al.	  2012;	  Pla	  et	  al.	  2012).	  On	  the	  other	  hand,	  the	   use	   of	   IgGs	   from	   alternative	   venom-­‐immunised	   animals	   (e.g.	   camelids)	   has	   given	  encouraging	   support	   for	   the	   potential	   use	   of	   camelid	   IgG	  by	   being	   less	   immunogenic	  and	  therefore	  reducing	  the	  incidence	  of	  adverse	  effects	  that	  are	  known	  to	  be	  commonly	  caused	  by	  the	  use	  of	  conventional	  IgGs	  (Herrera	  et	  al.	  2005;	  Cook	  et	  al.	  2010a;	  b;	  Cook	  
et	   al.	   2010c).	   Another	   strategy	   that	   has	   been	   pioneered	   by	   the	   Alistair	   Reid	   Venom	  Research	  Unit,	  involves	  the	  design	  and	  interrogation	  of	  toxin-­‐specific	  epitopes,	  directed	  to	   target	   only	   venom	   components	   that	   cause	   the	   most	   severe	   venom-­‐induced	  pathologies	   and	   thus	   improving	   the	   dose-­‐efficacy	   of	   the	   treatment	   and	   consequently	  leading	  to	  a	  reduced	  risk	  to	  the	  patient	  of	  treatment–induced	  adverse	  effects	  (Wagstaff	  
et	  al.	  2006).	  	  
	  
The	   challenge	   of	   developing	   a	   toxin-­‐specific	   antivenom	   started	   with	   a	   molecular	  approach,	   by	   inserting	   PCR-­‐amplified	   domains	   from	   known	   toxins	   into	   expression	  plasmids	  for	  DNA	  immunisation.	  The	  strategy	  demonstrated	  that	  immunised	  mice	  were	  capable	  of	  generating	  antibodies	  that	  can	  neutralise	  pathological	  activities	  of	  the	  target	  proteins	   (Harrison	   et	   al.	   2000).	   Although	   successful,	   the	   PCR	   approach	   also	   showed	  that	  the	  amplification	  of	  the	  target	  domains	  was	  highly	  limited	  by	  the	  primer	  design.	  A	  step	   forward	  was	   taken	   into	   the	  challenge	  when	  venom	  gland	   transcriptomes	  started	  being	   used	   as	   a	   valuable	   data	   resource	   (Wagstaff	   and	  Harrison	   2006;	   Casewell	   et	  al.	  2010),	   where	   the	   conserved	   nature	   of	   many	   proteins	   could	   be	   translated	   to	   their	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immunological	   reactivity	   among	   different	   species	   and	   genera,	   irrespective	   of	   the	  phylogenetic	   restrictions	   (Harrison	   et	   al.	   2003b;	   Harrison	   2004).	   Bioinformatic	  interrogation	  of	  transcriptomes	  was	  then	  taken	  into	  account	  as	  a	  valuable	  tool	  to	  reveal	  conserved	   sequences	   that	   could	   then	   be	   used	   as	   epitopes	   capable	   of	   generating	  antibodies	   that	   neutralize	   the	   venom-­‐induced	   pathology	   (Wagstaff	   et	   al.	   2006).	  Continuing	   the	   approach	   to	   generate	   rational,	   toxin-­‐specific	   antivenom,	   this	   study	  involves	   the	   bioinformatic	   interrogation	   of	   the	   genus	   Echis	   venom	   gland	  transcriptomes	  in	  order	  to	  identify	  epitopes	  capable	  of	  generating	  antibodies	  that	  will	  neutralize	   the	   most	   pathogenic	   toxin	   groups	   from	   the	   African	   Echis	   ocellatus,	   Echis	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1.7. Aims	  of	  the	  study	  
	  
-­‐ To	  interrogate	  the	  Echis	  ocellatus,	  Echis	  pyramidum	  leakeyi	  and	  Echis	  coloratus	  venom	   gland	   transcriptomes	   and	   extract	   sequences	   from	   the	   toxin	   groups	   of	  Snake	   Venom	   Metalloproteinases,	   C-­‐Type	   lectns,	   Serine	   Proteases,	  Phospholipases	   A2	   and	   Disintegrins	   in	   terms	   of	   numeric	   and	   clade	  representation	  across	  the	  ESTs.	  	  -­‐ To	  identify,	  based	  on	  bioinformatic	  tools,	  immunogenic	  areas	  of	  representative	  EST	  sequences	  predicted	  to	  be	  surface-­‐exposed,	  non-­‐glycosylated	  and	  that	  can	  serve	  as	  candidate	  epitopes	  for	  antibody	  recognition.	  	  	  -­‐ To	   extract	   sequences	   predicted	   to	   serve	   as	   candidate	   epitopes	   for	   antibody	  recognition	   and	   formulate	   toxin-­‐specific	   immunogens	   as	   constructs	   to	   raise	  murine	   antibodies	   capable	   of	   recognizing	   the	   toxic	   effects	   of	   the	   venom	  proteins.	  	  -­‐ To	   evaluate	   the	   binding	   and	   neutralization	   of	   antibodies	   raised	   against	  synthetic	   toxin-­‐specific	   immunogens	   to	   the	   toxic	   effects	   of	   the	   venom	   from	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2. METHODOLOGY	  
	  
2.1. Snakes	  and	  venom	  Snakes	   from	   the	   genus	  Echis	   used	   in	   this	   study:	  Echis	   ocellatus	   from	  Nigeria	   (Figure	  2.1a)	   Echis	   pyramidum	   leakeyi	   from	   Kenya	   (Figure	   2.1b),	   Echis	   coloratus	   from	   Egypt	  (Figure	   2.1c)	   and	  Echis	   carinatus	   sochureki	   from	  United	   Arab	   Emirates	   (Figure	   2.1d)	  were	   kept	   in	   the	   herpetarium	   of	   the	   Alistair	   Reid	   Venom	   Research	   Unit	   (ARVRU),	  Liverpool	  School	  of	  Tropical	  Medicine	  (LSTM).	  
	  
	  
Figure	  2.1:	  Species	  of	  the	  Echis	  genus	  under	  study	  
a)	  Echis	  ocellatus,	  Nigeria;	  b)	  Echis	  pyramidum	  leakeyi,	  Kenya	  c)	  Echis	  coloratus,	  Eygipt;	  
d)	  Echis	  carinatus	  sochureki,	  UAE.	  
	  
Venom	  extractions	  were	  carried	  out	  in	  a	  glass	  plate	  covered	  with	  parafilm	  as	  shown	  in	  (Figure	  2.2).	  Venom	  was	  immediately	  lyophilized	  and	  kept	  4°C	  until	  used.	  Dried	  venom	  from	  a	  pool	  of	  extractions,	  classified	  as	  Batch	  No.	  1	  and	  lot	  05	  was	  used	  throughout	  the	  study.	  A	   total	  of	  10mg	  of	  dried	  venom	  was	  resuspended	   in	  1ml	  of	  1XPBS	  and	   further	  aliquoted	  in	  100μl	  per	  tube	  and	  were	  stored	  at	  -­‐80˚C.	  
	  
a)# b)# c)# d)#
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Figure	  2.2:	  	  Venom	  extraction	  carried	  out	  at	  the	  Alistair	  Reid	  Venom	  Research	  Unit	  
	  
2.2. 	  Molecular	  cloning	  
2.2.1. Design	   of	   restriction	   sites	   for	   bioinformatically	   designed	   epitope-­‐string	  
immunogen	  constructs	  The	   epitope-­‐string	   immunogens	  were	  designed	   to	   generate	   IgGs	   that	   target	   the	  most	  pathogenic	  toxin	  groups	  from	  the	  venoms	  of	  the	  African	  genus	  Echis	  (Annex	  2.5.1)	  and	  constructed	  so	  that	  they	  could	  be	  cloned	  into	  the	  entry	  vector	  pUC57	  (Figure	  2.3)	  and	  subsequently	   excised	   and	   subcloned	   into	   the	   mammalian	   expression	   vector	   plasmid	  pVaxSec.	   The	   pVaxSec	   plasmid	   is	   a	   hybrid	   previously	   generated	   at	   ARVRU	   from	   a	  kanamycin-­‐selectable	   3.0	   Kb	   plasmid	   (pVax,	   Invitrogen)	   with	   the	   consensus	   Kozak,	  ATG	   start,	   and	   signal	   peptide	   domains	   from	   an	   ampicillin-­‐selectable,	   5.2	   Kb	   plasmid,	  pSecTag	  (Invitrogen)	  (Figure	  2.4).	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Figure	  2.3:	  Restriction	  map	  of	  entry	  vector	  plasmid	  pUC57	  	  
	  
Figure	  2.4:	  Restriction	  map	  of	  DNA	  immunisation	  plasmid	  pVaxSec	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Restriction	  sites	  were	  also	  designed	  to	  enable	  the	  excision	  of	  the	  inserts	  from	  pVaxSec	  or	  pUC57	  and	  further	  subclone	  them	  into	  a	  recombinant	  protein	  plasmid	  (Figure	  2.5):	  
• Clone	  into	  pUC57	  using	  the	  insert	  and	  plasmid	  digested	  with	  HindIII	  and	  XbaI.	  
• Excise	   the	   insert	   from	   pUC57	  with	  HindIII	   and	   XhoI	   (without	   cutting	   pUC57)	  and	   sub	   clone	   it	   into	   pVaxSec	   previously	   cut	   with	   HindIII	   and	   XhoI	   (The	   extra	   G	  preceding	   the	  KpnI	   site	   will	   shift	   the	   frame	   out	   in	   pVaxSec	   generating	   an	   early	   stop	  termination	  codon).	  	  
	  
Figure	  2.5:	  Restriction	  sites	  for	  cloning	  and	  subcloning	  of	  epitope-­‐string	  immunogens.	  5’end:	  HindIII	  and	  NheI;	  3’	  end:	  KpnI,	  XhoI	  and	  XbaI	  	  
2.2.2. Synthesis	  of	  Epitope-­‐string	  immunogens	  The	   codon	   structure	   for	   the	   epitope-­‐string	   immunogens	   was	   optimized	   for	   murine	  expression	   using	   GeneSript’s	   usage	   frequence	   table	   tool	   for	   mouse	   (available	   at:	  http://www.genscript.com/cgi-­‐bin/tools/codon_freq_table)	  and	  further	  synthesized	  as	  DNA	   constructs	   in	   the	   plasmid	   vector	   pUC57	   by	   de	   novo	   gene	   synthesis	   (GenScript,	  USA).	  	  
	  
Immunogen(
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2.3. Cloning	  and	  sub-­‐cloning	  of	  epitope-­‐string	  immunogens	  	  
2.3.1. Transformation	  of	  chemically	  competent	  E.	  coli	  cells	  with	  pUC57	  plasmid	  
constructs	  Transformation	  was	   carried	   out	   using	  OneShot®	  TOP10	   Chemically	   Competent	  E.	   coli	  and	  following	  manufacturer’s	  guidelines.	  One	  vial	  of	  25µL	  E.	  coli	  cells	  was	  thawed	  and	  used	   for	   each	   transformation.	  A	   total	   of	   0.1µL	  of	   immunogen	  plasmid	   in	  pUC57	   (200	  ng/µL)	  was	  added	  to	   the	  vial	  containing	  the	  E.coli	  and	  mixed	  gently,	   incubated	  on	   ice	  for	  30	  minutes	  and	  further	  heat	  shocked	  for	  30	  seconds	  at	  42ºC,	  to	  then	  be	  returned	  to	  ice	   for	   two	  minutes.	   250µl	   of	   pre-­‐warmed	   SOC	  media	   (Appendix	  A)	  were	   added	   into	  each	  vial	  of	  transformed	  cells	  and	  incubated	  at	  37ºC	  for	  a	  total	  of	  one	  hour	  in	  a	  shaking	  incubator	  (225rpm).	  Each	  sample	  (volumes	  10µL,	  20µL	  and	  150µL)	  was	  streaked	  into	  plates	  containing	  LB	  Agar	   (Appendix	  A)	  and	  ampicillin	  as	  selective	  antibiotic	   (1000x)	  for	  PUC57.	  Plates	  were	  incubated	  at	  37ºC	  and	  allowed	  to	  grow	  overnight.	  	  
	  
2.3.1.1. Preparation	  of	  Glycerol	  stocks	  	  Single	  colonies	  were	  picked	  from	  the	  plates	  and	  used	  to	  seed	  a	  3ml	  starter	  culture	  of	  LB	  medium	   broth	   containing	   the	   appropriate	   selective	   antibiotic	   and	   incubated	   at	   37ºC	  and	  225rpm	  for	  up	  to	  16	  hours.	  A	  0.5ml	  aliquot	  was	  removed	  from	  the	  starter	  cultures	  and	  then	  added	   into	  a	  sterile	  Eppendorf	   tube	  containing	  0.5ml	  of	  autoclaved	  glycerol.	  The	  stock	  cultures	  were	  stored	  at	  -­‐80ºC	  until	  further	  use.	  
	  
2.3.1.2. Preparation	  of	  bacterial	  cultures	  from	  -­‐80ºC	  glycerol	  stocks	  Glycerol	   stocks	   of	   the	   transformed	   E.	   coli	   cultures	   were	   streaked	   onto	   LB	   selective	  plates	  and	  incubated	  overnight	  at	  37ºC.	  Single	  colonies	  were	  picked	  at	  the	  next	  day	  to	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be	   grown	   the	   same	   way	   as	   described	   before	   in	   LB	   medium	   broth,	   containing	   the	  selective	  antibiotic.	  
	  
2.3.2. Plasmid	  purification	  Cell	   lysis	  and	  pUC57	  plasmid	  purification	  was	  carried	  out	  using	  the	  Plasmid	  Miniprep	  Kit	  from	  QIAGEN®.	  Cells	  from	  the	  starter	  cultures	  were	  harvested	  by	  centrifugation	  at	  6000	  x	  g	  for	  15	  min	  at	  4ºC,	  re-­‐suspended	  in	  0.3ml	  of	  re-­‐suspension	  buffer	  (50Mm	  Tris-­‐Cl;	  10mM	  EDTA;	  100µg/ml	  RNAseA),	   lysed	  with	  0.3	  ml	  of	   lysis	  buffer	  (200mM	  NaOH;	  1%	   SDS)	   and	   further	   neutralized	   and	   centrifuged	   at	   13,000	   rpm	   for	   a	   total	   of	   10	  minutes.	   The	   supernatant	  was	   added	   into	   the	   previously	   equilibrated	  QIAGEN-­‐tip	   20	  column.	   Elution	   of	   plasmid	  DNA	  was	   carried	   out	   using	   elution	   buffer	   (1.25mM	  NaCl;	  50mM	  Tris-­‐Cl,	  pH	  8.5;	  15%	  isopropanol	  v/v).	  To	  determine	  the	   final	  concentration	  of	  the	  samples,	  a	  2µl	  aliquot	  was	  removed	  from	  each	  sample	  and	  loaded	  into	  the	  ND-­‐1000	  NanoDrop	  spectrophotometer	  (Labtech,	  UK)	  	  (Annex	  2.5.2).	  	  Two	  aliquots	  of	  10µl	  were	  used	   to	   i)	   confirm	   the	   correct	   nucleotide	   sequence	   by	   automated	   Single	   Pass	   DNA	  sequencing	   (carried	  out	  by	  Beckman	  Coulter	  Genomics,	  Essex,	  UK)	   and	   to	   ii)	   confirm	  the	   appropriate	   molecular	   size	   of	   inset/immunogen	   by	   visualizing	   the	   size	   of	   the	  product	  of	  a	  restriction	  enzyme	  digestion	  reaction	  with	  HindIII	  and	  XhoI	  (for	  details	  see	  section	  2.2.)	  in	  an	  1%	  TAE	  agarose	  gel.	  
	  
2.3.2.1. Sanger	  DNA	  sequencing	  A	   total	   of	   10	   μl	   from	   each	   of	   the	   purified	   plasmids	   were	   sent	   to	   Beckman	   Coulter	  Genomics	   (UK)	   for	   high	   performance	   Sanger	   sequencing.	   	   Alignments	   of	   sequenced	  samples,	  with	  the	  original	  constructs	  can	  be	  found	  at	  the	  end	  of	  this	  chapter,	  in	  Annex	  2.5.5.	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2.3.3. Tris-­‐acetate-­‐EDTA	  (1%	  TAE)	  agarose	  gel	  electrophoresis	  Gels	  were	  prepared	  by	  mixing	  1g	  of	  agarose	  in	  100ml	  of	  TAE	  buffer	  (Appendix	  A)	  and	  melted	   in	   a	   microwave.	   When	   the	   mix	   cooled	   down	   to	   hand	   temperature,	   5μL	   of	  Ethidium	   Bromide	   was	   added.	   The	   mix	   was	   poured	   into	   the	   gel	   casting	   plate	   and	  allowed	   to	   solidify	   for	   approximate	  30	  min.	  Finally,	   enough	  TAE	  buffer	  was	  added	   to	  the	  tank	  so	  that	  the	  gel	  was	  completely	  covered	  and	  ready	  for	  the	  samples	  to	  be	  loaded	  into	   the	   wells.	   Together	   with	   5μl	   of	   1Kb	   DNA	   ladder	   (Promega,	   UK),	   the	   samples	  (usually	  10μl	  unless	  stated	  otherwise)	  were	  subjected	  to	  electrophoresis	  in	  the	  gel	  for	  one	  hour	  at	  100V.	  	  
	  
2.3.4. Double	   restriction	   enzyme	   digestion	   of	   Epitope-­‐string	   constructs	   from	  
pUC57	  Samples	   in	   pUC57	   were	   digested	   with	   the	   restriction	   enzymes	   HindIII	   and	   XhoI.	   A	  ‘digestion	  mix’	  was	  made	  with	  6μL	  of	  vector	  plasmid,	  2μL	  of	  Buffer	  B	   (Promega,	  UK),	  2μL	   of	   HindIII	   (Promega,	   UK),	   2μL	   of	   XhoI	   (Promega,	   UK)	   and	   8μL	   of	   H2O.	   After	  components	  were	  mixed,	   Further	   incubation	   at	   37°C	   for	   three	  hours	  was	   carried	  out	  and	  subsequently,	  3µL	  of	  6x	  DNA	  loading	  buffer	  were	  added	  to	  10μl	  of	  sample	  to	  then	  load	  them	  into	  a	  1%	  TAE	  agarose	  gel	  as	  described	  in	  section	  2.3.4.	  
	  
2.3.5. Double	  restriction	  enzyme	  digestion	  of	  acceptor	  plasmid	  pVaxSec	  For	   pVaxSec	   plasmids,	   digestion	   was	   carried	   out	   the	   same	   way	   as	   with	   the	   pUC57	  plasmids	   but	   the	   final	   step	   was	   followed	   by	   dephosphorylation	   by	   adding	   to	   20	   µL	  digestion	  mix,	  5	  µL	  of	  10X	  CIAP	  RxN	  buffer	  (Promega,	  UK),	  0.5	  µL	  1/10	  CIAP	  Alkaline	  Phosphatase	  (Promega,	  UK)	  and	  24.5	  µL	  ddH2O.	  After	  30	  minutes	  of	  incubation	  at	  37°C,	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a	  further	  0.5	  μL	  of	  1/10	  CIAP	  were	  added	  and	  incubated	  again	  at	  the	  same	  temperature	  for	  another	  30	  min.	   Subsequenly,	  0.5	  μL	  of	  0.5M	  EDTA	  were	  added	  and	   this	   time	   the	  sample	  was	  incubated	  at	  75°C	  for	  10	  minutes.	  3µL	  of	  6x	  DNA	  loading	  buffer	  were	  added	  to	  10μl	  of	  sample	  to	  subsequently	  load	  them	  into	  a	  1%	  TAE	  agarose	  gel	  as	  described	  in	  section	  2.3.3.	  
	  
2.3.6. Isolation	  of	  DNA	  bands	  from	  agarose	  gel	  Following	   electrophoresis,	   the	  DNA	   bands	  were	   visualized	   by	   placing	   the	   gel	   into	   an	  ultraviolet	   trans-­‐illuminator	   and	   the	   molecular	   weight	   for	   each	   of	   the	   bands	   was	  observed	   in	   order	   to	   confirm	   the	   presence	   of	   DNA	   bands	   of	   the	   desired	   size	   (Figure	  2.3).	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A	  scalpel	  was	  used	   to	  dissect	   the	   required	   restriction	  enzyme	  product	   containing	   the	  insert	   from	   the	   other	   content	   of	   the	   agarose	   gel.	   The	   gel	   containing	   the	   band	   was	  macerated	  and	  placed	   inside	  an	  Eppendorf	   tube.	  Purification	  of	   the	  band	  was	  carried	  out	  using	  WizardSV®Gel	  and	  PCR	  Clean-­‐Up	  System	  (Promega,	  UK).	  Briefly,	  the	  gel	  slice	  was	   mixed	   in	   a	   microcentrifuge	   tube	   with	   a	   volume	   of	   Membrane	   Binding	   Solution	  equal	   to	   10	   µl	   per	   10mg	   of	   gel.	   The	  mixture	  was	   vortexed	   and	   incubated	   at	   50-­‐60°C	  until	   gel	   slice	  was	   completely	   dissolved.	   The	   dissolved	  mixture	  was	   transferred	   to	   a	  minicolumn	  collection	   tube,	   incubated	  at	   room	   temperature	   for	  one	  minute	   and	   then	  centrifuged	  at	  16,000	  xg	  for	  another	  minute.	  The	  flow	  through	  was	  discarded	  and	  700	  μl	  of	  Membrane	  Washing	  Solution	  (ethanol	  added)	  added	  and	  centrifuged	  at	  16,000	  x	  g	  for	   five	   minutes.	   This	   wash	   step	   was	   repeated,	   the	   collection	   tube	   emptied,	   and	   the	  column	  assembly	  was	  re-­‐centrifuged	  with	  the	  microcentrifuge	  lid	  open	  to	  remove	  any	  traces	  of	  ethanol.	  The	  elution	  of	  DNA	  was	  carried	  out	  by	  transferring	  the	  minicolumn	  to	  a	   clean	   1.5ml	   microcentrifuge	   tube	   and	   adding	   50μl	   of	   nuclease-­‐free	   water.	   The	  assembly	  was	   then	   centrifuged	   at	   16,000	   x	   g	   for	   one	  minute	   and	   a	  2µl	   aliquot	   of	   the	  restriction	   enzyme	   product	   was	   loaded	   into	   the	   ND-­‐1000	   NanoDrop	  spectrophotometer	  (Labtech,	  UK)	  to	  determine	  the	  DNA	  concentration	  (Annex	  2.5.3).	  	  
	  
2.3.7. Ligation	  of	  immunogens	  into	  pVaxSec	  A	  3:1	  molar	  ratio	  of	  insert:vector	  was	  used	  to	  	  ligate	  the	  epitope-­‐string	  inserts	  into	  the	  vector	  plasmid	  for	  DNA	  immunisation	  (pVaxSec).	  The	  necessary	  volumes	  of	  each	  were	  calculated	  and	  mixed	  with	  0.3	  μl	  of	  ligase	  (Promega,	  UK),	  1	  μl	  of	  ligase	  buffer	  (Promega,	  UK)	  and	  the	  difference	  of	  ddH2O	  to	  make	  up	  to	  the	  closest	  exact	  volume	  (i.e.	  10	  or	  20	  μl).	  For	  the	  ‘vector	  control’,	  the	  volume	  of	  the	  insert	  was	  replaced	  with	  ddH2O	  and	  the	  rest	  of	  the	  components	  were	  added	  in	  the	  same	  way	  as	  described	  before.	  The	  samples	  were	  left	  at	  16°C	  over	  night.	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2.3.8. Transformation	  of	  ligation	  reaction	  into	  chemically	  competent	  E.	  coli	  cells	  Each	   pVaxSec	   ligation	   product	   was	   transformed	   (as	   previously	   described	   in	   section	  2.3.1)	   in	   TOP10	   chemically	   competent	   E.	   coli	   cells	   and	   subsequently	   streaked	   onto	  three	   plates	   (of	   10µl,	   100µl	   and	   200µl)	   and	   further	   grown	   in	   media	   containing	  Kanamycin	   (1000X)	   as	   selective	   antibiotic.	   Cell	   lysis	   and	   plasmid	   purification	   was	  carried	  out	  as	  described	  in	  section	  2.2.4.	  In	  order	  to	  confirm	  the	  final	  concentration	  of	  the	  ligation	  products,	  a	  2µl	  aliquot	  was	  removed	  from	  each	  sample	  and	  loaded	  into	  the	  ND-­‐1000	   NanoDrop	   spectrophotometer	   (Labtech,	   UK)	   (Annex	   2.5.4).	   20µl	   from	   each	  sample	  were	  removed	  and	  10µl	  were	  used	  to	  confirm	  the	  correct	  nucleotide	  sequence	  automated	   Single	   Pass	   DNA	   sequencing	   (carried	   out	   by	   Beckman	   Coulter	   Genomics,	  Essex,	  UK).	  
	  
2.4. Immunological	  assays	  
2.4.1. One	   dimension	   Sodium	   Doecyl	   Sulphate-­‐Poly	   Acrilamide	   Gel	  
Electrophoresis	  (SDS-­‐PAGE)	  A	   15%	   gel	   (unless	   otherwise	   stated)	   was	   prepared	   according	   to	   the	   Bio-­‐RAD	   mini	  protein	  II	  dual	  slab	  gel	  (Bio-­‐RAD,	  US)	  manufacturer’s	  instructions.	  Briefly,	  the	  two	  glass	  plates	  provided	  were	  thoroughly	  washed	  with	  detergent	  and	  70%	  EtOH	  to	  remove	  any	  dirt.	  Glass	  plates	  were	  subsequently	  placed	  onto	  the	  provided	  green	  plastic	  frames	  and	  the	  resolving	  gel	  was	  made	  by	  following	  the	  required	  recipe	  for	  reduced,	  non-­‐reduced	  or	   native	   samples	   (Appendix	   A).	   Immediately	   after	   pouring	   the	   resolving	   gel,	   1ml	   of	  ddH2O	  was	  added	   to	   the	   top.	  Gels	  were	  allowed	  to	  polymerize	   for	  a	   total	  of	  one	  hour	  and	  the	  stacking	  gel	  was	  then	  prepared.	  Once	  the	  ddH2O	  was	  drained	  out	  from	  the	  top	  of	  the	  resolving	  gel,	  the	  stacking	  gel	  mix	  was	  made	  by	  following	  the	  required	  recipe	  for	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reduced,	  non-­‐reduced	  or	  native	  samples	  (Appendix	  A)	  and	  was	  then	  poured,	   together	  with	   the	   required	   comb,	   which	   was	   placed	   and	   tithed	   preventing	   any	   air	   bubbles.	  Stacking	   gel	   was	   allowed	   to	   polymerize	   for	   one	   hour.	   Once	   set,	   glass	   plates	   were	  removed	  from	  the	  frames	  and	  inserted	  into	  the	  provided	  tanks	  filled	  with	  the	  required	  running	   buffer.	   1X	   TGS	   SDS	   Running	   buffer	   was	   used	   for	   reduced	   and	   non-­‐reduced	  samples,	   while	   TGS	   Running	   buffer	   not	   containing	   SDS	   was	   used	   for	   native	   samples	  (Appendix	  A).	  Samples	  were	  loaded	  according	  to	  the	  experiment	  carried	  out,	  together	  with	  5	  μl	  of	  225	  KDa	  broad	  range	  protein	  molecular	  weight	  marker	  (Promega,	  UK).	  The	  lid	  was	  placed	  on	  top	  of	  the	  tank	  and	  electrophoresis	  was	  performed	  for	  reduced	  and	  non-­‐reduced	  gels	  at	  a	  constant	  voltage	  of	  200V	  and	  for	  native	  gels	  at	  a	  constant	  current	  of	   20-­‐25mA.	   Protein	   bands	   were	   either	   stained	   with	   Coomassie	   blue	   (Appendix	   A)	  overnight	  (and	  subsequently	  de-­‐stained	  with	  Coomassie	  blue	  destain	  -­‐	  Appendix	  A)	  or	  transferred	  onto	  a	  nitrocellulose	  membrane	  for	  blotting	  (see	  section	  2.4.3).	  	  
	  
2.4.1.1. Preparation	  of	   reduced	  and	  non-­‐reduced	  venom	  samples	   for	  one-­‐
dimension	  SDS-­‐PAGE	  Venom	  samples	  were	  always	   loaded	   into	   the	  gel	   in	  a	   concentration	  of	  1λ.	   In	  order	   to	  reduce	  the	  sample,	  15μl	  of	  β-­‐mercaptoethanol	  were	  added	  to	  85μl	  of	  PLOB	  (Appendix	  A).	  The	  β-­‐mercaptoethanol	  was	  replaced	  with	  water	   for	  non-­‐reducing	  conditions.	  The	  venom	  was	  diluted	  to	  a	  concentration	  of	  1λ	  by	  adding	  20μl	  of	  venom	  (10mg/ml)	  to	  a	  solution	   containing	   80μl	   of	   1X	   PBS	   (Appendix	   A)	   and	   100μl	   of	   PLOB.	   The	   mix	   was	  subsequently	   boiled	   for	   10	   minutes	   to	   denature	   the	   proteins.	   Native	   venoms	   were	  prepared	  to	  the	  same	  concentration	  but	  without	  heat	  or	  β-­‐mercaptoethanol	  treatment.	  The	   samples	  were	   loaded	   in	   the	   required	   amount	   into	   the	   gel,	   or	   stored	   at	   -­‐20C	   for	  future	  use.	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2.4.2. Transfer	   of	   protein	   bands	   from	   Acrylamide	   gel	   to	   nitrocellulose	  
membrane	  (immunoblot)	  A	  nitrocellulose	  membrane	  was	  cut	  into	  the	  required	  dimensions	  of	  the	  gel	  and	  allowed	  to	  soak	   for	  several	  minutes	   in	   immunoblotting	   transfer	  buffer	   (Appendix	  A),	   together	  with	  six	  filter	  papers	  and	  two	  fibre	  pads.	  A	  roller	  was	  used	  to	  remove	  any	  remaining	  air	  bubbles.	  The	  gel	  holder	   cassette	  was	  assembled	   in	  a	   shallow	  vessel	   (Bio-­‐RAD,	  US)	  by	  leaving	  the	  red	  panel	  in	  contact	  with	  its	  bottom	  and	  the	  black	  panel	  slightly	  resting	  in	  angle	  against	   the	  wall.	  One	  of	   the	  pre-­‐soaked	   fibre	  pads	  was	  placed	  on	   top	  of	   the	  red	  panel,	  followed	  by:	  three	  filter	  papers,	  the	  SDS	  gel,	  the	  nitrocellulose	  membrane,	  three	  filter	  papers	  and	  finally,	  the	  other	  fibre	  pad.	  The	  cassette	  was	  closed	  and	  held	  firmly	  to	  then	  submerge	   it	   inside	   the	  blotting	   tank	  (Bio-­‐RAD,	  US)	  with	   the	  red	  panel	   facing	   the	  cathode.	  The	  tank	  was	  placed	  on	  top	  of	  a	  magnetic	  stirrer	  and	  subsequently	  filled	  with	  Immunoblotting	  buffer.	  An	   ice	  block	  and	  a	  magnetic	  bar	  were	  added	  and	  the	   transfer	  was	  carried	  out	  at	  constant	  voltage	  (100V)	  for	  one	  hour.	  	  Following	  the	  transfer,	  the	  gel	  was	   removed	   and	   further	   stained	   with	   Coomassie	   Blue	   overnight	   (and	   destained	   as	  described	   in	   section	   2.3.1)	   for	   reference	   on	   the	   quality	   of	   the	   transfer.	   The	  nitrocellulose	   membrane	   was	   also	   carefully	   removed	   from	   the	   cassette	   and	  subsequently	   stained	  with	   0.5%	  PonceauS	   (Appendix	  A)	   for	   two	  minutes	   in	   order	   to	  visualize	  the	  protein	  bands.	  Excess	  PonceauS	  was	  then	  washed	  with	  TBST	  (Appendix	  A)	  and	   the	  membrane	   trimmed	  using	  a	  scalpel	   (membrane	  was	   left	  complete	  or	  was	  cut	  into	   several	   strips,	   according	   to	   the	   experiment	   to	   carry	   out).	   The	   protein	  molecular	  weight	  marker	  area	  was	  removed	  from	  the	  membrane	  and	  its	  bands	  were	  marked	  with	  a	   ball	   pen.	   The	   membrane	   was	   then	   transferred	   into	   5%	   blocking	   solution	  (TBST/Skimmed	   milk)	   and	   left	   in	   a	   rocker	   at	   4	   C	   overnight,	   in	   order	   to	   block	   non-­‐specific	  sites.	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2.4.2.1. Probing	  with	  specific	  antibodies	  The	   blocked	   membrane	   was	   washed	   four	   times	   (15	   minutes	   each)	   with	   TBST	  (Appendix	  A)	  in	  the	  rocker	  and	  then	  incubated	  with	  the	  appropriate	  dilution	  of	  primary	  antibody,	   diluted	   1:200	   (unless	   stated	   otherwise)	   in	   5%	   blocking	   solution	   overnight.	  The	  membrane	  was	   left	   in	   the	   rocker	   at	   4	   C	   overnight.	   Subsequently,	   the	  membrane	  was	  washed	  again	  as	  described	  before	  and	  incubated	  with	  the	  appropriate	  secondary-­‐horseradish	   peroxidase	   conjugated	   antibody	   diluted	   1:5000	   in	   TBST.	   After	   the	  incubation,	  membrane	  was	  washed	  again	  as	  described	  before	  and	  subsequently	  placed	  into	  a	  developing	  solution	  containing	  1%PBS,	  50	  mg	  of	  DAB	  (Thermo	  scientific,	  USA)	  and	   25μl	   of	   hydrogen	   peroxide	   (Sigma,	   UK).	   After	   the	   bands	   were	   visualized,	   the	  membrane	  was	  washed	  with	  ddH20	  to	  prevent	  over-­‐development	  and	  was	  then	  left	  to	  dry.	  	  	  
	  
2.4.3. Enzyme-­‐linked	  immunoabsorbent	  assay	  (ELISA)	  Venoms	  (10mg/ml	  in	  1x	  PBS)	  were	  diluted	  to	  a	  1ng/µl	  solution	  in	  ELISA	  coating	  buffer	  (Appendix	  A).	  The	  solution	  was	  poured	  into	  a	  pipette	  reservoir	  before	  adding	  a	  total	  of	  100µL/well	   into	   the	   ELISA	   plate	   by	   using	   a	  multi	   channel	   pipette.	   The	   plate(s)	  were	  then	  wrapped	  in	  clingfilm	  and	  stored	  overnight	  at	  4°C.	  At	  the	  next	  morning,	  the	  plates	  were	  washed	  with	  TBST	  to	  remove	  the	  unbound	  protein.	  The	  washes	  were	  carried	  out	  by	   squeezing	   a	   bottle	   of	   TBST	   across	   the	   wells	   and	   subsequently	   washing	   the	   plate	  twice	   in	   the	   sink	   and	   then	  on	  paper	   towels	   to	   remove	   the	   excess	   liquid.	   The	  process	  was	  repeated	  for	  a	  total	  of	  two	  sets	  of	  three	  times	  waiting	  five	  minutes	  in	  between.	  In	  the	  last	  wash,	  the	  TBST	  was	  left	  in	  the	  plate	  and	  knocked	  off	  just	  before	  loading	  it	  with	  100µL/well	   with	   5%	   TBST/Milk.	   The	   plates	   were	   again	   wrapped	   in	   Clingfilm	   and	  incubated	  for	  a	  total	  of	  3	  hours	  at	  room	  temperature.	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Following	   the	   three	   hours,	   the	  TBST/Milk	  was	   removed	   and	   the	   plates	  were	  washed	  again.	   The	   primary	   antibodies	  were	   prepared	   in	   TBST/Milk	   in	   the	   required	   dilution.	  Plates	  (except	   for	  the	   first	  row	  of	  wells)	  were	   loaded	  with	  100µL	  and	  the	   first	  row	  of	  wells	  was	  loaded	  with	  the	  amount	  required	  to	  start	  the	  dilution	  throughout	  the	  plate.	  For	  example,	   for	  a	  1:5	  dilution,	  a	   total	  of	  120µL	  was	  added	  to	   then	  mix	  an	  pipette	  up	  20µL	  to	   then	  transfer	   it	   to	   the	  next	  set	  of	  wells.	  The	  method	  was	  repeated	  across	   the	  wells	   of	   the	   plates	   until	   one	   before	   to	   the	   last,	   where	   20µL	   were	   removed	   and	  discarded.	  The	   last	   set	  of	  wells	  was	  always	   left	  with	   just	  TBST/Milk	  as	  a	  control.	  The	  plates	  were	  wrapped	  in	  Clingfilm	  and	  stored	  overnight	  at	  4°C.	  Following	  the	  incubation	  overnight,	   flick	   off	   the	   IgG(or	   sera)/in	   TBST/Milk	   was	   flicked	   off	   and	   washed	   as	  described	  before.	  The	  secondary	  antibody	  was	  prepared	  to	  the	  required	  concentration	  and	   100µL	   of	   the	   mix	   were	   added	   to	   each	   well	   using	   a	   multi-­‐channel	   pipette	   and	  pipette	   reservoir.	   The	   plate(s)	   were	   then	   wrapped	   in	   Clingfilm	   and	   incubated	   for	   3	  hours	  at	  room	  temperature.	  After	  incubation,	  the	  secondary	  antibody	  mix	  was	  flick	  off	  and	  washed	  as	  described	  before.	  Enough	  substrate	  was	  made	  so	  that	  the	  plates	  could	  be	  read	  individually.	  For	  one	  96-­‐well	  plate	  was	  used	  200µL	  of	  ABTS	  solution,	  10ml	  of	  Citrate	  buffer,	  and	  10µL	  of	  Hydrogen	  peroxide	  (immediately	  before	  loading	  the	  wells).	  Absorbance	  measured	   at	   405	   nm	   using	   a	   BMG	   Labtech	   FLUOstar	   Omega	  microplate	  reader.	  
	  
2.5. Small	  scale	  affinity	  purification	  	  
2.5.1. Preparation	  of	  venom	  affinity	  purification	  columns	  1g	   of	   CNBr-­‐activated	   4	   Fast	   Flow	   Sepharose	   (GE	   Healthcare,	   UK)	   was	   swollen	   with	  1mM	   HCl,	   transferred	   to	   a	   3.5ml	   column	   (Bio-­‐Rad,	   UK)	   and	   washed	   two	   times	   with	  0.1M	  sodium	  hydrogen	  carbonate	  pH	  8.3.	  Five	  mg	  of	  venom	  or	  pool	  of	  venoms	  (1mg/ml	  0.1M	   sodium	   hydrogen	   carbonate	   pH	   8.3	   solution)	   were	   added	   to	   the	   column	   and	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stored	  at	  4°C	  overnight	  to	  couple	  the	  solution	  by	  end-­‐over-­‐end	  mixing.	  At	  the	  next	  day,	  columns	   were	   allowed	   to	   settle	   and	   excess-­‐liquid	   was	   drained.	   Active	   groups	   were	  blocked	   by	   repeating	   an	   end-­‐over-­‐end	   mixing	   for	   a	   total	   of	   2	   hours	   with	   1M	  Ethanolamine-­‐Cl	  pH	  9.0.	  Solution	  was	  subsequently	  washed	  and	  eluted	  in	  0.1M	  sodium	  phosphate	  pH	  7.5	  containing	  0.5M	  NaCl	  and	  0.1M	  glycine	  pH	  2.5	  containing	  0.1M	  HCl	  (respectively)	  before	  storage	  at	  4°C.	  	  
	  
2.5.2. Testing	  of	  IgG	  antisera	  Columns	  were	  equilibrated	  at	  room	  temperature	  and	  further	  washed	  with	  0.1M	  sodium	  phosphate	  pH	  7.5	   containing	  0.5M	  NaCl.	  3mg	  of	   IgG	  antisera	   (at	  1mg/ml	   in	   the	   same	  washing	   buffer)	   was	   added	   to	   the	   column	   and	   mixed	   by	   end-­‐over-­‐end	   overnight	   at	  room	  temperature.	  At	  the	  next	  day,	  columns	  were	  washed	  and	  eluted	  and	  the	  fraction	  containing	   the	   relevant	   IgGs	   (eluate)	   was	   concentrated	   using	   5	   kDa	   cut-­‐off	   Vivaspin	  columns	   (Sartorius	   Stedim	   Biotech,	   UK).	   Samples	   were	   quantified	   with	   an	   ND-­‐1000	  NanoDrop	   spectrophotometer	   (Labtech,	   UK)	   and	   results	   were	   calculated	   as	   a	  percentage	  of	  the	  3mg	  of	  IgG	  antisera	  added	  to	  each	  column.	  	  
	  
2.6. Neutralisation	  of	  venom	  lethality	  by	  the	  toxin-­‐specific	  IgG	  antisera.	  	  
2.6.1. Determination	  of	  venom	  lethalty	  (LD50)	  Taking	   into	  account	   that	   the	  determination	  of	   the	  median	   lethal	  dose	   (the	  amount	  of	  venom	   that	   kills	   50%	   of	   the	   injected	  mice)	   is	   an	   essential	   prerequisite	   to	   assess	   the	  antivenom	  efficacy,	  we	  determined	  the	  LD50	  for	  each	  of	  the	  four	  Echis	  venoms	  in	  mice	  by	   implementing	   the	   WHO-­‐recommended	   protocols	   (WHO	   2010).	   Briefly,	   varying	  doses	   of	   venom	  diluted	   in	   100μl	   PBS	  were	   injected	   intravenously	   by	   tail	   injection	   to	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groups	  of	  five	  male	  CD-­‐1	  mice	  (18–	  20g).	  7	  hours	  later,	  the	  number	  of	  surviving	  mice	  in	  each	  group	  was	  recorded.	  	  
	  
2.6.2. Determination	  of	  the	  IgG	  antisera	  effective	  dose	  (ED50)	  The	  median	  effective	  dose	  (ED50:	   the	   least	  amount	  of	  antivenom	  required	  to	  prevent	  death	   in	   50%	   of	   mice	   injected	   with	   five	   venom	   LD50s)	   was	   determined	   by	   using	   a	  previously	  described	  protocol	   (Cook	  et	  al.	   2010a).	  Briefly,	   several	   doses	   of	   the	   toxin-­‐specific	   IgG	   antisera	  were	  mixed	  with	   5	   venom	  LD50s	   and	   subsequently	  made	   up	   to	  200ml	  with	  PBS.	  The	  mixture	  was	  incubated	  at	  37uC	  for	  30	  minutes	  before	  injecting	  it	  to	  CD-­‐1	  mice	  belonging	  to	  groups	  of	  5.	  Seven	  hours	  later,	  the	  number	  of	  surviving	  mice	  was	  recorded	  and	  the	  median	  effective	  dose	  (ED50)	  were	  calculated.	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2.8. 	  Annexes	  
2.8.1. Molecular	  data	  of	  epitope-­‐string	  immunogen	  constructs	  	  	   	   	   	   Name	   Epitopes	  
in	  string	  
Bp	   Kb	  	   	   	  
PLA2	   PLA2Es	   10	   369	   0.369	  
SP	   SPEs	   10	   400	   0.400	  
CTL	  
CTL1Es	   10	   388	   0.388	  CTL2Es	   9	   388	   0.388	  
SVMP	  
MP	  
PI	  -­‐	  PII	   MET1Es	   12	   361	   0.361	  
PIII	  
MET2Es	   13	   463	   0.643	  MET3Es	   13	   514	   0.514	  
DIS	  
PII	   DIS1Es	   8	   493	   0.493	  
PIII	  
DISlike2Es	   10	   385	   0.385	  DISlike3Es	   10	   409	   0.409	  
CRI	   PIII	  
CRI1Es	   9	   412	   0.412	  CRI2Es	   9	   358	   0.358	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2.8.2. Concentration	   of	   pUC57	   purified	   plasmids	   (by	   miniprep)	   containing	  
epitope-­‐string	  inserts	  	  
Sample	  Name	   Concentration	  of	  product	  pUC57/PLA2Es	   153.1	  ηg/μl	  pUC57/SPEs	   238.8	  ηg/μl	  pUC57/CTL1Es	   210.3	  ηg/μl	  pUC57/CTL2Es	   150.6	  ηg/μl	  pUC57/MET1Es	   88.2	  ηg/μl	  pUC57/MET2Es	   280.6	  ηg/μl	  pUC57/MET3Es	   225.0	  ηg/μl	  pUC57/DIS1Es	   129.5	  ηg/μl	  pUC57/DISlike2Es	   36.9	  ηg/μl	  pUC57/DISlike3Es	   25.1	  ηg/μl	  pUC57/CRI1Es	   74.8	  ηg/μl	  pUC57/CRI2Es	   54.8	  ηg/μl	  pUC57/DIS2Es	   92.2	  ηg/μl	  	  
	  
2.8.3. Concentration	   of	   epitope-­‐string	   inserts	   and	  pVaxsec	   plasmid	   after	   being	  
digested	  with	  HindIII	  and	  XhoI.	  	  
Sample	  Name	  	   Concentration	  of	  product	  PLA2Es	   12.1	  ηg/μl	  SPEs	   18.6	  ηg/μl	  CTL1Es	   15.1	  ηg/μl	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CTL2Es	   11.2	  ηg/μl	  MET1Es	   11.4	  ηg/μl	  MET2Es	   19.5	  ηg/μl	  MET3Es	   16.3	  ηg/μl	  DIS1Es	   14.4	  ηg/μl	  DISlike2Es	   6.2	  ηg/μl	  DISlike3Es	   6.5	  ηg/μl	  CRI1Es	   74.8	  ηg/μl	  CRI2Es	   54.8	  ηg/μl	  DIS2Es	   2.76	  ηg/μl	  pVaxSec	   108.6	  ηg/μl	  
	  
2.8.4. Concentration	   of	   pVaxSec	   purified	   plasmids	   (by	   miniprep)	   containing	  
epitope-­‐string	  inserts.	  	  
Sample	  Name	  
	   Concentration	  of	  product	  pVaxSec/PLA2Es	   75.5	  ηg/μl	  pVaxSec/SPEs	   98.0	  ηg/μl	  pVaxSec/CTL1Es	   98.3	  ηg/μl	  pVaxSec/CTL2Es	   105.8	  ηg/μl	  pVaxSec/MET1Es	   91.9	  ηg/μl	  pVaxSec/MET2Es	   84.5	  ηg/μl	  pVaxSec/MET3Es	   88.6	  ηg/μl	  pVaxSec/DIS1Es	   129.5	  ηg/μl	  pVaxSec/DISlike2Es	   118.9	  ηg/μl	  pVaxSec/DISlike3Es	   110.9	  ηg/μl	  pVaxSec/CRI1Es	   87.6	  ηg/μl	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pVaxSec/CRI2Es	   102.	  ηg/μl	  pVaxSec/DIS2Es	   88.6	  ηg/μl	  
	  
	  
2.8.5. DNA	  alignment	  of	  sequencing	  result	  against	  immunogens	  PLA2_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  SPEs	  DNA	  sequence:	  
	  	  SP_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  SPEs	  DNA	  sequence:	  
	  	  
XCRXXXXXXXXXXT XXXXXXXXXXXXGT XXCT GGXGACGAXCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAG Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' NNNNGT NNCT GGNGACGANCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAG 1 PLA2_T7P_L03_FW
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 PLA2
CCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAAAGGCACACCCAAGGACGCCACAGAT AGAAAGAAGAGT T AT AGAT T T GAGAACGGGGACAT T A Majority
10 20 30 40 50 60 70
CCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAAAGGCACACCCAAGGACGCCACAGAT AGAAAGAAGAGT T AT AGAT T T GAGAACGGGGACAT T A 101 PLA2_T7P_L03_FW
- - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCAAAGGCACACCCAAGGACGCCACAGAT AGAAAGAAGAGT T AT AGAT T T GAGAACGGGGACAT T A 1 PLA2
T T T GT AAGAAAAACCT GAACACCT ACAACAAGAAAT AT CGGAAGAAAGGCAAGGGAAAGCCCCAGGACGCCACCGAT AGGAAGAAAACACT GCCAGACT G Majority
80 90 100 110 120 130 140 150 160 170
T T T GT AAGAAAAACCT GAACACCT ACAACAAGAAAT AT CGGAAGAAAGGCAAGGGAAAGCCCCAGGACGCCACCGAT AGGAAGAAAACACT GCCAGACT G 201 PLA2_T7P_L03_FW
T T T GT AAGAAAAACCT GAACACCT ACAACAAGAAAT AT CGGAAGAAAGGCAAGGGAAAGCCCCAGGACGCCACCGAT AGGAAGAAAACACT GCCAGACT G 77 PLA2
CAGCCCCAAGACT GAT CAGAAGAAAGAGAACCT CCAGACCT ACAAT AAGAAAT AT AAGAAAGGGCAGGGCAAGCCCCAGGACCCT T CCGAT AGGAAGAAA Majority
180 190 200 210 220 230 240 250 260 270
CAGCCCCAAGACT GAT CAGAAGAAAGAGAACCT CCAGACCT ACAAT AAGAAAT AT AAGAAAGGGCAGGGCAAGCCCCAGGACCCT T CCGAT AGGAAGAAA 301 PLA2_T7P_L03_FW
CAGCCCCAAGACT GAT CAGAAGAAAGAGAACCT CCAGACCT ACAAT AAGAAAT AT AAGAAAGGGCAGGGCAAGCCCCAGGACCCT T CCGAT AGGAAGAAA 177 PLA2
CAGAGAGAGAACGGAGAAAT CAT CT GT GAGAAGAAAGAAAAT GT GAAT ACT T ACGAT GAAAAAT ACAAAAAAGGAAAAGGCAAACCT AAAGAT GACACCG Majority
280 290 300 310 320 330 340 350 360 370
CAGAGAGAGAACGGAGAAAT CAT CT GT GAGAAGAAAGAAAAT GT GAAT ACT T ACGAT GAAAAAT ACAAAAAAGGAAAAGGCAAACCT AAAGAT GACACCG 401 PLA2_T7P_L03_FW
CAGAGAGAGAACGGAGAAAT CAT CT GT GAGAAGAAAGAAAAT GT GAAT ACT T ACGAT GAAAAAT ACAAAAAAGGAAAAGGCAAACCT AAAGAT GACACCG 277 PLA2
ACAGAGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
380 390 400
ACAGAGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCG 501 PLA2_T7P_L03_FW
ACAGAGGGT ACCCT CGAGT CT AGA                                                                             377 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGG 601 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT  701 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT G 801 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT G 901 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CA 1001 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GACCGACCT GT CCGGNGCCCT GAAT NNACT GCAANNNNNGGCANNGCGGCT AT CGT GGCT GGCCNGACGGGGNT CCT T GGNAACNNNNCT CGANNT T GNC 1101 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GAACCGGGAAGGACT NGCT GCT AT T GGCCAAAT GCCGGGCAGGAT NCCT GNNNNNACCT T GNNNNGGCNAAAAGNNCCNNNNGGNNNNNNNT GNNGGG 1201 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNGAANNNT T GANCCGGT ANNGNNCNT T NNNNNCAAGGNAANNNNNNNNNNGGANGGNNNNNGAAGGNNCCGGNNT NNNNNNNNAT NAT GGNAAAAANNN 1301 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGGNNNCGCNNNNNNNNNCCNNNNNNNGGNANNNNNNNNGGAANNNNNNNNNNNGGNNNNNNNNNNAANNNNNGGNNNNNNCNNNNT NNNNNNNGGGGNC 1401 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
XXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGNNGGGGNNNNNNT NNNNAANNNNNNN                                                                         1501 PLA2_T7P_L03_FW
                                                                                                     400 PLA2
Decoration 'Decoration #1': Shade (with solid black) residues that match PLA2 exactly.
XCRXXXXXXXXXXT XXXXXXXXAGGT CCXT GGAGAXGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' N' ' ' ' AGGT CCNT GGAGANGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCC 1 SP_T7P_N03
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 SP
GGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCCT CCCCT CCT CCCCT CCCT CT GT CGGGT CT AAAAAAGGCGGCGCT GAAT GT AAT AT CAACGAGCAT Majority
10 20 30 40 50 60 70
GGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCCT CCCCT CCT CCCCT CCCT CT GT CGGGT CT AAAAAAGGCGGCGCT GAAT GT AAT AT CAACGAGCAT  101 SP_T7P_N03
- - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCCT CCCCT CCT CCCCT CCCT CT GT CGGGT CT AAAAAAGGCGGCGCT GAAT GT AAT AT CAACGAGCAT  1 SP
AAGAAACT GAGT CT GCCAAAT AAGGACCAGCAGAAGCGCAAGAAACT GAGCCT CCCT T CCAACCCT CCCAGGCT GAAGAAGGGCGGCGCCGAGT GCGACA Majority
80 90 100 110 120 130 140 150 160 170
AAGAAACT GAGT CT GCCAAAT AAGGACCAGCAGAAGCGCAAGAAACT GAGCCT CCCT T CCAACCCT CCCAGGCT GAAGAAGGGCGGCGCCGAGT GCGACA 201 SP_T7P_N03
AAGAAACT GAGT CT GCCAAAT AAGGACCAGCAGAAGCGCAAGAAACT GAGCCT CCCT T CCAACCCT CCCAGGCT GAAGAAGGGCGGCGCCGAGT GCGACA 79 SP
T CAACGAACACAAGAAAAAGACCAAGAGAAAT AAGGAT CAGCAGAAAAAGAAACT GCCAAGCAACCCACCCT CT GT GGGGAGT AAGAAAGAGT GT AACAG Majority
180 190 200 210 220 230 240 250 260 270
T CA CGAACACAAGAAAAAGACC AGAGAAAT AAGGAT CAGCAGAAAAAGAAACT CCAAGCA CCACCCT CT T GGGGAGT AAGA AGAGT GT AACAG 301 SP_T7P_N03
T CAACGAACACAAGAAAAAGACCAAGAGAAAT AAGGAT CAGCAGAAAAAGAAACT GCCAAGCAACCCACCCT CT GT GGGGAGT AAGAAAGAGT GT AACAG 179 SP
GAAT AGACAT CGGT CT CT CAAGAAAAAGAAT AAGAGAAACAAAGAT GAGAT GAT GAAGAAACT GCCAAGCAAT CCAGCCAGCGT CGGT T CCGGGT ACCCT Majority
280 290 300 310 320 330 340 350 360 370
GAAT AGACAT CGGT CT CT CAAGAAAAAGAAT AAGAGAAACAAAGAT GAGAT GAT GAAGAAACT GCCAAGCAAT CCAGCCAGCGT CGGT T CCGGGT ACCCT  401 SP_T7P_N03
GAAT AGACAT CGGT CT CT CAAGAAAAAGAAT AAGAGAAACAAAGAT GAGAT GAT GAAGAAACT GCCAAGCAAT CCAGCCAGCGT CGGT T CCGGGT ACCCT  279 SP
CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
380
CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T G CC 501 SP_T7P_N03
CGAGT CT AGA                                                                                           379 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGC 601 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAA 701 SP_T7P_N03
                                                                                                   388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT  801 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGG 901 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T NNT T T T GNCNAGACCGACCT GT CC 1001 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGNGCCCT GAAT GACT T GCAAANNNNGGNANNGCGGCT AT CNGGGCT GGCNNGAAGGGGNT CCT T GGCANCT NGGCT CANNT T GNCCT GAANNNGGAAGG 1101 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNT GGT T GCNNT NGGNNNAAT GCCGGGCAGGAT T CCT GGCT NNNNCCT NNCCNNNNCAGAAAGT ACCNNNNGGNNGANNNANNGNNNNNNGNNNANT T NN 1201 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NCGGNNNNNNNCCT T NNNNNCCNNNNNAAT CNGNNNNNNNNANNNNNNGNAAGGNNCCGNNT T NNNNNNGNNAANNNNNAANNANNNNGGNNNNNNNNNN 1301 SP_T7P_N03
                                                                                                     388 SP
XXXXXXXXXXX Majority
AANNNNCCAGG                                                                                          1401 SP_T7P_N03
                                                                                                     388 SP
Decoration 'Decoration #1': Shade (with solid black) residues that match SP exactly.
	   	   39	  
CTL1_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  CTL1Es	  DNA	  sequence	  
	  	  CTL2_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  CTL2Es	  DNA	  sequence:	  
	  	  	  	   	  	  	  	  	  	  
XCRXXXXXXXXXXT XXXXXXXXAAAAXXGGGAAAGACAACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCCGG Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' AAAANNGGGAAAGACAACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCCGG 1 CTL1_T7P_P03
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 CTL1
CCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAAACAGT GCT CCAGCGAGT GGT CCGAT GGT AGCAAAAAAGT CT T CAGCGAAT ACAAAAAT T GGGT CGA Majority
10 20 30 40 50 60 70 80
CCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAAACAGT GCT CCAGCGAGT GGT CCGAT GGT AGCAAAAAAGT CT T CAGCGAAT ACAAAAAT T GGGT CGA 101 CTL1_T7P_P03
- - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCAAACAGT GCT CCAGCGAGT GGT CCGAT GGT AGCAAAAAAGT CT T CAGCGAAT ACAAAAAT T GGGT CGA 1 CTL1
T AAAAAGGAAAAGT T CT GCAACCGGT GGGACGAT GGGAAGAAACGCGAT T GCGAGT GGAAGT GGT CT GACGGCAAGAAGAAAGT GAT CAACGAGT ACAAG Majority
90 100 110 120 130 140 150 160 170 180
T AAAAAGGAAAAGT T CT GCAACCGGT GGGACGAT GGGAAGAAACGCGAT T GCGAGT GGAAGT GGT CT GACGGCAAGAAGAAAGT GAT CAACGAGT ACAAG 201 CTL1_T7P_P03
T AAAAAGGAAAAGT T CT GCAACCGGT GGGACGAT GGGAAGAAACGCGAT T GCGAGT GGAAGT GGT CT GACGGCAAGAAGAAAGT GAT CAACGAGT ACAAG 81 CTL1
ACCT GGGAGAAGAAGAAGT T CT GT ACAGAGCAGGCCAAT GGCGGAAAGAAAT GGAAGT GGAGCGACGGAGAAAGGCT GGAT AAGAAGGCCT T CGACAAAC Majority
190 200 210 220 230 240 250 260 270 280
ACCT GGGAGAAGAAGAAGT T CT GT ACAGAGCAGGCCAAT GGCGGAAAGAAAT GGAAGT GGAGCGACGGAGAAAGGCT GGAT AAGAAGGCCT T CGACAAAC 301 CTL1_T7P_P03
ACCT GGGAGAAGAAGAAGT T CT GT ACAGAGCAGGCCAAT GGCGGAAAGAAAT GGAAGT GGAGCGACGGAGAAAGGCT GGAT AAGAAGGCCT T CGACAAAC 181 CTL1
CCAAGAGGT CCAGAGAT AAGAAAAAGT T T T GT T CAGAGCAGGCAAAT GGGGGCAAGAAGCGGGACCAGAGCAAAAAGCAGCACT GT T CCGGGT ACCCT CG Majority
290 300 310 320 330 340 350 360 370 380
CCAAGAGGT CCAGAGAT AAGAAAAAGT T T T GT T CAGAGCAGGCAAAT GGGGGCAAGAAGCGGGACCAGAGCAAAAAGCAGCACT GT T CCGGGT ACCCT CG 401 CTL1_T7P_P03
CCAAGAGGT CCAGAGAT AAGAAAAAGT T T T GT T CAGAGCAGGCAAAT GGGGGCAAGAAGCGGGACCAGAGCAAAAAGCAGCACT GT T CCGGGT ACCCT CG 281 CTL1
AGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT  501 CTL1_T7P_P03
AGT CT AGA                                                                                             381 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAG 601 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACC 701 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CA 801 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT  901 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAANCGACCT GGCCGGT  1001 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GCCT GAAT GAACT GCAAGANNAGGNACGCGGCNAT CGGNCT GGCACGACGGNGT T CT T GCCNACT GT GCNNANNT T GCCNT GAANNGGAAGGANNGCT GN 1101 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNT GGNCAANNCCGGGCNNGNNNNNGGCNCNNCCT T GGCCNGGCGNANANNNCCT CNNNT NNANNAAT GNNNNNNNNAANNNT NNACNGNNACGGCCT T N 1201 CTL1_T7P_P03
                                                                                                     388 CTL1
XXXXXXXXXX Majority
NNNCNNNGGN                                                                                           1301 CTL1_T7P_P03
                                                                                                     388 CTL1
Decoration 'Decoration #1': Shade (with solid black) residues that match CTL1 exactly.
XCRXXXXXXXXXXT XXXBXXXXXXXXXGXXCXXT GGAGACAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' B ' ' ' ' NNNNNGNNCNNT GGAGACAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCC 1 CTL2_T7P_B05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 CTL2
CAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAGAGAT CAGT CT AAAAAACAGCAT T GT AGT AAAAAAGCCGT GGAT GAACCT AAAACT T GGG Majority
10 20 30 40 50 60 70
CAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCAGAGAT CAGT CT AAAAAACAGCAT T GT AGT AAAAAAGCCGT GGAT GAACCT AAAACT T GGG 101 CTL2_T7P_B05
- - - - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCAGAGAT CAGT CT AAAAAACAGCAT T GT AGT AAAAAAGCCGT GGAT GAACCT AAAACT T GGG 1 CTL2
AGGAGGCAAAGAAAT T CT GCACT CAGCAGCACAAGGGGAGCCAT AAGAAAT GCAGCT CCT CT GAGT GGAGT GACGGT T CAAAGAAAGCCGT GGAT GAGCC Majority
80 90 100 110 120 130 140 150 160 170
AGGAGGCAAAGAAAT T CT GCACT CAGCAGCACAAGGGGAGCCAT AAGAAAT GCAGCT CCT CT GAGT GGAGT GACGGT T CAAAGAAAGCCGT GGAT GAGCC 201 CTL2_T7P_B05
AGGAGGCAAAGAAAT T CT GCACT CAGCAGCACAAGGGGAGCCAT AAGAAAT GCAGCT CCT CT GAGT GGAGT GACGGT T CAAAGAAAGCCGT GGAT GAGCC 74 CTL2
CAAAACCT GGGCT GACAAGAAAGAACAGT ACT GCACAGAGCAGGAAAACGGCGGAAAGAAAAT CGGACT GAGGGAT CACT CT GAGAAGCAGCAGT GT AAG Majority
180 190 200 210 220 230 240 250 260 270
CAAAACCT GGGCT GACAAGAAAGAACAGT ACT GCACAGAGCAGGAAAACGGCGGAAAGAAAAT CGGACT GAGGGAT CACT CT GAGAAGCAGCAGT GT AAG 301 CTL2_T7P_B05
CAAAACCT GGGCT GACAAGAAAGAACAGT ACT GCACAGAGCAGGAAAACGGCGGAAAGAAAAT CGGACT GAGGGAT CACT CT GAGAAGCAGCAGT GT AAG 174 CTL2
AAAGAACCT AAGACCT GGGCAGACGCAGAGAAGAAGAAGT T T T GT CGGCAGCAGCAT AAAGGCAGCCAT GGGT ACCCT CGAGT CT AGAXXXXXXXXXXXX Majority
280 290 300 310 320 330 340 350 360
AAAGAACCT AAGACCT GGGCAGACGCAGAGAAGAAGAAGT T T T GT CGGCAGCAGCAT AAAGGCAGCCAT GGGT ACCCT CGAGT CT AGAGGGCCCGT T T AA 401 CTL2_T7P_B05
AAAGAACCT AAGACCT GGGCAGACGCAGAGAAGAAGAAGT T T T GT CGGCAGCAGCAT AAAGGCAGCCAT GGGT ACCCT CGAGT CT AGA             274 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
ACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT G 501 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T G 601 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGC 701 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGG 801 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACA 901 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAGACCGACCT GT CCGGT GCCCT GAAT GAACT GCAAG 1001 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
ACGAGGCAGCGCGGCT AT CGT GGCT GGCCACGACNGGCGT T CCT T GCGCANNT GT GCT CGACGT T GT NNNT GAANCNGGGAANGGACT GGCT GCT AT T GG 1101 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GCGAANNGCCGGGGCAGGACT CCT GGCANCNNCCT T GGT CCT GCCAAAAANNNT CNNNNNNGGCT NNNNNNAT GNGGNGGNNGGNNNNNNT T NNT CNGGN 1201 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNCNNGCCAT T NNNNNNCAANGGAAANT NNNNNNNNNGNNNCCNNNNNCGGAT NGAACCNGNCT NNNNANNNNGNNNNNNGGNNAAAAAANNNNGGGNNN 1301 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNCNNNCAAAT GGT T NCAGNNNNNGNNNNANNNCCAANGNNNNNNNNNCNGNNNNT NGGNNNNNNNNNNNNNANNNNNGGGNNNNNNNCNNNNNNNNNA 1401 CTL2_T7P_B05
                                                                                                     361 CTL2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNANNGGNNNNNNNNNGGGNNNNNNNNAAANNNNNNNNNCCNNNNNNNGNAANANNNGNNNNNNGNNNNNNNNNNNNNNNNNNNNNNNNNNNNN    1501 CTL2_T7P_B05
                                                                                                     361 CTL2
Decoration 'Decoration #1': Shade (with solid black) residues that match CTL2 exactly.
	   	   40	  
MET1_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  MET1Es	  DNA	  sequence:	  
	  	  MET2_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  MET2Es	  DNA	  sequence:	  
	  	  	  	  	  	  	  
XCRXXXXXXXXXXT XXXDXXXXXXXXXXACCAT GGXAXACGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' D' ' ' ' NNNNNNACCAT GGNANACGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCC 1 MET1_T7P_D05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 MET1
CAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACAAAAAACAAAGGAGACCT CACCGCT GT CAAAAAAGGGAAT CAGT GT AACT GCGGGGCCA Majority
10 20 30 40 50 60 70
CAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACAAAAAACAAAGGAGACCT CACCGCT GT CAAAAAAGGGAAT CAGT GT AACT GCGGGGCCA 101 MET1_T7P_D05
- - - - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCACAAAAAACAAAGGAGACCT CACCGCT GT CAAAAAAGGGAAT CAGT GT AACT GCGGGGCCA 1 MET1
AT GGT AAAAAGAT CT GGAAT AAGAGAGACCT GAT CACT GT GAAGAAAACCAAGAACAAT AACGAT CT CACT GCT AT T AAGAAAGGGAAT CAGT GCAACT G Majority
80 90 100 110 120 130 140 150 160 170
AT GGT AAAAAGAT CT GGAAT AAGAGAGACCT GAT CACT GT GAAGAAAACCAAGAACAAT AACGAT CT CACT GCT AT T AAGAAAGGGAAT CAGT GCAACT G 201 MET1_T7P_D05
AT GGT AAAAAGAT CT GGAAT AAGAGAGACCT GAT CACT GT GAAGAAAACCAAGAACAAT AACGAT CT CACT GCT AT T AAGAAAGGGAAT CAGT GCAACT G 74 MET1
T GGCGCCGCT GGAAAGAAAAT CT GGAGCAAT GGT GACCT GAT T ACCGT CACAT CCAAGAAAACAAAGAAT AACGGCGACCT CACT GCAAT CAAGAAAGGA Majority
180 190 200 210 220 230 240 250 260 270
T GGCGCCGCT GGAAAGAAAAT CT GGAGCAAT GGT GACCT GAT T ACCGT CACAT CCAAGAAAACAAAGAAT AACGGCGACCT CACT GCAAT CAAGAAAGGA 301 MET1_T7P_D05
T GGCGCCGCT GGAAAGAAAAT CT GGAGCAAT GGT GACCT GAT T ACCGT CACAT CCAAGAAAACAAAGAAT AACGGCGACCT CACT GCAAT CAAGAAAGGA 174 MET1
AT T AGGT GCGAT T GT GGGGCCAAT GGCAAGAAGACCT GGT CT AAGAGAGAT AT GAT CACAGT GAAGAAAGT CAAGT ACAACAGCGACCT GACAGCCAT T A Majority
280 290 300 310 320 330 340 350 360 370
AT T AGGT GCGAT T GT GGGGCCAAT GGCAAGAAGACCT GGT CT AAGAGAGAT AT GAT CACAGT GAAGAAAGT CAAGT ACAACAGCGACCT GACAGCCAT T A 401 MET1_T7P_D05
AT T AGGT GCGAT T GT GGGGCCAAT GGCAAGAAGACCT GGT CT AAGAGAGAT AT GAT CACAGT GAAGAAAGT CAAGT ACAACAGCGACCT GACAGCCAT T A 274 MET1
AGAAAGGGGAT CAGT GT AAT T GCGGT GCCAACGGGAAGAAGT T CGT CAAGT AT AAT AGT GAT T CAACAGCAGGGT ACCCT CGAGT CT AGAXXXXXXXXXX Majority
380 390 400 410 420 430 440 450 460
AGAAAGGGGAT CAGT GT AAT T GCGGT GCCAACGGGAAGAAGT T CGT CAAGT AT AAT AGT GAT T CAACAGCAGGGT ACCCT CGAGT CT AGAGGGCCCGT T T  501 MET1_T7P_D05
AGAAAGGGGAT CAGT GT AAT T GCGGT GCCAACGGGAAGAAGT T CGT CAAGT AT AAT AGT GAT T CAACAGCAGGGT ACCCT CGAGT CT AGA           374 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCAC 601 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT  701 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGC 801 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACA 901 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGANAGGCT AT T CGGCT AT GACT GGGCACAACAGA 1001 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GCAAGACCGACCT GT CCGGNGNCCT GAAT GAACT GCAA 1101 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNGGCNNNNCGGCNAT NGT GGCT GGCANNNNNGGCNNT CNT T GNNCNNNT GGNNNCACNT T GCCNT GAANCGGAANGGANGGNT GCAT T NGGNNAAN 1201 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NGNNGGGCAGGAT NCCT GGCT NNNACCT T NNNNNNGNNNNNAANT ACNNNNT NGGNNNNNGAT GGGNNNGGT GGAANNT T NGNNCCNNNNNNNNCCT T NN 1301 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNCANNNAANNNNNNNNNGGGNNNCNNT T NNNNNNNAACCNNNNT NNNNAANNNNNNT NNNAAAAANNNNNGGNNNNNNNNCCNAANNNCNNNNNNNN 1401 MET1_T7P_D05
                                                                                                     463 MET1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NAGNNNNNNNNNNGANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNGGNN                                                  1501 MET1_T7P_D05
                                                                                                     463 MET1
Decoration 'Decoration #1': Shade (with solid black) residues that match MET1 exactly.
XCRXXXXXXXXXXT XXXXXXXXXXAXXXXGAXXCCAT GGAXGACAGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACG Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' NNANNNNGANNCCAT GGANGACAGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACG 1 MET2_T7P_F05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 MET2
CGGCCCAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCT T CT GGT CCAAT AGGGAT CT GAT T AAT GT CAAAAAAGAAAACT ACT GT AACT GCGG Majority
10 20 30 40 50 60
CGGCCCAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCT T CT GGT CCAAT AGGGAT CT GAT T AAT GT CAAAAAAGAAAACT ACT GT AACT GCGG 101 MET2_T7P_F05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCT T CT GGT CCAAT AGGGAT CT GAT T AAT GT CAAAAAAGAAAACT ACT GT AACT GCGG 1 MET2
T CCAAACCT GAAAAAAT T CCGGCGGT AT AACGGCAACCT GCGAAAGAT CAGGAGAAAAAT T AAGAAACACGACGGCAACCAGT GCAAT T GT GGAGCAAAG Majority
70 80 90 100 110 120 130 140 150 160
T CCAAACCT GAAAAAAT T CCGGCGGT AT AACGGCAACCT GCGAAAGAT CAGGAGAAAAAT T AAGAAACACGACGGCAACCAGT GCAAT T GT GGAGCAAAG 201 MET2_T7P_F05
T CCAAACCT GAAAAAAT T CCGGCGGT AT AACGGCAACCT GCGAAAGAT CAGGAGAAAAAT T AAGAAACACGACGGCAACCAGT GCAAT T GT GGAGCAAAG 69 MET2
AAAT GGAACCAGAGGGAT CT CAT CAAT GT GACT AAGAAAGAGAACCAT T GCAAT T GT GGCCCAAACT CCAAGAAAGAAAT GT T CCGGAAGT ACAAT AGCG Majority
170 180 190 200 210 220 230 240 250 260
AAAT GGAACCAGAGGGAT CT CAT CAAT GT GACT AAGAAAGAGAACCAT T GCAAT T GT GGCCCAAACT CCAAGAAAGAAAT GT T CCGGAAGT ACAAT AGCG 301 MET2_T7P_F05
AAAT GGAACCAGAGGGAT CT CAT CAAT GT GACT AAGAAAGAGAACCAT T GCAAT T GT GGCCCAAACT CCAAGAAAGAAAT GT T CCGGAAGT ACAAT AGCG 169 MET2
ACT CCACCGCCAAGAAAAACGGAAGT T GCAAT T GT CCCGACAAGT CT AAGAAAT T CT GGAGT AAT AGAGAT CT GAT CCCT GT CAAGAAAGAGCAGT T T T G Majority
270 280 290 300 310 320 330 340 350 360
ACT CCACCGCCAAGAAAAACGGAAGT T GCAAT T GT CCCGACAAGT CT AAGAAAT T CT GGAGT AAT AGAGAT CT GAT CCCT GT CAAGAAAGAGCAGT T T T G 401 MET2_T7P_F05
ACT CCACCGCCAAGAAAAACGGAAGT T GCAAT T GT CCCGACAAGT CT AAGAAAT T CT GGAGT AAT AGAGAT CT GAT CCCT GT CAAGAAAGAGCAGT T T T G 269 MET2
CACCT GT GGGGCCAAGT CAAAGAAACGGAAGT AT ACAGGCGACAT CAT T GCT AT T AAGAAAAGCCGCAGT T GT AAAT GT GCCGCAT CCCCAAAGAAAAT C Majority
370 380 390 400 410 420 430 440 450 460
CACCT GT GGGGCCAAGT CAAAGAAACGGAAGT AT ACAGGCGACAT CAT T GCT AT T AAGAAAAGCCGCAGT T GT AAAT GT GCCGCAT CCCCAAAGAAAAT C 501 MET2_T7P_F05
CACCT GT GGGGCCAAGT CAAAGAAACGGAAGT AT ACAGGCGACAT CAT T GCT AT T AAGAAAAGCCGCAGT T GT AAAT GT GCCGCAT CCCCAAAGAAAAT C 369 MET2
T GGAGT AAAGGCGACCT CAT CAAT GT GGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
470 480 490 500 510
T GGAGT AAAGGCGACCT CAT CAAT GT GGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCA 601 MET2_T7P_F05
T GGAGT AAAGGCGACCT CAT CAAT GT GGGGT ACCCT CGAGT CT AGA                                                       469 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GA 701 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT  801 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GG 901 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGC 1001 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCNNNT T CGGCT GT CAGNGCAGG 1101 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGCGCCCGGT NNNT T T T GCAAGACCNNCT GT CCGGNNCCT GAAT GANNGCAAANNAAGCANNNNGNNNNNNGGCT GGCACAANGGNNNT NNT NGNNNNNG 1201 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNCNNT T T NCACNGAACCGNNANNNNNGNNNNNNNT GGNCNAAT GCNNGGNNNNNT CCNNNNNCT NNNCT T NNNNNNNNAAAANNNNNCT CNNNNNNN 1301 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNNGGNNNNNNNNANNT NNNNCGGNNNNGCCT T NNNANNANNNAANT NNNNNNNNNNNNNNNNCT NNGGNNNNNNNT NNNNNNNNNNNNNNNNAAAA 1401 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNGNNCCNCNNNNNNNNNNNNNNNNNNNNNNCNAAGGNNNCNNNNNNNNNNNNGNNNNNNNNNNNNNNNNNNNNT NNNNNNNNNNNNNGGGNNGNNN 1501 MET2_T7P_F05
                                                                                                     514 MET2
XXXXXXXX Majority
NNNNNNNN                                                                                             1601 MET2_T7P_F05
                                                                                                     514 MET2
Decoration 'Decoration #1': Shade (with solid black) residues that match MET2 exactly.
	   	   41	  
MET3_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  MET3Es	  DNA	  sequence:	  
	  	  DIS1_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  DIS1Es	  DNA	  sequence:	  
	  	  	  	  	  	  	  	  
XCRXXXXXXXXXXT XXXHXXXXXXXXGT AXXXT GGAGACGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCA Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' H' ' ' ' NNNNGT ANNNT GGAGACGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCA 1 MET3_T7P_H05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 MET3
GCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACAAGT T CCT GCACCT GT CACGGT AAT T CAAAAAAGT T CT GGT CCAACGGCGAT CT CAT CAAT Majority
10 20 30 40 50 60 70
GCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACAAGT T CCT GCACCT GT CACGGT AAT T CAAAAAAGT T CT GGT CCAACGGCGAT CT CAT CAAT  101 MET3_T7P_H05
- - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCACAAGT T CCT GCACCT GT CACGGT AAT T CAAAAAAGT T CT GGT CCAACGGCGAT CT CAT CAAT  1 MET3
GT CAAAAAAGT CCCCT CCT GT ACT T GCCAGACAAAGGCCAAGAAAT T CAGGAGAAAGT ACGGACGGAACCT GCGCAAGAAAGGCAACCACT GCAAT T GT G Majority
80 90 100 110 120 130 140 150 160 170
GT CAAAAAAGT CCCCT CCT GT ACT T GCCAGACAAAGGCCAAGAAAT T CAGGAGAAAGT ACGGACGGAACCT GCGCAAGAAAGGCAACCACT GCAAT T GT G 201 MET3_T7P_H05
GT CAAAAAAGT CCCCT CCT GT ACT T GCCAGACAAAGGCCAAGAAAT T CAGGAGAAAGT ACGGACGGAACCT GCGCAAGAAAGGCAACCACT GCAAT T GT G 76 MET3
GAGCT AACT CT AAGAAAT T T T GGAGT AAT CGAGACCT CAT CACT GT GAAGAAACAT GACGAGAACCAGT GT GAT GGGGCAAAT AAGAAAAGAAT GGT CGA Majority
180 190 200 210 220 230 240 250 260 270
GAGCT AACT CT AAGAAAT T T T GGAGT AAT CGAGACCT CAT CACT GT GAAGAAACAT GACGAGAACCAGT GT GAT GGGGCAAAT AAGAAAAGAAT GGT CGA 301 MET3_T7P_H05
GAGCT AACT CT AAGAAAT T T T GGAGT AAT CGAGACCT CAT CACT GT GAAGAAACAT GACGAGAACCAGT GT GAT GGGGCAAAT AAGAAAAGAAT GGT CGA 176 MET3
AAAGT ACAACGGT AAT CT GAAGAAAACCAGCT T CT GCACAT GT CACGCCAAT AGCAAGAAAT GGT CCACT AGGGACCAGAT T ACCGT GCAGAAGAAAAAG Majority
280 290 300 310 320 330 340 350 360 370
AAAGT ACAACGGT AAT CT GAAGAAAACCAGCT T CT GCACAT GT CACGCCAAT AGCAAGAAAT GGT CCACT AGGGACCAGAT T ACCGT GCAGAAGAAAAAG 401 MET3_T7P_H05
AAAGT ACAACGGT AAT CT GAAGAAAACCAGCT T CT GCACAT GT CACGCCAAT AGCAAGAAAT GGT CCACT AGGGACCAGAT T ACCGT GCAGAAGAAAAAG 276 MET3
AAAT ACT GCACCT GT GAGGAT T AT CCCAAGAAGT GGT CT AAAAAGGACCAGAT T AAGGT GCAGAAAAAAGGAAACCAGT GT GAT T GT GGAGCCAAGT CT G Majority
380 390 400 410 420 430 440 450 460 470
AAAT ACT GCACCT GT GAGGAT T AT CCCAAGAAGT GGT CT AAAAAGGACCAGAT T AAGGT GCAGAAAAAAGGAAACCAGT GT GAT T GT GGAGCCAAGT CT G 501 MET3_T7P_H05
AAAT ACT GCACCT GT GAGGAT T AT CCCAAGAAGT GGT CT AAAAAGGACCAGAT T AAGGT GCAGAAAAAAGGAAACCAGT GT GAT T GT GGAGCCAAGT CT G 376 MET3
GGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
480 490
GGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T  601 MET3_T7P_H05
GGT ACCCT CGAGT CT AGA                                                                                   476 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GG 701 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAG 801 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCG 901 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAAAGG 1001 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT AT T CGGCT AT GACT GGGCANANNAAAAAT CGGCT GCT CT GAT GCCGCCGT GT NCCGGCT GT CACCNNAGGGGCGCCCGGT T NT T T T NNCAANACCGAN 1101 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GT CCGNNNNCCT GAAT GAAT T GNAAANNAAGNAACCGGNNNNNNNNGGNNGGCNNNAANGGNNNT CCT T GNNNANNNNGGT CCANNT T NNNNNNNAAN 1201 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGNAANGANT GGNNNNT AT T GGNNNAANGCNGGGGNNNNNNCCT NNNNNCCCNT NGNNNNNNNAGAANNNNNCNNNNNNNNAGNNNNNGGGNNGNNNNNA 1301 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNT NNNNCNNT AT T GGNNNNNNNNNNANNNNNNNNNNNNNNNNACNNT NNNNNNNNNNNNNNT NNNNNANNNNNNNNGNAANANNNNGNNNNNNNNNANN 1401 MET3_T7P_H05
                                                                                                     493 MET3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNCCCNNNGGNNNNNCCCNNNNNNAANNCNNNNNNNNNNNNNNNNNAAAANNNNNNNNNNCNNN                                    1501 MET3_T7P_H05
                                                                                                     493 MET3
Decoration 'Decoration #1': Shade (with solid black) residues that match the Consensus exactly. 
XCRXXXXXXXXXXT XXXXXXXXXXXAXGAXXCCT GGAXXAXAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' NNNANGANNCCT GGANNANAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGC 1 DIS1_T7P_J05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 DIS1
CCAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACCGAT ACT GT CT CAACACCCGT CT CAGGAAAAAAGGACT AT T GT AAT GGT AAAACT T GC Majority
10 20 30 40 50 60 70
CCAGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCACCGAT ACT GT CT CAACACCCGT CT CAGGAAAAAAGGACT AT T GT AAT GGT AAAACT T GC 101 DIS1_T7P_J05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCACCGAT ACT GT CT CAACACCCGT CT CAGGAAAAAAGGACT AT T GT AAT GGT AAAACT T GC 1 DIS1
GAT T GCCCACGAAACCCCAAAAAAT GCGAGT CT GGCCCAT GCT GT GACAACT GCAAGAAAACCGAT ACAGT GAGT ACACCCGGCT CAGGAAAGAAAGACG Majority
80 90 100 110 120 130 140 150 160 170
GAT T GCCCACGAAACCCCAAAAAAT GCGAGT CT GGCCCAT GCT GT GACAACT GCAAGAAAACCGAT ACAGT GAGT ACACCCGGCT CAGGAAAGAAAGACG 201 DIS1_T7P_J05
GAT T GCCCACGAAACCCCAAAAAAT GCGAGT CT GGCCCAT GCT GT GACAACT GCAAGAAAACCGAT ACAGT GAGT ACACCCGGCT CAGGAAAGAAAGACG 73 DIS1
AT AT GGACGAT T ACT GCAGCGGAAT CACT T CCGACT GT GCCAGGAAT CCCAAGAAAGAAGGGGCCGAT T GT GCCAGCGGT CCT T GCT GT AAGAAAACT GA Majority
180 190 200 210 220 230 240 250 260 270
AT AT GGACGAT T ACT GCAGCGGAAT CACT T CCGACT GT GCCAGGAAT CCCAAGAAAGAAGGGGCCGAT T GT GCCAGCGGT CCT T GCT GT AAGAAAACT GA 301 DIS1_T7P_J05
AT AT GGACGAT T ACT GCAGCGGAAT CACT T CCGACT GT GCCAGGAAT CCCAAGAAAGAAGGGGCCGAT T GT GCCAGCGGT CCT T GCT GT AAGAAAACT GA 173 DIS1
CACCGT GAGCACCT CCGT CT CT GGCAAGAAAAAGGGAGAT T GGAT GGAT GAT T ACT GT ACT GGGAT T AGCAGCGAT T GCCCCCGAAACCCCCT GGGGT AC Majority
280 290 300 310 320 330 340 350 360 370
CACCGT GAGCACCT CCGT CT CT GGCAAGAAAAAGGGAGAT T GGAT GGAT GAT T ACT GT ACT GGGAT T AGCAGCGAT T GCCCCCGAAACCCCCT GGGGT AC 401 DIS1_T7P_J05
CACCGT GAGCACCT CCGT CT CT GGCAAGAAAAAGGGAGAT T GGAT GGAT GAT T ACT GT ACT GGGAT T AGCAGCGAT T GCCCCCGAAACCCCCT GGGGT AC 273 DIS1
CCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
380
CCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T G 501 DIS1_T7P_J05
CCT CGAGT CT AGA                                                                                        373 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
ACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GG 601 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGC 701 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGG 801 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T  901 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CGGCT AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAGACCGACCT G 1001 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CCGGT GCCCT GAAT GAACT GCAANNCAAGGCANNGCGGCT AT CGT GGCT GGCCACGACGGGCGT T CCT T GNNCNNNT GT GCT CGNCGT T GT NANT GAAN 1101 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CGGGAAGGNNNT GGNT NNNAT T GGNCNAANNGCCGGGGCAGGAT T CCT GGCANNNNCCT T NNNCCT GCCAAAAAGNNCCNNCT GGNNGAAGGANNNNNGG 1201 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GNNGGT AANNT T NAT CCGNNACNNGCNNT T NNNCCNNAAGGNAANT NNNNNNNNNNNNNCGNNNCCGNAT GGAACCNNNNT T NNNNNNNNNNT NNNNNGN 1301 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NAAAANANNNNGGGNNNCNNNNNCNNNANGNNCCNNNNNNNGNNNNANNCCANNNNNNNNNNNNCNNNNNNNGNNNNNNNNNNNNNAT NNNNGGNNNNAN 1401 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNT NNNT NNNNNNNNNNGGGNNGT NNNNGGNNNNNNNNNNNNNNAANNNNNNNNNNNNNNNANNANNNGGNNNNNNNGNNNNNT NNNNNNNNNNNNCC 1501 DIS1_T7P_J05
                                                                                                     385 DIS1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNNNNNNNNNNNNNNNNNNNNNNANAAT NNNANNNNNNNNN                                                         1601 DIS1_T7P_J05
                                                                                                     385 DIS1
Decoration 'Decoration #1': Shade (with solid black) residues that match DIS1 exactly.
	   	   42	  
DIS2_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  DISlike1Es	  DNA	  sequence:	  
	  	  DIS3_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  DISlike2Es	  DNA	  sequence:	  
	  	  	  	  	  	  	  	  	  
XCRXXXXXXXXXXT XXXXXXXXAAAAXXXXGGAAXCGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGC Majority
10 20 30 40 50 60 70 80 90 100
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' AAAANNNNGGAANCGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGC 1 DIS2_T7P_L05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 DIS2
CGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCCT CCCCGAGAGT T GT ACT GGGCAGT CAGCCGAGAAAAAGACCGACAT CGT GAGT CCT CCCGT GT G Majority
110 120 130 140 150 160 170 180 190 200
CGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCCT CCCCGAGAGT T GT ACT GGGCAGT CAGCCGAGAAAAAGACCGACAT CGT GAGT CCT CCCGT GT G 101 DIS2_T7P_L05
- - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCCT CCCCGAGAGT T GT ACT GGGCAGT CAGCCGAGAAAAAGACCGACAT CGT GAGT CCT CCCGT GT G 1 DIS2
CGGCAAAAAAT GGT AT T GT AGGAACCCT T GCT GT GACGCT AAGAAACGGT CT GAGT GCGAT CT GCCAGAAT ACT GT ACCGGCCAGAGCAAGAAAAAGGAC Majority
210 220 230 240 250 260 270 280 290 300
CGGCAAAAAAT GGT AT T GT AGGAACCCT T GCT GT GACGCT AAGAAACGGT CT GAGT GCGAT CT GCCAGAAT ACT GT ACCGGCCAGAGCAAGAAAAAGGAC 201 DIS2_T7P_L05
CGGCAAAAAAT GGT AT T GT AGGAACCCT T GCT GT GACGCT AAGAAACGGT CT GAGT GCGAT CT GCCAGAAT ACT GT ACCGGCCAGAGCAAGAAAAAGGAC 78 DIS2
AT CGCCT CCCCCGCCGT GT GCGGAAAAAAGCCAGAGGACT GT CAGAACCCCT GCT GT GAT GCAAAAAAGGGGGAAT GCT GT GACCAGT GCAGGT T CAGAC Majority
310 320 330 340 350 360 370 380 390 400
AT CGCCT CCCCCGCCGT GT GCGGAAAAAAGCCAGAGGACT GT CAGAACCCCT GCT GT GAT GCAAAAAAGGGGGAAT GCT GT GACCAGT GCAGGT T CAGAC 301 DIS2_T7P_L05
AT CGCCT CCCCCGCCGT GT GCGGAAAAAAGCCAGAGGACT GT CAGAACCCCT GCT GT GAT GCAAAAAAGGGGGAAT GCT GT GACCAGT GCAGGT T CAGAC 178 DIS2
CT AAAAAGGAT AT CGT GAGCCCT CCCGT GT GCGGCAACAAGAAGGCCGAT T GT AGAAAT CCT T GT T GT GAT GCCAAAAAAGAAT ACT GCACT GGT CAGAG Majority
410 420 430 440 450 460 470 480 490 500
CT AAAAAGGAT AT CGT GAGCCCT CCCGT GT GCGGCAACAAGAAGGCCGAT T GT AGAAAT CCT T GT T GT GAT GCCAAAAAAGAAT ACT GCACT GGT CAGAG 401 DIS2_T7P_L05
CT AAAAAGGAT AT CGT GAGCCCT CCCGT GT GCGGCAACAAGAAGGCCGAT T GT AGAAAT CCT T GT T GT GAT GCCAAAAAAGAAT ACT GCACT GGT CAGAG 278 DIS2
CGCCGAAT GCCCCGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
510 520 530 540 550 560 570 580 590 600
CGCCGAAT GCCCCGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCC 501 DIS2_T7P_L05
CGCCGAAT GCCCCGGGT ACCCT CGAGT CT AGA                                                                     378 DIS2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
610 620 630 640 650 660 670 680 690 700
CT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT  601 DIS2_T7P_L05
                                                                                                     409 DIS2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
710 720 730 740 750 760 770 780 790 800
AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGC 701 DIS2_T7P_L05
                                                                                                     409 DIS2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
810 820 830 840 850 860 870 880 890 900
GGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCA 801 DIS2_T7P_L05
                                                                                                     409 DIS2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
910 920 930 940 950 960 970 980 990 1000
AGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T NNCCGGCCG 901 DIS2_T7P_L05
                                                                                                     409 DIS2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
1010 1020 1030 1040 1050 1060 1070 1080 1090 1100
T T T GGGT GGAGAGGNNAT T NNGCNAT GACT GGGNNNAACNGANAAT CGGCT GCT NNGAT GCCGCCNNGT T CCGGNT GCCNCNNAAGGGCNNCCNGNT CNT  1001 DIS2_T7P_L05
                                                                                                     409 DIS2
XXXXX Majority
T T T GG                                                                                                1101 DIS2_T7P_L05
                                                                                                     409 DIS2
Decoration 'Decoration #1': Shade (with solid black) residues that match the Consensus exactly. 
XCRXXXXXXXXXXT XXXXXXXXXXXXXXXXAAAAGAAXCT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCCGGC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' N' ' ' ' NNNNNNNNAAAAGAANCT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCAGCCGGC 1 DIS3_T7P_N05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 DIS3
CAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGCAGGGACAGAAT GCCGACCAGCCAGAGAT AAGAAAACCGACAT CGT GAGCCCAT CCGT GT GCGGGAAA Majority
10 20 30 40 50 60 70 80
CAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGCAGGGACAGAAT GCCGACCAGCCAGAGAT AAGAAAACCGACAT CGT GAGCCCAT CCGT GT GCGGGAAA 101 DIS3_T7P_N05
- - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCGCAGGGACAGAAT GCCGACCAGCCAGAGAT AAGAAAACCGACAT CGT GAGCCCAT CCGT GT GCGGGAAA 1 DIS3
AAGT GT T GT AAT CAGT GT AGGT T CAGACCAGCT AAGAAACCCGCAGACT GCCAGAACCCCT GCT GT GAT GCCGCCAAGAAGT T CAAGCCT GCCGGCACCG Majority
90 100 110 120 130 140 150 160 170 180
AAGT GT T GT AAT CAGT GT AGGT T CAGACCAGCT AAGAAACCCGCAGACT GCCAGAACCCCT GCT GT GAT GCCGCCAAGAAGT T CAAGCCT GCCGGCACCG 201 DIS3_T7P_N05
AAGT GT T GT AAT CAGT GT AGGT T CAGACCAGCT AAGAAACCCGCAGACT GCCAGAACCCCT GCT GT GAT GCCGCCAAGAAGT T CAAGCCT GCCGGCACCG 82 DIS3
AGT GT CGGGGAAAGAAAAAGGACAT CGCCAGCCCT CCCGT GT GCGGGAAAAAGCCT GAGAAT T GT CGCGACCCAT GCT GT GAT GCA CCAAAAA T GCGA Majority
190 200 210 220 230 240 250 260 270 280
AGT GT CGGGGAAAGAAAAAGGACAT CGCCAGCCCT CCCGT GT GCGGGAAAAAGCCT GAGAAT T GT CGCGACCCAT GCT GT GAT GCAGCCAAAAAGT GCGA 301 DIS3_T7P_N05
AGT GT CGGGGAAAGAAAAAGGACAT CGCCAGCCCT CCCGT GT GCGGGAAAAAGCCT GAGAAT T GT CGCGACCCAT GCT GT GAT GCAGCCAAAAAGT GCGA 182 DIS3
CCT GCCAGAAT ACT GT ACCGGCCAGT CCGCCAAAAAGAGGACAGAT AT CAT T T CACCT CCT GT CT GT GGGAAGAAGT GCT GCGAT CAGT GT AGAT T CAAG Majority
290 300 310 320 330 340 350 360 370 380
CCT GCCAGAAT ACT GT ACCGGCCAGT CCGCCAAAAAGAGGACAGAT AT CAT T T CACCT CCT GT CT GT GGGAAGAAGT GCT GCGAT CAGT GT AGAT T CAAG 401 DIS3_T7P_N05
CCT GCCAGAAT ACT GT ACCGGCCAGT CCGCCAAAAAGAGGACAGAT AT CAT T T CACCT CCT GT CT GT GGGAAGAAGT GCT GCGAT CAGT GT AGAT T CAAG 282 DIS3
CGGGCT GGAACCGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
390 400 410
CGGGCT GGAACCGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCC 501 DIS3_T7P_N05
CGGGCT GGAACCGGGT ACCCT CGAGT CT AGA                                                                      382 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT A 601 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCG 701 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAA 801 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGC 901 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T T GGGT GGAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAACGCAGGGGCGCCCGGT T CT T  1001 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T T T NNNAAGACCGACCT GT CCGGNGCCNNGAAT GAAT T GCAANNNNNGGCNGGCNGGT NAT CNNGGNT T GGCCNNNAAGGGNNT T CT T GGNCAAT T GGNC 1101 DIS3_T7P_N05
                                                                                                     412 DIS3
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNANNT T NNCCT NNAANGGGNAAGGNNNNGGNNGCT T T NGGNNGNNNGNNNGGGGGGGGNNNCCGGGGNN                              1201 DIS3_T7P_N05
                                                                                                     412 DIS3
Decoration 'Decoration #1': Shade (with solid black) residues that match DIS3 exactly.
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DIS4_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  DIS2Es	  DNA	  sequence:	  
	  	  CRI1_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  CRI1Es	  DNA	  sequence:	  
	  	  CRI2_T7P	  (forward	  DNA	  sequence	  from	  sequencing	  result)	  aligned	  with	  CRI2Es	  DNA	  sequence:	  
	  
XCRXXXXXXXXXXT XXXXXXXXXAAXXT AT T CCAT T AAXCGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCC Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' ' ' ' ' ' NAANNT AT T CCAT T AANCGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCC 1 DIS4_T7P_P05
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 DIS4
AGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGAT T ACT GCACCGGCAT CAGCT CAGACT GT CCACGAAAT AAGAAACCCAGAGAAGGAGAACA Majority
10 20 30 40 50 60 70
AGCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGAT T ACT GCACCGGCAT CAGCT CAGACT GT CCACGAAAT AAGAAACCCAGAGAAGGAGAACA 101 DIS4_T7P_P05
- - - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCGAT T ACT GCACCGGCAT CAGCT CAGACT GT CCACGAAAT AAGAAACCCAGAGAAGGAGAACA 1 DIS4
T T GT AT CAGCGGCCCCT GT T GT CGGAACT GCAAGAAACACGACT ACT GCAAT GGCAAGACCT GT AAGAAACAGCCCAAGGAGAAAGAAGACT GCGAGAGC Majority
80 90 100 110 120 130 140 150 160 170
T T GT AT CAGCGGCCCCT GT T GT CGGAACT GCAAGAAACACGACT ACT GCAAT GGCAAGACCT GT AAGAAACAGCCCAAGGAGAAAGAAGACT GCGAGAGC 201 DIS4_T7P_P05
T T GT AT CAGCGGCCCCT GT T GT CGGAACT GCAAGAAACACGACT ACT GCAAT GGCAAGACCT GT AAGAAACAGCCCAAGGAGAAAGAAGACT GCGAGAGC 75 DIS4
GGACCT T GCT GT GAT AACT GT AAAAAAGT CGGT GACAACAT GAAT GAT T AT T GCACT GGAAT T AGCAGCGAT T GCCCAAGAAACGGGT ACCCT CGAGT CT Majority
180 190 200 210 220 230 240 250 260 270
GGACCT T GCT GT GAT AACT GT AAAAAAGT CGGT GACAACAT GAAT GAT T AT T GCACT GGAAT T AGCAGCGAT T GCCCAAGAAACGGGT ACCCT CGAGT CT  301 DIS4_T7P_P05
GGACCT T GCT GT GAT AACT GT AAAAAAGT CGGT GACAACAT GAAT GAT T AT T GCACT GGAAT T AGCAGCGAT T GCCCAAGAAACGGGT ACCCT CGAGT CT  175 DIS4
AGAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
AGAGGGCCCGT T T AAACCCGCT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAG 401 DIS4_T7P_P05
AGA                                                                                                  275 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GT GCCACT CCCACT GT CCT T T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAG 501 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CAAGGGGGAGGAT T GGGAAGACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT  601 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GCCAGCT GGGGCGCCCT CT GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT C 701 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GAT CAAGAGACAGGAT GAGGAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT AT GAC 801 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GGGCACAACAGACAAT CGGCT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAGACCGACCT GT CCGGT GCCC 901 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GAAT GAACT GCAAGACGAGGCAGCGCGGCT AT CGT GGCT GGCCACGACGGGCGT T CCT T GCGCAGCT GT GCT CGACGT T GT CACT GAAACNGGAANGGA 1001 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GGCT GCT AT T GGGCGAAGT GCCGGGGCAGGAT CT CCT GGCAT CT CACCT T GGT CCNNCCGNNNAAGNNT CCAT CAT GGCT GAAGCANNGCGGCGGCT G 1101 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNT ACGCT T GAT CCGGNNACT T GCCAT T CGNNNCCAAGGGAAANT NNGAT CGAGGNNNNNCGT NNNCGNNNNNNANCNGNNT T GGCANNNNGGANNNNNN 1201 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGAAAAAANNNT CNGGGNNNNNNCCNNCCAAAT GNNCCNNGNNNAAGGNAANNNGNCCAAAGGGNNNNNNNNNNT NGGCNNNGGGNNNGCCGGT T NNNAN 1301 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNGGGGNNAAAGGCNNNT T NGGNNT NNNNNNNGGGNNNNNNNGNNGGGNNNNNNNT NNNNAANNNNNNNNNNCCGNNNNNNNNAAANNNGGGNNNNG 1401 DIS4_T7P_P05
                                                                                                     277 DIS4
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGNNNNNNNNNNGGT NNNNNNCCNNNNNNNNCNNNNNNN                                                              1501 DIS4_T7P_P05
                                                                                                     277 DIS4
Decoration 'Decoration #1': Shade (with solid black) residues that match DIS4 exactly.
XCRXXXXXXXXXXT XXXBXXXXXXXGACCCXT GGXGAXAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCA Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' B ' ' ' ' NNNGACCCNT GGNGANAGACCACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCA 1 CRI1_T7P_B07
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 CRI1
GCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGT GT T CCACAGAGACGGT AAACCCT GCCT CAAAAAGGACGCCT GCT T CGAGAT CAAT AAGGAA Majority
10 20 30 40 50 60 70
GCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGT GT T CCACAGAGACGGT AAACCCT GCCT CAAAAAGGACGCCT GCT T CGAGAT CAAT AAGGAA 101 CRI1_T7P_B07
- - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCGT GT T CCACAGAGACGGT AAACCCT GCCT CAAAAAGGACGCCT GCT T CGAGAT CAAT AAGGAA 1 CRI1
GGT AAAAAGAAT GGGAGAAAAAT CCCCT GCGCCCCT AAGAAAAAGCACT T CCAT AGGAACGGGCAGCCAT GCCT GAAAAAGGACGCT T GT T T CGAGAAAA Majority
80 90 100 110 120 130 140 150 160 170
GGT AAAAAGAAT GGGAGAAAAAT CCCCT GCGCCCCT AAGAAAAAGCACT T CCAT AGGAACGGGCAGCCAT GCCT GAAAAAGGACGCT T GT T T CGAGAAAA 201 CRI1_T7P_B07
GGT AAAAAGAAT GGGAGAAAAAT CCCCT GCGCCCCT AAGAAAAAGCACT T CCAT AGGAACGGGCAGCCAT GCCT GAAAAAGGACGCT T GT T T CGAGAAAA 76 CRI1
ACAAGGAT GGCAT CAAAAAGCACT T T CAT AGAAAT GGAAAGCCCT GCCAGAAAAAGGACAGCT GT T T T CAGGAAAACCT CAAGGGCT CCAAAAAGAAT GA Majority
180 190 200 210 220 230 240 250 260 270
ACAAGGAT GGCAT CAAAAAGCACT T T CAT AGAAAT GGAAAGCCCT GCCAGAAAAAGGACAGCT GT T T T CAGGAAAACCT CAAGGGCT CCAAAAAGAAT GA 301 CRI1_T7P_B07
ACAAGGAT GGCAT CAAAAAGCACT T T CAT AGAAAT GGAAAGCCCT GCCAGAAAAAGGACAGCT GT T T T CAGGAAAACCT CAAGGGCT CCAAAAAGAAT GA 176 CRI1
T GT GAAAAT CCCT T GT GCCCCCGAAGAT AAAAAAGT GT T T CAGCGGAACGGT CAGCCCT GCCAGGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXX Majority
280 290 300 310 320 330 340 350
T GT GAAAAT CCCT T GT GCCCCCGAAGAT AAAAAAGT GT T T CAGCGGAACGGT CAGCCCT GCCAGGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCG 401 CRI1_T7P_B07
T GT GAAAAT CCCT T GT GCCCCCGAAGAT AAAAAAGT GT T T CAGCGGAACGGT CAGCCCT GCCAGGGGT ACCCT CGAGT CT AGA                  276 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T  501 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAG 601 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
ACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT  701 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAG 801 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACAAT CGG 901 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAGACCGACCT GT CCGGT GCCCT GAAT GAACT GCAAGANNAG 1001 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GCAGCGCGGCT AT CGT GGCT GGCCACGACGGGCGT T CCT T GNNNAGCT GT GCT CGACGT T NT CACT GAAACGGNAANGGACT GGCT GCT AT T GGGCGAAT  1101 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GCCGGGGCAGGAT T CCT GGNNNNNNCCT GGT CCT GCCNAAAANNNNNT CAT GGCNGAANCANNNGGGNNNGGNNNNNT T GAT CNGGT ACT T GCCNT T CN 1201 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NCNNNAAGNAAAANT NNNNNNNNNNNNCCNNNNT NGNAT GGNANCGGNCT NNNNNNNNNNNNNNNNGGNNAAAANNNNNNGGNNNNNNCNNCCNAAT GT T  1301 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NCAGNNNAAGGNNAAT NNCCAANNNNNNNNNNNNNNGNNNNT NGNNNNNNNNNNNNNAAT NNNNGGGNNAANNNNNNNNNNNNNNNNNNNNNNNGNNNNN 1401 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNGGGNNNNNNNNAAAANAANNNNNNNCANNNNNNNNAAANNNNGNNNNNNNNNNNNNNT CT NNNNNNNNCNNNNNNNNNNNNNNNCCNNNNNT NNN 1501 CRI1_T7P_B07
                                                                                                     358 CRI1
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NNNNNNNNNNNNNT NNNNNNNNNNNGGNNNNNNNNNT CCGNNNNNN                                                       1601 CRI1_T7P_B07
                                                                                                     358 CRI1
Decoration 'Decoration #1': Shade (with solid black) residues that match CRI1 exactly.
XCRXXXXXXXXXXT XXXDXXXXXAAAAAXCCT G XGAXGACACACT CCT GCT AT GGT CT CT GCT CT GGGT T CCA GT T CCACT GGT GAC CGGCCCA Majority
' CR' ' ' ' ' ' ' ' ' ' T ' ' ' D' ' ' ' NAAAAANCCT GGNGANGACACACT CCT GCT AT GGGT ACT GCT GCT CT GGGT T CCAGGT T CCACT GGT GACGCGGCCCA 1 CRI2_T7P_D07
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  1 CRI2
GCCGGCCA GCGCGC GCCGT AC AAGCT T GCT A C AACT CCA AGAAACGGT GAACCT T GCCT GAAGAAAAA G ACGGAAAAT CCCCT T CT CCC Majority
10 20 30 40 50 60 70
GCCGGCCAGGCGCGCGCGCCGT ACGAAGCT T GCT AGCGAACT CCAGAGAAACGGT GAACCT T GCCT GAAGAAAAACGGACGGAAAAT CCCCT GT GCT CCC 101 CRI2_T7P_D07
- - - - - - - - - - - - - - - - - - - - - - - - - AAGCT T GCT AGCGAACT CCAGAGAAACGGT GAACCT T GCCT GAAGAAAAACGGACGGAAAAT CCCCT GT GCT CCC 1 CRI2
CAGAAGAAGGGCT CT T T GAAT GGAACAAGAAAGCCGAGAAGAAAAGGAGCCACAGAAACGGGAAGCCAT GCCT GAAGAAAAAT GACGT GCCCAT CCCT T Majority
80 90 100 110 120 130 140 150 160 170
CAGAAGAAGGGCT GCT T T GAAT GGAACAAGAAAGCCGAGAAGAAAAGGAGCCACAGAAACGGGAAGCCAT GCCT GAAGAAAAAT GACGT GCCCAT CCCT T  201 CRI2_T7P_D07
CAGAAGAAGGGCT GCT T T GAAT GGAACAAGAAAGCCGAGAAGAAAAGGAGCCACAGAAACGGGAAGCCAT GCCT GAAGAAAAAT GACGT GCCCAT CCCT T  76 CRI2
GT GCT CAGGAAAAGAAACACT T CCAT AGGAACGGCAAGCCCT GCCT CAAGAAAAAT GGACGGT ACAT T AAGT GCGCCCGCCAGGACAAGAAAGAT GT CT G Majority
180 190 200 210 220 230 240 250 260 270
GT GCT CAGGAAAAGAAACACT T CCAT AGGAACGGCAAGCCCT GCCT CAAGAAAAAT GGACGGT ACAT T AAGT GCGCCCGCCAGGACAAGAAAGAT GT CT G 301 CRI2_T7P_D07
GT GCT CAGGAAAAGAAACACT T CCAT AGGAACGGCAAGCCCT GCCT CAAGAAAAAT GGACGGT ACAT T AAGT GCGCCCGCCAGGACAAGAAAGAT GT CT G 176 CRI2
T T T T GAAGAT AAT AAGCGGGGCGAAAGT AAAAAAGAGT T CCAGAGAAAT GGGGAGCCT T GCCT CGGGT ACCCT CGAGT CT AGAXXXXXXXXXXXXXXXXX Majority
280 290 300 310 320 330 340 350
T T T T GAAGAT AAT AAGCGGGGCGAAAGT AAAAAAGAGT T CCAGAGAAAT GGGGAGCCT T GCCT CGGGT ACCCT CGAGT CT AGAGGGCCCGT T T AAACCCG 401 CRI2_T7P_D07
T T T T GAAGAT AAT AAGCGGGGCGAAAGT AAAAAAGAGT T CCAGAGAAAT GGGGAGCCT T GCCT CGGGT ACCCT CGAGT CT AGA                  276 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GAT CAGCCT CGACT GT GCCT T CT AGT T GCCAGCCAT CT GT T GT T T GCCCCT CCCCCGT GCCT T CCT T GACCCT GGAAGGT GCCACT CCCACT GT CCT T  501 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CCT AAT AAAAT GAGGAAAT T GCAT CGCAT T GT CT GAGT AGGT GT CAT T CT AT T CT GGGGGGT GGGGT GGGGCAGGACAGCAAGGGGGAGGAT T GGGAAG 601 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
ACAAT AGCAGGCAT GCT GGGGAT GCGGT GGGCT CT AT GGCT T CT ACT GGGCGGT T T T AT GGACAGCAAGCGAACCGGAAT T GCCAGCT GGGGCGCCCT CT  701 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGT AAGGT T GGGAAGCCCT GCAAAGT AAACT GGAT GGCT T T CT T GCCGCCAAGGAT CT GAT GGCGCAGGGGAT CAAGCT CT GAT CAAGAGACAGGAT GAG 801 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GAT CGT T T CGCAT GAT T GAACAAGAT GGAT T GCACGCAGGT T CT CCGGCCGCT T GGGT GGAGAGGCT AT T CGGCT AT GACT GGGCACAACAGACAAT CGG 901 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
CT GCT CT GAT GCCGCCGT GT T CCGGCT GT CAGCGCAGGGGCGCCCGGT T CT T T T T GT CAAGACCGACCT GT CCGGT GCCCT GAAT GAACT GCAAGACGAG 1001 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GCAGCGCGGCT AT CGT GGCT GGCCACGACGGGCGT T CCT T GCGCAGCT GT GCT CGACGT T NNCACT GAANCGGGAANGGACT GGCT GCT AT T GGGCNAAT  1101 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T GCCGGGGCAGGAT CT CT GGCNNNNACCT T GGT CCT NCCNAAAAGNNCCNT CAT GGCT GNNNNANNNNNNGGT T NNNNCCNT T NAT CCGNNACNNGCCAT  1201 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T CNNNCCCANNGAANNT CNNNNNNNNNNANNGNNNNCNNT GGAACCGGNNNNNNNNNNNNANT NNNGNNNAAAANNT NNNGNGNCCGCCANCCAANT NT T  1301 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
NCAGNNNNAGGNNNNNNCCNNNNNNNNNNNNNNNNNNCNT GGNNNNNNNNNNNCANNNAT GGGNNAAAGGCNNNT NNNNNNNNNNNNNNNNNNNNNNNNN 1401 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
GGNNNNNNNANNNNNNNNNNNNNCNNNNNNNNNNNANNGNNGNNNNNNNNNNNNNNNNNNNNNNNNGNCCCNNNNNNNNNNNNCNNNNNNNNNNNNNNNN 1501 CRI2_T7P_D07
                                                                                                     358 CRI2
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Majority
T NNNNNNNNNNNNGNNNNNNNNNNNNNNNNNNNNNNNNNGNNNNNNNANNNNNNNNNNN                                          1601 CRI2_T7P_D07
                                                                                                     358 CRI2
Decoration 'Decoration #1': Shade (with solid black) residues that match CRI2 exactly.
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3. BIOINFORMATIC	  DESIGN	  OF	  TOXIN-­‐SPECIFIC	  IMMUNOGENS	  TO	  IMPROVE	  THE	  
TREATMENT	  OF	  ENVENOMATIONS	  CAUSED	  BY	  THE	  GENUS	  ECHIS	  IN	  AFRICA	  
	  
3.1. INTRODUCTION	  
	  Antivenom	   is	   the	   only	   effective	   treatment	   against	   the	   systemic	   effects	   of	   snakebite.	  	  Developed	  by	  a	  century-­‐old	  immunisation	  protocol,	  antivenom	  IgG	  is	  formulated	  from	  sera	  of	  horses	  or	  sheep	  hyper-­‐immunised	  with	  increasing	  doses	  of	  venom,	  and	  can	  be	  monospecific	  (against	  the	  venom	  of	  a	  single	  snake	  species)	  or	  polyspecific	  (against	  the	  venom	  of	  multiple	  species).	  Antivenom	  aims	  to	  bind	  and	  neutralize	  most,	   if	  not	  all,	  of	  the	  venom	  toxins.	  However,	  snake	  venoms	  comprise	  more	  than	  a	  hundred	  proteins	  and	  peptides	  which	  exhibit	  a	  significant	  diversity	  in	  terms	  of	  isoform	  complexity	  (Calvete	  et	  
al.	   2007)	   toxicity	   and	   immunogenicity	   (Harrison	   et	   al.	   2011).	   Therefore,	   being	  formulated	  with	  whole	  venom,	  antivenom	  contains	   therapeutically	   redundant	   IgGs	   to	  non-­‐toxic	  venom	  components,	  and	  a	   lack	  of	  high	  titre	   IgGs	  to	  highly	  toxic,	  but	  weakly	  immunogenic	   components	   (Harrison	   2004;	   Visser	   et	   al.	   2008;	   Wagstaff	   et	   al.	   2009;	  Harrison	  et	  al.	  2011).	  
	  
The	  Alistair	  Rid	  Venom	  Research	  Unit	  is	  pioneering	  a	  new	  approach	  aiming	  to	  address	  the	   challenges	   of	   current	   antivenom	   therapy	   by	   using	   the	   rationale	   of	   generating	  venom	   toxin-­‐specific	   antibodies.	   Based	   on	   preliminary	   work	   illustrating	   extensive	  cross-­‐specific	   and	   cross-­‐generic	   reactivity	  of	   a	   toxin-­‐specific	   antibody	   (Harrison	  et	  al.	  2000;	  Harrison	  et	  al.	  2002;	  Harrison	  et	  al.	  2003b;	  Harrison	  2004),	  the	  new	  concept	  was	  progressed	   by	   using	   venom	   gland	   transcriptomes	   (Wagstaff	   and	   Harrison	   2006;	  Casewell	   et	   al.	   2010),	   as	   the	   data	   resource	   informing	   the	   design	   of	   immunogens	   to	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generate	  toxin-­‐specific	  IgG.	  This	  approach	  is	  dependent	  upon	  bioinformatic	  selection	  of	  motifs	   exhibiting	   isoform	   representation	   within	   the	   group	   of	   toxins	   and	   maximal	  predicted	   immunogenicity	   (Wagstaff	  and	  Harrison	  2006;	  Casewell	  et	  al.	  2010),	  where	  their	  conserved	  nature	  could	  be	  translated	  to	  their	  immunological	  inter	  a	  intra	  specific	  reactivity	   (Harrison	   et	   al.	   2003b;	   Harrison	   2004).	   Bearing	   in	   mind	   that	   most	   of	   the	  pathologically-­‐important	  venom	  toxin	  groups	  show	  a	  high	  isoform	  diversity,	  the	  effort	  of	   a	   toxin-­‐specific	   approach	  based	  on	   transcriptomic	  data	  has	  been	  possible	  with	   the	  bioinformatic	   selection	   of	   motifs	   within	   each	   toxin	   group,	   which	   helps	   predict	   their	  immunogenic	   conformation,	   therefore	   generating	   antibodies	   that	  will	   be	  predicted	   to	  neutralise	  the	  toxin	  induced	  pathology	  (Wagstaff	  et	  al.	  2006).	  
	  
Continuing	   the	   approach	   to	   generate	   rational,	   toxin-­‐specific	   antivenom,	   this	   study	  involves	   the	   bioinformatic	   interrogation	   of	   the	   genus	   Echis	   venom	   gland	  transcriptomes	   (for	   Echis	   ocellatus,	   Echis	   pyramidum	   leakeyi	   and	   Echis	   coloratus)	   in	  order	   to	   identify	   epitopes	   on	   the	   basis	   of	   i)	   aminoacid	   sequence	   conservation,	   ii)	  antigenicity,	   (iii)	   surface	   exposure	   and	   (iv)	   coverage	   across	   the	   EST	   data,	   therefore	  capable	  of	  generating	  antibodies	  that,	  this	  time,	  would	  be	  predicted	  to	  generate	  a	  cross-­‐reactive	  antivenom	  against	  all	  the	  most	  medically	  important	  species	  that	  belong	  to	  the	  African	  Echis	  species.	  Based	  on	  the	  hypothesis	  that	  the	  most	  abundant	  toxins	  expressed	  by	   the	   venom	   gland	   are	   also	   the	   ones	   that	   account	   for	   the	   pathogenicity	   of	  envenomations,	   five	   major	   toxin	   groups	   were	   selected	   as	   a	   target	   of	   the	   study:	  Phospholipases	   A2	   (PLA2),	   Serine	   proteases	   (SP)	   C-­‐type	   lectins	   (CTLs),	  Metalloproteinases	   (SVMPs)	   and	   Disintegrins	   (Figure	   3.1)	   to	   design	   epitope-­‐string	  immunogens	  (Casewell	  et	  al.	  2009)	  predicted	  to	  raise	  toxin-­‐specific	  antibodies	  capable	  of	  neutralizing	  the	  toxic	  effects	  of	  the	  Echis	  venoms.	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Figure	  3.1:	  The	  relative	  abundance	  and	  diversity	  of	  each	  Echis	  genus	  venom	  toxin	  families.	  Phospholipase	  A2	  (PLA2),	  Serine-­‐proteases	  (SP),	  C-­‐type	  lectins	  (CTL),	  Snake	  venom	  Metalloproteinases	  (SVMPs)	  and	  Disintegrins	  (DIS)	  (Casewell	  et	  al.	  2009).	  	  	  
3.2. METHODS	  	  
	  A	   series	   of	   objectives	   summarized	   in	   Figure	   3.2	  were	   carried	   out	   in	   order	   to	   design	  immunogens	   capable	   of	   generating	   a	   cross-­‐reactive	   antibody	   response	   among	   the	  different	  isoforms	  of	  the	  most	  pathogenic	  venom	  toxins	  from	  the	  African	  Echis	  genus.	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Figure	  3.2:	  Systematic	  pipeline	  used	  in	  the	  design	  of	  toxin-­‐specific	  epitope-­‐string	  immunogens	  against	  the	  venom	  of	  the	  African	  genus	  Echis.	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provided	  as	  well	  across	  the	  document.	  (Please	  refer	  to	  the	  databases	  contained	  on	  the	  CD	  attached	  to	  this	  document)	  if	  any	  further	  detail	  is	  required.	  	  	  
	  
3.2.1. Objective	  1:	  Sequence	  analysis	  of	  Echis	  venom	  gland	  expressed	  sequence	  
tag	  (ESTs)	  data	  and	  extraction	  of	  representative	  isoforms	  
Echis	   venom	   gland	   transcriptomic	   data	   previously	   generated	   and	   analysed	   at	   the	  Alistair	  Reid	  Venom	  Research	  Unit	  by	  sequencing	  ~1000	  ESTs	  from	  venom	  gland	  cDNA	  libraries	  for	  the	  species	  Echis	  coloratus,	  Echis	  ocellatus,	  Echis	  pyramidum	  leakeyi	  and	  the	  Asian	  Echis	  carinatus	  sochureki	  was	  used	  throughout	  the	  study	  (Wagstaff	  and	  Harrison	  2006;	   Casewell	   et	   al.	   2009;	   Wagstaff	   et	   al.	   2009).	   Due	   to	   the	   large	   amount	   of	   toxin	  isoforms	  available	  for	  each	  of	  the	  chosen	  toxin	  groups	  for	  Echis,	  a	  phylogenetic	  survey	  of	   the	   resulting	   trees	  was	  used	  out	   to	   select	  key	  numerically	   representative	   isoforms	  contained	  within	  each	  of	  the	  clades	  to	  create	  a	  non	  redundant	  selection	  of	  sequences.	  Analyses	  were	  carried	  by	  Nicholas	  Casewell	  before	   the	  beginning	  of	   the	  study,	  where	  briefly,	   full	   length	   Echis	   ESTs	   (annotated	   as	   SVMPs,	   CTLs,	   PLA2s	   and	   SPs)	   were	  compiled	   into	   nucleotide	   toxin	   family	   datasets	   alongside	   all	   existing	   non-­‐redundant	  Viperidae	   sequences	   identified	   by	   sequence	   database	   searches	   in	   GenBank,	   EMBL,	  dbEST	  and	  UniProt.	  Non-­‐Serpentes	  outgroup	  sequences	  for	  each	  family	  were	  identified	  by	   sequence	   similarity	   searches	   against	   a	  number	  of	  non-­‐Serpentes	  databases	  before	  inclusion	   in	   the	   datasets.	   Datasets	  were	   translated	   and	   trimmed	   to	   the	   open	   reading	  frame	  of	  the	  proteins	  in	  MEGA4;	  redundant	  sequences	  and	  those	  containing	  frameshifts	  or	   truncations	  as	   the	  result	  of	   indels	  were	  excluded.	  Gene	   trees	  were	  produced	  using	  optimised	  models	  of	  sequence	  evolution	  combined	  with	  Bayesian	  inference;	  translated	  DNA	  datasets	  were	  subjected	  to	  analysis	  in	  ModelGenerator	  v0.8	  (Keane	  et	  al.	  2006)	  to	  select	   appropriate	  models	   of	   evolution	   for	  maximal	   extraction	   of	   phylogenetic	   signal	  (Castoe	   et	  al.	   2005;	   Castoe	   and	  Parkinson	  2006),	  with	   the	  model	   favoured	  under	   the	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Akaike	   Information	   Criterion	   (AIC)	   selected	   (Posada	   and	   Buckley	   2004).	   Bayesian	  inference	  analyses	  were	  undertaken	  in	  MrBayes	  v3.1	  (Huelsenbeck	  and	  Ronquist	  2001;	  Huelsenbeck	   et	   al.	   2001;	   Ronquist	   and	   Huelsenbeck	   2003)	   on	   the	   freely	   available	  bioinformatic	   platform	   Bioportal	   (www.bioportal.uio.no).	   Each	   dataset	   was	   run	   in	  duplicate	  using	  four	  chains	  for	  5x10-­‐6	  generations	  and	  sampling	  every	  500th	  tree.	  
	  
With	  the	  extraction	  of	  the	  full-­‐length	  sequences	  of	  the	  chosen	  representative	  isoforms,	  a	  database	  (here	  referred	  to	  as	  db-­‐1)	  was	  generated	  in	  order	  to	  categorize	  and	  analyse	  the	  data	  available	  by	  species	  and	  toxin	  groups.	  The	  individual	  representative	  isoforms	  chosen	  were	  further	  examined	  for	  their	  nucleotide	  coding	  (NTCS)	  and	  aminoacid	  (AAS)	  sequences	   (using	   ExPASy	   translate	   tool,	   available	   at	  http://web.expasy.org/translate/)	   (Figure	   3.3,	   For	   details	   please	   refer	   to	   the	  attached	  CD,	  the	  sheets	  named	  ‘EOC,	  EPL,	  ECO	  and	  ECS	  in	  db-­‐1).	  In	  order	  to	  predict	  the	  protein	   structure	   profile	   (PSP)	   for	   each	   isoform,	   a	   further	   analysis	   included	   the	  examination	  of	  the	  i)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	   ii)	  Emini	  surface	  accessibility	  scale	   plot	   and	   iii)	   hydrophylicity	   plot	   (Protean	   from	   DNASTAR,	   Wisconsin,	   United	  States).	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Figure	  3.3:	  Screen	  shot	  of	  db-­‐1	  showing	  the	  sheet	  ‘EOC’	  (for	  Echis	  ocellatus).	  	  	  Red	  arrows	  and	  boxes	  show	  an	  example	  of	  the	  arrangement	  of	  the	  data	  linked	  to	  each	  of	  the	  toxin	  groups.	  a)	  Nucleotide	  full	  length	  sequence	  (NTFL),	  b)	  Nucleotide	  coding	  sequence	  (NTCS),	  c)	  aminoacid/protein	  sequence	  (PS),	  d)	  Protein	  structure	  profile	  containing	  Hydrophylicity	  (blue),	  Antigenicity	  (pink)	  and	  surface	  probability	  (yellow)	  plots.	  	  
	  
3.2.2. Objective	  2:	  Identification	  of	  catalytic	  residues,	  conserved	  areas	  and	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http://www.megasoftware.net/),	   and	   the	   analysis	   was	   followed	   by	   manual	  adjustments	   by	   eye.	   In	   order	   to	   predict	   candidate	   antigenic	   domains	   (areas	   of	  conserved	   antigenicity	   predicted	   to	   have	   immunogenic	   potential	   for	   antigen	  presentation	  and	  antibody	  recognition),	   the	  aminoacid	  sequence	  alignments,	   together	  with	  the	  protein	  structure	  profiles	  for	  each	  of	  the	  isoforms	  were	  used	  as	  a	  template	  to	  manually	   create	  antigenic	  profile	   and	   surface	  exposure	  alignments	   (for	  details	  please	  refer	  to	  	  the	  sheet	  ‘Alignm	  PSP’	  in	  db-­‐1	  or	  to	  appendices	  3.5.1.2	  ,3.5.2.2,	  3.5.3.2,	  3.5.4.2).	  	  
	  
3.2.3. Objective	  3:	  Refinement	  of	  antigenic	  domains	  using	  bioinformatic	  
predictions	  In	  order	  to	  design	  immunogens	  capable	  of	  neutralizing	  the	  biological	  activity	  of	  each	  of	  the	   toxin	   groups,	   a	   set	   of	   bioinformatic	   approaches	  was	   used	   to	   refine	   the	   candidate	  antigenic	   domains.	   Bioinformatic	   predictions	   were	   carried	   out	   for	   each	   of	   the	  sequences	  from	  the	  representative	  isoforms	  in	  order	  to	  examine	  whether	  the	  antigenic	  domains	  represented	  suitable	  protein	  segments	  for	  antibody	  recognition.	  By	  using	  the	  PDBs	   predicted	   previously,	   accessible	   segments	   that	   could	   correspond	   to	   linear	  epitopes	   were	   predicted	   by	   using	   PEPOP	   (computational	   tool	   for	   the	   design	   of	  immunogenic	   peptides,	   available	   at	   http://diagtools.sysdiag.cnrs.fr/PEPOP/)	  (Moreau	  et	  al.	  2008)	  and	  were	  manually	  mapped	  onto	  the	  sequence	  alignments.	  Ellipro,	  as	   a	   tool	   for	   antibody-­‐epitope	   prediction	   (Ponomarenko	   et	   al.	   2008)	   (available	   at:	  http://tools.immuneepitope.org/tools/ElliPro/iedb_input)	   was	   also	   used	   to	  predict	   possible	   linear	   epitopes,	   this	   time	   the	   predictions	   were	   carried	   out	   on	   the	  sequence	   that	   contained	   the	   highest	   expressed	  EST	  numeric	   representation	   from	   the	  venom	   of	   E.	   ocellatus	   as	   a	   template,	   bearing	   in	   mind	   that	   this	   species	   is	   the	   most	  medically	   important	   of	   the	   group,	   and	   therefore,	   the	   most	   important	   in	   terms	   of	  neutralization.	  N-­‐linked	  glycosylation,	  as	  an	   important	  post-­‐translational	  modification	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affecting	   antigenicity	   directly	   by	   interfering	   with	   the	   binding	   of	   antibodies	   to	   the	  underlying	  peptides,	  was	  predicted	  using	  Net-­‐N-­‐Glyc	   (Gupta	  et	  al.	   2004)	   (available	  at	  http://www.cbs.dtu.dk/services/NetNGlyc/)	   which	   searches	   for	   the	   presence	   of	  the	   glycosylation	   motif	   Asn-­‐Xaa-­‐Ser/Thr	   inside	   the	   query	   sequence.	   This	   prediction	  was	   done	   for	   each	   of	   the	   representatives	   and	   these	   sites	   were	   further	   avoided.	  Modelling	  of	  antigenic	  domains	  onto	  the	  three	  dimensional	  structure	  of	  the	  previously	  predicted	  PDB	   sequence	  was	  done	  with	  with	   the	  purpose	  of	   confirming	   their	   surface	  exposure.	  Mapping	  was	  preformed	  in	  at	   least	  two	  of	  the	  most	  closely	  related	  PDBs	  by	  using	   YASARA	   (Krieger	   et	   al.	   2002),	   a	   tool	   used	   for	   the	   molecular	   visualisation	   and	  modelling	   of	   the	   structure	   of	   proteins	   (available	   for	   download	   at:	  http://www.yasara.org/).	   A	   visual	   analysis	  was	   then	   carried	   out	   in	   order	   to	   avoid	  that	   antigenic	  domains	   could	  be	   affected	  by	  being	  buried	   inside	   the	   structure	   and	  by	  dimerization,	   where	   applicable.	   	   Altogether,	   the	   bioinformatic	   tools	   implemented	  allowed	   refining	   the	   antigenic	   domains	   as	   structural	   and	   functional	   areas	   with	   a	  potential	   for	   antigen	   presentation	   and	   antibody	   recognition.	   A	   different	   number	   and	  colour	  was	  assigned	  to	  each	  antigenic	  domain	  in	  order	  to	  aid	  identification.	  
	  
3.2.4. Objective	  4:	  Evaluation	  of	  each	  peptide	  sequence	  as	  candidate	  epitopes	  
and	  construction	  of	  database	  3	  (db-­‐3)	  In	   order	   to	   formulate	   peptide	   sequences	   that	  when	   used	   as	   an	   immunogens,	  will	   be	  predicted	   to	   generate	   a	   cross-­‐reactive	   antibody	   response	   by	   targeting	   the	  maximum	  number	  of	  isoforms	  (belonging	  to	  its	  toxin	  group),	  the	  individual	  peptide	  composition	  for	  each	  antigenic	  domain	  was	  extracted	  and	  carefully	  refined	  by	  testing	  the	  frequency	  of	   the	   peptides	   across	   an	   Echis	   EST	   database.	   Analysis	   were	   undertaken	   by	   using	   a	  previously	  developed	   computational	   tool	   (created	   in	  Access,	  Microsoft	  Office	   -­‐	   Figure	  3.4).	  For	  further	  details	  please	  refer	  to	  Wagstaff	  et	  al.	  2006)	  referred	  to	  as	  database-­‐2	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(db-­‐2),	   which	   served	   to	   find	   the	   individual	   matches	   to	   each	   query	   peptide	   (of	   a	  minimum	  length	  of	  10	  aminoacids).	  	  
	  
	  
Figure	  3.4:	  Screen	  shot	  of	  db-­‐2	  	  Developed	  in	  Access	  by	  Simon	  C	  Wagstaff	  predicting	  a	  cross-­‐reactive	  antibody	  response	  against	  a	  query	  peptide	  (using	  the	  peptide	  sequence:	  NLNTYNKKYR	  as	  an	  example).	  	  
All	   of	   the	   resulting	   data	   was	   recorded	   into	   a	   new	   database,	   here	   referred	   to	   as	  database-­‐3	  (db-­‐3)	  (created	  in	  Excel,	  Microsoft	  Office)	  by	  reporting	  i)	  number	  of	  isoform	  hits,	   ii)	   the	  number	  of	  EST	  hits,	   iii)	   the	  number	  of	  cluster	  hits	  and	  iv)	  a	  score	  that	  the	  database	  assigns	  automatically	  on	  the	  basis	  of	  coverage	  (calculated	  by	  multiplying	  the	  total	  number	  of	  hits,	   the	  number	  of	  times	  a	  cluster	   is	  hit	  and	  the	  number	  of	  EST	  hits)	  	  (for	  details	  please	  refer	  to	  the	  sheets	  named	  with	  the	  different	  toxin	  groups	  ‘PLA2’,	  ‘SP’,	  ‘CTL’,	  ‘SVMP’	  and	  ‘DIS’	  in	  db-­‐3,	  Figure	  3.5)	  
	  
 
	   	   54	  
	  
Figure	  3.5:	  Screen	  shot	  of	  db-­‐3	  showing	  the	  sheet	  ‘PLA2’:	  peptide	  sequence	  analysis	  after	  predictions	  carried	  out	  in	  db-­‐2	  for	  the	  toxin	  group	  Phospholipase	  A2.	  	  
All	  of	   the	  predicted	  peptides	  were	   then	  organised	   into	  a	  new	   table	   in	  order	   to	  match	  them	  against	   all	   of	   the	  EST	   sequences	   they	  hit,	   and	  have	   a	   visual	   idea	   of	   the	   specific	  coverage	  for	  each	  of	  them	  (for	  details	  please	  refer	  to	  the	  sheets	  marked	  with	  the	  toxin	  group	  name	  followed	  by	  “t”:	   ‘PLA2	  (t)’,	   ‘SP(t)’,	   ‘CTL(t)’,	   ‘SVMP(t)’	  and	   ‘DIS(t)’	   in	  db-­‐3).	  This	   data	   was	   of	   good	   use	   to	   then	   physically	   locate	   the	   sequences	   with	   the	   highest	  number	  of	  hits	  across	  the	  ESTs	  and	  therefore,	  the	  maximum	  representation	  across	  the	  species.	   Highest-­‐scored	   sequences	   were	   then	   organized	   onto	   a	   summary	   table	   (for	  details	  please	   refer	   to	   the	   sheets	  marked	  with	   the	   toxin	  group	  name	   followed	  by	   “s”:	  
	   	   55	  
‘PLA2	   (s)’,	   ‘SP(s)’,	   ‘CTL(s)’,	   ‘SVMP(s)’	   and	   ‘DIS(s)’	   in	   db-­‐3)	   in	   order	   to	   visualise	   and	  check	  the	  final	  EST	  coverage	  of	  each	  of	  them.	  	  
	  
3.2.5. Objective	  5:	  Arrangement	  of	  epitopes	  into	  an	  epitope-­‐string	  immunogen	  Epitopes	   within	   the	   immunogens	   were	   separated	   by	   two	   lysines	   (KK)	   to	   promote	  antigen	  presentation	  and	  were	  further	  evaluated	  in	  different	  combinations	  (modified	  in	  terms	   of	   position	   when	   necessary)	   to	   accomplish	   a	   representative	   Jameson-­‐Wolf	  antigenic	  index,	  and	  therefore	  a	  predicted	  convenient	  structural	  surface-­‐exposure.	  The	  chosen	  final	  epitope-­‐strings	  were	  then	  included	  into	  one	  string	  (or	  sometimes	  two)	  per	  toxin	  group	  as	  immunogens	  capable	  of	  neutralising	  the	  biological	  activity	  of	  the	  toxins	  (for	  details	  please	  refer	   to	   the	  sheets	  marked	  with	   “JW”:	   ‘JW1’	   for	  PLA2,	   ‘JW2’	   for	  SP,	  ‘(JW3)	  for	  CTL’,	  ‘JW4’	  for	  SVMPs	  and	  ‘JW5’	  for	  DIS	  in	  db-­‐3,	  Figure	  3.6).	  	  
	  
	  
Figure	  3.6:	  Screen	  shot	  of	  db-­‐3	  showing	  the	  sheet	  ‘JW1’	  for	  PLA2	  as	  an	  example	  of	  the	  re-­‐arrangement	  of	  epitopes	  inside	  the	  epitope-­‐string	  according	  to	  their	  antigenic	  profile.	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3.2.6. Objective	  6:	  Codon	  optimization	  and	  synthesis	  of	  epitope-­‐string	  




3.3.1. Phospholipase	  A2	  A	  total	  of	  four	  clades	  containing	  Echis	  sequences	  were	  selected	  for	  the	  PLA2	  toxin	  group	  as	  well-­‐supported	  branches,	  from	  which	  a	  total	  of	  nine	  representative	  isoforms	  (Figure	  3.7)	   were	   selected	   on	   the	   basis	   of	   EST	   representation,	   cluster	   diversity	   and	   branch	  support.	   By	   using	   the	   sequence	   EPL00012	   (52	   ESTs)	   for	   the	   Ser49	   group	   and	   the	  sequence	   EPL00071	   (51	   ESTs)	   for	   the	   Asp49	   group	   as	   a	   query,	   the	   resulting	   PDBs	  2QHD	   from	   Echis	   coloratus	   (80%	   identity)	   and	   1OZ6	   from	   Vipera	   ammodytes	  
ammodytes	   (74%	   identity),	   were	   obtained	   as	   the	   highest	   identity-­‐ranked	   structures	  and	  were	  used	  as	   a	   template	   for	   the	  mapping	  of	   important	   catalytic	   residues.	  Taking	  into	  account	   that	  Ca2+	   is	   the	  most	   important	  cofactor	   for	  catalysis	  of	   this	  enzyme,	   the	  conserved	  Ca2+	  binding	  loop	  located	  between	  residues	  25	  and	  33	  (Y25-­‐G-­‐C-­‐Y/F-­‐C-­‐G-­‐X-­‐G-­‐G33),	   the	   aminoacid	   in	   the	   position	   49	   (usually	   Aspartate)	   and	   the	   pentagonal	  bipyramidal	   cage	   for	  Ca2+	  binding	   composed	  of	   three	   carbonyl	   oxygen	  atoms	   (Y/F28,	  G30,	  and	  G32)	  and	  two	  water	  molecules	  was	  mapped	  (Banumathi	  et	  al.	  2001).	  With	  the	  use	  of	  db-­‐1,	  aligned	  aminoacid	  sequences	  from	  the	  chosen	  representatives	  of	  the	  PLA2	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toxin	  group	  were	  used	  to	  map	  key	  target	  catalytic	  areas	  such	  as	  the	  residues	  required	  for	  calcium	  binding	  to	  the	  enzyme	  (Figure	  3.8).	  	  
	  
	  
Figure	  3.7:	  Phospholipase	  A2	  amino	  acid	  phylogenetic	  analysis	  showing	  the	  clades	  	  (red	  boxes)	  and	  representative	  sequences	  chosen	  for	  the	  analysis	  (blue	  boxes)	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Figure	  3.8:	  Aminoacid	  sequence	  alignment	  of	  Echis	  PLA2	  representatives	  	  (including	  Echis	  carinatus	  sochureki)	  showing	  key	  catalytic	  residues	  like	  the	  Ca2+	  binding	  loop	  that	  lies	  between	  the	  residues	  25	  to	  33	  (with	  a	  consensus	  sequence	  of	  Y25-­‐G-­‐C-­‐Y/F-­‐C-­‐G-­‐X-­‐G-­‐G33)	  and	  the	  residues	  that	  form	  part	  of	  the	  bipyramidal	  cage	  for	  Ca2+	  binding:	  	  Asp49,	  Y/F28,	  G30	  and	  G32.	  	  
	  
Further	   alignment	   of	   the	   Jameson	  wolf	   antigenic	   index	   plots	   (Figure	   3.9a)	   as	  well	   as	  alignment	   of	   Emini’s	   surface	   accessibility	   scale	   plot	   (Figure	   3.10)	   identified	   three	  candidate	  antigenic	  domains	  for	  the	  PLA2	  toxin	  group,	  here	  referred	  to	  as	  AdPLA2_1	  –	  3	  (green,	   blue	   and	   yellow	   respectively).	   AdPLA2_1	   was	   located	   from	   the	   aminoacid	  position	  48	  to	  58,	  which	  contained	  the	  calcium-­‐binding	  loop,	  AdPLA2_2	  from	  the	  69	  to	  the	  92,	   very	   close	   to	   the	   catalytic	   residue	  of	   Ser/Asp49	  and	  AdPLA2_3	   (yellow)	   from	  the	  114	   to	  123	   (Figure	  3.9a).	  Net-­‐N-­‐glyc	  predicted	  N-­‐Glycosylation	  sites	   (Figure	  3.9b,	  shown	  in	  light	  blue	  boxes)	  were	  avoided.	  ElliPro	  further	  confirmed	  that	  the	  prediction	  on	   the	   location	  of	   the	  antigenic	  domains	  was	  correct	   (Figure	  3.9b,	   shown	   in	  magenta	  boxes)	   by	   predicting	   linear	   antibody	   epitope	   sites.	   Bioinformatic	   predictions	   carried	  out	  with	  PEPOP	  showed	  a	  number	  of	  aminoacids	  that	  were	  expected	  to	  be	  buried	  into	  the	  structure	  (Figure	  3.9b,	  shown	  in	  orange	  arrows	  below	  the	  alignment).	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Figure	  3.9:	  Design	  of	  Antigenic	  domains	  for	  the	  Phospholipase	  A2	  toxin	  group	  
	  a)	  Alignment	  of	  antigenic-­‐index	  (Jameson-­‐Wolf)	  profiles	  showing	  the	  candidate	  antigenic	  domains	  in	  colors	  AdPLA2_1	  (Green),	  AdPLA2_2	  (Blue),	  AdPLA2_3	  (Yellow)	  
b)	  sequence	  alignment	  of	  representative	  sequences	  aligned	  together	  with	  sequences	  from	  the	  PDB	  files	  showing	  bioinformatic	  predictions	  of	  each	  antigenic	  domain:	  predicted	  buried	  aminoacid	  residues	  (Orange	  arrows,	  PEPOP),	  B-­‐cell	  epitopes	  (purple	  boxes,	  Ellipro),	  Glycosylation	  sites	  (light	  blue	  boxes),	  catalytic	  sites	  (dark	  purple	  arrow	  –	  Lys/Ser49).	  c)	  three-­‐dimensional	  mapping	  of	  antigenic	  domains	  onto	  the	  	  structure	  of	  an	  acidic,	  monomeric	  Asp49	  phospholipase	  A2	  from	  Echis	  carinatus	  (PDB	  ID:	  1OZ6)	  to	  confirm	  their	  surface-­‐exposure.	  Structure	  is	  shown	  rotated	  among	  the	  Y	  axis	  at	  0°	  (top	  left),	  90°	  (top	  right),	  180°	  (bottom	  left)	  and	  270°	  (bottom	  right)	  degrees.	  	  
Antibody-Epitope 
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Figure	  3.10:	  Emini’s	  surface	  accessibility	  scale	  plot	  alignment	  for	  PLA2	  representative	  isoforms	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Figure	  3.11:	  Three	  dimensional	  mapping	  of	  antigenic	  domains	  	  AdPLA2_1	  (Green),	  AdPLA2_2	  (Blue),	  AdPLA2_3	  (Yellow)	  onto	  an	  heterodimeric	  Ser49	  PLA2	  from	  Echis	  carinatus	  (PDB:	  2QHD	  –	  domains	  are	  mapped	  onto	  chain	  A,	  chain	  B	  is	  coloured	  in	  light	  blue)	  at	  a)	  0°	  showing	  the	  N-­‐terminal	  and	  rotated	  among	  the	  Y	  axis	  at	  b)	  90°,	  c)	  180°	  and	  d)	  270°	  degrees.	  	  
Sequence	  refinement	  for	  each	  of	  the	  PLA2	  antigenic	  domains	  carried	  out	  in	  db-­‐2	  (sheet	  ‘PLA2’	  in	  db-­‐3)	  resulted	  in	  a	  total	  of	  18	  possible	  sequence	  variations	  for	  AdPLA2_1,	  13	  for	   AdPLA2_2	   and	   8	   for	   AdPLA2_3	   (Table	   3.1,	   sheet	   ‘PLA2-­‐t’	   in	   db-­‐3)	   matched	  successfully	   against	   the	   toxin	   group	   isoforms.	   The	   best-­‐scored	   sequences,	   the	   ones	  showing	  more	  coverage	  against	  the	  EST	  data:	  4	  for	  AdPLA_1,	  3	  for	  AdPLA2_2	  and	  3	  for	  AdPLA2_3	  (Table	  3.2,	   sheet	   ‘PLA2-­‐s’	   in	  db-­‐3),	  were	  chosen	  as	   the	   final	  epitopes	   to	  be	  used	   in	   the	  string,	  and	  after	  conducting	  a	  series	  of	  changes	   in	   terms	  of	   their	  position,	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the	   construct	   that	   showed	   the	   highest	   antigenicity	   (Figure	   3.12,	   sheet	   ‘JW1’	   In	   db-­‐3)	  was	  chosen	  and	  named	  ‘PLA2Es’.	  
	  
	  
Table	  3.1:	  Table	  generated	  in	  db-­‐3	  under	  the	  name	  of	  “PLA2-­‐t”	  showing	  the	  coverage	  of	  all	  the	  different	  peptide	  sequences	  tested	  against	  the	  Echis	  EST	  sequences.	  Sequences	  showing	  the	  best	  coverage	  are	  highlighted	  in	  red.	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Table	  3.2:	  Table	  generated	  in	  db-­‐3	  (sheet	  “PLA2-­‐s”)	  showing	  the	  summary	  coverage	  of	  the	  best-­‐scored	  peptide	  sequences	  tested	  against	  the	  Echis	  EST	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3.3.2. Serine	  proteases	  A	  total	  of	  four	  clades	  containing	  Echis	  sequences	  were	  selected	  for	  the	  PLA2	  toxin	  group	  as	  well-­‐supported	  branches	  from	  which	  a	  total	  of	  nine	  representative	  isoforms	  (Annex	  3.5.1.1)	  were	  selected	  on	  the	  basis	  of	  EST	  representation,	  cluster	  diversity	  and	  branch	  support.	  Phylogenetic	  analyses	  revealed	  a	  total	  of	  eleven	  clades	  for	  the	  SP	  toxin	  group	  were	   selected	   as	   well-­‐supported	   branches	   from	   which	   a	   total	   of	   19	   representative	  isoforms	   from	   Echis	   ocellatus,	   Echis	   pyramidum	   leakeyi	   and	   Echis	   coloratus	   were	  selected	   to	   carry	   out	   the	   analyses	   based	   of	   EST	   representation,	   cluster	   diversity	   and	  branch	   support.	   Serine	   Proteases	   are	   known	   for	   their	   thrombin-­‐like	   interaction	  with	  macromolecules	  and	  use	  a	  conserved	  catalytic	  triad	  composed	  of	  Ser195,	  Asp102,	  and	  His57.	  Subsequent	  alignment	  of	  the	  Jameson	  Wolf	  antigenic	  index	  plot	  (Annex	  3.5.1.2)	  as	   well	   as	   the	   alignment	   of	   surface	   probability-­‐plot	   (Annex	   3.5.1.3)	   identified	   three	  candidate	   antigenic	   domains	   close	   to	   areas	   of	   the	   catalytic	   triad,	   here	   referred	   to	   as	  AdSP_1	   (red),	   AdSP_2	   (green)	   and	   AdSP_3	   (yellow).	   AdSP_1	   was	   located	   from	   the	  aminoacid	  position	  29	  to	  38,	  AdSP_2	  from	  the	  79	  to	  the	  91,	  and	  AdSP_3	  from	  the	  133	  to	  the	   143.	   Bioinformatic	   predictions	   revealed	   the	   three	   domains	   as	   non-­‐glycosilated,	  accessible	  and	  good	  candidates	  for	  antibody-­‐epitope	  binding	  (Figure	  3.13).	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Figure	  3.13:	  Sequence	  alignment	  of	  representative	  SP	  sequences	  aligned	  together	  with	  the	  PDB	  (2AIP)	  	  Showing	  location	  of	  antigenic	  domains	  (AdSP)	  and	  bioinformatic	  predictions:	  predicted	  buried	  aminoacid	  residues	  (Orange	  lines,	  PEPOP),	  B-­‐cell	  epitopes	  (purple	  horizontal	  boxes,	  Ellipro),	  Glycosylation	  sites	  (light	  blue	  boxes),	  catalytic	  sites	  (dark	  purple	  vertical	  boxes)	  	  
Mapping	  of	  antigenic	  domains	  was	  carried	  out	  using	  the	  sequence	  EOC00049	  (5	  ESTs)	  as	  a	  template	  to	  find	  the	  most	  closely	  related	  PDB	  with	  structural	  data	  available	  (Please	  refer	   to	   db-­‐1,	   sheet	   `template	   PDBs’	   for	   detail)	   and	   analyses	   revealed	   the	   PDB	   2AIP	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from	  Agkistrodon	  contortrix	  contortrix	   (79%	   identity)	  as	  appropriate	   for	   the	  mapping	  of	   antigenic	   domains,	   which	   after	  mapping,	   then	   confirm	   them	   as	   available	   and	  well	  exposed	  in	  surface	  (Figure	  3.14).	  	  
	  
	  
Figure	  3.14:	  Three-­‐dimensional	  mapping	  of	  antigenic	  domains	  	  AdSP_1	  (red),	  AdSP_2	  (green)	  AdSP_3	  (yellow)	  onto	  the	  structure	  of	  a	  monomeric	  serine	  protease	  from	  Agkistrodon	  contortrix	  contortrix	  (PDB	  ID:	  2AIP)	  to	  confirm	  their	  surface-­‐exposure.	  Structure	  is	  shown	  rotated	  among	  the	  Y	  axis	  at	  0°	  (top	  left),	  90°	  (top	  right),	  180°	  (bottom	  left)	  and	  270°	  (bottom	  right)	  degrees.	  	  	  
Sequence	  refinement	   for	  each	  of	   the	  SP	  antigenic	  domains	  by	  db-­‐2	  (sheet	  SP	   in	  db-­‐3)	  resulted	   in	   a	   total	   of	   5	   sequence	   variations	   for	   the	   antigenic	   domain	   AdSP_1,	   7	   for	  AdSP_2	  and	  11	   for	  AdSP_3	  matched	  across	   the	  EST	  data.	  From	  the	   table	  generated	   to	  compare	  the	  EST	  hits	  (sheet	  ‘SP-­‐t’	  in	  db-­‐3),	  the	  best-­‐scored	  sequences:	  3	  for	  AdSP_1,	  3	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for	  AdSP_2	  and	  4	  for	  AdSP_3	  (sheet	  ‘SP-­‐s’	  in	  db-­‐3)	  were	  chosen	  as	  the	  final	  epitopes	  to	  be	  used	  in	  the	  string	  and	  were	  further	  tested	  for	  their	  antigenicity	  as	  a	  construct	  (sheet	  ‘JW2’	  In	  db-­‐3),	  separating	  the	  epitopes	  by	  two	  lysine	  spacers,	  as	  shown	  in	  Figure	  3.15.	  The	  final	  construct	  was	  named	  ‘SPEs’.	  
	  
	  
Figure	  3.15:	  Epitope-­‐sting	  immunogen	  construct	  (SPEs)	  for	  the	  Serine	  Protease	  toxin	  group.	  	  Epitopes	  are	  spaced	  by	  two	  lysine	  (KK)	  residues	  	  (orange	  boxes)	  a)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	  b)	  Emini	  surface	  accessibility	  scale	  plot,	  charge	  predictions:	  c)	  Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	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glycosylated	  and	  non	  accessible.	  On	  the	  contrary,	   the	  antigenic	  domains	  magenta,	  red	  and	  green	   (from	  now	  on	   referred	   to	   as	  AdCTL_1	  –	  3	   respectively)	   showed	   to	  be	  well	  exposed	   in	   surface,	   immunogenic	   and	   not	   glycosylated	   (Figure	   3.16).	   AdCTL_1	   was	  located	   from	   the	   aminoacid	   position	   40	   to	   59,	   AdCTL_2	   from	   55	   to	   65	   and	   AdCTL_3	  from	  97	  to	  109.	  	  
	  
	  	  
showing	  location	  of	  antigenic	  domains	  (AdCTL)	  and	  bioinformatic	  predictions:	  
Figure	  3.16:	  Sequence	  alignment	  of	  representative	  CTL	  sequences	  aligned	  together	  with	  the	  PDB	  (1UKM)	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predicted	  buried	  aminoacid	  residues	  (Orange	  lines,	  PEPOP),	  B-­‐cell	  epitopes	  (purple	  horizontal	  boxes,	  Ellipro),	  Glycosylation	  sites	  (light	  blue	  boxes),	  catalytic	  sites	  (dark	  purple	  vertical	  boxes)	  	  
Adopting	  the	  design	  principles	  mentioned	  before,	  an	  additional	  structural	  analysis	  was	  carried	   out	   taking	   into	   account	   that	   CTLs	   exist	   as	   heterodimers	   formed	   by	   domain	  swapping,	  which	   could	  hide	   some	  potential	   areas	   for	   antibody	  binding.	  Conveniently,	  analyses	  on	   the	  sequence	  EPL00010	  (39	  ESTs)	  as	  a	   template	   to	   find	   the	  most	   closely	  related	  PDB	  with	  structural	  data	  available,	  revealed	  the	  dimeric	  PDBs	  1OZ7	  from	  Echis	  
carinatus	   (47%	   identity)	   and	   1UKM	   from	   Echis	   multisquamatus	   (42%	   identity)	   as	  appropriate	   for	   the	  mapping	   of	   antigenic	   domains,	  which	   subsequently	   by	   structural	  mapping	   helped	   confirming	   the	   antigenic	   domains	   as	   available	   and	   well	   exposed	   in	  surface	  (Figure	  3.17)	  (Please	  refer	  to	  db-­‐1,	  sheet	  `template	  PDBs’	  for	  detail).	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Figure	  3.17:	  Three	  dimensional	  mapping	  of	  antigenic	  domains	  AdCTL_1	  (magenta),	  AdCTL_2	  (green)	  and	  AdCTL_3	  (red)	  onto	  homodimeric	  C-­‐Type	  lectins	  from	  Echis	  
Multisquamatus	  and	  Echis	  carinatus	  (1UKM	  =	  Ems	  16	  and	  1OZ7	  =	  Echicetin,	  respectively)	  	  	  a)	  0°	  and	  rotated	  among	  the	  Y	  axis	  at	  b)	  90°,	  c)	  180°	  and	  d)	  270°	  degrees.	  Antigenic	  domains	  were	  mapped	  onto	  the	  Chain	  A	  of	  the	  structure	  (Chain	  B	  is	  colored	  in	  light	  blue	  for	  better	  understanding).	  	  
Sequence	  refinement	  for	  each	  of	  the	  CTL	  antigenic	  domains	  by	  db-­‐2	  (sheet	  CTL	  in	  db-­‐3)	  resulted	   in	  a	   total	  of	  12	  sequence	  variations	   for	  AdCTL_1,	  15	   for	  AdCTL_2	  and	  42	   for	  AdCTL_3.	  From	  the	  table	  generated	  to	  compare	  the	  EST	  hits	  (sheet	  ‘CTL-­‐t’	  in	  db-­‐3),	  the	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3.3.4. Snake	  Venom	  Metalloproteinases	  	  Due	  to	  the	  high	  abundance	  of	  SVMP	  transcripts	  in	  found	  in	  Echis,	  phylogenetic	  analysis	  of	   SVMPs	  were	   carried	   out	   in	   two	   different	   sets,	   one	   for	   the	   PIs	   and	   PIIs	   (and	   their	  varients)	  and	  another	  for	  PIIIs	  (and	  its	  variants).	  Phylogenetic	  trees	  revealed	  a	  total	  of	  three	  well-­‐supported	   clades	   for	   the	   SVMP	  PI-­‐PII	   group	   (Annex	  3.5.3.1)	   and	   a	   total	   of	  thirteen	  well-­‐supported	   clades	   for	   the	  SVMP	  PIII	   group	   (Annex	  3.5.4.1).	  Within	   these	  clades,	  a	  total	  of	  9	  and	  29	  representative	  isoforms	  were	  selected	  respectively.	  Sequence	  alignment	  of	  the	  representatives	  helped	  mapping	  key	  target	  catalytic	  areas	  such	  as	  the	  ‘‘H-­‐box’’	   amino	   acid	  motif	   (HEX2HX2GX2HD)	   in	   the	  metalloproteinase	   (MET)	  domain	  and	   the	   integrin-­‐binding	   motif	   of	   the	   Disintegrin	   and	   Disintegrin-­‐like	   domains.	  Subsequent	   alignment	   of	   the	   antigenic	   index	   plots	   of	   the	   representatives	   (Annex	  3.5.3.2,	   3.5.4.2),	   as	   well	   as	   alignment	   of	   surface	   accessibility	   scale	   (Annex	   3.5.3.3,	  3.5.4.3)	  revealed	  that	  the	  antigenic	  domains	  for	  the	  SVMPs	  were	  similar	  for	  both	  PI-­‐PII	  and	   PIII	   groups,	   but	   due	   to	   the	   low	   sequence	   homology	   between	   each	   other,	  immunogens	  were	   instead	   designed	   according	   to	   their	   already	   established	   structural	  classification	   (Figure	   3.19,	  modified	   from	   fox	   &	   Serrano	   2005)	   by	   targeting	   epitopes	  against	  i)	  the	  Metalloproteinase	  (MET)	  domain	  of	  PIs,	  PIIs	  and	  PIIIs	  ii)	  the	  disintegrin	  (DIS)	   domain	   of	   PIIs	   ii),	   the	   disintegrin-­‐like	   (DIS-­‐like)	   domain	   of	   PIIIs	   and	   iv)	   the	  cysteine-­‐rich	  (CRI)	  domain	  of	  PIIIs.	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Figure	  3.19:	  SVMP	  Classification	  according	  to	  Fox	  and	  Serrano	  (2005)	  showing	  the	  target	  domain	  areas	  for	  the	  design	  of	  toxin-­‐specific	  immunogens.	  	  
For	   the	   MET	   domain	   of	   PIs,	   PIIs	   and	   PIIIs,	   a	   total	   of	   three	   antigenic	   domains	   were	  found:	   AdMET_1	   (red)	   located	   from	   the	   aminoacid	   position	   215	   to	   221,	   AdMET_2	  (green)	   from	  the	  253	  to	   the	  260	  and	  AdMET_3	  (yellow)	   from	  the	  346	  to	   the	  355.	  For	  the	  DIS	  domain	  of	  PIIs,	  a	  total	  of	  three	  antigenic	  domains	  were	  found:	  AdDIS_1	  (pink),	  located	  from	  the	  aminoacid	  position	  396	  to	  the	  414	  (this	  domain	  starts	  at	  the	  end	  of	  the	  Metalloproteinase	   domain,	   but	   extends	   to	   the	   disintegrin	   domain),	   AdDIS_2	   (orange)	  from	   the	  422	   to	   the	  441	   and	  AdDIS_3	   (purple)	   from	   the	  450	   to	   the	  484.	  These	   same	  antigenic	  domains	  were	  used	  for	  the	  Dis-­‐like	  domain	  of	  PIIIs,	  but	  instead	  were	  named	  AdDISlike_1	   (pink),	   AdDISlike_2	   (orange)	   and	   AdDISlike_3	   (purple)	   (Figure	   3.20	   and	  3.21).	   For	   the	   CRI	   domain,	   a	   total	   of	   three	   antigenic	   domains	   were	   found:	   AdCRI_1	  (dark	  green),	   located	  from	  the	  aminoacid	  position	  492	  to	  the	  503,	  AdCRI_2	  (magenta)	  from	   the	   536	   to	   the	   551	   and	  AdCRI_3	   (blue)	   from	   the	   603	   to	   the	   614.	   Bioinformatic	  predictions	   confirmed	   all	   of	   the	   antigenic	   domains	   as	   well	   exposed	   in	   surface,	  immunogenic	  and	  not	  glycosylated	  (Figure	  3.21).	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Figure	  3.20:	  Sequence	  alignment	  of	  SVMP	  P-­‐I	  and	  P-­‐II	  representative	  sequences	  aligned	  with	  the	  PDBs	  (3DSL,	  2WD,	  2W13)	  showing	  location	  of	  antigenic	  domains	  (AdMET,	  AdDIS)	  and	  catalytic	  sites	  (purple	  dashed	  boxes)	  	  
	  
Figure	  3.21:	  Sequence	  alignment	  of	  SVMP	  P-­‐III	  representative	  sequences	  aligned	  with	  the	  PDB	  (2DW0,	  3DSL,	  3ERO)	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Showing	  location	  of	  antigenic	  domains	  (AdMET,	  AdDIS	  and	  AdCRI)	  and	  bioinformatic	  predictions:	  predicted	  buried	  aminoacid	  residues	  (Orange	  lines,	  PEPOP),	  B-­‐cell	  epitopes	  (purple	  horizontal	  boxes,	  Ellipro),	  Glycosylation	  sites	  (light	  blue	  boxes),	  catalytic	  sites	  (purple	  dashed	  boxes).	  	  
Mapping	   of	   antigenic	   domains	   onto	   a	   structure	   was	   carried	   out	   using	   the	   sequence	  EPL0005	  (134	  ESTs)	  for	  the	  PI-­‐PII	  group	  and	  EOC00024	  (55	  ESTs)	  as	  a	  template	  to	  find	  the	  most	  closely	  related	  PDB	  with	  structural	  data	  available	  (Please	  refer	  to	  db-­‐1,	  sheet	  `template	  PDBs’	   for	  detail).	  On	   the	  basis	  of	   sequence	  similarity,	  analyses	  revealed	   the	  PDBs	  2DW0	  from	  Crotalus	  atrox	  (58%	  identity)	  and	  3DSL	  from	  Bothrops	  jararaca	  (57%	  identity)	  as	  appropriate	   for	  the	  mapping	  of	  antigenic	  domains,	  which	   in	  turn,	  confirm	  them	  as	  available	  and	  well	  exposed	  in	  surface	  (Figure	  3.22)	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Figure	  3.22:	  Three-­‐dimensional	  mapping	  of	  	  AdMET1_1	  (red),	  AdMET2_2	  (green)	  and	  AdMET3_3	  (yellow);	  DIS	  –AdDIS/DISlike_1	  (pink),	  AdDIS/DISlike_2	  (orange)	  and	  AdDIS/DISlike_3	  (purple);	  and	  AdCRI_1	  (dark	  green)	  and	  AdCRI_2	  (magenta)	  antigenic	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domains	  onto	  homodimeric	  PIII	  SVMPs	  (2DW0,	  VAP2B	  from	  Crotalus	  atrox	  and	  3DSL,	  Bothropasin	  from	  Bothrops	  jararaca)	  	  a)	  0°	  and	  rotated	  among	  the	  Y	  axis	  at	  b)	  90°,	  c)	  180°	  and	  d)	  270°	  degrees.	  Antigenic	  domains	  were	  mapped	  onto	  the	  Chain	  A	  of	  the	  structure	  (Chain	  B	  is	  coloured	  in	  light	  blue	  for	  better	  understanding).	  	  
Sequence	  refinement	  for	  each	  of	  the	  SVMP	  antigenic	  domains	  by	  db-­‐2	  (sheet	  ‘SVMP’	  in	  db-­‐3)	   resulted	   in	   a	   total	   of	   72	   sequence	   variations	   for	   the	   MET	   domain	   (13	   for	  AdMET_1,	  19	  for	  AdMET_2	  and	  39	  for	  AdMET_3),	  95	  for	  the	  DIS	  (6	   for	  AdDIS_1,	  6	   for	  AdDIS_2	  and	  9	  for	  AdDIS_3)	  and	  Dis-­‐like	  (for	  12	  AdDISlike_1,	  25	  for	  AdDISlike_2	  and	  37	  for	  AdDISlike_3)	  domain	  and	  62	   for	   the	  CRI	  domain	   (23	   for	  AdCRI_1,	  19	   for	  AdCRI_2	  and	  20	  for	  AdCRI_3).	  From	  the	  table	  generated	  to	  compare	  the	  EST	  hits	  (sheet	  ‘SVMP-­‐t’	  in	  db-­‐3),	  the	  best-­‐scored	  sequences:	   	  38	  for	  the	  MET	  domain	  (10	  for	  AdMET_1,	  11	  for	  AdMET_2	  and	  17	  for	  AdMET_3),	  26	  for	  the	  DIS	  (3	  for	  AdDIS_1,	  2	  for	  AdDIS_2	  and	  3	  for	  AdDIS_3)	   and	   Dis-­‐like	   (6	   for	   AdDISlike_1,	   5	   for	   AdDISlike_2	   and	   9	   for	   AdDISlike_3)	  domain	  and	  18	   for	   the	  CRI	  domain	   (8	   for	  AdCRI_1,	  5	   for	  AdCRI_2	  and	  5	   for	  AdCRI_3)	  were	   chosen	   as	   the	   final	   epitopes	   to	   be	   used	   in	   the	   string.	   Due	   to	   the	   significant	  sequence	  diversity	  and	  abundance	  of	  chosen	  sequences	   for	   the	  MET,	  DIS,	  DISlike	  and	  CRI	   groups,	   best-­‐scored	   epitopes	   were	   evenly	   divided	   and	   included	   sometimes	   into	  more	   than	   one	   string	   per	   group	   and	   were	   further	   tested	   for	   their	   antigenicity	   as	   a	  construct	  (sheet	  ‘JW4’	  In	  db-­‐3),	  separating	  the	  epitopes	  by	  two	  lysine	  spacers.	  
	  
3.3.4.1. Metalloproteinase	  domain	  The	   final	   constructs	   for	   the	   MET	   domain	   were	   named	   ‘MET1Es’,	   ‘MET2Es’	   and	  ‘MET3Es’.	   MET1Es	   covered	   the	   PI-­‐PII	   group	   (Figure	   3.23),	   while	   ‘MET2Es’	   and	  ‘MET3Es’	  the	  PIII	  group	  (Figure	  3.24).	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Figure	  3.23:	  Epitope-­‐sting	  immunogen	  construct	  (MET1Es)	  for	  the	  Metalloproteinase	  domain	  of	  the	  group	  PI-­‐PII	  toxin	  group.	  	  Epitopes	  are	  spaced	  by	  two	  lysine	  (KK)	  residues	  	  (orange	  boxes)	  a)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	  b)	  Emini	  surface	  accessibility	  scale	  plot,	  charge	  predictions:	  c)	  Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	  .	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Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	  	  
	  
3.3.4.2. Disintegrin	  and	  Disintegrin-­‐like	  domains:	  The	   final	   constructs	   for	   the	   DIS	   domain	   were	   named	   ‘DIS1Es’,	   ‘DISlike1Es’	   and	  ‘DISlike2Es’.	   ‘DIS1Es’	   covered	   the	   disintegrin	   domain	   of	   the	   PII	   group	   (Figure	   3.25),	  while	   ‘DISlike2Es’	   and	   ‘DISlike3Es’	   covered	   the	   DIS-­‐like	   domain	   of	   the	   PIII	   group	  (Figure	  3.26).	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Figure	  3.26:	  Epitope-­‐sting	  immunogen	  constructs	  (DISlike1Es	  and	  DISlike2Es)	  for	  the	  Disintegrin-­‐like	  domain	  of	  the	  group	  PIII	  SVMPs.	  	  Epitopes	  are	  spaced	  by	  two	  lysine	  (KK)	  residues	  	  (orange	  boxes)	  a)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	  b)	  Emini	  surface	  accessibility	  scale	  plot,	  charge	  predictions:	  c)	  Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	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Figure	  3.27:	  Epitope-­‐sting	  immunogen	  constructs	  (CRI1Es	  and	  CRI2Es)	  for	  the	  Cysteine-­‐rich	  domain	  of	  the	  group	  PIII	  SVMPs.	  	  Epitopes	  are	  spaced	  by	  two	  lysine	  (KK)	  residues	  	  (orange	  boxes)	  a)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	  b)	  Emini	  surface	  accessibility	  scale	  plot,	  charge	  predictions:	  c)	  Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	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alignment	  of	  Emini’s	  surface	  accessibility	  scale	  plots	  (Annex	  3.5.5.1	  and	  Annex	  3.5.5.2	  respectively)	  identified	  the	  same	  antigenic	  domains	  that	  were	  previously	  found	  for	  the	  disintegrin	   domain	   for	   the	   PI-­‐PII	   group.	   The	   PI-­‐PII	  Disintegrin	   antigenic	   domain	   that	  starts	  in	  the	  metalloproteinase	  domain,	  and	  extends	  to	  the	  disintegrin	  domain	  was	  not	  used	  for	  this	  toxin	  group.	  Antigenic	  domains	  here	  referred	  to	  as	  AdDIS_1	  (orange)	  and	  AdDIS2_2	  (purple)	  showed	  to	  be	  located	  from	  the	  aminoacid	  position	  51	  to	  76	  and	  89	  to	   the	   111	   respectively.	   Bioinformatic	   predictions,	   consequently	   with	   the	   results	  obtained	   for	   the	   PI-­‐PII	   group	   predictions,	   revealed	   the	   two	   domains	   as	   non	  glycosilated,	   accessible	   and	   good	   candidates	   for	   antibody-­‐epitope	   binding	   (Figure	  3.28).	  	  
	  
Figure	  3.28:	  Sequence	  alignment	  of	  DDisintegrin	  representative	  sequences	  aligned	  with	  the	  PDB	  (1Z1X,	  1TEJ)	  	  Showing	  location	  of	  antigenic	  domains	  (AdDIS_1,	  AdDIS_2)	  and	  bioinformatic	  predictions:	  predicted	  buried	  aminoacid	  residues	  (Orange	  lines,	  PEPOP),	  Ellipro	  and	  Net-­‐N-­‐Glyc	  showed	  no	  results	  for	  this	  sequences.	  	  
Mapping	  of	  antigenic	  domains	  was	  carried	  out	  using	  the	  sequence	  ECO00024	  (36	  ESTs)	  as	  a	  template	  to	  find	  the	  most	  closely	  related	  PDB	  with	  structural	  data	  available	  (Please	  refer	   to	   db-­‐1,	   sheet	   `template	   PDBs’	   for	   detail).	   Analyses	   revealed	   the	   PDB	   1TEJ,	   a	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heterodimeric	  disintegrin	  from	  Echis	  carinatus	  (82%	  identity)	  as	  the	  most	  appropriate	  for	   the	   structural	   mapping	   of	   antigenic	   domains,	   which	   then	   confirmed	   them	   as	  available	  and	  well	  exposed	  in	  surface	  (Figure	  3.29).	  
	  
	  
Figure	  3.29:	  Three-­‐dimensional	  mapping	  of	  AdDIS_1	  and	  AdDIS_2	  antigenic	  domains	  onto	  heterodimeric	  disintegrin	  from	  Echis	  carinatus	  (1TEJ)	  	  
a)	  0°	  and	  rotated	  among	  the	  Y	  axis	  at	  b)	  90°,	  c)	  180°	  and	  d)	  270°	  degrees.	  Antigenic	  domains	  were	  mapped	  onto	  the	  Chain	  A	  of	  the	  structure	  (Chain	  B	  is	  colored	  in	  light	  blue	  for	  better	  understanding).	  	  
Sequence	  refinement	  for	  each	  of	  the	  DIS	  antigenic	  domains	  by	  db-­‐2	  (sheet	  DIS	  in	  db-­‐3)	  resulted	   in	   a	   total	   of	   5	   sequence	  variations	   for	  AdDIS_1	   and	  6	   for	  AdDIS_2.	   From	   the	  table	   generated	   to	   compare	   the	   EST	   hits	   (sheet	   ‘DIS-­‐t’	   in	   db-­‐3),	   the	   best-­‐scored	  sequences:	  2	  for	  AdDIS_1	  and	  3	  for	  AdDIS_2	  (sheet	  ‘DIS-­‐s’	  in	  db-­‐3)	  were	  chosen	  as	  the	  final	  epitopes	  to	  be	  used	  in	  the	  string	  and	  were	  further	  tested	  for	  their	  antigenicity	  as	  a	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construct	  (sheet	  ‘JW5’	  In	  db-­‐3),	  separating	  the	  epitopes	  by	  two	  lysine	  spacers,	  as	  shown	  in	  Figure	  3.30.	  The	  final	  construct	  was	  named	  ‘DIS2Es’.	  
	  
	  
Figure	  3.30:	  Epitope-­‐sting	  immunogen	  constructs	  (DIS2Es)	  for	  the	  the	  Disintegrins	  toxin	  group.	  	  Epitopes	  are	  spaced	  by	  two	  lysine	  (KK)	  residues	  	  (orange	  boxes)	  a)	  Jameson-­‐Wolf	  antigenic	  index	  plot,	  b)	  Emini	  surface	  accessibility	  scale	  plot,	  charge	  predictions:	  c)	  Alpha	  regions,	  d)	  Beta	  regions,	  e)	  Flexible	  regions	  and	  f)	  boxes	  indicating	  the	  colour	  of	  the	  antigenic	  domain	  that	  the	  epitopes	  belong	  to.	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   Name	   Epitopes	  in	  string	   Length	   Kb	   Mw	  	   	   	   bp	   a.a	  
PLA2	   PLA2Es	   10	   369	   123	   0.369	   1440	  
SP	   SPEs	   10	   400	   119	   0.400	   1333	  
CTL	  
CTL1Es	   10	   388	   122	   0.388	   1426	  CTL2Es	   9	   388	   107	   0.388	   1291	  
SVMP	  
MP	  
PI	  -­‐	  PII	   MET1Es	   12	   361	   144	   0.361	   1560	  
PIII	  
MET2Es	   13	   463	   161	   0.643	   1868	  MET3Es	   13	   514	   154	   0.514	   1776	  
DIS	  
PII	   DIS1Es	   8	   493	   118	   0.493	   1248	  
PIII	  
DISlike2Es	   10	   385	   126	   0.385	   1379	  DISlike3Es	   10	   409	   127	   0.409	   1377	  
CRI	   PIII	  
CRI1Es	   9	   412	   109	   0.412	   1256	  CRI2Es	   9	   358	   108	   0.358	   1273	  
DIS	   DIS2Es	   5	   227	   82	   0.277	   1268	  	  
Table	  3.3:	  Summary	  of	  Epitope-­‐string	  immunogens	  composition.	  Kb:	  Kilobases,	  Mw:	  Molecular	  weight	  (Da)	  	  
3.4. DISCUSSION	  
	  
In	  the	  current	  study	  we	  successfully	  designed	  bioinformatically	  a	  set	  of	  epitope-­‐string	  immunogens	   predicted	   to	   be	   capable	   of	   generating	   antibodies	   that	   will	   generate	   a	  cross-­‐reactive	  response	  against	   the	  most	  pathogenic	   toxin	  groups	   (Phospholipases	  A2	  (PLA2),	   Serine	   proteases	   (SP)	   C-­‐type	   lectins	   (CTLs),	   Metalloproteinases	   (SVMPs)	   and	  Disintegrins)	   from	   the	   medically	   important	   African	   species	   Echis	   ocellatus,	   Echis	  
pyramidum	  leakeyi	  and	  Echis	  coloratus.	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Up	  to	  date,	  the	  amino	  acid	  residues	  of	  an	  antibody	  that	  are	  in	  contact	  with	  an	  antigen	  (paratope)	  are	  known	  to	  be	  contained	  in	  six	  loops	  of	  its	  N-­‐terminal	  region	  (these	  loops	  are	  called	  the	  CDR	  -­‐	  Complementarity	  Determining	  Regions,	  three	  from	  the	  light	  chain	  CDRL1–3	   and	   three	   from	   the	   heavy	   chain	   CDRH1–3)	   (Getzoff	   et	  al.	   1987;	   Chothia	   et	  al.	  1989;	   Mian	   et	   al.	   1991;	   Ramaraj	   et	   al.	   2012).	   On	   the	   other	   hand,	   the	   residues	   of	   an	  Antigen	  in	  contact	  with	  an	  Antibody	  (epitopes)	  are	  much	  more	  diverse.	  Up	  to	  date,	  the	  specific	  molecular	  mechanism	  that	  underlies	  the	  generation	  (during	  immunisation)	  of	  antivenom	   neutralizing	   antibodies,	   such	   as	   the	   toxin	   epitopes	   for	   B	   lymphocyte	  recognition	   of	   immunized	   animals,	   as	   well	   as	   the	   toxin	   epitopes	   recognized	   by	   the	  neutralizing	   antibodies	   during	   a	   treatment	   is	   not	   fully	   understood	   (Menez	   1985;	  Wagstaff	   et	   al.	   2006;	   Stock	   et	   al.	   2007;	   Calvete	   et	   al.	   2009;	   Espino-­‐Solis	   et	   al.	   2009;	  Gutierrez	  et	  al.	  2009;	  Calvete	  2010;	  Lomonte	  2012).	  	  	  
In	  the	  view	  of	  snake	  venom	  as	  antigens,	  it	  is	  important	  to	  take	  into	  account	  that	  toxin	  families	  have	  been	  characterized	  for	  having	  complex	  evolutionary	  histories,	  leading	  to	  a	   diverse	   array	   of	   functional	   and	   pathological	   activities	   under	   gene	   duplication	   and	  positive	  selection	  (Kini	  and	  Chan	  1999;	  Fry	  et	  al.	  2003b;	  Fox	  and	  Serrano	  2005;	  2008;	  Casewell	   et	   al.	   2011).	   One	   of	   the	   major	   forces	   driving	   the	   evolution	   of	   venom	   toxin	  families	   has	   been	   shown	   to	   be	   the	   specificity	   and	   adaptation	   towards	   specific	   diets	  (Daltry	  et	  al.	  1996).	  Nevertheless,	  in	  the	  medically	  important	  Echis	  genus,	  adaptation	  to	  specific	  diets	  (Pook	  et	  al.	  2009)	  has	  been	  shown	  to	  occur	  within	  venom	  toxin	  families	  rather	   than	   from	   variations	   in	   the	   expression	   levels	   of	   complete	   toxin	   families	  (Casewell	  et	  al.	   2009).	  Consequently,	   the	   sequence	  diversity	   found	   for	   the	   transcripts	  belonging	   to	   the	   toxin	  group’s	  object	  of	   this	   study	  was	  not	   surprising.	  With	   the	  main	  objective	   of	   selecting	   ortholog	   linear	   (or	   continuous)	   surface-­‐exposed	   epitope-­‐
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sequences	  (Worthington	  and	  Morgan	  1994)	  that	   in	  their	  recombinant	  form	  were	  able	  to	  generate	  antibodies	  that	  could	  neutralize	  the	  toxic	  effects	  of	  the	  venom,	  phylogenetic	  analyses	  were	  of	  good	  use	  for	  grouping	  isoforms	  into	  similarity	  clusters,	  thus	  allowing	  us	   to	   identify	   areas	   of	   shared	   antigenicity	   and	   sequence	   conservation.	   Detailed	  sequence	   analyses	   revealed	   that,	   despite	   the	   presence	   of	   considerable	   aminoacid	  diversity	  among	  the	  isoforms,	  conserved	  areas	  of	  antigenicity	  and	  solvent	  accessibility	  were	   still	   retained.	   Jameson-­‐Wolf	   antigenic	   index	   for	   predicting	   antigenicity	   and	  Emini’s	  solvent	  accessibility	  scores	  for	  predicting	  surface	  exposure	  are	  complementary,	  where	   the	   former	   bases	   its	   predictions	   of	   antigenicity	   on	   a	   set	   of	   scores	   for	   surface	  accessibility	   parameters	   and	   regional	   backbone	   flexibility	   from	   the	   protein	   sequence	  provided	  (Jameson	  and	  Wolf	  1988)	  and	  the	  later	  on	  solvent	  accessibility	  scores	  (Emini	  
et	  al.	   1985)	   that	  are	   calculated	  based	  on	  surface	  accessibility	   scale	   (Janin	  and	  Wodak	  1978)	  and	  reflect	   the	  surface	  exposure	  probabilities	   for	  amino	  acids.	  Accordingly,	  we	  can	  broadly	  suggest	  that	  the	  conservation	  seen	  on	  both	  predictions	  could	  be	  due	  to	  the	  evolutionary	  ‘preservation’	  of	  structural	  features	  among	  the	  toxins,	  which	  would	  allow	  performing	  a	  specific	  function.	  	  
	  Due	  to	  the	  limitations	  of	  the	  structural	  information	  currently	  available	  for	  toxin	  groups	  to	   confirm	   in	   a	  molecular	   detail	   the	   predictions	   carried	   out,	   use	   of	   the	  most	   closely-­‐related	   3D	   structures	   available	   (sometimes	   from	   a	   genus	   that	   has	   a	   different	  geographical	  range	  from	  Echis)	  helped	  mapping	  the	  results	  as	  well	  as	  approaching	  the	  accuracy	  of	  the	   location	  of	  the	  antigenic	  domains.	  Epitope-­‐prediction	  implemented	  by	  using	  PEPOP	  (Moreau	  et	  al.	  2008)	  and	  Ellipro	  (Ponomarenko	  et	  al.	  2008),	  and	  carried	  out	   by	   using	   the	   resulting	   PDB	   files,	   showed	   in	   a	   more	   detailed	   manner,	   the	  accessibility	  of	  the	  segments	  and	  its	  possible	  contribution	  in	  the	  activation	  of	  B-­‐cells	  for	  further	   antibody	   production	   by	   adding	   the	   specificity	   of	   interactions	   in	   terms	   of	  molecular	  and	  atomic	  forces	  that	  could	  be	  generated	  when	  in	  contact	  with	  antibodies.	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This	  predicted	  interaction	  on	  the	  other	  hand,	  was	  carefully	  examined	  to	  not	  be	  affected	  by	  other	  factors,	  such	  as	  glycosylation	  that	  is	  sometimes	  not	  present	  as	  a	  parameter	  for	  the	   prediction	   of	   surface	   exposed	   epitopes.	   Venoms	   contain	   an	   abundance	   of	  glycoproteins	   with	   N-­‐linked	   carbohydrates	   that	   can	   influence	   activity	   and	   the	  immunological	  properties	  of	  the	  toxins.	  Glycosylation	  is	  known	  to	  affect	  the	  binding	  of	  the	   antibodies	   to	   the	   underlying	   peptide	   (Johnson	   and	   Desrosiers	   2002;	   Sirois	   et	   al.	  2007)	  and	  was	  an	  important	  post-­‐translational	  modification	  to	  take	  into	  account	  when	  designing	   the	   epitope-­‐string	   immunogens.	   Protein	   glycosylation	   has	   been	   shown	   to	  greatly	  promote	  the	  maturation	  of	  proteins	  in	  the	  lumen	  of	  the	  secretory	  pathway	  and	  additionally,	   it	   can	   act	   to	   protect	   a	   protein	   from	   proteolysis	   or	   antigenic	   recognition	  (Hebert	  et	  al.	  2005;	  Soares	  and	  Oliveira	  2009).	  	  	  After	  the	  final	  establishment	  of	  the	  antigenic	  domains,	  sequence	  divergence	  across	  the	  isoforms	  within	  the	  regions	  had	  to	  be	  overcome	  in	  order	  to	  generate	  a	  set	  of	  epitopes	  that	  had	  the	  maximum	  coverage	  possible	  across	  the	  ESTs,	  and	  that	  could	  therefore	  be	  predicted	   to	   cross-­‐react	   in	   terms	   of	   neutralization	   by	   an	   antibody.	   Recognition	   of	   an	  exogenous	  antigen	  by	  dendritic	  cells	  (DCs),	  monocytes	  and	  neutrophils	   is	   followed	  by	  its	   processing	   into	   peptides	   to	   be	   loaded	   and	   displayed	   on	   major	   histocompatibility	  complex	   (MHC)	   class	   II	   molecules,	   where	   CD4+	   T	   cells	   will	   recognize	   the	   antigenic	  peptides	  displayed.	  It	  has	  been	  previously	  reported	  that	  the	  optimal	  length	  for	  peptide-­‐MHC	  affinity	  is	  of	  approximately	  18–20	  amino	  acids	  long	  (Sercarz	  and	  Maverakis	  2003;	  O'Brien	   et	   al.	   2008).	   However,	   studies	   using	   peptides	   extracted	   from	   snake	   venom	  toxins,	  although	  vary	  in	  length;	  tend	  to	  utilize	  shorter	  sequences	  (Harrison	  et	  al.	  2000;	  Wagstaff	  et	  al.	  2006;	  Lomonte	  2012).	  	  Accordingly,	  epitopes	  were	  designed	  to	  have	  up	  to	  a	  maximum	  of	  10	  amino	  acids	   long	  and	  additionally;	   lysine	  spacers	  were	  added	   in	  between	   the	   sequences	   in	   order	   to	   enhance	   their	   processing	   as	   individual	   epitopes	  (Wagstaff	  et	  al.	  2006).	  Lysine	  spacers	  were	  used	  under	  the	  rationale	  used	  for	  multiple	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antigenic	  peptides	  (MAPs)	  where	  branched	  peptides	  are	  bound	  via	  a	   lysine	  backbone	  (Tam	  1988).	  	  Specific	  details	  about	  the	  design	  of	  the	  epitope-­‐string	  immunogens	  for	  each	  of	  the	  toxin	  groups	  is	  outlined	  below.	  	  
	  
3.4.1. Phospholipase	  A2	  Some	  features	  of	  the	  Lys49	  myotoxins	  involving	  their	  neutralization	  by	  polyclonal	  and	  monoclonal	   antibodies	   have	   been	   investigated	   (Lomonte	   et	   al.	   1985;	   Lomonte	   et	   al.	  1990;	  Moura-­‐da-­‐Silva	   et	  al.	   1991;	   Lomonte	   et	  al.	   1992;	   Calderon	   and	   Lomonte	   1998;	  Angulo	   et	   al.	   2001)	   but	   their	   immunorecognition	   at	   molecular	   level	   has	   only	   been	  studied	   in	  detail	   recently,	  by	  utilizing	  a	   library	  of	  overlapping	  synthetic	  peptides	   that	  covered	   the	  complete	  sequence	  of	  myotoxin	   II	  Lys49	  PLA2	  homologue	   from	  Bothrops	  
asper	   in	   order	   to	   identify	   linear	   B-­‐cell	   epitopes	   (Lomonte	   2012).	   Although	   evident	  sequence	  divergence	  is	  found	  between	  Bothrops	  and	  Echis	  genus,	  results	  correlate	  with	  the	  predictions	  carried	  on	  the	  Phospholipase	  A2	  toxin	  group	  in	  the	  current	  study.	  For	  Lomonte	   and	   collaborators,	   linear	   epitope	   I	   (KDATDRCCYV	   -­‐	   contained	   within	  AdPLA2_1	  of	   the	  current	   study)	   showed	  reactivity	  against	   rabbit	   serum	  antibodies	   to	  
Bothrops	  asper	  myotoxin	   II.	  Although	  epitope	   I	   failed	   to	  produce	  an	  evident	   response	  against	  equine	  antibodies	  of	  Crotalidae	  polivalent	  antivenom,	  its	  proximity	  to	  the	  linear	  epitope	   II	   (CCYVHKCCYK	   –	   partially	   contained	   within	   AdPLA2_1,	   Figure	   3.9),	   which	  displayed	   one	   of	   the	   best	   recognition	   by	   antibodies,	   could	  make	   AdPLA2_1	   a	   strong	  immunogen	   candidate.	   The	   low	   of	   homology	   between	   the	   sequences	   of	  Bothrops	   an	  
Echis	   could	   be	   the	   reason	   why	   current	   predictions	   showed	   the	   full	   sequence	   of	   the	  homologous	   epitope	   II	   to	   have	   low	  antigenicity.	  Additionally,	   it	   contains	   the	   catalytic	  residue	   of	   Asp/Ser	   49,	   which	   we	   thought	   could	   be	   a	   complex	   (buried)	   target	   for	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neutralization.	  Localization	  of	  both	  sections	  of	  the	  AdPLA2_2	  is	  in	  agreement	  with	  the	  homologous	  epitope	  sequences	  III	  and	  IV	  (CNPKKDRY	  and	  SYSWKDKTIV	  respectively)	  from	   Bothrops	   asper	   myotoxin	   II,	   which	   displayed	   a	   strong	   reactivity	   when	   tested	  against	   rabbit	   serum.	  On	   the	  other	  hand,	  AdPLA2_3	   (located	   in	   the	  C-­‐terminus	  of	   the	  sequence,	  Figure	  3.9)	  contains	  sequences	  that	  are	  homologous	  to	  the	  region	  115-­‐129	  of	  myotoxin	   II,	   a	   heparin-­‐binding	   site	   involved	   in	   the	   cytolytic	   mechanism	   of	   action.	  Besides	   from	   being	   predicted	   as	   highly	   antigenic	   region,	   studies	   have	   successfully	  demonstrated	   that	  specific	  antibodies	  against	   it	  are	  able	   to	  bind	   to	   the	  native	  protein	  and	   inhibit	   its	   myotoxic	   and	   cytolytic	   effects	   in	   vitro	   (Calderon	   and	   Lomonte	   1998).	  Nevertheless,	   studies	   have	   shown	   that	   is	   of	   significant	   antigenic	   variability	   and	  although	   antibodies	   against	   it	   can	   bind	   to	   Lys49	   myotoxins,	   its	   mechanisms	   of	  neutralization	  are	  still	  controversial	  (Angulo	  et	  al.	  2001).	  	  
	  
3.4.2. Serine	  proteases	  The	   specific	   epitopes	   that	   play	   a	   role	   in	   the	   neutralization	   of	   this	   toxin	   group	   by	  antibodies	  from	  antivenoms	  is	  not	  yet	  understood.	  The	  SPs	  from	  snake	  venom	  exhibit	  the	   common	  catalytic	  mechanism	  of	   serine	  proteases,	  which	   is	  based	  on	   the	   catalytic	  triad	   formed	   by	   serine	   (Ser195),	   histidine	   (His57)	   and	   aspartate	   (Asp102)	   residues	  (Serrano	   and	   Maroun	   2005)	   (Figure	   3.13).	   	   Literature	   suggests	   a	   wide	   variety	   of	  activities	   catalysed	   by	   this	   toxin	   group	   by	   exhibiting	   coagulant	   and	   procoagulant,	   as	  well	   as	   anticoagulant	   activities,	   inhibitors	   of	   platelet	   function,	   and	   activators	   of	   the	  fibrinolytic	   system.	  Discrepancy	   among	   a	   range	   of	  molecular	  weights	   (from	  25	   up	   to	  65–70	   kDa)	   for	   SPs	   has	   been	   suggested	   to	   be	   the	   result	   of	   post-­‐translational	  modifications	   in	   their	   molecular	   diversity,	   among	   which	   glycosylation	   could	   be	   the	  most	  prominent	  (Zhu	  et	  al.	  2005;	  Silva-­‐Junior	  et	  al.	  2007;	  Soares	  and	  Oliveira	  2009).	  In	  terms	  of	  antigenicity,	  glycosylation	  was	  the	  most	   important	  characteristic	  to	  take	  into	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account	   for	   the	   design	   of	   the	   SP	   epitope-­‐string	   immunogens.	  N-­‐	   linked	   glycosylation	  sites	   in	  SPs	  are	  usually	   localized	  close	   to	   residues	  of	   the	  catalytic	   triad	   (Asp	  and	  His)	  and	   on	   loops	   around	   of	   the	   groove	   that	   containing	   the	   catalytic	   triad	   (Soares	   and	  Oliveira	  2009).	  Sequence	  conservation,	  as	  well	  as	  antigenicity	  for	  the	  purposes	  of	  this	  study	  was	  also	  found	  to	  be	  located	  close	  to	  the	  catalytic	  residues	  of	  the	  toxin	  group.	  To	  overcome	   this,	   sequences	   that	   contained	   glycosylation	   motif	   Asn-­‐Xaa-­‐Ser/Thr	   inside	  the	  sequence	  were	  avoided,	  as	  was	  the	  case	  for	  the	  sequences	  contained	  in	  the	  AdSP_2,	  adjacent	  to	  the	  His57	  catalytic	  residue.	  	  	  
	  
3.4.3. C-­‐Type-­‐lectins	  The	  toxin	  group	  of	  C-­‐Type	  lectins	  was	  the	  most	  diverse	  in	  terms	  of	  amino	  acid	  sequence	  and	  several	  efforts	  were	  made	  in	  order	  to	  determine	  the	  chain	  origin	  of	  the	  sequences,	  taking	   into	   account	   that	   structurally,	   this	   toxin	   group	   can	   be	   found	   as	   heterodimers.	  Previous	   studies	   have	   demonstrated	   in	   Echicetin	   (from	  Echis	  carinatus)	   that	   that	   the	  level	  of	  amino	  acid	  sequence	  homology	  between	  the	  two	  subunits	   is	  of	  approximately	  50%	   (Jasti	   et	   al.	   2004a).	   In	   agreement,	   comparison	   of	   the	   two	   chains	   from	   the	  most	  closely	  related	  sequences	  with	  structures	  available	  also	  showed	  significant	  divergence	  between	   its	   two	   chains.	   It	   has	   been	   reported	   that	   despite	   the	   target,	   amino	   acids	  exposed	  at	  the	  surface	  of	  the	  concave	  domain	  that	  is	  formed	  by	  the	  swapped	  loops	  in	  C-­‐Type	  lectins	  are	  variable,	  because	  of	  structural	  reasons	  that	  make	  them	  less	  likely	  to	  be	  under	   evolutionary	   pressures	   to	   remain	   conserved	   (Polgar	   et	  al.	   1997;	   Zelensky	   and	  Gready	  2005).	  CTLs	  have	  been	   found	  to	  exist	  as	  either	  αβ,	   (αβ)2,	  or	  (αβ)4	  oligomeric	  forms	  (Polgar	  et	  al.	  1997),	  therefore,	  the	  biggest	  effort	  for	  this	  toxin	  group	  was	  to	  find	  antigenic	   surface-­‐exposed	   areas.	   The	   location	   of	   the	   antigenic	   domains	   AdCTL_1,	  AdCTL_2	   and	   AdCTL_3	   was	   in	   agreement	   with	   previous	   studies	   by	   Harrison	   et	   al.	  (2003a)	  where	  the	  predicted	  antigenic	  profiles	  of	  CTL	  sequences	  from	  Echis	  (and	  Bitis)	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indicated	  that	  the	  neutralisation	  of	  this	  group	  of	  toxins	  would	  require	  antibodies	  with	  numerous	   and	   distinct	   specificities.	   Accordingly,	   the	   sequence	   variability	   previously	  mentioned,	   lead	   to	   the	   need	   of	   using	   several	   sequences	   as	   epitopes,	   resulting	   in	   a	  considerably	   large	   epitope-­‐string	   that	   had	   to	  be	  divided	   into	   two	   for	  better	   coverage	  within	  the	  Echis	  sequences.	  	  
	  
Additionally,	   studies	   have	   demonstrated	   that	   the	   E.	   ocellatus	   echicetin-­‐like	   CTLs	   is	  associated	  with	   the	   quaternary	   structure	   of	   PIIId	   (formerly	   named	   PIV)	   SVMPs	   (Fox	  and	  Serrano	  2008;	  Wagstaff	  et	  al.	  2009).	  However,	  Casewell	  et	  al.	  (2009)	  demonstrated	  that	  PIIId	  SVMPs	  are	  absent	  from	  the	  E.	  p.	  leakeyi	  venom	  gland	  EST	  database	  (vgDbEST)	  and	   present	   only	   in	   2%	   of	   the	   E.	   c.	   sochureki	   transcriptome.	   Additionally,	   authors	  demonstrated	  that	  the	  Echis	  vgDbESTs	  (except	  for	  E.	  p.	  leakeyi)	  contained	  clusters	  with	  a	  high	  degree	  of	  sequence	  similarity	  to	  another	  PIV-­‐related	  CTL	  Factor	  X	  activator	  light	  chain	   2	   from	   M.	   lebetina	   (Siigur	   et	   al.	   2004).	   Taking	   into	   account	   the	   suggested	  representational	  profile	  of	  CTLs	  matching	   that	  of	   the	  PIV	  SVMPs,	  we	   can	  additionally	  predict	   that	  our	  epitope-­‐string	   immunogens	   could	   therefore	  neutralize	   the	  activity	  of	  the	  related	  pathologies	  to	  the	  P-­‐IIId	  SVMPs.	  	  
	  
3.4.4. Snake	  Venom	  Metalloproteinases	  Snake	   venom	   Metalloproteinases	   are	   known	   to	   be	   complex	   multi-­‐domain	   proteins	  associated	   with	   the	   conspicuous	   hemorrhage	   of	   viperid	   bites.	   SVMPs	   are	   usually	  abundant	  in	  venoms	  and	  their	  neutralization	  is	  known	  to	  be	  clinically	  relevant	  in	  order	  to	  overcome	  envenoming.	  Several	  studies	  have	  focused	  on	  the	  mechanism	  of	  inhibition	  by	   antibodies,	   which	   were	   taken	   into	   account	   for	   the	   design	   of	   the	   epitope-­‐string	  immunogens	  against	   the	   toxin	  group	  during	   this	  study.	   	  SVMPs	  are	  classified	   in	   three	  main	   groups:	   P-­‐Is,	   comprises	   only	   the	   metalloproteinase	   domain;	   P-­‐IIs	   have	   a	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metalloproteinase	   domain	   followed	   by	   a	   disintegrin	   domain,	   which	   is	   sometimes	  proteolytically	  cleaved	  and	  forms	  the	  classical	  disintegrin	  group;	  and	  P-­‐	  IIIs	  comprise	  a	  metalloproteinase,	   disintegrin-­‐like	   and	   cysteine-­‐rich	   domains	   (reviewed	   by	   Fox	   and	  Serrano,	  2008).	  On	  the	  basis	  of	  their	  domain	  organization,	  immunogens	  were	  designed	  to	   be	   able	   to	   generate	   antibodies	   predicted	   to	   neutralize	   the	   activity	   of	   SVMPs	   by	  binding	  to	  the	  Metalloproteinase	  domain	  (predicted	  to	  bind	  to	  P-­‐Is,	  P-­‐IIs	  and	  P-­‐IIIs),	  the	  Disintegrin	   domain	   (predicted	   to	   bind	   to	   P-­‐IIs	   and	   cleaved	   disintegrins),	   the	   Dis-­‐like	  and	  Cysteine-­‐rich	  domain	  (predicted	  to	  bind	  to	  PIIIs).	  	  Specific	  details	  for	  each	  domain	  are	  described	  below.	  	  
	  
Metalloproteinase	  domain	  	  
Several	  attempts	  have	  been	  made	   in	  order	   to	  neutralize	   the	  multiple	   tissue-­‐damaging	  activities	   that	   includine	   hemorrhage,	   myonecrosis,	   dermonecrosis,	   blistering,	   and	  edema	  (Rucavado	  et	  al.	  1995;	  Rucavado	  et	  al.	  1998;	  Jimenez	  et	  al.	  2008)	  of	  P-­‐I	  SVMPs.	  Bap1	  is	  a	  P-­‐I	  SVMP	  formed	  by	  a	  single	  chain	  of	  202	  amino	  acids	  and	  shows	  the	  highest	  sequence	   identity	   with	   SVMPs	   isolated	   from	   other	   venoms	   of	   Crotalinae	   snakes	   and	  was	  found	  to	  resemble	  a	  close	  identity	  with	  the	  Echis	  sequences	  analysed	  in	  this	  study.	  The	   amino	   acid	   sequences	   of	   Bap1	   and	   crystal	   structure	   have	   been	   previously	  described	   (Watanabe	   et	   al.	   2003;	   Lingott	   et	   al.	   2009).	   Tanjoni	   et	   al.	   (2003a)	   tested	  monoclonal	  Jararaghin	  antibodies	  (MAJar	  1	  –	  7)	  against	  Bap1,	  and	  only	  MAJar4	  showed	  to	  have	  a	  positive	  (although	  very	  small)	  response.	  Taking	  into	  account	  that	  binding	  for	  the	   other	   Jararhagin	   domains	   was	   positive	   during	   that	   study;	   authors	   suggest	   the	  presence	   of	   perhaps	   an	   epitope	   within	   the	   interdomains.	   In	   agreement,	   during	   our	  analyses	  an	  important	  area	  of	  antigenicity	  was	  found	  to	  be	  located	  exactly	  in	  the	  start	  of	  the	  disintegrin	  and	  disintegrin-­‐like	  domain,	  taking	  up	  some	  of	  the	  residues	  located	  in	  the	   C-­‐terminal	   sequence	   of	   the	   metalloproteinase	   domain.	   This	   antigenic	   domains	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(AdDIS_1	  and	  AdDISlike_2,	  for	  the	  disintegrin	  and	  disintegrin-­‐like	  domain	  respectively)	  were	  chosen	  after	  also	  confirming	  their	  surface	  exposure	  and	  lack	  of	  glycosylation.	  	  
	  
Fernandez	  et	  al.	  (2010)	  demonstrated	  that	  a	  series	  of	  monoclonal	  antibodies	  were	  able	  to	  bind	  to	  Bap1	  and	  cross-­‐react	  with	  venoms	   from	  other	  species	   in	   their	  native	  state.	  However,	   no	   successful	   results	  were	   found	  when	   treating	   the	   enzyme	  with	   reducing	  agents,	  which	  evidenced	   that	  epitopes	   require	  native-­‐like	  structures	   to	  be	   recognized	  by	  the	  antibodies	  they	  obtained.	  The	  specific	  location	  of	  the	  epitopes	  that	  play	  a	  role	  in	  this	  binding	  is	  yet	  to	  be	  studied.	  Wagstaff	  et	  al.	  (2006)	  on	  the	  contrary,	  demonstrated	  that	  DNA	  immunisation	  with	  the	  sequence	  of	  a	  metalloproteinase	  domain	  from	  an	  Echis	  
ocellatus	  SVMP	  transcript	   is	  able	  to	  react	  under	  reduced	  conditions	  against	  the	  whole	  venom,	   suggesting	   the	   possible	   presence	   of	   linear	   epitopes	   within	   the	   domain.	  Reactivity	   of	   antibodies	   raised	   against	   EoMP1,	   an	   extracted	   epitope	   sequence	  (synthesised	   as	   a	   MAP)	   that	   contains	   the	   complete	   catalytic	   zinc-­‐binding	   motif,	  together	  with	   the	  Met-­‐turn	   residue,	   however,	   showed	   to	   be	   able	   to	   bind	   only	   to	   the	  
Echis	   SVMP	   transcript	   it	   was	   designed	   from.	   Results	   are	   in	   agreement	   with	   our	  predictions,	  where	   the	   catalytic	  motif	   and	   the	  Met-­‐turn	   residue	   showed	   to	   be	   buried	  inside	   the	  structure,	   suggesting	   that	  antibodies	   raised	  against	   it	  would	  not	  be	  able	   to	  bind	   in	   the	   native	   state	   of	   the	   protein.	   This	  was	   overcomed	   in	   the	   current	   design	   by	  excluding	   the	   predicted	   buried	   areas	   and	   generating	   an	   epitope-­‐sequence	   that	   is	  located	   in	   a	   surface-­‐exposed	   area,	   which	   lies	   exactly	   between	   the	   catalytic	   sites.	  Antigenic	   domains	   AdMET_1	   and	   AdMET_2	   were	   also	   added	   as	   regions	   to	   extract	  candidate	  epitope-­‐sequences.	  Although	  AdMET_2	  and	  AdMET_3	  showed	   to	  contain	  or	  be	   adjacent	   glycosylation	   motifs	   respectively	   for	   the	   P-­‐III	   group	   (Figures	   3.20	   and	  3.21),	  antigenic	  domains	  were	  still	  retained	  and	  epitope	  sequences	  were	  chosen	  on	  the	  basis	  of	  not	  including	  de	  glycosylation	  motif	  NDS/NVT.	  	  	  
	   	   95	  
Dis-­‐like	  domain,	  Disintegrin	  domain	  and	  proteolytically	  cleaved	  Disinegrins	  
Alignment	   of	   the	   Disintegrin	   domain	   of	   P-­‐IIs	   and	   Dis-­‐like	   domain	   of	   P-­‐IIIs	   showed	  significant	   sequence	   divergence	   during	   the	   analyses.	   Taking	   into	   account	   that	   P-­‐IIs	  SVMPs	   undergo	   a	   proteolytic	   processing	   that	   results	   in	   the	   release	   of	   the	   disintegrin	  domain	   as	   a	   post-­‐translational	   modification,	   alignments	   were	   separated	   in	   two	  different	  sets	  containing	  the	  P-­‐I,	  P-­‐II	  group	  and	  the	  P-­‐III	  group;	  alignment	  of	  the	  cleaved	  Disintegrins	  was	   aligned	  as	  well	   separately	   to	   the	  P-­‐II	   group.	   It	   is	  worth	   to	  note	   that	  although	   an	   important	   sequence	   divergence	  was	   found	   to	   occur	   between	  Disintegrin	  and	   Dis-­‐like	   sequences,	   the	   antigenicity	   showed	   to	   be	   fairly	   conserved	   across	   the	  groups,	  leading	  to	  use	  the	  same	  antigenic	  areas	  for	  them.	  We	  generated	  a	  strategy	  of	  re-­‐naming	   them	   accordingly	   to	   their	   group	   for	   easier	   understanding,	   where	   antigenic	  domains	   AdDIS_1	   (pink),	   AdDIS_2	   (orange)	   and	   AdDIS_3	   (purple)	   (Figure	   XX)	  correspond	  to	  P-­‐II	  SVMPs	  and	  the	  Disintegrin	  cleaved	  group,	  while	  antigenic	  domains	  AdDISlike_1	  (pink),	  AdDISlike_2	  (orange)	  and	  AdDISlike_3	  (purple)	  correspond	  to	  P-­‐III	  SVMPs	  (Figure	  3.20).	  	  
	  
The	   Disintegrin	   domain	   has	   been	   studied	   previously	   on	   the	   basis	   of	   its	   pathological	  properties,	   where	   the	   most	   remarkable	   is	   the	   binding	   to	   platelet	   integrins	   and	  responsible	   for	   a	   serious	   haemorrhagic	   effect	   during	   envenomation	   cases.	   Based	   on	  previous	   successful	   studies	   by	  Wagstaff	   et	   al.	   2006,	   antigenic	   domains	   AdDIS_2	   and	  AdDIS_3	   were	   located	   adjacent	   to	   the	   predicted	   buried	   integrin	   α5β1	   binding	   RGD	  (Figure	  3.20	  and	  3.28).	  Several	  studies	  carried	  out	  on	  Jararhagin,	  a	  P-­‐III	  SVMP	  isolated	  from	  the	  venom	  of	  Bothrops	  jararaca,	  and	  the	  main	  component	  responsible	  for	  the	  local	  and	   systemic	   hemorrhage	   induced	   during	   envenomation	   (Paine	   et	   al.	   1992),	   have	  successfully	   highlighted	   the	   importance	   of	   the	   disintegrin-­‐like	   and	   cysteine-­‐rich	  domain	   for	   the	  neutralization	  of	  haemorrhagic	  activity	  of	  P-­‐III	  SVMPs	   (Harrison	  et	  al.	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2000;	  Harrison	  et	  al.	  2002;	  Moura-­‐da-­‐Silva	  et	  al.	  2003),	  which	  was	  taken	  into	  account	  during	   the	   design	   of	   immunogens	   for	   the	   current	   study.	   Although	   the	   specific	  sequences	  that	  play	  a	  role	  in	  the	  generation	  of	  neutralizing	  antibodies	  is	  not	  yet	  known,	  a	  study	  previously	  mentioned	  developed	  by	  Tanjoni	  et	  al.	  (2003a)	  successfully	  showed	  that	   monoclonal	   antibodies	   are	   able	   to	   bind	   to	   epitopes	   located	   in	   both	   C-­‐	   and	   N-­‐	  terminus	   of	   the	   disintegrin-­‐like	   region	   of	   Jararhagin.	   Binding	   and	   neutralization	   of	  activity	  with	  a	  monoclonal	  antibody	  (MAJar3)	  to	  the	  JD49	  fragment,	  which	  includes	  the	  sequence	   SECDPA,	   an	   antagonist	   sequence	   that	   has	   been	   previously	   shown	   to	   be	  involved	   in	   the	   recognition	   of	   the	   α2β1	   integrin	   binding	   to	   collagen	   (Kamiguti	   et	   al.	  1997),	   helped	   remarking	   the	   importance	   in	   the	   design	   of	   epitopes	   targeting	   the	  disintegrin	  and	  cysteine-­‐rich	  areas.	  Accordingly,	  Wagstaff	  et	  al.	  2006	  included	  a	  similar	  area	   to	   the	   one	   recognized	   by	   MAJar3	   as	   a	   potential	   target	   for	   neutralization	   in	   his	  study.	   For	   our	   results,	   we	   found	   that	   the	   section	   could	   be	   divided	   into	   two	   distinct	  antigenic	   domain	   on	   the	   basis	   of	   antigenicity,	   and	   therefore,	   AdDISlike_2	   and	  AdDISlike_3	  were	   selected.	   AdDISlike_2	   (Figure	   3.22),	   for	   being	   close	   to	   the	   catalytic	  residue	  of	  Calcium	  binding	  interestingly	  showed	  a	  high	  degree	  of	  conservation,	  which	  made	   it	   a	   good	   epitope	   candidate	   that	   would	   be	   predicted	   to	   cross-­‐react	   among	   the	  
Echis	  group.	  	  
	  
The	   addition	   of	   AdCRI_1	   was	   important	   for	   the	   data	   (Figure	   3.22),	   since	   the	   study	  carried	   out	   by	   Tanjoni	   successfully	   demonstrated	   the	   presence	   of	   two	   monoclonal	  antibodies	   that	   are	   capable	   of	   recognizing	   the	   whole	   Jararhagin	   molecule,	   but	   not	  recombinant	   fragments	  of	   the	  domains,	  meaning	   that	  epitope	  should	  be	   located	   in	  an	  interdomain	   location.	   	   AdCRI2	  was	   an	   area	   of	   highly	   conserved	   antigenicity	   that	  was	  chosen	  but	  up	  to	  date,	  no	  studies	  have	  shown	  if	  perhaps	  is	  involved	  in	  the	  recognition	  by	  antibodies.	  On	  the	  other	  hand,	  AdCRI_3	  corresponds	  to	  the	  same	  epitope	  sequence	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used	   by	  Wagstaff	   et	   al.	   (2006),	   EoMPep	  6,	   C-­‐terminal	  motif,	  which	  was	   able	   to	   show	  cross-­‐reactivity	  to	  distinct,	  and	  larger	  SVMP	  molecular	  mass	  variants	  that	  according	  to	  the	  author,	  are	  likely	  to	  be	  multimeric	  SVMPs.	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3.5. ANNEXES	  	  
	  
3.5.1. Serine	  Proteases	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3.5.1.2. Jameson	  Wolf	  antigenic	  index	  plot	  alignment	  (Jameson	  Wolf)	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Surface Probability Plot - Emini1
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Surface Probability Plot - Emini1
7.08
>MVL IRVLANLLVLQLSYAQKSSELVIGGAECD INEHRSLVLVYNXXXSGFLCGGTLINREWVLSAAHCYMKNMRIYLGLHNFSLPNNDQQRRGARETYFCLPSRNYTKWDKDIML IKLNRPVNYSTHI APLRLPSNPPHLGSVCHIMGWGAI TSPNETHPDVPHCANINI LRYSICRAAYGGLPAQSRTLCAGI LGRRIGSCKGDSGGPLICNGQIQGI VSWGAKVCARPRAPGLYTKVFDXTDWIQSI XAGNTTAXXPP*
Surface Probability Plot - Emini1
7.33
>MVL IRVLANLLVLQLCYAQKSSELVIGGAECN INEHRSLALVFNXXXSGFICGGTLINQEWVLSAAHCDVENMQIYLGLHNFSPPNKEHKERVAKEKFFCLPSRNYTLWDKDIML IKLNRPVKNSAHI APLHLPSNPPRLGSVCRIMGWGSI ISPNEKMSYVPHCANINI LRYSLCQVI YGGLPDKSRTLCAGI LGTRIGSCKGDSGGPLICDGQIQGI VSWVSKPCAHHGAPGMXXXXXXXXXXXXXXXXXXXXXXXXX*
Surface Probability Plot - Emini1
8.46
>MVL I IVLANLLVLQLSYAQKSSELVIGGAECN INEHRSLALVFNXXXSGFICGGTLINHEWVLSAAHCDVENMQIYLGLHNFSPPNKEHKKRVAKEKFFCLSSKSYTLWDKDIML IKLNKPVKNSAHI EPLSLPSNPPRLHSVCRIMGWGSI TSPNEKMSYVPHCANINI LRYSVCQAI YGGLPDKSRTLCAGI LGRRIGSCKGDSGGPLICDGQIQGI VSWVSKPCAHHGAPGMYTKVFDYTDWMQSI IAGSTTATCPP*
Surface Probability Plot - Emini1
8.46






















	   	   101	  
3.5.2. C-­‐Type	  lectins	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3.5.2.2. Jameson	  Wolf	  antigenic	  index	  plot	  alignment	  (Jameson	  Wolf)	  
showing	  the	  candidate	  antigenic	  domains	  
	  




























Antigenic Index - Jameson-Wolf0
3.1
>MGRF ISVSFSLLVVFLSLSGTGAAPDCPTNWTAYENHCYRVFDEPKKWKDAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESEXXXXI IWMGLSXXKIWNKCDWAWSNGAKLKYEAWAEXXESYCI YIASNNKXXEWNSRPCEMFGHFACKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ICVSFGLLVVFLSLSETGAXXDCLPDWFLYEGHCYKVFDEPKPWADAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESPXXXXI VWMGLNXXKIWNQCDWTWTNGAKLKYEAWAEXXESYCI HI TSTKKXXEWKSLPCRNYGHFACKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVMFLSLSGTEAXXECLPDWFHYEGHCYRVFDEPKTWADAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESPXXXXI VWMGLSXXKVWNQCDWGWTNGAKLNYEAWAEXXESYCI HI TSTKKXXEWKSLPCRNYGHFACKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGAGLCCPLGWSSFDQHCYKVFEPLKNWTDAEEFCRQQHKGSQLASIHSSEEEAFVSKLASKVLKFAXXXXSVWIGLNXXNPWKECKWEWSDDSRFDYKAWNRXXRPYCTVMVLNPDKIFWFTRGCEKSVSFVCKFLTDPAVXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGAGLCCPLGWSSFDQHCYKVFEPLKNWTDAEEFCRQQHKGSQLASIHSSEEEAFVSKLASKVLKFAXXXXSVWIGLNXXNPWKECKWEWSDNAKFDYKAWNRXXRPYCTVMVLKPDKIFWFTRGCEKSVSFVCKFLTDPAVXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVVFLSLSGTEAGVCCPLGWSGYDQNCYKAFEELMNWADAEKFCTQQHKGSHLVSLHNI AEADFVVKKI VSVLKDGXXXXVIWMGLNXXDVWNECNWGWTDGAQLDYKAWNVXXESNCF IFKTAENXXHWSRTDCSGTHSFVCKFQVXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVVFLFLSGI EAAFCCPLGWSGYDENCYKAFEKQMNWADAERFCTQQHKGSHLVSLHNI AEADFVI KKTSPVLKGSXXXXVFWLGLNXXDVWNECNWGWTDGAQLDYKAWNVXXESNCF IYNTAXNXXHWLRTDCRSTHNF ICKFGVXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGADQDCLPDWSSHERHCYKVINEYKTWEEAEQYCTEEANGGHLVSFHNRQEVAFVVKLGYTI LKADXXXXVVWIGLRXXDFWRECQWEWSNGAKLNYKGWSDXXEPNCF IAYTVGNXXRWVRRKCSSTHPF ICKARI PRXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGIGADQECLPGWSFYEGHCYKVFSEYKNWVDAEQYCTEQENGGHLVSFHNREEVDFVVKLGYTI LKADXXXXI VWIGLRXXDFWRECHWEWSNGAQLDYKGWSDXXEPNCF IAYTVGNXXKWLRRKCSSTQQF ICKARVPHXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGIGADQNCLPGWSFYEGHCYKVF IQRKTWVDAEQYCTERATGGHLI SFHNSEEVDFMVSLAYPI LSATXXXXLVWIGMSXXDFWRDCDWKWSDGAKLDYKAWNNXXEPNCFTAKTTDNXXQWLRRDCIGTRNFVCKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFSLLVVFLSLSETGADXXCLPDWSSHEGHCYKVFTQKMTWADAEKFCTEQVKTGHLVSFHSSEEVDFMVSLAFPI LKVDXXXXFVWIGMSXXDYLRDCEWKWSDGERLDYKAWNNXXELNCFVSKTTDNXXQWLRRDCSRTCNFVCKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVMFLSLSETGADXXCLPDWSSYEGHCYKVFNQKMTWTDAEKFCTEQVKTGHLVSFHSSEEVDFMVSLAFPI LKVDXXXXFVWIGMSXXDFWRDCEWKWSDGERLDYKAWNNXXELNCFVSKTTDNXXQWLRRDCNRRCNFVCKYPAXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGADXXCLPDWSPYQGHCYRVFNQKMTWADAEKFCTEQANGGHLASFHSSKEVDFMVSLAFPMLKVDXXXXFVWIGMSXXDFWRDCEWKWSDGAKLDYKAWNNXXELNCFVSKTTDNXXQWLRWDCSRTNNVACKYPLXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISASFSLLVVFLSLSGTGADEMCPPDWSSNGEYCYGLFKEPKTWADAEEFCKHQGKGGHLVSIQSKREEI LVKLVASANLEKRXXNYLIWTGLSXXXERQHCSSHWTDGSFRSYEXXI PI LYSECFVMQKEQKTXMLI AMPCEKTFPFMCKHPVPGKDSAV*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLFLSGTGADFDCPSGWTAYDQHCYHAVDEPKTWADADKFCSEQANGGHLVSIQSREKRNFVAQLVSGF IHRPXXGIYVWIGLTDRRTEQQCNPEWNDGSQI IYVNWKEGQSVMCHGLANWTNFHEWDNI NCADHYRFVCPFPSQXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSRTGADFDCPSGWTAYDQHCYQAVDEPKTWEEAEKFCTEQANGGHLVSIQSREEGNFVAQLVSGF IQRPXXGIYVWIGLRDRRKEQQCTSEWNDGSKI IYVNWKEGESKMCQGLAKWTDFHEWDNI NCADRYRFVCKFPSQCXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLLVFLSLSGTGADFECPPEWSAYDLHCYKAFDKPKRSRDAEEFCKKQANSGHLASIESREEGDFVAQLI SENI KSSXXADYVWIGLWNKRREQYCTSQWTDGSNVIYKNMVERFTKNCFGLEKKTGYRKWVNLRCGDDYPFVCKFLPQCXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFSLLVVFLSLSGTGADFECPPEWSSYDLHCYKAFDKPKRSRDAEKFCTEQAKGGHLASIESSEEGDFVAKLI SENI KSSXXADYVWIGLWNKRREQYCTSQWTDGSNVIYKNVI ERFTKNCFGLEKKTEYRTWFNLRCGDDYPFVCKFPPQCXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFKLLVVFLSLSGTGAGLHCPPNSAPYRYFCYRVFKEYKTWEEAEQYCTDRPNNGHLVSIESMEEREFVAQLLSKVTEKHXXI THFWIGLRI EDKEQLCGSEWTDGSRVSYDNLHKRESRKCFALKKETAYRTWFHTNCAERYPFVCKVPPYCXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVVFLSLSGTGADLDCPPNSAPYRYFCYRVFKEHMTWEEAERFCQERPNNGHLVSIESSEEGDFVAQLLSKVTEKHXXI THFWIGLRI VDKEQHCRSEWSDGSSVSYDNLHKRESRKCFALEKETGYRTWFHMYCADSYPFVCKVPPYCXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVVFLSLSGTGADDHCQPGWSFYAEYCYKVFSQQMNWTDAEEFCKKQAEGGHLAAIDWVGRVNFVAELVSEGLKDYKYPYYVWIGLSDQSERQQCSSKWTDGSLVCYDXXNGVDTTKCFALDRQTGCRTWVARPCRQRYPF ICVRWAPIEDPAV*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGADXXCLPGWSFYEGHCYKVI TQEMNWTDAEKFCTEQPNGGHLASIEWLGKANFVAELVSESLKDYKYNFYVWIGLSDQTERQQCSSEWSDGSSVSYDXXDGVYSAKCFGLPEKTEYHTWVALPCKQKHRF ICMSWLPPEDAAV*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSETGADQECLPGWSLYERRCYKVFTERKTWEEAEKFCNXQWDGGHLVSIESTAKAEFLTQLVSQKLRKXXXKYNVWIGLRDHSEKQHCSSYWTDGSF ISYQNVVYXXPAKCFMLDERTEFRKWVPFRCDI KFPF ICKSKI PRXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVVFLSLSETGADQDCLRGWTFYERRCYRVFNQEKTWEEAEKFCNXRWDGGHLVSIESTAKAEFVTQLLSKNLKEXXXKYHVWIGLRDQSKKQHCSELWTDGSF I TYENVVYXXPTKCFVLNKYTEFRNWVPFRCDIGLPF ICKSKI PRXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFFSVSFGLLVLFLSLSETGADQDCLRGWSFYERRCYRVFNQQKTWEEAEKFCNXRWDDGHLVSIESTAKAEFLTQLVSENLREXXXRHHVWIGLRDHSEKQQCSSYWTDGSF ISYENVI NXXPAKCFVLNQYTEFRNWVAFRCDIGLPF ICKSKI PRXXXXX*
04G05%ECO00153%
10H02%ECO00127%
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSGTGADXXCLPGWSSYEGHCYKVFNEYKTWKDAEKFCSEQANDGHLVSIESAEEAEFVAQLI PENXXXXXXIYYVWIGLSYEGTRKHCSSEWSDGSSVSYENWNKQEPRKCI RLEKKTDFRKWVNFYCEKPSRFTCEI XXXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRFLSVSFGLLVVFLSLSGTAADXXCLPGWSSHEGHCYKVFNQEMTWADAEKFCTQQANDGHLVSIESAEEADFVAQLI SENI KSSXXIYYVWIGLSYEGPSKQCSSEWSDRSTVTYENWNKVEPRKCVGLEEQTGYRKWVNFYCKQRNHFTCEI XXXXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MGRF ISVSFGLLVVFLSLSETGADXXCLPGWSSHEGHCYKVFSREMKWADAEKFCTQQANGGHLVSIESAEEADFVSQLVSRNI KSSXXMYYVWIGLSYEGPSKQCSSEWSDGSTVTYENWSKEEPRKCVGLEEKTEFRKWVNLYCERSNHFTCEI XXXXXXXXX*
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3.5.2.3. Emini’s	  surface	  accessibility	  scale	  plot	  alignment	  
	  






























Surface Probability Plot - Emini1
5.16
>MGRF ISVSFSLLVVFLSLSGTGAAPDCPTNWTAYENHCYRVFDEPKKWKDAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESEXXXXI IWMGLSXXKIWNKCDWAWSNGAKLKYEAWAEXXESYCI YIASNNKXXEWNSRPCEMFGHFACKYPAXXXXXXX*
Surface Probability Plot - Emini1
3.74
0.0613
>MGRF ICVSFGLLVVFLSLSETGAXXDCLPDWFLYEGHCYKVFDEPKPWADAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESPXXXXI VWMGLNXXKIWNQCDWTWTNGAKLKYEAWAEXXESYCI HI TSTKKXXEWKSLPCRNYGHFACKYPAXXXXXXX*
Surface Probability Plot - Emini1
3.74
0.0818
>MGRF ISVSFGLLVMFLSLSGTEAXXECLPDWFHYEGHCYRVFDEPKTWADAEKFCSEQANGGHLVSVHSRKEAGLVGVLAYQTLESPXXXXI VWMGLSXXKVWNQCDWGWTNGAKLNYEAWAEXXESYCI HI TSTKKXXEWKSLPCRNYGHFACKYPAXXXXXXX*








Surface Probability Plot - Emini1
2.67
0.0613
>MGRFFSVSFGLLVVFLSLSGTEAGVCCPLGWSGYDQNCYKAFEELMNWADAEKFCTQQHKGSHLVSLHNI AEADFVVKKI VSVLKDGXXXXVIWMGLNXXDVWNECNWGWTDGAQLDYKAWNVXXESNCF IFKTAENXXHWSRTDCSGTHSFVCKFQVXXXXXXX*
Surface Probability Plot - Emini1
2.67
0.0613
>MGRFFSVSFGLLVVFLFLSGI EAAFCCPLGWSGYDENCYKAFEKQMNWADAERFCTQQHKGSHLVSLHNI AEADFVI KKTSPVLKGSXXXXVFWLGLNXXDVWNECNWGWTDGAQLDYKAWNVXXESNCF IYNTAXNXXHWLRTDCRSTHNF ICKFGVXXXXXXX*
Surface Probability Plot - Emini1
3.27
0.0613
>MGRF ISVSFGLLVVFLSLSGTGADQDCLPDWSSHERHCYKVINEYKTWEEAEQYCTEEANGGHLVSFHNRQEVAFVVKLGYTI LKADXXXXVVWIGLRXXDFWRECQWEWSNGAKLNYKGWSDXXEPNCF IAYTVGNXXRWVRRKCSSTHPF ICKARI PRXXXXX*
Surface Probability Plot - Emini1
3.05
0.0613
>MGRF ISVSFGLLVVFLSLSGIGADQECLPGWSFYEGHCYKVFSEYKNWVDAEQYCTEQENGGHLVSFHNREEVDFVVKLGYTI LKADXXXXI VWIGLRXXDFWRECHWEWSNGAQLDYKGWSDXXEPNCF IAYTVGNXXKWLRRKCSSTQQF ICKARVPHXXXXX*
Surface Probability Plot - Emini1
3.28
0.0613
>MGRF ISVSFGLLVVFLSLSGIGADQNCLPGWSFYEGHCYKVF IQRKTWVDAEQYCTERATGGHLI SFHNSEEVDFMVSLAYPI LSATXXXXLVWIGMSXXDFWRDCDWKWSDGAKLDYKAWNNXXEPNCFTAKTTDNXXQWLRRDCIGTRNFVCKYPAXXXXXXX*












Surface Probability Plot - Emini1
6.87
>MGRF ISASFSLLVVFLSLSGTGADEMCPPDWSSNGEYCYGLFKEPKTWADAEEFCKHQGKGGHLVSIQSKREEI LVKLVASANLEKRXXNYLIWTGLSXXXERQHCSSHWTDGSFRSYEXXI PI LYSECFVMQKEQKTXMLI AMPCEKTFPFMCKHPVPGKDSAV*
Surface Probability Plot - Emini1
7.07
>MGRF ISVSFGLLVVFLFLSGTGADFDCPSGWTAYDQHCYHAVDEPKTWADADKFCSEQANGGHLVSIQSREKRNFVAQLVSGF IHRPXXGIYVWIGLTDRRTEQQCNPEWNDGSQI IYVNWKEGQSVMCHGLANWTNFHEWDNI NCADHYRFVCPFPSQXXXXXX*
Surface Probability Plot - Emini1
9.96
>MGRF ISVSFGLLVVFLSLSRTGADFDCPSGWTAYDQHCYQAVDEPKTWEEAEKFCTEQANGGHLVSIQSREEGNFVAQLVSGF IQRPXXGIYVWIGLRDRRKEQQCTSEWNDGSKI IYVNWKEGESKMCQGLAKWTDFHEWDNI NCADRYRFVCKFPSQCXXXXX*
Surface Probability Plot - Emini1
8.48
>MGRF ISVSFGLLLVFLSLSGTGADFECPPEWSAYDLHCYKAFDKPKRSRDAEEFCKKQANSGHLASIESREEGDFVAQLI SENI KSSXXADYVWIGLWNKRREQYCTSQWTDGSNVIYKNMVERFTKNCFGLEKKTGYRKWVNLRCGDDYPFVCKFLPQCXXXXX*
Surface Probability Plot - Emini1
8.48
>MGRF ISVSFSLLVVFLSLSGTGADFECPPEWSSYDLHCYKAFDKPKRSRDAEKFCTEQAKGGHLASIESSEEGDFVAKLI SENI KSSXXADYVWIGLWNKRREQYCTSQWTDGSNVIYKNVI ERFTKNCFGLEKKTEYRTWFNLRCGDDYPFVCKFPPQCXXXXX*
Surface Probability Plot - Emini1
8.16
>MGRF ISVSFKLLVVFLSLSGTGAGLHCPPNSAPYRYFCYRVFKEYKTWEEAEQYCTDRPNNGHLVSIESMEEREFVAQLLSKVTEKHXXI THFWIGLRI EDKEQLCGSEWTDGSRVSYDNLHKRESRKCFALKKETAYRTWFHTNCAERYPFVCKVPPYCXXXXX*
Surface Probability Plot - Emini1
8.16
>MGRFFSVSFGLLVVFLSLSGTGADLDCPPNSAPYRYFCYRVFKEHMTWEEAERFCQERPNNGHLVSIESSEEGDFVAQLLSKVTEKHXXI THFWIGLRI VDKEQHCRSEWSDGSSVSYDNLHKRESRKCFALEKETGYRTWFHMYCADSYPFVCKVPPYCXXXXX*
Surface Probability Plot - Emini1
5.81
>MGRFFSVSFGLLVVFLSLSGTGADDHCQPGWSFYAEYCYKVFSQQMNWTDAEEFCKKQAEGGHLAAIDWVGRVNFVAELVSEGLKDYKYPYYVWIGLSDQSERQQCSSKWTDGSLVCYDXXNGVDTTKCFALDRQTGCRTWVARPCRQRYPF ICVRWAPIEDPAV*
Surface Probability Plot - Emini1
6.05
>MGRF ISVSFGLLVVFLSLSGTGADXXCLPGWSFYEGHCYKVI TQEMNWTDAEKFCTEQPNGGHLASIEWLGKANFVAELVSESLKDYKYNFYVWIGLSDQTERQQCSSEWSDGSSVSYDXXDGVYSAKCFGLPEKTEYHTWVALPCKQKHRF ICMSWLPPEDAAV*
Surface Probability Plot - Emini1
4.74
>MGRF ISVSFGLLVVFLSLSETGADQECLPGWSLYERRCYKVFTERKTWEEAEKFCNXQWDGGHLVSIESTAKAEFLTQLVSQKLRKXXXKYNVWIGLRDHSEKQHCSSYWTDGSF ISYQNVVYXXPAKCFMLDERTEFRKWVPFRCDI KFPF ICKSKI PRXXXXX*
Surface Probability Plot - Emini1
6.96
>MGRFFSVSFGLLVVFLSLSETGADQDCLRGWTFYERRCYRVFNQEKTWEEAEKFCNXRWDGGHLVSIESTAKAEFVTQLLSKNLKEXXXKYHVWIGLRDQSKKQHCSELWTDGSF I TYENVVYXXPTKCFVLNKYTEFRNWVPFRCDIGLPF ICKSKI PRXXXXX*
Surface Probability Plot - Emini1
4.74
>MGRFFSVSFGLLVLFLSLSETGADQDCLRGWSFYERRCYRVFNQQKTWEEAEKFCNXRWDDGHLVSIESTAKAEFLTQLVSENLREXXXRHHVWIGLRDHSEKQQCSSYWTDGSF ISYENVI NXXPAKCFVLNQYTEFRNWVAFRCDIGLPF ICKSKI PRXXXXX*
Surface Probability Plot - Emini1
8.33
>MGRF ISVSFGLLVVFLSLSGTGADXXCLPGWSSYEGHCYKVFNEYKTWKDAEKFCSEQANDGHLVSIESAEEAEFVAQLI PENXXXXXXIYYVWIGLSYEGTRKHCSSEWSDGSSVSYENWNKQEPRKCI RLEKKTDFRKWVNFYCEKPSRFTCEI XXXXXXXXX*
Surface Probability Plot - Emini1
3.57
0.0613
>MGRFLSVSFGLLVVFLSLSGTAADXXCLPGWSSHEGHCYKVFNQEMTWADAEKFCTQQANDGHLVSIESAEEADFVAQLI SENI KSSXXIYYVWIGLSYEGPSKQCSSEWSDRSTVTYENWNKVEPRKCVGLEEQTGYRKWVNFYCKQRNHFTCEI XXXXXXXXX*
Surface Probability Plot - Emini1
8.33
>MGRF ISVSFGLLVVFLSLSETGADXXCLPGWSSHEGHCYKVFSREMKWADAEKFCTQQANGGHLVSIESAEEADFVSQLVSRNI KSSXXMYYVWIGLSYEGPSKQCSSEWSDGSTVTYENWSKEEPRKCVGLEEKTEFRKWVNLYCERSNHFTCEI XXXXXXXXX*
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3.5.3. Snake	  Venom	  Metalloproteinases	  (PI-­‐PII)	  
3.5.3.1. Phylogenetic	  analysis	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3.5.3.2. Jameson	  Wolf	  antigenic	  index	  plot	  alignment	  (Jameson	  Wolf)	  
showing	  the	  candidate	  antigenic	  domains	  
	  
	  


















Antigenic Index - Jameson-Wolf0
3.4
>XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXTAIRKWI HQI VNDMIVMYRDLNIHLTLAAIVIWNKKDMI TVTSSAEDTLNLFGKWRETKYLKYRKHDNTQLLTGLKLNDDTIGLAYVGCMCDPKQSVGI IENHSKEHLLVAATMAHEMGHNLGMNHDANQCNCGANGCVMSAMLTEHTSYQFSDCSMKEYQSYLTKHNPQCI LNKPLRTDTVSTPVSGNELLQNSANPCSDPATCQAREGADCASGPCCRDCKFLEEGTI CNMARGDDMDDYCNGKTCDCPRNPHKXXXXXXXXWPASYXXXXXX*
Antigenic Index - Jameson-Wolf0
3.4
>MIHVFLVTICLAVFPYQGSSKTLKSGNVNDYEIVNPQKI TGLPKGAVKQPEKKHEDVVQYEFEVNGEPVVLHLEKNKGLFSEDYSETHYSPDGREI TTNPPVEDHCYYHGRI KNDADSTASI STCNGLKGFFTLRGETYLI EPLKVPDSEAHAVYKYEDGKKKDEAPKMCGVTQTNWESDEPI KKTSQLAATSEQQHFDPRHIQLI I VADHAMFVKYNSDSTAVTTWTHQI VNNMIVIYRDLNIHI TLAALEIWSNGDLI TVTSSAPTTLRSFGEWRERDLLNRRTHDNAQLLTAVHLXGSLIGYGYVGTMCDPKWSVGI IEDHSTDPIWVAATIAHEMGHNLGINHDGNQCNCGAAGCVMSARI SQHPSYHFSDCSMNEYQNYLTNHNPQCI VNQRLRTDTVSTSVSGNELLQNSANPCYDAATCQAREGADCASGPCCRDCKFLKEGTI CKRARGDNMDDYCNGKTCDCPRNPHKGXEHDPMERPAPAKGSVLM*
Antigenic Index - Jameson-Wolf0
3.4
>MIQVLLVTICLAVFPYQGSSKTLKSGNVNDYEVVNPQKI TGLPKGAVKQPEKKYEDAMQYEFEVNGEPVVLHLEKNKGLFSEDYSETHYSPDGREI TTNPPVEDHCYYHGRI KNDADSTASI STCNGLKGFFTLRGETYLI EPLKVPDSEAHAVYKYEDAKKKDEAPKKCGVTQAKWESDEPI KKASNLVATSEQQRFDPRYIQLVI VADHXMI TKNKGDLTAVRTWVHQI FNDMTVMYRNLNIHI TLVAIVTWSKRDMI TVTSSARGTLKLFGTWRETKLLEKIKHDNAQLLTGINLNNNTIGLASIGGMCNPKKSVGIVQDHSKEHLLVAATMAHEMGHNLGMKHDGDQCNCGANGCIMSATLTEHPSYQFSDCSMNQYQSYLTNRNPKCI LNKPLRTDTVSTPVSGNELLQNSANPCSDPATCQAREGADCASGPCCRDCKFLEEGTI CNMARGDDMDDYCNGKTCDCPRNPHKXXXXXXXXWPAPAKGSMLM*
Antigenic Index - Jameson-Wolf0
3.4
>MIQVLLVTICLAVFPYQGSSKTLKSGNVNDYEVVNPQKI TGLPVGAFKQPEKKHEDAVQYEFEVNGEPVVLHLEKNKGLFSEDYSETHYSPDGREI TTNPPVEDHCYYHGRI KNDADSTASI STCNGLKGFFTLRGETYLI EPLKVPDSEAHAVYKYEDGKKKDEAPKMCGVTQTNWESDEPI KKTSQLAATSEQQRFDPRHIQLI I VADHAMFVKYNSDSTAI TTWVHQI VNDMIVMYRDLNIHI TLAALEIWSNGDLI TVTSSAPTTLRSFGEWRERDLLNRRTHDNAQLLTAVHLXDNLIGYGFVGTMCDPKWSVGI TEDHST IHLWVAATMAHEMGHNLGINHDGNQCNCGAAGCIMSAI I SEHPSYQFSDCSMNDYQSYLTNHNPQCI LNQPLRTDTVSTPVSGNELLQNSANPCYDPATCQPTEGADCASGPCCHDCKFLKEGTI CKRARGDNMHDYCNGKTCDCPRNPHKGXEHDPMEWPAPAKGSVLM*
Antigenic Index - Jameson-Wolf0
3.4
>MIQVLLVTICLAVFPYQGSSKTLKSGNVNDYEVVNPQKI TGLPVGAVKQPEKKYEDALQYEFEVNGEPVVLHLEKNKGLFSEDYSETHYSPDGREI TTKPPVEDHCYYHGRI KNDADSTASI STCNGLKGFFTLRGETYLI EPLKVPDSEAHAVYKYEDVKKKDGAPKKCGVTQTNWESYEPI KKTSQLAATSETTHFDPRYI ELVI VADHAMVTKNKGDLTAIRTWVHQI VNDMIVMYRDLNIHI TLTAVVIWNKRDLI TVTSSAEDTLNLFGTWRETKYLKHRKHDNAQLLTGI I LDDDTIGLAYMEGMCDPRNSVGIVQDHSI VHLLVAATMAHEMGHNLGMDHDGIRCDCGANGCVMSEELTEHPSYQFSDCSKNEYRSYLTDHNPQCI LNQPLRTDTVSTPVSGNELLQNSANPCYDPVTCQSREGADCASGPCCHNCKFLKEGTI CNIARGDDMDDYCNGKTCDCPRNPHKXXXXXXXXWPAPAKGSVLM*
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Surface Probability Plot - Emini1
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Antigenic Index - Jameson-Wolf0
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Surface Probability Plot - Emini1
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3.5.5. Disintegrins	  
3.5.5.1. Jameson	  Wolf	  antigenic	  index	  plot	  alignment	  (Jameson	  Wolf)	  
showing	  the	  candidate	  antigenic	  domains	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4. DNA	  IMMUNISATION	  WITH	  TOXIN-­‐SPECIFIC	  EPITOPE-­‐STRING	  IMMUNOGENS	  
TO	  GENERATE	  THERAPEUTIC	  ANTIBODIES	  AGAINST	  THE	  VENOM	  OF	  AFRICAN	  
ECHIS	  GENUS	  
	  
4.1. INTRODUCTION	  	  	  	  
Snake	   antivenom	   is	   made	   of	   IgG	   formulated	   from	   horses	   or	   sheep	   immunised	   with	  whole	   venom	   and	   large	   volumes	   are	   usually	   required	   to	   achieve	   a	   curative	   dose	   in	  envenomed	   patients,	   incurring	   both	   high	   costs	   and	   serious	   adverse	   effects.	   This	   is	  because	   many	   of	   the	   venom	   proteins	   used	   in	   antivenom	   production	   are	   weakly	  immunogenic	   or	   non-­‐toxic	   and	   IgG	   to	   these	   are	   therefore	   therapeutically	   redundant,	  diluting	  the	  effectiveness	  of	  the	  treatment	  to	  the	  pathogenic	  toxins	  (Malasit	  et	  al.	  1986).	  Also,	  IgG	  titres	  are	  typically	  very	  low	  against	  the	  weakly	  immunogenic,	  but	  highly	  toxic,	  low	   molecular	   weight	   venom	   proteins	   (Harrison	   2004;	   Wagstaff	   et	   al.	   2009).	  Accordingly,	   a	   toxin-­‐secific	   antivenom	   that	   only	   targets	   the	   most	   pathogenic	   toxin	  groups	   would	   be	   predicted	   to	   overcome	   these	   issues	   and	   thereby	   improve	   clinical	  efficacy,	   affordability,	   and	   safety	   of	   antivenom	   treatment	   of	   snakebite	   victims.	  (Harrison	  et	  al.	  2011).	  	  
	  
DNA	   immunisation	   offers	   a	   technically	   appropriate	   strategy	   for	   the	   development	   of	  toxin-­‐specific	  antivenom	  therapy.	  The	  potential	  of	  DNA	  immunisation	  as	  a	  vaccine	  tool	  was	   initially	   recognised	   after	   the	   observation	   that	   intramuscular	   injected	   DNA	   was	  expressed	  by	   in	  vivo	   transfected	  host	   cells	   (Wolff	  et	  al.	   1990),	   in	   a	  manner	   similar	   to	  that	  of	   an	   infective	  virus	   (Tighe	  et	  al.	   1998;	  Leitner	  et	  al.	   1999).	  Further	   studies	   then	  demonstrated	  that	  DNA	  Immunisation	  is	  capable	  of	  inducing	  both	  humoral	  and	  cellular	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responses	  and	  can	  be	  delivered	  through	  a	  variety	  of	  different	  routes	  including,	  among	  others:	  subcutaneous	  (Katsumi	  et	  al.	  1994),	  intra-­‐venous,	  intra-­‐peritoneal	  (Fynan	  et	  al.	  1993),	   intra-­‐nasal	   (Fynan	   et	   al.	   1993;	   Klavinskis	   et	   al.	   1997;	   Kuklin	   et	   al.	   1997),	  intramuscular	  and	  epidermal	  (Fynan	  et	  al.	  1993).	  	  
	  
The	   last	   two	   routes	  have	  proved	   to	  be	   the	  most	   valuable	   from	  a	   therapeutic	  point	  of	  view	  due	   to	   their	   ability	   to	   engender	  Th1/Th2	  distinct	   responses.	  The	  Th2	   response,	  associated	  with	  potent	  antibody	  production,	  has	  been	  shown	  to	  be	  stimulated	  by	  direct	  immunisation	  of	  the	  dendritic	  cell-­‐rich	  epidermis	  of	  mice	  (i.e.	  epidermal)	  with	  the	  use	  of	  biolistic	  approaches	   (Feltquate	  et	  al.	  1997).	  Epidermal	  DNA	   immunisation	   involves	  the	   bombardment	   of	   the	   epidermis	   with	   helium	   propelled	   gold	   beads	   coated	   with	  plasmid	  DNA	  using	  an	  instrument	  called	  the	  GeneGun	  (Yang	  et	  al.	  1990;	  Williams	  et	  al.	  1991)	  (Figure	  4.1).	  The	  Th2-­‐type	  immune	  bias	  of	  epidermal	  DNA	  immunisation	  offers	  an	   attractive	   approach	   for	   rapidly	   generating	   antigen-­‐specific	   antibodies,	   and	   thus	  attractive	  for	  the	  development	  of	  venom	  toxin-­‐specific	  IgGs	  to	  improve	  the	  treatment	  of	  snakebite.	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Harrison	   et	   al.	   (2000;	   2002;	   2003b;	   2004)	   carried	   out	   a	   series	   of	   Gene	   Gun	   DNA	  immunisation	   studies	   with	   cDNA	   encoding	   JD9:	   a	   carboxyl-­‐disintegrin	   and	   cysteine-­‐rich	   domain	   of	   Jararhagin,	   an	   SVMP	   from	   the	   venom	   of	   Bothrops	   jararaca.	   Results	  demonstrated	   that	   (i)	   antibodies	   from	   mice	   immunised	   with	   DNA	   by	   intramuscular	  injection	  were	  significantly	  lower	  than	  mice	  immunised	  with	  the	  GeneGun,	  (ii)	  antigen-­‐specific	   IgG	   titres	  were	  significantly	  higher	   in	  mice	  simultaneously	   immunised	  with	  a	  plasmid	   expressing	   murine	   cytokine	   granulocyte/macrophage-­‐colony	   stimulating	  factor	   (GM-­‐CSF),	   (iii)	   the	   antigen-­‐specific	   IgG	   generated	   by	   epidermal	   JD9	   DNA	  immunisation	   substantially	   neutralised	   venom-­‐induced	   haemorrhage	   in	   an	   ex	   vivo	  model,	  and	  (iv)	  exhibited	  significant	  cross-­‐reactivity	  to	  venom	  components	  in	  snakes	  of	  other	   species	   and	   genera.	   Studies	   in	   other	   groups	   demonstrated	   that	   DNA	  immunisation	   was	   successful	   in	   generating	   murine	   antibodies	   against	   a	   P-­‐III	   type	  metalloproteinase	  from	  the	  venom	  of	  Crotalus	  durissus	  durissus	  (Azofeifa-­‐Cordero	  et	  al.	  2008)	  and	  of	  equine	  antibodies	  against	  the	  venom	  of	  a	  P-­‐II	  type	  metalloproteinase	  from	  
Bothrops	  asper	  (Arce-­‐Estrada	  et	  al.	  2009).	  The	  Harrison	  group	  extended	  this	  concept	  by	  generating	  multiple	   IgG	   specificities	   to	   the	   hemotoxic	   group	   of	   SVMPs	   in	  E.	  ocellatus	  venom.	   Multiple	   specificities	   were	   required	   because	   of	   the	   extreme	   isomeric	  complexity	   of	   this	   protein	   group.	   This	   was	   achieved	   by	   a	   novel	   approach	   of	   (i)	  identifying	   sequences	   encoding	   antigenic	   and	   structurally	   significant	   epitopes	   that	  were	  maximally	  conserved	  across	  the	  various	  SVMP	  groups,	  and	  (ii)	  engineering	  these	  epitopes	  into	  a	  single	  synthetic	  multiepitope	  DNA	  immunogen	  (epitope	  string;	  Wagstaff	  et	  al.	  2006).	  	  
	  
The	   objective	   of	   the	   research	   in	   this	   chapter	   was	   to	   extend	   the	   work	   achieved	  previously	   in	   our	   group	   by	   generating	   toxin-­‐specific	   IgGs	   to	   all	   the	  most	   pathogenic	  toxins	   in	   Echis	   venom	   –	   Metalloproteinases,	   SVMPs;	   C-­‐Type	   lectins,	   CTLs;	   Serine	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Proteases,	  SPs;	  Phospholipases	  A2,	  PLA2s	  and	  Disintegrins,	  DISs).	  To	  achieve	   this,	   the	  toxin	   group-­‐specific	   	   ‘epitope	   string’	   immunogens	   designed	   in	   the	   last	   chapter	  (Chapter	  3)	  were	  subcloned	  into	  a	  mammalian	  expression	  plasmid	  (pVaxSec)	  and	  used	  to	  DNA	  immunise	  mice.	  	  
	  
4.2. METHODS	  	  
The	   DNA	   sequences	   encoding	   the	   epitope-­‐string	   immunogen	   constructs	   (for	   details	  please	   refer	   to	   Chapter	   3,	   Figure	   XX)	   were	   cloned	   into	   a	   pUC57	   vector	   using	   the	  methods	   described	   in	   Chapter	   2	   (section	   2.3).	   The	   immunogen	   sequences	  were	   then	  subcloned	   into	   a	  mammalian	   expression	   plasmid	   (pVaxSec)	   constructed	   by	   Harrison	  (Wagstaff	   et	   al.	   2006).	   The	   following	   methods	   section	   describes	   the	   experimental	  strategy	  for	  preparing	  these	  as	   immunogens	  for	  DNA	  immunisation.	  All	  methods	  here	  described	  were	   applied	   to	   the	   constructs	   designed	   against	   each	   of	   the	   toxin	   groups:	  Phospholipase	  A2	  (PLA2Es),	  Serine	  Proteases	  (SPEs),	  C-­‐Type-­‐lectins	  (CTL1Es,	  CTL2Es)	  Metalloproteinases:	   Metalloproteinase	   domain	   (MET1Es,	   MET2Es,	   MET3Es)	  Disintegrin	   domain	   (DIS1Es,	   DISlike1Es,	   DISlike2Es)	   Cystein-­‐rich	   domain	   (CRI1Es,	  CRI2Es),	  Disintegrins	  (Dis2Es)	  and	  pVaxSec	  (control).	  
	  
4.2.1. 	  Scale-­‐up	  of	  pVaxSec	  plasmid	  constructs	  containing	  epitope-­‐string	  
immunogens	  Previously	   transformed	   pVaxSec	   colonies	   (as	   described	   in	   chapter	   2,	   section	   2.3.1)	  were	  grown	  in	  500ml	  of	  LB	  medium	  containing	  Kanamycin,	  and	  plasmid	  DNA	  purified	  using	   the	   MegaPrep	   plasmid	   purification	   kit	   (Qiagen,	   Crawley,	   United	   Kingdom)	   by	  following	  manufacturer’s	  instructions.	  Purified	  plasmids	  were	  recovered	  in	  a	  volume	  of	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35ml	   sterile,	   de-­‐ionised	   water	   and	   their	   final	   concentration	   was	   determined	   as	  previously	   described.	   Samples	   were	   stored	   at	   -­‐20°C	   until	   use.	   Correct	   (in-­‐frame)	  insertion	   of	   epitope-­‐string	   encoding	   DNA	   into	   the	   plasmid	   was	   confirmed	   by	  sequencing	  as	  described	  previously.	  	  
	  
4.2.2. Preparation	  of	  DNA/gold	  microcarriers	  (shots)	  for	  GeneGun	  
immunisation	  Purified	   DNA	   encoding	   each	   pVaxSec	   epitope-­‐string	   construct	   (and	   pVaxSec-­‐alone	  vehicle	  control)	  was	  precipitated	  onto	  1.6μm	  gold	  (Au)	  beads	  and	  then	  	  coated	  on	  the	  inner	   surface	   of	   plastic	   tubing	   (Tefzel)	   to	   make	   individual	   half-­‐inch	   length	   ‘bullets’	  containing	  DNA/Au.	  By	  following	  manufacturer’s	  instructions	  (Helios	  Gene	  Gun	  System	  instruction	  manual,	  Bio-­‐Rad,	  Hercules,	  CA),	  the	  amount	  of	  DNA	  was	  adjusted	  to	  provide	  individual	  shots	  of	  1μgDNA/0.5mgAu	  (please	  refer	  to	  Annex	  4.5.1	  for	  further	  details	  on	  calculations).	   Briefly,	   the	   calculated	   amounts	   of	   DNA	   and	   gold	   were	   mixed	   together	  with	  a	  carrier	  protein	  solution	  (0.05M	  Spermidine)	  ensuring	  adhesion	  of	  the	  DNA	  onto	  the	  gold	  bead.	  The	  DNA/Au	  mixture	  was	  then	  precipitated	  onto	  the	  beads	  by	  dropwise	  addition	   of	   CaCl2	   (1M),	   until	   separation	  was	   completely	   visible.	   Next,	   several	  washes	  with	  Ethanol	  (EtOH)	  were	  performed	  to	  remove	  any	  residuals	  from	  the	  DNA/Au	  mix.	  	  	  
	  
The	  DNA/Au	  solution	  in	  EtOH	  was	  slowly	  added	  to	  the	  Tefzel	  tubing	  with	  the	  help	  of	  a	  syringe.	  The	  tubing	  was	  then	  installed	  into	  the	  tubing	  station	  (Figure	  4.2)	  and	  the	  gold	  particles	  were	   left	   to	   ‘sit’	  at	   the	  bottom	  of	   the	   tube	   for	  approximately	  one	  minute.	  By	  using	  the	  already-­‐attached	  syringe,	  the	  EtOH	  was	  carefully	  and	  slowly	  removed	  without	  disturbing	   the	   settled	   DNA/gold	   particles.	   Immediately	   afterwards,	   the	   tube	   was	  turned	  180°	  allowing	  the	  gold	  beads	  to	  cover	  the	  walls	  of	  the	  tubing.	  Nitrogen	  gas	  was	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added	   to	   the	   system	   to	   remove	   the	   ethanol	   and	   dry	   the	   DNA-­‐coatedgold	   beads	   that	  were	  now	  evenly	  dispersed	  in	  the	  tube.	  	  
	  
Figure	  4.2:	  Components	  and	  controls	  on	  the	  Tubing	  Prep	  Station	  (BioRad,	  US)	  fully	  assembled.	  Figure	  taken	  from	  BioRad	  (http://www.bio-­‐rad.com/en-­‐uk/product/helios-­‐gene-­‐gun-­‐system)	  
	  
The	  Tefzel	   tubing	  was	   then	   removed	   from	   the	   tubing	   station	   and	   assembled	   into	   the	  tubing	   cutter	   (Figure	   4.3a),	   collecting	   the	   individual	   half-­‐inch	   bullets	   inside	   a	  scintillation	  vial	   containing	  a	  desiccant	  capsule.	  As	   the	   last	   step,	   the	  scintillation	  vials	  were	  removed	  from	  the	  tubing	  cutter	  and	  sealed	  to	  avoid	  any	  humidity	  (Figure	  4.3b).	  A	  total	   of	   fifteen	  different	   samples	   containing	   the	  DNA/Gold	   bullets	  were	  made	   for	   the	  immunisations	  and	  were	  kept	  at	  -­‐20°C	  until	  used	  for	  GeneGun	  delivery.	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Figure	  4.3:	  a)	  Tefzel	  tubing	  cutter	  for	  DNA/Au	  bullets	  b)	  Scintillation	  vials	  containing	  gold	  bullets.	  Figure	  ‘a’	  taken	  from	  BioRad	  (http://www.bio-­‐rad.com/en-­‐uk/product/helios-­‐gene-­‐gun-­‐system)	  
	  
4.2.3. Confirmation	  of	  the	  presence	  of	  DNA	  coated	  to	  the	  gold	  beads	  in	  TAE	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4.2.4. DNA	  Immunisation	  of	  BALB/c	  mice	  by	  Gene	  Gun	  According	   to	   the	   immunisation	  methods	   carried	  out	  previously	   (Harrison	  et	  al.	   2000;	  Wagstaff	   et	   al.	   2006),	   groups	   of	   six	   Balb/c	   female	   mice	   (18	   –	   20g,	   Charles	   River	  laboratories,	  UK)	  were	  immunised	  with	  the	  pVaxSec	  constructs	  as	  follows	  (Table	  4.1):	  
Toxin	  group	  target	   DNA	  Construct	  name	   Immunisation	  group	  name	  
PLA2	   pVaxSec/PLA2Es	   A	  
SP	   pVaxSec/SPEs	   B	  
CTL	  
pVaxSec/CTL1Es	   C	  
pVaxSec/CTL2Es	   D	  
SVMP	  
MP	  
PI	   -­‐	  
PII	   pVaxSec/MET1Es	   E	  
PIII	  
pVaxSec/MET2Es	   F	  
pVaxSec/MET3Es	   G	  
DIS	  
PII	   pVaxSec/DIS1Es	   H	  
PIII	  
pVaxSec/DISlike2Es	   I	  
pVaxSec/DISlike3Es	   J	  
CRI	   PIII	  
pVaxSec/CRI1Es	   K	  
pVaxSec/CRI2Es	   L	  
DIS	   pVaxSec/DIS2Es	   M	  	  
Table	  4.1:	  Detail	  of	  immunisation	  groups	  
	  
Immunisations	   followed	   a	   schedule	   of	   12	   weeks	   (3	   months)	   by	   delivering	   4mg	   of	  DNA/gold	  at	  weeks	  0,	  2,	  4,	  8,	  and	  12.	  Serum	  samples	  were	  examined	  two	  weeks	  after	  the	  last	  three	  immunisations	  	  (weeks	  6,	  10	  and	  14)	  to	  assess	  seroconversion.	  Before	  the	  start	   of	   each	   immunisation,	   mice	   were	   lightly	   anaesthetised	   using	   a	   mixture	   of	  isoflurane	  and	  oxygen	  (5%);	   the	   immunisation	  area	   (abdomen)	  was	  shaved	  and	  mice	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were	  hold	  from	  the	  back	  by	  leaving	  exposed	  the	  target	  area.	  Each	  mouse	  was	  subjected	  to	  four	  ‘‘shots’’	  (each	  containing	  1μgDNA/0.5mg	  Au)	  into	  the	  epidermal	  layer	  expelled	  under	  a	  burst	  of	  helium	  gas	  at	  350	  psi	  using	  the	  Helios	  GeneGun	  (Bio-­‐Rad)	  (Figure	  4.4).	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4.2.5. Collection	  of	  sera	  after	  the	  completion	  of	  mice	  immunisations	  A	   sample	   of	   blood	   was	   collected	   from	   each	  mouse	   two	   weeks	   after	   the	   end	   of	   each	  immunisation	  month	  by	  tail	  snip,	  or,	  at	  the	  end	  of	  the	  schedule	  (third	  month)	  by	  cardiac	  puncture	  under	   terminal	   anaesthesia	  using	  Schedule	  1	   for	  humane	  killing	  of	   animals.	  Blood	  samples	  were	  allowed	  to	  clot	  and	  were	  then	  centrifuged	  at	  3000	  rpm	  for	  20	  min.	  Serum	  samples	  were	  collected	  from	  the	  supernatant	  and	  transferred	  to	  a	  sterile	  1.5ml	  vial	   tube	   and	   stored	   at	   -­‐20°C	   until	   used	   for	   immunological	   tests.	   To	   assess	   the	  immunogenicity	   of	   the	   DNA	   epitope	   string	   immunogens,	   serum	   samples	   taken	   from	  each	  of	  the	  mice	  were	  pooled	  accordingly	  to	  each	  of	  the	  immunisation	  groups.	  Pooled	  serum	   from	   each	   of	   the	   bleedings	   was	   tested	   by	   immunoblot	   (for	   details	   on	   the	  protocol	   please	   refer	   to	   chapter	   2,	   section	   2.4.1)	   against	   the	   venom	   from	   the	   target	  species.	  
	  
4.3. RESULTS	  	  
The	   presence	   of	   DNA	   in	   the	   bullets	   (B1	   and	   B2,	   Figure	   4.5)	   was	   confirmed	   by	   the	  presence	   of	   DNA	   bands	   of	   the	   same	   molecular	   weight	   as	   the	   plasmid	   control	   (at	  0.5μg/μl)	   in	   1%	   TAE	   agarose	   gels.	   The	   concentration	   (determined	   by	   Nanodrop	  spectrophotometry)	   of	   DNA	   purified	   from	   the	   gold	   ranged	   from	   0.07	   –	   0.09	   μg/μl,	  giving	  a	  total	  amount	  of	  0.7	  –	  0.8	  μg	  of	  DNA	  per	  bullet.	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Figure	  4.5:	  1%	  TAE	  Agarose	  gels	  verifying	  the	  presence	  of	  DNA	  in	  the	  bullets.	  	  Plasmid	  controls	  (0.5μg/μl)	  (A:	  pVaxSec/PLA2Es,	  B:	  pVaxSec/SPEs,	  C:	  pVaxSec/CTL1Es,	  D:	  pVaxSec/CTL2Es,	  E:	  pVaxSec/MET1Es,	  F:	  pVaxSec/MET2Es,	  G:	  pVaxSec/MET3Es,	  H:	  pVaxSec/DIS1Es,	  I:	  pVaxSec/DISlike1Es,	  J:	  pVaxSec/DISlike2Es,	  K:	  pVaxSec/DIS2Es,	  L:	  pVaxSec/CRI1Es,	  M:	  pVaxSec/CRI2Es)	  are	  followed	  by	  the	  wells	  of	  DNA	  purified	  from	  two	  random	  bullets	  (B1	  and	  B2,	  0.07	  –	  0.09	  μg/μl).	  
	  
4.3.1. Immunological	  assays	  	  
4.3.1.1. Responses	  of	  Balb/c	  mice	  immunised	  with	  the	  pVaxSec	  epitope	  

















































































A% B% C% D% E% F% G%
H% I% J% K% L% M%
	   	   120	  
E.	  coloratus	  and	  DISlike2Es	  for	  the	  venom	  of	  E.	  carinatus	  sochureky.	  Results	  on	  the	  first	  and	  second	  bleeding	  are	  not	  shown	  in	  this	  chapter	  due	  to	  the	  lack	  of	  reactivity	  among	  the	  venoms	  under	  study.	  	  
	  
	  
Figure	  4.6:	  Coomassie	  stained	  15%	  reduced	  SDS	  PAGE	  of	  E.	  ocellatus	  (EOC),	  E.	  
pyramidum	  leakeyi	  (EPL),	  E.	  coloratus	  (ECO),	  and	  E.	  carinatus	  sochureki	  (ECS).	  Venoms	  at	  a	  concentration	  of	  1mg/ml.	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Figure	  4.7:	  Immunoblots	  of	  venoms	  E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	  E.	  coloratus	  and	  
E.	  carinatus	  sochureki	  (1mg/ml)	  incubated	  with	  pooled	  sera	  (diluted	  1:100)	  from	  each	  group	  of	  DNA	  immunised	  mice.	  Red	  boxes	  indicate	  visible	  bands.	  A:	  pVaxSec/PLA2Es,	  B:	  pVaxSec/SPEs,	  C:	  pVaxSec/CTL1Es,	  D:	  pVaxSec/CTL2Es,	  E:	  pVaxSec/MET1Es,	  F:	  pVaxSec/MET2Es,	  G:	  pVaxSec/MET3Es,	  H:	  pVaxSec/DIS1Es,	  I:	  pVaxSec/DISlike1Es,	  J:	  pVaxSec/DISlike2Es,	  K:	  pVaxSec/DIS2Es,	  L:	  pVaxSec/CRI1Es,	  M:	  pVaxSec/CRI2Es.	  PI:	  Pre	  immune	  sera,	  pVaxSec:	  plasmid	  control.	  	  
4.3.1.2. Cross-­‐reactivity	  of	  toxin-­‐specific	  antibodies	  against	  African	  viper	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mice	   with	   a	   series	   of	   venoms	   from	   other	   snake	   species	   from	  West,	   North,	   East	   and	  South	  Africa	   (Figure	  4.8).	  Results	   showed	   little	   response	   from	   the	   serum	  as	  well	   as	  a	  low	  cross	  reactivity	  among	  the	  venoms	  (Figure	  4.9)	  when	  compared	  to	  the	  antivenom	  positive	  control	  (Figure	  4.10).	  Cross-­‐reactive	  bands	  were	  visible	  only	   in	  the	  groups	  of	  CTL1Es,	  DIS1Es	  and	  CRI2Es.	  	  
	  
Figure	  4.8:	  Coomassie	  stained	  15%	  reduced	  SDS	  PAGE	  of	  African	  Viper	  venoms.	  	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Egypt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Egypt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	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Figure	  4.9:	  Western	  blot	  of	  African	  viper	  venoms	  incubated	  with	  sera	  from	  DNA-­‐immunised	  mice	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Eygipt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Eygipt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	  
Bitis	  gabonica	  (West	  Africa).	  Bottom	  left:	  negative	  controls	  (pre-­‐immune	  sera	  and	  mice	  immunised	  with	  vector	  plasmid	  pVaxsec	  only).	  	  
	  
Figure	  4.10:	  Western	  blot	  of	  African	  viper	  venoms	  incubated	  with	  the	  positive	  control	  EchitabG	  antivenom	  (1:5000).	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Eygipt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Eygipt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	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4.4. DISCUSSION	  	  
Although	   DNA	   immunisation	   has	   been	   a	   widely	   used	   and	   successful	   strategy	   in	   the	  toxin-­‐specific	   antivenom	   approach,	   we	  were	   not	   able	   to	   replicate	   this	   success	   in	   the	  current	   study.	   Our	   results	   showed	   a	   disappointingly	   low,	   and	   in	   some	   epitope-­‐string	  immunised	  mice,	   even	  absence	  of	   IgG	   reactivity	   to	  DNA	   immunisation,	  particularly	   in	  comparison	  with	  results	  obtained	  using	  the	  same	  methodology	  (Wagstaff	  et	  al.	  2006).	  This	   discussion	   examines	   the	   possible	   explanation	   for	   the	   weak	   seroconversion	  observed	  in	  the	  epitope	  string	  DNA	  immunised	  mice	  of	  this	  study.	  
	  
The	  delivery	  of	  DNA	  to	  the	  skin	  by	  gene	  gun	  is	  known	  to	  produce	  a	  physical	  stress	  or	  ‘danger	  signal’	  in	  the	  form	  of	  a	  local	  epidermal	  injury.	  In	  order	  to	  produce	  an	  immune	  response,	   the	   DNA-­‐coated	   gold	   beads	   need	   to	   penetrate	   and	   transfect	   dendritic	   cells	  (DCs	  -­‐	  Langerhans)	  and	  to	  a	  lesser	  extent	  myocites	  or	  keratinocytes).	  The	  plasmid	  DNA	  is	   then	   processed	   by	   the	   cell	   machinery,	   producing	   a	   protein	   that	   is	   shown	   as	   an	  antigen	  to	  the	  immune	  system	  (i.e.	  Lymph	  nodes)	  (Lu	  et	  al.	  1996;	  Porgador	  et	  al.	  1998;	  Watts	   and	   Kennedy	   1999).	   A	   successful	   cell	   transfection	   during	   DNA	   immunisation	  relies	   strongly	   in	   the	   plasmid	   encoding	   the	   antigen	   of	   interest,	   which	   among	   other	  components	  like	  CpG	  motifs,	  must	  contain	  an	  expression	  cassette	  with	  a	  promoter	  and	  sequences	   for	   the	   stabilisation	   of	   the	  mRNA	   transcripts	   (Klinman	   et	  al.	   1997).	   In	   the	  current	  study	  sequence	  analysis	  of	   the	  constructs	  showed	  that	   they	  were	  all	   in-­‐frame	  and	  had	  all	   the	  required	  molecular	  signals	   for	  mammalian	  expression	  –	   therefore	   the	  manufacture	   for	  pAxSec	  constructs	  was	  ruled	  out	  as	   the	  reason	   to	  explain	   the	   lack	  of	  seroconversion.	  	  
	  
	   	   126	  
Some	   of	   the	   antibodies	   obtained	   during	   the	   study	   did	   show	  weak	   binding	   to	   venom	  proteins	   of	   the	   same	   molecular	   weight	   as	   the	   toxins	   they	   were	   designed	   to	   target,	  suggesting	   a	   correct	   protein	   expression	  within	   transfected	   cells:	   C-­‐Type	   lectins	   (14.2	  kDs),	   the	   disintegrins	   (7.0	   kDs)	   and	   the	   P-­‐III	   SVMPs	   (55	   kDs)	   -­‐	   samples	   EsCTL_1,	  EsDIS_1,	  EsDIS_2,	  EsMET_2	  and	  EsMET_3	  respectively	  (Figure	  4.7).	  However,	  their	  low	  titre	  added-­‐up	  to	   the	   lack	  of	  response	  of	  sera	   from	  the	  other	  DNA-­‐immunised	  groups	  questions	   whether	   the	   amount	   of	   antigen	   DNA	   was	   insufficient	   to	   stimulate	   the	  required/expected	   immune	   response.	   It	   is	   known	   that	   subsequent	   to	   immune	  activation,	  any	  transfected	  cell	  that	  is	  expressing	  an	  immunogenic	  protein	  can	  become	  a	   target	   for	   removal	  by	   immune-­‐mediated	  mechanisms.	  Consequently,	   it	   is	   likely	   that	  not	  all	  the	  amount	  of	  DNA	  delivered	  during	  the	  immunisations	  ends	  up	  being	  expressed	  and	  presented	  to	  the	  antigen	  presenting	  cells	  (Payette	  et	  al.	  2001;	  Moreno	  and	  Timón	  2004).	  The	  minimum	  amount	  of	  DNA	  that	  can	  give	  a	  detectable	  level	  of	  gene	  expression	  is	  1ng	  of	  plasmid.	  Our	  use	  of	  1μg	  of	  DNA/0.5mg	  Au	  is	  clearly	  in	  excess	  of	  this	  minimal	  amount	  and	  proven	  to	  be	  successful	   in	  inducing	  seroconversion	  (Harrison	  et	  al.	  2000;	  2002;	  2003b;	  2004;	  Wagstaff	  et	  al.	  2006).	  In	  this	  study	  the	  agarose	  gel	  (Figure	  4.5)	  and	  nanodrop	   DNA	   quantification	   did	   show	   that	   the	   DNA	   concentration	   of	   the	   epitope	  string	  pVaxSec	  constructs	  were	  significantly	  lower	  than	  the	  control	  pVaxSec	  construct.	  The	  lack	  of	  sufficient	  DNA/immunising	  bullet	  is	  therefore	  likely	  to	  account	  for	  the	  weak	  immune	  responses	  obtained	  in	  this	  DNA	  immunisation	  study.	  	  	  
	  
Owing	  to	  the	  lack	  of	  seroconversion	  in	  the	  DNA-­‐immunised	  mice	  of	  this	  study	  and	  the	  often	  reported	  difficulty	  replicating	  success	  of	  murine	  DNA	  immunisation	  protocols	  in	  higher	   order	   animals	   (Babiuk	   et	   al.	   2003),	   necessarily	   required	   for	   a	   large	   scale-­‐production	  of	  antivenom,	   the	  next	   step	   in	   the	   research	  project	   focused	  on	  generating	  the	  same	  immunogens	  as	  recombinant	  proteins.	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4.5. ANNEXES	  
4.5.1. Summary	  table	  of	  calculations	  needed	  from	  each	  of	  the	  components	  in	  the	  
process	  of	  coupling	  the	  DNA	  with	  the	  gold	  microcarriers	  Component	   	   Example	  DNA	   conc	  ng/μl	  DNA	  	   Initial	  plasmid	  concentration	   from	  the	   Medi	   or	   Mega	   prep	   (i.e.	   Y1	  ng/μl)	   600ng/μl	  μg	   DNA	  needed	   (#	   of	   mice)(#of	   shots)(#	   of	  immunizations)	  	  =	  Y2	  μg	  DNA	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5. PRODUCTION	  OF	  RECOMBINANT	  PROTEIN	  EPITOPE-­‐STRING	  IMMUNOGENS	  
TO	  GENERATE	  MURINE	  TOXIN-­‐SPECIFIC	  ANTIBODIES	  AGAINST	  THE	  VENOMS	  
OF	  AFRICAN	  ECHIS	  GENUS	  
	  
5.1. INTRODUCTION	  	  
Snake	   venoms	   have	   more	   than	   a	   hundred	   proteins	   and	   peptides	   that	   exhibit	   a	  significant	   diversity	   in	   terms	   of	   isoform	   complexity,	   toxicity	   and	   immunogenicity	  (Calvete	   et	   al.	   2007;	   Harrison	   et	   al.	   2011).	   Antivenom,	   the	   only	   effective	   treatment	  against	   snakebite,	   is	   formulated	   as	   purified	   IgGs	   from	   the	   sera	   of	   horses	   or	   sheep	  hyper-­‐immunised	  with	  increasing	  doses	  of	  venom	  (i.e.	  monospecific	  from	  the	  venom	  of	  a	  single	  snake	  species	  or	  polyspecific	  from	  the	  venom	  of	  multiple	  species).	  However,	  it	  frequently	  contains	  therapeutically	  redundant	  IgGs	  to	  non-­‐toxic	  venom	  components,	  as	  well	  as	  a	   lack	  of	  high	   titre	   IgGs	   to	  highly	   toxic,	  but	  weakly	   immunogenic	  components	  (Harrison	   2004;	  Wagstaff	   et	   al.	   2009;	   Harrison	   et	   al.	   2011).	   The	   consequence	   of	   the	  century	  old	  immunisation	  protocol	  is	  the	  need	  to	  administer	  large	  volumes	  to	  achieve	  venom-­‐neutralisation	   in	   an	   envenomed	   patient,	   which	   greatly	   increases	   the	   risk	   of	  antivenom-­‐induced	   adverse	   effects	   and	   reduces	   its	   affordability.	   An	   antivenom	   that	  only	  targets	  the	  most	  pathogenic	  toxin	  groups	  is	  therefore	  predicted	  to	  overcome	  these	  issues	  by	  improving	  its	  clinical	  efficacy	  (Harrison	  et	  al.	  2011).	  
	  
The	  Venom	  Unit	  has	  been	  pioneering	  a	  new	  approach	  to	  address	  the	  current	  antivenom	  challenges	  by	  using	  the	  rationale	  of	  generating	  venom	  toxin-­‐specific	  antibodies.	  Based	  on	  preliminary	  work	  illustrating	  extensive	  cross-­‐specific	  and	  cross-­‐generic	  reactivity	  of	  a	   toxin-­‐specific	   antibody	   (Harrison	   et	   al.	   2000;	   Harrison	   et	   al.	   2002;	   Harrison	   et	   al.	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2003b;	  Harrison	  2004;	  Azofeifa-­‐Cordero	  et	  al.	  2008),	   the	  concept	  progressed	  to	  using	  venom	  gland	  transcriptomes	  (Wagstaff	  and	  Harrison	  2006;	  Casewell	  et	  al.	  2010)	  as	  the	  data	  resource	  informing	  the	  design	  of	  synthetic	  immunogens	  to	  generate	  toxin-­‐specific	  IgGs.	   This	   approach,	   dependent	   upon	   bioinformatic	   selection	   of	   motifs	   exhibiting	  maximal	   predicted	   immunogenicity	   and	   isoform	   representation	   within	   the	   group	   of	  toxins,	   successfully	   showed	   that	   IgGs	   raised	   by	   immunisation	   of	  mice	  with	   synthetic	  DNA	   immunogens	   can	   replicate	   the	   toxin-­‐neutralizing	   capabilities	   of	   conventional	  antivenom	  (Wagstaff	  et	  al.	  2006).	  	  
	  
This	  PhD	  project	  has	  extended	   this	   toxin-­‐specific	  antivenom	  approach	  with	  a	  view	   to	  ultimately	  generating	  a	   therapy	  against	  all	   the	  African	   species	  of	   the	  Echis	   genus.	  We	  first	  conducted	  a	  bioinformatic	  interrogation	  of	  the	  venom	  gland	  transcriptomes	  of	  the	  medically	   important	   species	   Echis	   ocellatus,	   Echis	   pyramidum	   leakeyi	   and	   Echis	  
coloratus	  to	  identify	  epitopes	  on	  the	  basis	  of	  i)	  sequence	  conservation,	  ii)	  antigenicity,	  (iii)	  surface	  exposure	  and	  (iv)	  coverage	  across	  the	  EST	  data.	  According	  to	  pathogenicity	  and	  representation	  in	  the	  Expressed	  Sequence	  Tag	  (EST)	  data,	  five	  major	  toxin	  groups	  were	  selected	  as	  a	  target	  for	  the	  design	  of	  epitope-­‐string	  immunogens:	  Phospholipases	  A2	  (PLA2),	  Serine	  proteases	  (SP)	  C-­‐type	  lectins	  (CTLs),	  Metalloproteinases	  (SVMPs)	  and	  Disintegrins	   (Casewell	   et	   al.	   2009),	   based	   on	   the	   hypothesis	   that	   the	   raised	   toxin-­‐specific	   antibodies	   would	   be	   capable	   of	   neutralizing	   the	   toxic	   effect	   of	   the	   venoms	  (Please	  refer	  to	  chapter	  3	  for	  further	  details	  on	  the	  bioinformatic	  design).	  	  
	  
In	   this	   project	   we	   elected	   to	   deliver	   the	   epitope-­‐string	   immunogens	   as	   recombinant	  proteins	   on	   the	   basis	   that	   (i)	   encouraging	   murine	   immune	   responses	   to	   DNA	  immunisation	   have	   been	   frequently	   produced	   disappointing	   outcomes	   after	   DNA	  immunisation	   of	   higher	   order	   animals	   (Babiuk	   et	   al.	   2003)	   and	   (ii)	   that	   the	   murine	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immune	   responses	   to	   DNA	   immunisation	   in	   the	   early	   stages	   of	   this	   project	   was	  unsuccessful.	   Taking	   into	   account	   that	   the	   production	   of	   high	   volumes	   of	   soluble	  recombinant	   proteins	   is	   problematic,	   particularly	   for	   the	   number	   of	   constructs	   here	  designed,	  we	   established	   a	   collaboration	  with	   the	   Oxford	   Protein	   Production	   Facility	  (OPPF),	   which	   has	   an	   automatic	   system	   that	   incorporates	   both	   DNA-­‐cloning	   and	  protein	   expression	   technologies	   in	   high-­‐throughput	   platforms	   that	   allow	   parallel	  testing	  of	  multiple	  protein	  variants,	  leading	  to	  the	  determination	  of	  protein	  solubility	  in	  optimal	   yields.	   Here	   we	   describe	   (i)	   the	   expression	   of	   epitope-­‐string	   constructs	   as	  soluble	   recombinant	   protein	   immunogens	   predicted	   to	   raise	   antibodies	   against	   the	  most	   pathogenic	   toxin	   groups	   from	   the	   venoms	   of	   the	   African	   Echis	   species,	   (ii)	   the	  cross-­‐specific	  and	  cross-­‐generic	  murine	  antibody	  responses	  to	  the	  target	  venom	  toxin	  groups	  induced	  by	  immunization	  with	  the	  protein	  immunogens,	  and	  (iii)	  the	  extension	  of	  the	  rationale	  to	  immunize	  larger	  animals	  for	  antivenom	  production.	  
	  
5.2. METHODS	  	  
5.2.1. Small-­‐scale	   screen	   for	   optimal	   expression	   conditions	   of	   epitope-­‐string	  
immunogens	  as	  recombinant	  proteins	  Small-­‐scale	   screen	   for	   optimal	   protein	   expression	   conditions	   of	   the	   epitope-­‐string	  immunogens	  was	  carried	  by	  the	  Oxford	  Protein	  Production	  Facility	  (OPPF,	  Oxford,	  UK-­‐	  http://www.oppf.rc-­‐harwell.ac.uk/OPPF/public/services/cloning.jsp),	   as	  described	  by	  Bird	   (2011).	   Briefly,	   epitope-­‐string	   immunogens	   (Chapter	   3)	   were	   excised	   from	   the	  pUC57	  plasmid	  vector	  with	  the	  restriction	  enzymes	  KpnI	  and	  HindIII	  and	  subsequently	  inserted	   into	   a	   set	   of	   fusion	   vector	   backbones	   (using	   the	   ligase-­‐less	   technology	  InFusion™	   cloning	   from	   Clontech)	   for	   protein	   expression	   that	   belong	   to	   the	   pOPIN	  family	   (pOPINF,	   pOPINS3C	   and	   pOPINM)	   and	   provide	   (i)	   an	   N-­‐linked	   sequence	   that	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codes	   for	   a	   fusion	   tag	   to	   aid	   purification	   (His:	   Polyhistidine	   only,	   SUMO:	   Small	  Ubiquitin-­‐like	   Modifier,	   MBP:	   Maltose	   Binding	   Protein,	   respectively)	   	   and	   (ii)	   a	   3C	  protease	   cleavage	   site	   to	   further	   remove	   the	   tag	   from	   the	   protein	   of	   interest	   (Figure	  5.1).	   The	   immunogen/vector	   constructs	   were	   then	   cloned	   into	   the	   E.	   coli	   strains	  Rosetta	  DE3	  plysS	  and	  B834	  and	  grown	  under	  differential	  induction	  media	  conditions	  (IPTG	   induction	   using	   Power-­‐Broth	   and	   auto-­‐induction	   using	   overnight	   express™	  instant	   TB	  medium	   TBONEX).	   Optimal	   expression	   of	   constructs	   was	   selected	   on	   the	  basis	  of	  solubility	  and	  predicted	  yield	  of	  the	  recombinant	  product	  obtained.	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5.2.2. Scale-­‐up	   of	   epitope-­‐string	   immunogens	   under	   optimal	   expression	  
conditions	  	  Scale-­‐up	   of	   the	   constructs	  with	   the	   objective	   of	   obtaining	   sufficient	   yields	   of	   soluble	  recombinant	   protein	   for	   immunisations	  was	   done	   according	   to	   the	   conditions	   under	  which	  an	  optimal	  expression	  was	  achieved	  during	   the	  small-­‐scale	   screen.	  Briefly,	  one	  vial	  of	  50µL	  of	  Rosetta	  DE3	  plysS	  or	  B834	  E.	  coli	  cells	  was	  thawed	  and	  mixed	  with	  1	  µL	  of	   the	   required	   construct.	   300µl	   of	   pre-­‐warmed	   (no	   antibiotic)	   Power-­‐Broth	   media	  (Appendix	  A)	  were	  added	  into	  each	  vial	  of	   transformed	  cells	  and	  further	   incubated	  at	  37ºC	   for	   a	   total	   of	   one	   hour	   without	   shaking.	   Each	   sample	   was	   streaked	   into	   plates	  containing	   LB	   Agar	   (Appendix	   A)	   and	   the	   required	   selective	   antibiotic	   (1000x	   -­‐	  Ampicillin	  as	  selective	  antibiotic	  for	  all	  the	  vector	  backbones	  and	  Chloramphenicol	  for	  the	  growth	  of	  the	  Rosetta	  DE3	  plysS	  E.	  coli	  strain).	  Plates	  were	  incubated	  at	  37ºC	  and	  allowed	  to	  grow	  overnight.	  Single	  colonies	  were	  picked	  at	  the	  next	  day	  and	  inoculated	  in	  starter	  cultures	  of	  15ml	  of	  antibiotic-­‐containing	  Power-­‐Broth	  media	  at	  37ºC	  with	  a	  constant	  shaking	  at	  225rpm	  for	  up	  to	  16	  hours.	  Cultures	  were	  then	  diluted	  into	  500ml	  of	  the	  required	  antibiotic-­‐containing	  media	  (50	  µg/ml):	  induction	  media	  (Power-­‐Broth	  supplemented	  with	  1%	  glucose)	  or	  auto-­‐induction	  media	  (Overnight™	  Express	  Instant	  TB	   medium	   TBONEX)	   and	   further	   grown	   with	   shaking	   at	   250	   rpm	   and	   37°C.	   IPTG	  induction	   cultures	  were	   induced	  with	  1mM	   IPTG	  when	   the	  A600	   reached	  0.6–0.7.	   Cell	  growth	   was	   continued	   for	   around	   18	   hours	   at	   250	   r.p.m	   and	   20	   °C.	   Auto-­‐induction	  cultures	  were	  grown	  until	   the	  A600	  reached	  0.5–0.6	  and	  shaker	   temperature	  was	  then	  reduced	  to	  25	  °C	  for	  a	  further	  20–24	  h.	  	  
	  
After	  expression,	  bacterial	  cultures	  were	  harvested	  in	  a	  centrifuge	  at	  30,000g	  for	  a	  total	  of	   1h	   and	   the	   supernatant	   containing	   the	   growth	  media	   was	   discarded.	   Lysis	   of	   the	  bacterial	   host	  was	   accomplished	   by	   re-­‐suspending	   the	   bacterial	   pellet	   in	   lysis	   buffer	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(50mM	  Tris,	  500mM	  NaCl,	  20mM	  Imidazole,	  2ml	  10%	  Tween	  20)	  supplemented	  with	  protease	  inhibitors	  and	  DNaseI.	  Lysate	  was	  homogenized	  by	  continuous	  stirring	  before	  adding	   it	   into	   a	   basic	   Z	   cell	   disruptor	   at	   40	   Kpsi.	   Samples	   were	   then	   transferred	   to	  appropriate	  centrifugation	  tubes	  and	  were	  further	  harvested	  for	  30	  minutes	  at	  30,000g	  and	  4C	  to	  decant	  and	  subsequently	  discard	  the	  bacterial	  cell	  remains.	  Resulting	  lysates	  containing	  the	  proteins	  of	  interest	  were	  used	  for	  purification	  
	  
5.2.2.1. Protein	  purification	  Lysates	  from	  soluble	  samples	  were	   loaded	  into	  an	  ÄKTA	  express	  (GE	  Healthcare)	  and	  maintained	  at	  4°C	  during	   the	  whole	  process.	   First,	   samples	  were	   injected	   into	  a	  1	  ml	  pre-­‐charged	   (washed	  with	  Nickel	  wash	  buffer	   -­‐	   50	  mM	  Tris	  pH7.5,	   500	  mM	  NaCl,	   20	  mM	   imidazole)	  HiTrap™	  Chelating	   Sepharose™	  Nickel	   column	   (GE	  Healthcare)	  where	  the	   polyhistidine-­‐tag	   of	   the	   protein	  was	   able	   to	   bind	  with	  micromolar	   affinity	   to	   the	  nickel	   ions	   inside	   the	  matrix	   of	   the	   column.	   Elution	   of	   the	   bound	   lysate	   components	  was	  done	  with	  50	  mM	  Tris	  pH	  7.5,	  500	  mM	  NaCl,	  500	  mM	  imidazole	  and	  subsequently	  injected	   on	   to	   a	   16/60	   HiLoad™	   Superdex	   75	   or	   200	   gel	   filtration	   column	   (GE	  Healthcare)	  previously	   equilibrated	   in	  20	  mM	  Tris	  pH	  7.5,	   200	  mM	  NaCl,	   to	   separate	  the	  components	  based	  on	  size-­‐exclusion.	  Protein-­‐containing	  fractions,	  detected	  by	  their	  absorbance	  at	  280	  nm,	  were	  collected	  in	  the	  wells	  of	  a	  96-­‐deep	  well	  block.	  An	  analysis	  of	   the	   peak	   fractions	   on	   SDS-­‐Page	   gels	   (Novex®	   NuPAGE®	   SDS-­‐PAGE	   Gel	   System)	  (10μl	  fraction	  +	  10μl	  loading	  buffer)	  allowed	  confirming	  the	  appropriate	  molecular	  size	  of	  the	  purified	  products	  and	  helped	  choosing	  the	  final	  fractions	  to	  be	  pooled.	  For	  non-­‐soluble	  products,	  protocol	  was	  carried	  out	  as	  before	  with	  the	  exception	  that	  8	  M	  Urea	  was	  added	  to	  the	  standard	  wash	  and	  purification	  was	  done	  at	  room	  temperature	  with	  a	  de-­‐salt	  column	  instead	  of	  the	  gel	  filtration	  column.	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5.2.2.2. Removal	  of	  fusion	  tags	  with	  3C	  Protease	  For	   immunisation	   purposes,	   a	   cleavage	   reaction	  with	   3C	   protease	  was	   performed	   to	  remove	  the	  fusion	  tag	  from	  the	  protein	  of	  interest.	  The	  reaction	  was	  done	  overnight	  on	  10mg	  of	  protein	  sample	  (a	  1	  mg	  test	  was	  carried	  out	  to	  begin	  with)	  by	  adding	  50μl	  of	  3C	   Protease.	   The	   cleavage	  mixture	  was	   then	   passed	   through	   a	   pre-­‐charged	   HiTrap™	  Chelating	   Sepharose™	   FF	   column	   (GE	   Healthcare)	   nickel	   column	   to	   remove	   any	   un-­‐cleaved	  fusion	  and	  to	  remove	  the	  His-­‐Tagged	  3C	  protease.	  	  Three	  rounds	  of	  wash	  buffer	  (5ml	   each)	   were	   then	   applied	   to	   the	   column	   with	   increasing	   concentrations	   of	  imidazole	  (50	  mM	  Tris	  pH7.5,	  500	  mM	  NaCl	  and	  20mM,	  50mM	  or	  100mM	  imidazole)	  to	  remove	  any	  non-­‐specific	  binding	  of	  the	  cleaved	  product	  to	  the	  sample,	  followed	  by	  the	  addition	   of	   Elution	   buffer	   (50	  mM	  Tris	   pH	   7.5,	   500	  mM	  NaCl,	   500	  mM	   imidazole).	   A	  sample	  from	  each	  step	  was	  analysed	  by	  SDS-­‐PAGE	  by	  loading	  10μl	  to	  each	  well.	  
	  
5.2.3. Preparation	  of	  recombinant	  proteins	  for	  immunisation	  	  Pooled	   peak	   fractions	   recovered	   for	   each	   of	   the	   protein	   samples	   during	   purification	  were	   concentrated	   to	   1mg/ml	   using	   Amicon	   centrifugal	   filters	   (10k	   or	   30k	   where	  appropriate)	   and	   carefully	   aliquoted	   to	   deliver	   10μg	   of	   the	   recombinant	   protein	  immunogen/immunisation.	  
	  
5.2.4. Immunisation	   of	   BALB/c	   mice	   by	   subcutaneous	   injection	   with	  
recombinant	  protein	  immunogens	  Based	  on	  previous	  successful	  results	  on	  immunisation	  with	  Multiple	  Antigenic	  Peptides	  (Wagstaff	   et	   al.	   2006),	   groups	   of	   five	   Balb/c	   female	   mice	   (18	   –	   20g,	   Charles	   River	  laboratories,	  UK)	  were	  immunised	  at	  four	  sites	  for	  a	  period	  of	  12	  weeks	  (3	  months)	  by	  delivering	   samples	   at	   weeks	   0,	   2	   (with	   Freund’s	   complete	   adjuvant),	   4	   and	   8	   (with	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Freund’s	   incomplete	   adjuvant)	   and	   12	   (with	   no	   adjuvant).	   A	   sample	   of	   blood	   was	  collected	   from	   each	   mouse	   at	   the	   end	   of	   the	   experiment	   by	   cardiac	   puncture	   after	  terminal	  anaesthesia.	  Blood	  samples	  were	  incubated	  at	  4°C	  for	  a	  total	  of	  3h	  to	  allow	  the	  formation	  of	  the	  clot.	  Samples	  were	  centrifuged	  at	  3000	  rpm	  for	  20	  min	  to	  separate	  the	  serum	  from	  other	  blood	  components	  and	  stored	  at	  -­‐20°C.	  	  
	  
5.2.5. Immunisation	  of	  sheep	  with	  recombinant	  protein	  immunogens	  	  As	  opposed	  to	  the	  protocol	  carried	  out	  in	  mice	  for	  the	  current	  study,	   immunogens	  for	  sheep	  immunisation	  were	  pooled	  according	  to	  the	  toxin	  groups	  they	  belonged	  to	  (Table	  B1),	   with	   the	  main	   objective	   of	   excluding	   a	   possible	   redundancy	   and	   optimizing	   the	  immunisation	  strategy	  by	  utilizing	  fewer	  animals	  (Table	  B1).	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A	   total	   of	   8	   sheeps	   were	   immunised	   with	   75μg	   of	   protein/immunisation	   on	   five	  occasions	  at	  weeks	  1,	  4,	  8,	  12	  and	  16	  by	  IgInnovations	  (Wales,	  UK).	  A	  sample	  of	  serum	  was	   taken	   from	   each	   sheep	   on	  week	   14	   and	   a	   final	   bleeding	   at	  week	   18	  when	   anti-­‐venom	   IgG	   was	   predicted	   to	   reach	   a	   plateau	   (16	   weeks,	   personal	   communication,	  MicroPharm	  Ltd).	  Purification	  of	  IgG	  was	  done	  by	  caprylic	  acid	  precipitation,	  briefly,	  a	  litre	  of	  blood	  was	  allowed	  to	  clot	  and	  was	  subsequently	  centrifuged	  and	  stored	  at	  22°C	  until	   the	   addition	   of	   5%	   caprylic	   acid	   (Sigma,	   UK)	  with	   vigorous	   stirring	   during	   two	  hours	   to	  precipitate	  non-­‐IgG	  proteins.	  The	  suspension	  was	  centrifuged	  at	  13,000	  rpm	  for	  one	  hour	  and	  the	  supernatant	  IgG	  was	  then	  dialysed	  with	  three	  changes	  of	  20	  mM	  sodium	   phosphate	   buffer	   (PBS	   -­‐	   pH	   7.4).	   An	   SDS-­‐PAGE	   analysis	   of	   the	   purification	  process	  was	  done	  in	  7.5%	  gels	  (Figure	  B1)	  and	  all	  the	  IgG	  antisera	  preparations	  were	  formulated	   to	   a	   concentration	   of	   30mg/ml	   in	   PBS	   and	   stored	   at	   22°C	   for	   further	  experiments.	  	  
	  
5.2.6. Immunological	  assays	  Immunoblotting	  was	  performed	  to	  determine	  seroconversion	  against	   the	  venom	  of	  E.	  
ocellatus,	  E.	  pyramidum	  leakeyi,	  E.	  coloratus	  (and	  from	  the	  geographically	  distant	  Asian	  viper	  E.	  carinatus	  sochureki-­‐	  Indian	  subcontinent),	   and	   from	  other	  geographically	  and	  phylogenetically	   distant	   vipers	   (E.	   leucogaster:	   Mali,	   Cerastes	   cerastes:	   Eygipt,	   Bitis	  
arietans:	   Ghana,	   B.	   arietans:	   Zimbabwe,	   B.	   gabonica:	   West	   Africa).	   Venoms	   were	  separated	  under	  reduced	  or	  native	  conditions	  (as	  described	  in	  Chapter	  2,	  section	  2.4.1)	  and	   incubation	   in	   test	   antisera	   was	   done	   at	   1/500	   dilution	   unless	   stated	   otherwise.	  ELISA	  was	  additionally	  performed	  as	  described	  in	  chapter	  2.4.3.	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5.3. RESULTS	  	  
5.3.1. Construction	   of	   epitope-­‐string	   immunogens	   as	   recombinant	   protein	  
constructs	  
Recombinant	   proteins	   that	   are	   likely	   to	   be	   devoid	   of	   a	   biological	   function	   for	   the	  bacterial	   host	   usually	   fall	   into	   the	   category	   of	   exogenous	   and	   can	   be	   sometimes	  problematic	   to	   express	   and	   scale-­‐up	   (Rozkov	   2001;	   Baneyx	   and	   Mujacic	   2004).	   The	  small-­‐scale	  screen	  carried	  out	  by	  OPPF	  showed	  a	  number	  of	  combinations	  in	  which	  the	  constructs	  were	  expressed	  (Annex	  5.5.1)	  that	  helped	  to	  rapidly	  identify	  (on	  the	  basis	  of	  solubility,	   lowest	   degree	   of	   proteolysis	   and	   predicted	   expression	   yield)	   the	   optimal	  expression	   characteristics	   for	   each	   construct	   for	   subsequent	   scale-­‐up	   of	   the	   proteins	  for	   immunisation.	  The	  chosen	  optimal	  combination	  of	   fusion	  vector,	  E.	  coli	   strain	  and	  induction	  system	  for	  each	  construct	  is	  summarized	  in	  Figure	  5.2.	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Figure	  5.2:	  Results	  of	  small-­‐scale	  expression	  screen	  of	  constructs.	  	  
a)	  Optimal	  conditions	  required	  for	  expression	  of	  constructs	  highlighting	  their	  predicted	  molecular	  weights	  (MW	  –	  in	  Da)	  based	  on	  the	  mass	  of	  the	  immunogen	  alone	  and	  the	  vector’s	  fusion	  tag.	  (MBP:	  Maltose	  Binding	  Protein,	  SUMO:	  Small	  Ubiquitin-­‐like	  Modifier,	  His:	  Polyhistidine	  only)	  constructs	  (predicted).	  Amp:	  Amplicillin,	  Kan:	  Kanamycyn,	  Chlor:	  Chloramphenicol.	  b)	  SDS-­‐PAGE	  of	  expressed	  proteins	  according	  to	  the	  optimal	  expression	  conditions.	  The	  construct	  MET3Es_PRC	  was	  found	  to	  be	  the	  only	  expressed	  as	  an	  insoluble	  protein.	  	  	  




Name MW Name Tag MW OPPF$# Name Predicted$MW E.coli$strain
PLA2Es 14536 pOPINM MBP 42711 8478 PLA2Es_RPC 57098 Rosetta TBONEx
SPEs 13444 pOPINM MBP 42711 8481 SPEs_RPC 56005 Rosetta TBONEx
CTL1Es 14457 pOPINSC3 SUMO 13213 8485 CTL1Es_RPC 27521 Rosetta IPTG
CTL2Es 12948 pOPINF His 2158 8486 CTL2Es_RPC 14957 Rosetta IPTG
MET1Es 15736 pOPINF His 2158 8489 MET1Es_RPC 17745 Rosetta IPTG
MET2Es 18817 pOPINF His 2158 8492 MET2Es_RPC 20826 Rosetta IPTG
MET3Es 17901 pOPINF His 2158 8495 MET3Es_RPC 19909 Rosetta TBONEx
DIS1Es 12616 pOPINSC3 SUMO 13213 8507 DIS1Es_RPC 25680 Rosetta TBONEx
DIS2Es 12693 pOPINM MBP 42711 8521 DIS2Es_RPC 51824 Rosetta IPTG
DISlike1 13695 pOPINM MBP 42711 8509 DISlike1_RPC 56487 Rosetta IPTG
DISlike2 13909 pOPINM MBP 42711 8512 DISlike2_RPC 56471 B834H IPTG
CRI1Es 12866 pOPINF His 2158 8514 CRI1Es_RPC 14701 Rosetta IPTG
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(Freund’s	  complete	  and	  incomplete	  was	  used	  in	  the	  current	  study,	  which	  contains	  the	  antigen	   in	   the	  aqueous	  phase	  of	   its	  emulsion	   (Jennings	  1995)).	  Results	  demonstrated	  that	  expression	  of	   the	  constructs	  as	  soluble	  products	  could	  be	  accomplished	   for	  all	  of	  the	   immunogens	   except	   MET3Es_RPC,	   which	   consistently	   showed	   little	   or	   very	  proteolysed	  expression	  during	  soluble	  purification	  protocols.	  The	  additional	  presence	  of	  proteolysis	   in	  several	  expressed	  soluble	  samples	  (with	  CTL1Es_RPC	  being	  the	  most	  evident)	  was	  also	  evident	  during	  the	  small-­‐scale	  screen,	  which	  was	  mainly	  attributable	  to	  the	  fact	  that	  recombinant	  proteins	  are	  known	  to	  be	  easily	  recognized	  as	  a	  target	  by	  bacterial	   host	   proteases	   (Baneyx	   and	  Mujacic	   2004).	   A	   decision	  was	  made	   to	   not	   to	  exclude	  constructs	  exhibiting	  significant	  proteolysis	  from	  immunisation	  of	  mice,	  on	  the	  basis	   that	   proteolysis	   of	   the	   protein	   of	   the	   epitope-­‐string	   structure	   might	   in	   fact	  enhance	   presentation	   of	   individual	   epitopes	   within	   the	   construct	   to	   the	   murine	  immune	  system.	  	  
	  
Additionally,	   both	   the	   soluble	   and	   insoluble	   screens	   showed	   an	   unusual	   but	   minor	  migration	  of	  the	  protein	  constructs	  on	  SDS-­‐PAGE	  analysis	  (i.e.	  higher/lower	  molecular	  weights	  than	  expected).	  This	  phenomenon	  was	  further	  explained	  by	  OPPF	  as	  a	  possible	  failure	  of	   the	  proteins	   to	   induce	  a	   complete	   ‘‘reconstructive	  denaturation”,	  which	  has	  been	   previously	   reported	   as	   “gel	   shifting”	   and	   is	   a	   consequence	   of	   changes	   in	   the	  detergent-­‐loading	   levels	   of	   polypeptides	   that	   subsequently	   impacts	   on	   the	   SDS-­‐PAGE	  migration	  rates	  (Rath	  et	  al.	  2009).	  	  
	  
5.3.2. Scale-­‐up	  of	  constructs	  for	  immunisation	  	  Scale-­‐up	  of	   the	  constructs	  was	  done	   to	  obtain	  sufficient	  amounts	   for	   immunisation	  of	  mice	   (and	   sheep	   -­‐	   Chapter	   5)	   and	   for	   immunological	   experiments.	   The	   purification	  curves	  for	  each	  of	  the	  constructs,	  together	  with	  the	  SDS-­‐PAGE	  analysis	  of	  the	  fractions,	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are	   shown	   in	   Annex	   5.5.2.	   Although	   the	   design	   of	   the	   synthetic	   epitope-­‐string	  constructs	  avoided	  venom	  domains	  that	  are	  known	  to	  confer	  pathogenicity,	  constructs	  CTL2Es_RPC	  MET2Es_RPC,	  MET3Es_RPC	  and	  CRI1Es_RPC	  showed	  a	  consistent	  toxicity	  to	   the	  bacterial	   hosts	   as	   evidenced	  by	   the	   loss	   of	   cellular	  mass	   after	   induction	   in	   the	  form	  of	  a	  black	  pellet	  and	   the	   subsequent	   low	  yield	  obtained	  after	   the	  purification	  of	  the	  protein.	  All	  these	  factors	  lead	  to	  highly	  variant	  yields	  of	  the	  constructs,	  with	  some	  requiring	   considerable	   scale-­‐up	   	   (in	   volumes	   of	   up	   to	   8L	   of	   media)	   to	   acquire	   the	  amounts	  needed.	  	  The	  final	  yield	  of	  purified	  protein	  for	  each	  epitope-­‐string	  immunogen	  is	   illustrated	   in	   Table	   5.1,	   which	   additionally	   shows	   the	   amount	   (litres)	   of	   growth	  media	  required	  to	  express	  the	  protein.	  
	  
	  
Table	  5.2:	  Final	  yields	  in	  relation	  to	  amount	  of	  growth	  media	  obtained	  after	  protein	  purification	  of	  toxin-­‐specific	  epitope-­‐string	  constructs	  against	  the	  most	  pathogenic	  toxin	  groups	  of	  the	  genus	  Echis.	  	  






PLA2Es_RPC 2 3.25 1.62
SPEs_RPC 2 9.61 4.81
CTL1Es_RPC 8 7.43 0.93
CTL2Es_RPC 4 1.26 0.32
MET1Es_RPC 2 3.70 1.85
MET2Es_RPC 8 0.76 0.10
MET3Es_RPC 8 9.00 1.13
DIS1Es_RPC 4 20.41 5.10
DIS2Es_RPC 4 15.80 3.95
DIS3Es_RPC 4 5.73 1.43
DIS4Es_RPC 4 26.68 6.67
CRI1Es_RPC 8 13.00 1.63
CRI2Es_RPC 2 5.64 2.82
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the	  recombinant	  immunogens	  was	  an	  objective	  in	  order	  to	  avoid	  generating	  redundant	  tag-­‐specific	   IgGs	   in	   the	   immunised	   animals.	   However,	   SDS-­‐PAGE	   analysis	   of	   the	   3C	  protease-­‐digested	  protein	  immunogens	  (Figure	  5.3)	  illustrated	  that	  it	  was	  not	  possible	  to	  remove	  the	  tag	  from	  the	  epitope-­‐string	  immunogens	  after	  a	  24-­‐hour	  incubation	  with	  the	  enzyme.	  	  
	  
Figure	  5.3:	  SDS-­‐PAGE	  of	  samples	  recovered	  from	  tag	  cleavage	  by	  3C	  Protease.	  	  1:	  Sample	  after	  incubation	  with	  3C	  protease,	  2:	  Wash	  buffer	  with	  imidazole	  at	  20mM,	  3:	  50mM,	  4:	  100mM,	  5:	  Elution.	  C3	  Protease	  Molecular	  weight:	  22	  KDa	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very	   limited	   amount	   of	   protein	   material	   in	   most	   of	   the	   cases,	   we	   were	   unable	   to	  undertake	   the	   experiment	   under	   reduced	   conditions,	   which	   could	   have	   lead	   us	   to	  answer	   if	   the	   folding	   of	   the	   proteins	   was	   responsible	   for	   inhibiting	   enzyme	   activity.	  	  Consequent	   to	   the	   inability	   to	   remove	   the	   tags,	   an	   additional	   experiment	   was	  performed	  to	  express	  the	  fusion	  tags	  as	  immunisation	  controls,	  and	  to	  be	  able	  to	  detect	  possible	   immunological	   interference.	   The	   optimal	   conditions	   for	   scale-­‐up	   of	   the	   Tag-­‐proteins,	   together	   with	   the	   final	   quantities	   obtained	   for	   each	   product	   are	   shown	   in	  Table	  5.2	   (Please	   refer	   to	  Annex	  5.5.3	   for	  a	  detail	  of	   the	  purification	  curves	  and	  SDS-­‐PAGE	  analysis	  of	  the	  fractions).	  	  
	  
	  
Table	  5.3:	  Optimal	  conditions	  for	  tag	  scale-­‐up	  and	  final	  yields	  obtained	  after	  purification.	  pOPINM	  (MBP	  Tag),	  pOPINF	  (HisGFP	  Tag),	  pOPINSC3	  (SUMO	  Tag).	  MW:	  Molecular	  Weight.	  	  
5.3.4. Immunological	   assessment	   of	   the	   humoral	   immune	   response	   of	   mice	  
immunised	  with	  venom	  toxin-­‐specific	  recombinant	  protein	  immunogens	  
5.3.4.1. Protein-­‐specific	  reactivity	  to	  venoms	  from	  the	  Echis	  genus	  Immunoblotting	  was	  performed	  with	  the	  serum	  from	  the	  terminal	  bleeding	  of	  the	  mice	  to	  determine	  sero-­‐conversion	  against	   the	  venoms	   from	  the	  medically	   important	  Echis	  species	   in	   Africa	   (E.	   ocellatus,	   E.	   pyramidum	   leakeyi	   and	   E.	   coloratus)	   and	   from	   the	  phylogenetically	   related	  but	   geographically	  distant	  Asian	  viper,	  E.	  carinatus	  sochureki	  (Indian	  subcontinent)	  (Figure	  5.4).	  	  
CELL$HOST
Name Fusion$Tag MW E.coli$strain
pOPINSC3 SUMMO 13214.00 B8342 Both 2 5.40 2.70
pOPINF HisGFP 28061.00 Rosetta TBOnEx 2 1.09 0.55
pOPINM MBP 42711.00 Rosetta TBOnEx 2 0.80 0.40
FUSION$VECTOR
INDUCTION LITERS FINAL$YIELD$(mg) mg/L
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Figure	  5.4:	  Immune	  reactivity	  of	  pooled	  sera	  (1:500)	  from	  mice	  immunised	  with	  toxin-­‐specific	  epitope-­‐strings	  to	  Echis	  venoms.	  	  Panels	  on	  the	  left	  show	  the	  SDS-­‐PAGE	  profile	  of	  each	  venom	  fractionated	  under	  the	  same	  conditions	  (7ug	  venom,	  15%	  reduced	  gel).	  	  	  Results	   obtained	   from	   the	   murine	   antisera	   rose	   against	   toxin-­‐specific	   epitope-­‐string	  recombinant	   protein	   immunogens	   revealed	   a	   high	   degree	   of	   specificity	   to	   proteins	  belonging	  to	  certain	  molecular	  weight	  areas	  when	  compared	  to	  the	  polyspecific	  binding	  of	   the	   antivenom	   positive	   control.	   In	   addition,	   molecular	   weight	   of	   immunoreactive	  bands	  showed	  to	  be	  conserved	  across	  the	  venoms	  of	  E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	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raised	   to	   the	   tag	   controls	   against	   the	  Echis	  venoms.	  Although	   some	  bands	   showed	   to	  correlate	   with	   the	   approximate	   molecular	   weight	   of	   the	   target	   toxin	   groups	   as	  previously	  described	  by	  (Mackessy	  2009b),	  results	  need	  to	  be	  further	  confirmed	  by	  LC-­‐MS,	  which	  was	  not	  possible	  to	  be	  undertaken	  during	  the	  development	  of	  the	  study.	  
	  
5.3.4.2. Analysis	  of	  seroconversion	  in	  individual	  immunised	  mice.	  	  	  The	   results	   above	   were	   obtained	   from	   sera	   pooled	   from	   the	   five	   Balb/c	   mice	  immunised	   with	   each	   toxin-­‐specific	   epitope-­‐string	   immunogen.	   Whilst	   encouraging,	  non-­‐specific	   binding	   obtained	   in	   the	   pooled-­‐sample	   suggested	   that	   the	   results	  might	  have	   had	   hidden	   individual	   differences	   to	   immunisation.	   Therefore,	   immunoblotting	  was	   repeated	   with	   the	   terminal	   bleeding	   sera	   from	   each	   mouse	   belonging	   to	   each	  immunisation	  group	  to	  determine	  their	   individual	  reactivity	  against	   the	  Echis	  venoms	  Figure	  5.5	  shows	  the	  results	  obtained	  for	  the	  venom	  of	  Echis	  ocellatus.	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The	  panel	  on	  the	  left	  shows	  the	  SDS-­‐PAGE	  profile	  of	  E.	  ocellatus	  venom	  fractionated	  under	  the	  same	  conditions	  (7ug	  venom,	  15%	  reduced	  gel).	  	  	  
The	   results	   of	   this	   experiment	   showed	   quite	   distinctive	   individual	   responses	   to	  immunisation	  despite	  using	   inbred	  mice	  and	  multiple	   immunization	  events,	  and	  were	  replicated	   in	   immunoblots	   performed	   with	   E.	   pyramidum	   leakeyi,	   E.	   coloratus	   and	   E.	  
carinatus	  sochureki	   venoms	   (not	   shown).	   This	   confirmed	   that	   pooling	   the	   samples	   to	  avoid	   individual	   variations	   was	   the	   most	   accurate	   way	   of	   approaching	   the	   possible	  individual	   immunological	   interferences.	   In	   addition	   to	   the	   differential	   immunological	  responses,	   this	   experiment	   showed	   in	   more	   detail	   that	   some	   of	   the	   recombinant	  protein	  immunogens	  were	  much	  more	  immunogenic	  than	  others	  and	  that	  serum	  from	  the	   fusion	   tag-­‐immunised	   mice	   showed	   little	   to	   no	   reactivity	   to	   the	   venoms	   under	  study.	  	  
	  
5.3.4.3. Reactivity	   of	   sera	   from	  mice	   immunised	   with	   the	   Echis-­‐genus	   toxin-­‐
specific	   epitope-­‐string	   immunogens	   to	   venoms	   from	   other	  medically	  
important	  African	  vipers.	  The	  cross-­‐reactivity	  obtained	  for	  the	  pooled	  murine	  toxin-­‐specific	  antisera	  against	  the	  
Echis	  venoms	  (Figure	  5.4)	  suggested	  that	  the	  phylogenetic	  analyses	  performed	  as	  part	  of	   the	   bioinformatic	   design	   of	   the	   toxin-­‐specific	   epitope-­‐strings	   (Chapter	   3)	   could	   be	  translated	  at	  the	  level	  of	  cross-­‐species	  conservation	  of	  snake	  venom	  protein	  sequences.	  Nevertheless,	  we	  also	  aimed	  to	  test	  the	  cross-­‐genera	  reactivity,	  which	  is	  of	  importance	  to	   test	   the	  potential	  polyspecificity	  of	   the	   toxin-­‐specific	   antivenom.	  Consequently,	   the	  following	   experiments	   interrogated	   the	   binding	   of	   the	   sera	   from	   each	   group	   of	  mice	  immunised	  with	  the	  epitope-­‐string	  immunogens	  to	  the	  venom	  of	  phylogenetically	  and	  geographically	  distant	  viper	  species	  (Figure	  5.6).	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Figure	  5.6:	  Immunoblot	  of	  African	  viper	  venoms	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Eygipt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Eygipt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	  
Bitis	  gabonica	  (West	  Africa)	  against	  immunogen’s	  sera	  from	  recombinant	  protein-­‐immunised	  mice	  (1:500).	  	  
The	  results	  showed	  a	  clear	  positive	  sero-­‐conversion	  response	  against	   the	  target	   toxin	  groups	  and	  an	  important	  cross-­‐reactivity	  among	  the	  venoms	  from	  other	  viper	  species	  (whilst	  conserving	  the	  target	   toxin	  areas	   throughout).	  Specificity	  of	   the	  bands	  against	  the	  approximate	  molecular	  weight	  of	   the	   target	   toxin	  group	  was	   shown	   to	  be	   clearer	  during	   this	   experiment,	   when	   compared	   to	   the	   previous	   immunoblots.	   It	   was	   also	  apparent	   that	   immunisation	   with	   the	   insoluble	   construct	   MET3Es_RPC	   generated	   a	  strong	   and	   specific	   immune	   response	   to	   its	   target	   toxin	   group,	   comparing	  well	   with	  responses	  of	  mice	   immunised	  with	  soluble	   immunogens	  –	  suggesting	  that	   insolubility	  may	   not	   necessarily	   negate	   the	   immunogenic	   potential	   of	   a	   recombinant	   protein	  immunogen.	   On	   the	   other	   hand,	   sera	   from	   mice	   immunised	   with	   the	   proteolysed	  construct	   CTL1Es_RPC	   bound	   to	   proteins	   of	   higher	   than	   expected	   molecular	   weight,	  suggesting	   that	  perhaps	   the	  proteolysed	  peptides	   could	  be	  mimicking	  epitopes	  of	   the	  multimeric	   P-­‐IIId	   SVMP	   (formerly	   classified	   as	   a	   PIV	   class	  member),	  which	   has	   been	  demonstrated	   to	   contain	   an	   additional	   C-­‐type	   lectin	   like	   domain	   (Fox	   and	   Serrano	  2008).	  	  
	  
In	   addition,	  we	   compared	   the	   immunoreactivity	   of	  mice	   immunised	  with	   the	   protein	  tags	   to	   the	  response	  obtained	   for	   the	  pre-­‐immune	  sera	  against	   the	  venom	  proteins	  of	  the	  Echis	  venoms	  (Figure	  5.7).	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Figure	  5.7:	  Immunoblot	  of	  African	  viper	  venoms	  against	  negative	  controls	  (tags	  and	  pre-­‐immune	  sera	  at	  1:500).	  	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Eygipt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Eygipt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	  
Bitis	  gabonica	  (West	  Africa).	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Figure	  5.8:	  Immunoblot	  of	  African	  viper	  venoms	  against	  mixed	  monospecifics	  at	  equal	  ratios	  and	  antivenom	  EchiTabG	  (1:1000	  and	  1:5000	  respectively).	  	  A:	  Echis	  ocellatus	  (Nigeria),	  B:	  Echis	  pyramidum	  leakeyi	  (Kenya),	  C:	  Echis	  leucogaster	  (Mali),	  D:	  Echis	  coloratus	  (Eygipt),	  E:	  Echis	  carinatus	  sochureki	  (United	  Arab	  Emirates),	  F:	  Cerastes	  cerastes	  (Eygipt),	  G:	  Bitis	  arietans	  (Ghana),	  H:	  Bitis	  arietans	  (Zimbabwe),	  I:	  
Bitis	  gabonica	  (West	  Africa).	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5.3.4.4. Responses	  of	  mixed	  monospecific	  serum	  to	  native	  venom	  proteins	  	  Taking	  into	  account	  that	  neutralization	  of	  the	  toxin	  groups	  relies	  strongly	  on	  the	  ability	  of	   the	   raised	   antibodies	   to	   bind	   to	   conformational	   epitopes	   in	   the	   native	   form	  of	   the	  proteins,	  an	  additional	  set	  of	   immunoblot	  experiments	  were	  undertaken	  with	  venoms	  of	  the	  Echis	  species	  under	  native	  conditions	  in	  order	  to	  screen	  for	  the	  native	  binding	  of	  the	  antibodies	  (Figure	  5.9).	  	  
	  
Figure	  5.9:	  Immunoblot	  of	  E.	  ocellatus	  (EOC),	  E.	  pyramidum	  leakeyi	  (ECO),	  E.	  coloratus	  (ECO),	  and	  E.	  carinatus	  sochureki	  (ECS)	  venoms	  at	  1mg/ml	  	  	  
a)	  reduced	  and	  b)	  native	  conditions	  against	  antivenom	  (EchitabG)	  at	  1:1000	  and	  Mixed	  monospecific	  sera	  at	  1:500.	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purify	  IgG	  and	  therefore	  make	  a	  more	  accurate	  comparison	  to	  the	  antivenom	  positive	  control.	  	  
	  
5.3.5. Purification	   of	   sera	   from	   sheep	   immunised	   with	   recombinant	   protein	  
immunogens	  	  Antivenom	   immunization	  protocols	   are	   currently	   carried	  out	   in	  higher	  order	   animals	  (i.e.	  horses	  or	  sheep)	  with	  the	  main	  objective	  of	  obtaining	  sufficient	  serum	  volumes	  for	  IgG	  purification.	  We	  elected	   to	   replicate	   this	  approach	  by	   immunizing	  sheep	  with	   the	  toxin-­‐specific	  epitope-­‐string	  recombinant	  protein	  immunogens,	  in	  order	  to	  evaluate	  the	  specificity	   of	   the	   raised	   immunoglobulins	   by	   performing	   the	   necessary	   preclinical	  studies	   that	   enable	   the	   comparison	   of	   efficacy	   of	   this	   new	   approach	   to	   that	   of	  conventional	  antivenom.	  	  Caprylic	  acid	  purification	  is	  shown	  in	  Figure	  5.10	  
	  
	  
Figure	  5.10:	  SDS-­‐PAGE	  of	  Caprylic	  acid	  purification	  showing	  samples	  from	  week	  14	  of	  the	  immunisation	  schedule.	  	  Samples	  EI-­‐1:	  PLA2Es,	  EI-­‐2:	  SPEs,	  EI-­‐3:	  CTLEs,	  EI-­‐4:	  METEs,	  EI-­‐5:	  DISlikeEs,	  EI-­‐6:	  DISEs,	  EI-­‐7:	  CRIEs,	  EI-­‐8:	  TAGs	  and	  PI:	  Pre	  immune,	  taken	  before	  (A)	  and	  after	  (B)	  the	  addition	  of	  caprylic	  acid.	  
	  
EI#2%EI#1% EI#3% EI#4% EI#5% EI#6% EI#7% EI#8% PI%
A"""""""B" A"""""""B" A"""""""B" A"""""""B" A"""""""B" A"""""""B" A"""""""B" A"""""""B" A"""""""B"
	   	   152	  
	  
5.3.6. Immunological	   assessment	   of	   the	   humoral	   immune	   response	   of	   sheep	  
immunised	  with	  venom	  toxin-­‐specific	  recombinant	  protein	  immunogens	  The	  specificity	  of	   the	   individual	   toxin-­‐specific	  ovine	   IgG	  and	  a	  mixture	  of	  all	   the	   toxin	  group-­‐specific	  ovine	  IgG	  antisera	  prepared	  by	  mixing	  in	  (i)	  equal	  volumes	  (and	  termed	  MM1)	  or	  (ii)	  in	  a	  ratio	  dictated	  by	  the	  percentage	  representation	  of	  the	  toxin	  group	  in	  the	   proteome	   (and	   termed	   MM2)	   (Wagstaff	   et	   al.	   2009),	   was	   determined	   by	  immunoblotting	  with	  venoms	  of	  E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	  E.	  coloratus	  and	  E.	  
carinatus	   sochureki	   venoms	   under	   reduced	   conditions	   and	   compared	   to	   that	   of	  antivenom	  positive	  control	  (EchiTAbG)	  (Figure	  5.11).	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  (1:1000)	  from	  the	  14th	  week	  of	  the	  sheep	  immunisation	  schedule	  against	  the	  venoms	  of	  
E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	  E.	  coloratus	  and	  E.	  carinatus	  sochureki	  venoms	  venoms.	  Samples	  EI-­‐1:	  PLA2Es,	  EI-­‐2:	  SPEs,	  EI-­‐3:	  CTLEs,	  EI-­‐4:	  METEs,	  EI-­‐5:	  DISlikeEs,	  EI-­‐6:	  DISEs,	  EI-­‐7:	  CRIEs,	  EI-­‐8:	  TAGs	  and	  PI:	  Pre	  immune	  
	  
Reactivity	  of	  the	  IgG	  antisera	  to	  the	  venoms	  in	  reduced	  conditions	  by	  immunoblotting	  showed	  a	  high	  degree	  of	  non-­‐specific	  binding	  across	  the	  samples	  when	  compared	  to	  the	  results	  obtained	  under	   the	  same	  conditions	  with	  sera	   from	  mice	   immunised	  with	   the	  same	   recombinant-­‐protein	   epitope-­‐string	   immunogens.	   A	   promising	   result	   was	  observed	   for	   the	  mixed-­‐monospecific	   IgG	   antisera	  when	   compared	   to	   the	   antivenom	  positive	  control	  (Figure	  5.11).	  However,	  the	  consistent	  presence	  of	  background	  bands	  in	  the	  IgG	  antisera	  belonging	  to	  the	  pre-­‐immune	  sample,	  which	  was	  known	  to	  contain	  redundant	  IgGs	  (Figure	  5.10),	  revealed	  the	  need	  to	  further	  examine	  the	  binding	  of	  the	  immunoglobulins.	   Accordingly,	   an	   end-­‐point	   ELISA	   was	   done	   with	   the	   objective	   of	  testing	  the	  individual	  reactivity	  of	  the	  toxin-­‐specific	  IgG	  antisera	  to	  venom	  proteins	  in	  native	   state,	   for	  which	   the	   venom	   in	   native	   state	   of	   the	  most	   pathogenically	   relevant	  
Echis	  species,	  Echis	  ocellatus	  (Figure	  5.12).	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Figure	  5.12:	  Indirect	  ELISA	  of	  venom	  from	  E.	  ocellatus	  (50	  μg)	  incubated	  with	  serial	  dilutions	  (horizontal	  axis)	  against	  toxin-­‐specific	  IgG	  antisera	  	  (PLA2:	  Phospholipase	  A2,	  SP:	  Serine	  proteases,	  CTL:	  C-­‐Type	  lectins,	  MET:	  Metalloproteinase	  domain,	  DIS:	  Disintegrin	  domain	  and	  CRI:	  Cysteine-­‐rich	  domain	  of	  SVMPs).	  Negative	  controls	  were	  added	  from	  IgG	  antisera	  raised	  against	  the	  tags	  (TAGs,	  purple	  bars)	  and	  from	  the	  pre-­‐immune	  IgG	  sample	  (PI,	  light	  blue	  bars).	  Optical	  density	  (at	  405nm)	  determined	  is	  located	  on	  the	  vertical	  axis.	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would	   be	   obtained	   by	   testing,	   under	   the	   same	   conditions	   as	   above,	   the	   mixed-­‐monospecific	   IgG	   antisera	   (MM1;	   MM2).	   Consequently,	   an	   additional	   ELISA	   and	   a	  (native)	  immunoblot	  was	  done	  to	  calculate	  and	  visualize	  (respectively)	  the	  reactivity	  of	  the	  mixed	  monospecific	   IgG	  antisera	  MM1	  and	  MM2	  against	  venoms	  of	   the	   four	  Echis	  species	  (E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	  E.	  coloratus	  and	  E.	  carinatus	  sochureki)	  and	  be	   able	   to	   generate	   a	   more	   accurate	   comparison	   of	   venom	   reactivity	   of	   the	   pooled	  toxin-­‐specific	  IgGs	  and	  antivenom	  (Figures	  5.13	  and	  5.14).	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Figure	  5.14:	  Mixed	  monospecific	  sheep	  IgG	  antisera	  native	  immunoblot	  	  E.	  ocellatus	  (EOC),	  E.	  pyramidum	  leakeyi	  (ECO),	  E.	  coloratus	  (ECO),	  and	  E.	  carinatus	  
sochureki	  (ECS)	  venoms	  at	  1mg/ml	  against	  Mixed-­‐monospecific	  IgG	  antisera	  at	  equal	  (MM1)	  and	  proteome	  (MM2)	  ratio	  at	  1:1000	  and	  antivenom	  (AV:	  EchiTAbG)	  at	  1:5000.	  	  
ELISA	  results	  on	  toxin-­‐specific	  IgG	  antisera	  showed	  again	  an	  absence	  of	  a	  plateau	  in	  the	  curve	  and	  a	  difficulty	  to	  reach	  an	  OD	  value	  of	  1.	  Antivenom	  on	  the	  other	  hand	  did	  show	  the	  mentioned	  characteristic	  but	  displayed	  an	  unexpected	  weaker	  binding	   to	   the	  one	  obtained	   previously	   by	   Casewell	   (2010).	  We	   repeated	   this	   experiment	   obtaining	   the	  same	   result	   consistently	   and	  we	   currently	   have	   no	   explanation	   to	   this	   phenomenon.	  Native	   immunoblotting	   results	   on	   the	   other	   hand,	   showed	   a	   lower	   binding	   when	  compared	  to	  antivenom	  positive	  control	  but	  a	  higher	  and	  more	  extensive	  binding	  when	  IgG	  antiserum	  was	  formulated	  according	  to	  the	  abundance	  of	  the	  proteome	  (MM2).	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venom	  proteins	  to	  the	  IgG	  samples	  in	  a	  different	  configuration	  to	  that	  of	  ELISA	  and	  (ii)	  better	  reflects	  the	  in	  vivo	  situation	  of	  venom-­‐antivenom	  interaction.	  We	  therefore	  used	  a	  CnBr-­‐activated	  venom-­‐affinity	  column	  of	  the	  pooled	  Echis	  venoms	  -­‐	  to	  isolate	  all	  anti-­‐Echis	  venom	  IgGs	  by	  eluting	  the	  venom-­‐specific	  IgG	  that	  remained	  bound	  to	  the	  column	  after	   extensive	   washing.	   We	   additionally	   prepared	   affinity	   purification	   columns	   for	  each	  of	  the	  Echis	  venoms	  (For	  details	  on	  the	  protocol	  please	  refer	  to	  chapter	  2,	  section	  2.5)	   and	   incubated	   them	   with	   each	   of	   the	   toxin-­‐specific	   IgG	   antiserum	   samples	   to	  measure	   the	   toxin/toxin-­‐specific	   IgG	  antiserum	  interactions	  by	  calculations	  according	  to	  the	  proteome	  representation.	  	  
	  
The	  small-­‐scale	  affinity	  purification	  of	  the	  individual	  toxin-­‐specific	  IgG	  antisera	  and	  of	  the	   pooled	   hyper-­‐immune	   serum	   revealed	   that	   there	   was	   minimal/trace	   specific	  binding	  to	  the	  venom.	  For	  the	  latter,	  we	  eluted	  approximately	  10ml	  of	  the	  toxin-­‐specific	  solution	   (from	   a	   total	   of	   7L	   of	   serum).	   Despite	   the	   low	   amount	   obtained,	   we	   again	  investigated	  the	  ability	  of	  the	  recovered	  antibodies	  to	  react	  against	  the	  Echis	  venoms	  by	  ELISA	  and	  immunoblot	  (Figures	  5.15	  and	  5.16).	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Figure	  5.15:	  Venom	  from	  E.	  ocellatus,	  E.	  p.	  leakeyi,	  E.	  coloratus	  and	  E.	  c.	  sochureki	  incubated	  with	  serial	  dilutions	  (horizontal	  axis)	  of	  affinity	  purified	  mixed-­‐monospecific	  IgG	  antisera.	  	  Optical	  density	  determined	  is	  located	  on	  the	  vertical	  axis.	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The	   toxin-­‐specific	   approach	   in	   the	   design	   of	   antivenoms	   is	   potentially	   a	   significant	  progression	   to	   improve	   the	   clinical	   efficacy	   and	   safety	   of	   conventional	   antivenom	  treatment	   of	   snakebite.	   Previous	   reports	   from	   our	   group	   indicated	   that	   a	   single	  synthetic	   DNA	   immunogen	   replicated	   the	   toxin-­‐neutralizing	   capabilities	   of	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conventional	   antivenom	  by	  generating	   antibodies	   that	  neutralized	   the	   toxic	   effects	  of	  SVMPs	   (Harrison	   et	   al.	   2000;	   Wagstaff	   et	   al.	   2006).	   In	   this	   study	   we	   successfully	  constructed	   several	   epitope-­‐string	   recombinant	   protein	   immunogens	   that	   generated	  toxin-­‐specific	   murine	   antibody	   responses	   against	   the	   venoms	   of	   Echis	   and	   other	  phylogenetically	  and	  geographycally	  distant	  vipers,	  which	  showed	  a	  logical	  progression	  from	   earlier	   efforts	   in	   generating	   a	   polyspecific	   antivenom	   for	   Africa	   and	   from	   our	  current	  use	  of	  the	  constructs	  as	  DNA	  immunogens	  (Chapter	  4).	  	  
	  
The	  delivery	  of	  immunogens	  as	  recombinant	  proteins	  has	  been	  previously	  shown	  to	  be	  a	   successful	   strategy	   for	   vaccine	   delivery	   (Pereira-­‐Chioccola	   et	   al.	   1999;	  Wang	   et	   al.	  2004;	   Wagstaff	   et	   al.	   2006).	   In	   agreement,	   antibodies	   from	   the	   epitope-­‐string	  recombinant	  protein	  immunised	  mice	  revealed	  a	  high	  degree	  of	  specificity	  to	  proteins	  belonging	  to	  certain	  molecular	  weight	  areas	  when	  compared	  to	  the	  polyspecific	  binding	  of	   the	   antivenom	   positive	   control.	   In	   addition,	   molecular	   weight	   of	   immunoreactive	  bands	  showed	  to	  be	  conserved	  across	  the	  venoms	  of	  E.	  ocellatus,	  E.	  pyramidum	  leakeyi,	  
E.	   coloratus	   and	   E.	   carinatus	   sochureki.,	   which	   was	   especially	   apparent	   in	   the	  immunoblots	   performed	   with	   venoms	   of	   many	   viper	   species	   (Figure	   5.5).	   This	  importantly	   illustrated	   that	   the	   IgGs	   exhibited	   toxin-­‐specificity	   and	   that	   this	   was	  apparent	   despite	   snake	   species	   phylogenetic	   and	   geographic	   divergences.	   The	   cross-­‐generic	   binding	   capability	   of	   the	   antibodies	   raised	   against	   the	   bioinformatically-­‐designed	  toxin-­‐specific	  epitope-­‐string	   immunogens	  was	  also	  evident	  when	  comparing	  the	  reactivity	  of	  the	  mixed	  monospecific	  sample	  to	  the	  antivenom	  control	  (Figure	  5.7).	  	  Results	   demonstrated	   that	   the	   sequence	   conservation	   of	   the	   transcripts	   used	   for	   the	  design	  of	  the	  immunogens	  (Chapter	  3)	  could	  be	  utilised	  to	  predict	  cross-­‐taxa	  conserved	  immunogenicty	  of	  the	  immunogen.	  These	  consistently	  conserved	  sequences,	  predicted	  to	   be	   under	   high	   evolutionary	   pressures	   perhaps	   due	   to	   their	   biological	   significance	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related	   (directly	   or	   indirectly)	   to	   toxin-­‐induced	   pathologies,	   provide	   encouragement	  for	   the	   development	   of	   serotherapies	   that	   are	   based	   on	   the	   design	   of	   toxin-­‐specific	  immunogens.	  	  
	  
An	  addition	  to	  the	  above	  was	  noted	  for	  the	  CTL	  toxin	  group,	  where	  the	  right	  molecular	  weight	  target	  was	  only	  observed	  for	  the	  antibodies	  raised	  against	  the	  construct	  CTL2Es	  while	   CTL1Es	   showed	   to	   be	   binding	   to	   proteins	   of	   much	   higher	   molecular	   weights.	  Casewell	  et	  al.	  (2009)	  demonstrated	  that	  the	  ESTs	  of	  the	  venom	  gland	  transcriptomes	  of	  Echis	  contained	  clusters	  with	  a	  high	  degree	  of	   sequence	   similarity	   to	  a	  PIV-­‐related	  CTL	  Factor	  X	  activator	  light	  chain	  2	  from	  M.	  lebetina	  (Siigur	  et	  al.	  2004)	  which	  suggests	  that	  the	  CTL2	  epitope-­‐string	  immunogen	  could	  be	  binding	  to	  P-­‐IIId	  SVMPs.	  This	  could	  be	  further	  explained	  by	  the	  fact	  that	  this	  immunogen	  was	  the	  one	  that	  showed	  the	  most	  proteolysis	  during	   the	  purifications,	  and	   it	  could	  be	  suggested	  that	   this	   is	  responsible	  for	   perhaps	   mimicking	   the	   epitopes	   that	   present	   a	   much	   higher	   molecular	   weight,	  characteristic	  of	  P-­‐IIId	  SVMPs	  (Fox	  and	  Serrano	  2008).	  	  
	  
Immunisations	  with	  the	  protein	  immunogen	  attached	  to	  the	  tag	  was	  shown	  to	  have	  no	  relevant	  effect	  when	  compared	  to	  antibodies	  from	  mice	  immunised	  with	  the	  tag	  alone	  (Figure	   5.6).	   Neverhteless,	   the	   differences	   seen	   in	   the	   reactivity	   of	   the	   sera	   from	  individual	   in-­‐bred	  mice	   of	   the	   same	   immunisation	   group	   against	   the	   venom	  proteins	  (Figure	  5.4)	  demonstrated	  that	  perhaps,	  the	  presence	  of	  tag-­‐protein	  inside	  the	  sample	  given	   for	   immunisation	  (10ug)	  could	  have	  generated	  a	  redundancy	  that	  consequently	  reduced	   the	   amount	   of	   toxin-­‐specific	   immunogen	   that	   can	   ensure	   an	   immunological	  equivalence	   across	   all	   animals.	   Therefore,	   the	   need	   to	   elucidate	   the	   folding	   and	  conformational	   characteristics	   of	   the	   recombinant	   proteins	   to	   identify	   the	   options	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available	  to	  accomplish	  the	  removal	  of	  the	  tag	  is	  of	  great	  importance	  for	  future	  studies	  with	  the	  objective	  of	  immunising	  animals	  with	  the	  immunogen	  only.	  	  
	  
Knowledge	  on	  the	  three-­‐dimensional	  structure	  of	  the	  immunogens	  would	  additionally	  be	   predicted	   to	   identify	   if	   the	   conformation	   of	   the	   immunogens	   is	   interfering	   or	  enhancing	  the	  processing	  of	  the	  protein	  as	  individual	  epitopes	  during	  immunisations.	  It	  is	   known	   that	   B	   cells	   process	   vaccine	   antigens	   into	   small	   peptides	   that	   are	   then	  displayed	   at	   their	   surface	   through	   MHC	   class	   II	   molecules,	   becoming	   available	   for	  binding	  by	  a	  specific	  subset	  of	  CD4+	  T	  cells	  (Siegrist	  2008).	  Whilst	  we	  included	  double	  lysine	  spacers	  between	  individual	  epitopes	  comprising	  the	  epitope-­‐string	  immunogens	  	  to	   enhance	   the	   processing	   and	   presentation,	   of	   the	   antigens	   as	   individual	   epitopes	  (Wagstaff	   et	   al.	   2006),	   the	   exact	   mechanisms	   underlying	   this	   activity	   are	   far	   from	  understood.	   Further	   investigation	   needs	   to	   be	   undertaken	   to	   determine	   the	   exact	  processing	  of	  the	  constructs,	  which	  then	  induce	  B	  cell	  proliferation	  and	  differentiation	  into	  antibody-­‐secreting	  plasma	  cells	  that	  generate	  the	  specific	  antibodies.	  	  	  
	  
The	   low	   reactivity	   of	   the	   antibodies	   to	   the	   venoms	   in	   a	   native	   conformational	   state	  (Figure	  5.8),	  which	  failed	  to	  show	  an	  effect	  similar	  to	  that	  of	  antivenom,	  suggested	  that	  perhaps	   the	   conformational	   features	   of	   the	   toxins	   are	   interfering	  with	   the	  binding	   of	  the	   antibodies	   raised	   against	   the	   epitope-­‐string	   immunogens,	   and	   that	   possibly	   the	  predicted	   surface-­‐exposure	   of	   the	   epitopes	   could	  have	  been	  misleading.	   Even	   though	  efforts	  were	  made	  to	  predict	   the	  appropriate	  surface-­‐exposed	  epitope	  sequences,	   it	   is	  unknown	   if	   the	   amino	   acid	  distance	  used	   to	   avoid	   the	   glycosylation	   sites	   is	   accurate.	  Therefore,	   a	   hypothesis	   that	   rises	   from	   this	   issue	   is	   the	   possibility	   of	   glycans	   on	   the	  native	   venoms	  preventing	   antibody	   access	   to	   the	  underlying	  peptide.	   Several	   reports	  on	   viruses,	   for	   example,	   have	   shown	   that	   the	   presence	   of	   glycosylation	   can	   interfere	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with	   the	   antibody	   immune	   response	   against	   the	   epitopes	   covered	   (Johnson	   and	  Desrosiers	  2002;	  Sirois	  et	  al.	  2007).	  	  
	  
The	  promising	  results	  of	  the	  toxin-­‐specific	  antibodies	  under	  reduced	  conditions	  of	  the	  venom	  proteins,	  and	  the	  low	  response	  obtained	  when	  the	  toxins	  maintain	  their	  three-­‐dimensional	   structure	   highlighted	   the	   need	   to	   acquire	   sufficient	   volumes	   of	   sera	  (unavailable	   in	   mice	   studies)	   to	   allow	   us	   to	   purify	   IgG	   enabling	   a	   more	   rational	  comparison	   to	  antivenom.	   In	  addition,	   the	  purification	  of	   IgG	  would	  be	  of	  great	  value	  for	   the	  characterization	  of	   the	  venom	  toxins	  and	  subsequent	  validation	  of	  epitopes	   in	  the	   bioinformatic	   design	   of	   the	   project.	   Immunisation	   of	   sheep	   with	   a	   pool	   toxin-­‐specific	   recombinant	   protein	   constructs	   by	   Ig-­‐Innovations	   (Wales,	   UK)	   allowed	   us	   to	  purify	  toxin-­‐specific	  IgG	  in	  a	  similar	  manner	  to	  that	  of	  current	  antivenom	  manufacture,	  but	  results	  showed	  to	  be	  difficult	  to	  compare	  their	  neutralizing	  capacity	  to	  that	  of	  the	  antivenom	  EchiTAbG.	  Purification	  with	  caprylic	  acid	  of	   serum	   from	  hyper-­‐immunised	  sheep	   revealed	   the	   existence	   of	   IgG	   in	   the	   pre-­‐immune	   sera,	   thus	   confirming	   the	  presence	   of	   redundant	   immunoglobulins.	   We	   suggest	   that	   as	   a	   consequence,	  immunological	   experiments	   showed	   a	   disappointingly	   unspecific	   binding	   to	   reduced	  venom	  proteins	  as	  well	  as	  a	  low	  reactivity	  of	  the	  antibodies	  to	  native	  venom	  proteins.	  	  
	  
Although	  one	  of	   the	  hypotheses	   that	   rise	   from	   the	   results	   obtained	   suggests	   strongly	  that	   the	   presence	   of	   tag-­‐protein	   inside	   the	   immunisation	   samples	   could	   have	   diluted	  the	   amount	  of	   toxin-­‐specific	   protein	  delivered	   to	   the	   sheep;	   it	   is	   known	   that	  purified	  IgG	  from	  immunised	  animals	  during	  conventional	  antivenom	  manufacture	  can	  contain	  not	   only	   antibodies	   against	   the	   immunogen	   of	   interest.	   Consequently,	   a	   series	   of	   key	  secondary	   processes	   have	   been	   carried	   out	   in	   the	   past	   years	   in	   order	   to,	   through	  affinity	   purification,	   identify	   and	   quantify	   the	   specific	   venom	   toxins	   exhibiting	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immunoreactivity	  towards	  immobilized	  antivenom	  IgG	  molecules,	  and	  the	  set	  of	  toxins	  lacking	  immunoreactive	  epitopes	  (Calvete	  et	  al.	  2009;	  Pla	  et	  al.	  2012).	  In	  an	  attempt	  to	  identify	   the	  neutralizing	   capacity	   of	   the	   sheep	   toxin-­‐specific	   IgGs,	   subsequent	   affinity	  purification	   revealed	   that	   although	   there	   was	   minimal/trace	   specific	   binding	   to	   the	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5.5. ANNEXES	  
5.5.1. OPPF	  Small-­‐scale	  expression	  screen	  
	  
	  





B834 Rosetta B834 Rosetta
A01 PLA2Es 12481 8477 16545 ./. .+.(big) ./. (+) .+
B01 SPEs 12482 8480 15452 ./. .+.(big) ./. (+) .++
C01 CTL1Es 12483 8483 16466 ./. ./. ./. (+).(prot) ./.
D01 CTL2Es 12484 8486 14957 .++ .++ ./. ./ .+
E01 MET1Es 12485 8489 17745 ./. .+++.(big) ./. (+) .+
F01 MET2Es 12486 8492 20826 ./. .+.(big) ./ ./. (+)
G01 MET3Es 12487 8495 19909 ./. ./. ./. ./. .+
A02 DIS1Es 12488 8505 14625 .+++.(big) .++.(big) ./ .++.(big) .+++
F02 DIS2Es 12493 8479 11271 ./. .+.(big) ./. ./ .++
B02 DISlike1Es 12489 8508 15934 .++.(big) .++.(big) .++.(big) .++.(big) .+++
C02 DISlike2Es 12490 8511 15918 .++.(big) .+.(big) ./. (+).(big) .++
D02 CRI1Es 12491 8514 14701 .+.(big) .+++ ./. .++ ./
E02 CRI2Es 12492 8517 14875 ./. ./. ./. .++.(big) .+
A03 PLA2Es 12481 8482 27600 ./. ./. .++.(prot) .+++
B03 SPEs 12482 8485 26507 .+.(prot) .+.(prot) ./. .++.(prot) .++
C03 CTL1Es 12483 8488 27521 ./. .+.(prot) ./. .+.(prot) .+
D03 CTL2Es 12484 8490 26012 .+.(prot) (+).(prot) ./. ./. .+
E03 MET1Es 12485 8494 28800 .+ .+++.(prot) ./. ./. .+++
F03 MET2Es 12486 8497 31881 ./. (+).(prot) ./. ./. ./.
G03 MET3Es 12487 8500 30964 ./. ./ ./. ./. ./.
A04 DIS1Es 12488 8507 25680 ./. .++.(prot) ./. .+++ .+++
F04 DIS2Es 12493 8522 22326 (+) .+.(prot) ./. ./ (+)
B04 DISlike1Es 12489 8510 26989 ./. .++.(prot) .++.(big) .+++ .+++
C04 DISlike2Es 12490 8513 26973 .++ ..+ ./. .++ ./.
D04 CRI1Es 12491 8516 28756 ./. .+++.(small) (+) .+++ ./.
E04 CRI2Es 12492 8519 25930 ./. (+).(prot) ./. .+.(prot) .+
A05 PLA2Es 12481 8478 57098 ./. .+.(prot) .(+).(prot) .++ ./.
B05 SPEs 12482 8481 56005 ./. .+.(prot) .(+).(prot) .++ ./.
C05 CTL1Es 12483 8484 57019 .+.(prot) .+.(prot) ./ .+.(prot) ./.
D05 CTL2Es 12484 8487 55510 .++.(prot) .+++.(prot) .++.(prot) .++.(prot) ./.
E05 MET1Es 12485 8491 58298 .+.(prot) .++.(prot) ./. .++ ./.
F05 MET2Es 12486 8493 61379 (+).very.prot .(+).very.prot ./. .+.(prot) ./.
G05 MET3Es 12487 8496 60462 (+).very.prot .(+).very.prot ./. .+.MBP ./.
A06 DIS1Es 12488 8506 55178 .MBP.Only .MBP.Only .MBP.Only .MBP.Only ./.
F06 DIS2Es 12493 8521 51824 .++ .++ (+) .+.(prot) ./.
B06 DISlike1Es 12489 8509 56487 .+++ .+++ .+ .+ ./.
C06 DISlike2Es 12490 8512 56471 .+++ .+ ./. .++ ./.
D06 CRI1Es 12491 8515 55254 MBP.Only MBP.Only MBP.Only MBP.Only ./.












VECTOR WELL NAME OPTIC # OPPF0# MW Vector + immunogen
IPTG0Induced0expression Autoinduction0expression
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5.5.2. Absorbance	  curve	  and	  SDS-­‐Page	  analysis	  of	  fractions	  obtained	  during	  the	  
purification	  of	  the	  constructs.	  
	  
	  








































 Sys 1018:Sample2_Fractions  Sys 1018:Sample2_Inject  Sys 1018:Sample2_Logbook  Sys 1018:Sample2_UV







30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 ml
D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 F12 F11 F10 F9 F7
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 Sys 1018:Sample1_Fractions  Sys 1018:Sample1_Inject  Sys 1018:Sample1_Logbook  Sys 1018:Sample1_UV







 40  60  80 100 120 ml
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60.0 80.0 100.0 120.0 ml
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60.0 80.0 100.0 120.0 ml
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30.0 40.0 50.0 60.0 70.0 80.0 ml
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40.0 45.0 50.0 55.0 60.0 65.0 ml
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50.0 60.0 70.0 80.0 90.0 100.0 ml
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40.0 50.0 60.0 70.0 80.0 90.0 ml
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50.0 60.0 70.0 80.0 ml
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Purification	  of	  the	  Cysteine-­‐rich	  domain	  construct	  (CRI1Es_RPC)	  showing	  the	  a)	  absorbance	  curve	  (well	  name	  containing	  the	  fractions	  are	  labelled	  above	  the	  x-­‐axis)	  and	  b)	  SDS	  PAGE	  gel	  analysis	  of	  fractions	  according	  to	  the	  peak	  profile.	  Molecular	  weights	  are	  indicated	  in	  red	  arrows:	  tag	  alone	  (His	  -­‐	  2	  kDa),	  immunogen	  alone	  (12	  kDa)	  and	  immunogen	  +	  tag	  (14	  kDa).	  Fractions	  A8	  –	  B6	  were	  pooled	  for	  immunisations.	  
	  

















A2 A3 A4 A5 A6 A7 A8 A9A10 A12 B11 B9 B8 B7 B5
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30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 ml
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5.5.3. Absorbance	  curve	  and	  SDS-­‐Page	  analysis	  of	  fractions	  obtained	  during	  the	  
purification	  of	  the	  fusion	  tags.	  
	  
	  






























 Sys 1018:Sample1_Fractions  Sys 1018:Sample1_Inject  Sys 1018:Sample1_Logbook  Sys 1018:Sample1_UV







30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 ml
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20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 ml
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50.0 60.0 70.0 80.0 90.0 ml
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6. GLYCOSYLATION	  IN	  ECHIS	  VENOM	  PROTEINS	  
	  
6.1. INTRODUCTION	  	  
Carbohydrate-­‐peptide	   linkage,	   also	   known	   as	   glycosylation,	   is	   known	   to	   commonly	  occur	  as	  a	  post-­‐translational	  modification	  of	  secretory	  proteins	  (Lis	  and	  Sharon	  1993;	  Spiro	  2002;	  Soares	  and	  Oliveira	  2009;	  Varki	  et	  al.	  2009),	  generally	  impacting	  upon	  their	  biological	  activity,	  molecular	   integrity,	  stability,	  solubility,	  and	  immunogenicity	  (Veiga	  
et	  al.	  1999;	  Asgari	  et	  al.	  2003;	  Valdez-­‐Cruz	  et	  al.	  2004;	  Harrison	  et	  al.	  2007;	  Gerwig	  et	  
al.	  2013).	  Glycosylation	  is	  known	  to	  occur	  in	  proteins	  belonging	  to	  animal	  venoms,	  and	  although	   it	   has	   been	   predicted	   through	   bioinformatic	   tools	   to	   happen	   extensively	   in	  snake	  venom	  proteins	  (Soares	  and	  Oliveira	  2009),	  it	  has	  only	  been	  demonstrated	  for	  a	  few	   toxin	   groups,	   being	  most	   commonly	   found	   in	  thrombin-­‐like	   serine	  proteases	   like	  ancrod	   from	   Agkistrodon	   rhodostoma	   (Pfeiffer	   et	   al.	   1992;	   Pfeiffer	   et	   al.	   1993),	  batroxobin	   from	   Bothrops	   moojeni	   (Lochnit	   and	   Geyer	   1995),	   BPA	   from	   Bothrops	  
jararaca	   (Murayama	   et	   al.	   2003)	   and	   kangshuanmei	   from	   Agkistrodon	   halys	  
brevicaudus	   stejnegeri	   (Sakai	   et	  al.	   2006).	   It	   has	   additionally	   been	   shown	   to	   occur	   in	  several	  snake	  venom	  metalloproteinases	  (SVMPs)	  such	  as	  the	  H2-­‐proteinase,	  HR1B	  and	  HR2a	   from	  Trimmeresurus	   flavoviridis	   (Miyata	   et	   al.	   1989;	   Takeya	   et	   al.	   1989),	  LHFII	  from	   Lachesis	   muta	   muta	   (Sanchez	   et	   al.	   1991),	   Jararhagin	   from	  Bothrops	  
jararaca	  	   (Paine	  et	  al.	  1992),	  atrolysin	  A	  (Ht-­‐a)	   from	  Crotalus	  atrox	  	   (Hite	  et	  al.	  1994),	  rhodostomin	  and	  rhodostoxin,	  from	  Calloselasma	  rhodostoma	  (Au	  et	  al.	  1991;	  Tan	  et	  al.	  1997)	  and	  bilitoxin-­‐1	  Agkistrodon	  bilineatus	  (Nikai	  et	  al.	  2000)	  and	  additionally,	  in	  the	  three-­‐finger	  cytotoxin	  from	  Naja	  kaouthia	  (Osipov	  et	  al.	  2004)	  and	  in	  the	  L-­‐amino	  acid	  oxidase	  from	  the	  venom	  of	  Calloselasma	  rhodostoma	  (Ande	  et	  al.	  2006).	  	  
	   	   183	  
The	   first	   stages	   of	   this	  modification	   usually	   take	   place	   in	   the	   endoplasmic	   reticulum	  (ER),	   (Abeijon	   and	  Hirschberg	  1992),	  where	   one	  or	  more	   sugar	   groups	   (glycans)	   are	  attached	   covalently	   to	   the	   polypeptide	   backbone	   through	   a	  modification	   via	  O-­‐	   or	  N-­‐	  linkages	  (Lis	  and	  Sharon	  1993;	  Spiro	  2002;	  Sinclair	  and	  Elliott	  2005;	  Varki	  2006).	  An	  O-­‐linked	  oligosaccharide	  (O-­‐glycan)	  is	  linked	  to	  the	  to	  a	  hydroxyl	  group	  of	  a	  serine	  (ser)	  or	  threonine	  (thr)	  residue	  of	  the	  polypeptide	  chain	  via	  N-­‐acetylgalactosamine	  (GalNAc)	  (Hansen	  et	  al.	  1995).	  On	  the	  other	  hand,	  an	  N-­‐(Asn)-­‐linked	  oligosaccharide	  (N-­‐glycan)	  is	   covalently	   linked	   to	   an	  asparagine	   (asn)	   residue	  of	   a	  polypeptide	   chain,	   commonly	  involving	  GlcNAc	   and	   the	   consensus	   peptide	   sequence:	   Asn-­‐X-­‐Ser/Thr.	  N-­‐Glycans	   are	  the	   most	   commonly	   found	   in	   nature	   and	   can	   generally	   be	   divided	   into	   three	   main	  classes:	   oligomannose	   (or	  high-­‐mannose)	   type,	   complex	   type,	   and	  hybrid	   type,	  which	  shares	  a	  pentasaccharide	  core	  region	  (Bause	  1983;	  Kornfeld	  and	  Kornfeld	  1985;	  Varki	  
et	  al.	  2009)	  (Figure	  6.1).	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Modified	  from	  Glycobiology,	  New	  England	  Biolabs	  (https://www.neb.com	  /products/glycobiology/)	  
	  
Snake	  venom	  glycans	  can	  be	  of	  both	  N-­‐	  and	  O-­‐	  linked	  type	  and	  occur	  frequently	  in	  loops	  proximal	   to	   catalytic	   sites	   (Gowda	   and	   Davidson	   1992).	   The	   glycans	   attached	   to	   the	  polypeptide	   by	   an	   Asparagine	   residue	   have	   been	   studied	   in	  more	   detail	   and	   several	  authors	   have	   reported	   that	   snake	   venom	  glycoproteins	   share	   the	   common	   feature	   of	  being	   of	   complex-­‐type	   structures,	   meaning	   that	   besides	   the	   core	   of	   2	   N-­‐acetylglucosamines	   (GlcNAc)	   attached	   to	   the	   Asn	   residue,	   they	   can	   additionally	   be	  linked	   to	   different	   combinations	   of	   mannose,	   N-­‐acetylglucosamine,	   N-­‐acetylgalactosamine,	  fucose	  and	  sialic	  acid	  residues	  (Gowda	  and	  Davidson	  1992;	  Soares	  and	  Oliveira	  2009).	  	  
	  
This	  post-­‐translational	  modification	   in	   snake	  venom	  proteins	  has	  been	  demonstrated	  to	   represent	   from	   5	   to	   90%	   of	   the	   molecular	   mass	   of	   venom	   proteins	   (Gowda	   and	  Davidson	  1992;	  Murayama	  et	  al.	  2003),	  therefore	  implying	  that	   is	  an	  important	  factor	  to	   take	   into	   consideration	   for	   the	   design	   of	   antibody-­‐based	   therapies	   (Sinclair	   and	  Elliott	  2005)	  against	  snakebite	  –	  the	  primary	  aim	  of	  the	  Alistair	  Reid	  Venom	  Research	  Unit.	  Currently,	   there	   is	   substantial	   evidence	   from	  non-­‐venom	  studies	   to	   suggest	   that	  (i)	  neutralizing	  antibodies	  can	  be	  raised	  against	  carbohydrate	  groups	  (Kieliszewski	  and	  Lamport	  1986;	  Wei	  et	  al.	  2010;	  Wolfert	  and	  Boons	  2013)	  and	  that	  (ii)	  glycosylation	  can	  affect	   the	   antibody	   interaction	   with	   the	   underlying	   peptide	   sequence	   (Gribben	   et	   al.	  1990;	  Huang	  et	  al.	  1997;	  Hermeling	  et	  al.	  2004;	  Wei	  et	  al.	  2010).	  In	  consideration	  of	  the	  latter,	  and	  our	  evidence	  demonstrating	  that	  antibodies	  raised	  against	  linear	  epitopes	  of	  the	  most	  pathogenic	  groups	  of	  Echis	  venom	  toxins	  	  show	  a	  considerably	  lower	  binding	  to	  native,	  rather	  than	  reduced	  venom	  proteins	  (Chapter	  5)	  –	  in	  this	  study	  we	  attempted	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6.2.1. Deglycosylation	  of	  venom	  proteins	  under	  denaturing	  and	  native	  
conditions	  To	   determine	   the	   extent	   and	   type	   of	   glycan-­‐binding	   of	   the	   Echis	   venom	   proteins	  relevant	  to	  this	  study,	  we	  utilized	  PNGase	  F	  and	  Endo	  H,	  which	  specifically	  cleave	  Asn-­‐linked	   glycans.	   While	   PNGase	   F	   catalyses	   the	   cleavage	   of	   most	   types	   of	   N-­‐linked	  oligosaccharides	  (high	  mannose,	  hybrid	  and	  complex)	  between	   the	   innermost	  GlcNAc	  (Elder	   and	   Alexander	   1982),	   Endo	   H	   is	   specific	   for	   high-­‐mannose	   and	   hybrid-­‐type	  oligosaccharides	  and	  hydrolyses	  the	  bond	  connecting	  the	  two	  GlcNac	  groups	  that	  form	  the	  diacetylchitobiose	  core	  from	  the	  asparagine	  residue	  (Tarentino	  et	  al.	  1985)	  (Figure	  6.2).	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Figure	  6.2:	  Schematic	  representation	  of	  cleavage	  sites	  of	  N-­‐linked	  glycans	  with	  PNGase	  F	  and	  Endo	  H.	  Modified	  from	  Promega	  (http://www.promega.co.uk)	  	  	  
Briefly,	  by	   following	  manufacturer’s	   instructions	   (New	  England	  Biolabs,	  UK),	   samples	  (10	  μg)	  were	  mixed	  with	  2	  μl	  of	  10X	  G7	  Reaction	  Buffer	  (500	  mM	  Sodium	  Phosphate	  pH	  7.5),	  2	  µl	  of	  10%	  NP-­‐40,	  ddH20	  and	  1-­‐2	  μl	  PNGase	  F,	  or	  with	  2	  μl	  of	  10X	  G5	  Reaction	  Buffer,	   ddH20	   and	   1-­‐5	   μl	   Endo	  H	   to	   accomplish	   a	   total	   reaction	   volume	   of	   20	   μl.	   For	  venoms	   under	   reduced	   conditions,	   a	   previous	   step	   was	   undertaken	   in	   order	   to	  denature	  the	  proteins	  with	  1	  μl	  of	  10X	  Denaturing	  Buffer	  (5%	  SDS,	  400	  mM	  DTT)	  and	  ddH20	  to	  make	  a	  10	  μl	   total	  reaction	  volume,	  before	  heating	  at	  100°C	  for	  10	  minutes.	  For	  control	  samples	  (glycosylated),	   the	  enzyme	  volume	  was	  replaced	  with	  ddH20	  and	  egg	   albumin	   was	   used	   as	   an	   internal	   standard	   control.	   Digestion	   samples	   were	   left	  overnight	   at	   37°C	   and	   reaction	   products	  were	   analysed	   by	   native	   and	   reduced	   SDS–PAGE	  (for	  details	  in	  the	  methodology	  please	  refer	  to	  chapter	  2,	  Section	  2.4.1).	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6.2.2. SDS-­‐PAGE	  analysis	  of	  venoms	  treated	  with	  deglycosylation	  enzymes	  	  	  To	  analyse	  the	  changes	  in	  molecular	  weight	  of	  de-­‐glycosylated	  venom	  proteins,	  and	  the	  extent	  in	  which	  glycan	  groups	  were	  present	  after	  treatment	  with	  the	  enzymes	  PNGase	  F	  and	  Endo	  H,	  we	  stained	  the	  SDS-­‐PAGE	  gels	  with	  Coomassie	  (as	  described	  in	  Chapter	  2,	  Section	  2.4.1)	  and	  Schiff’s	  reagents	  (Doerner	  and	  White	  1990).	  The	  latter	  gels	  were	  loaded	   with	   a	   total	   of	   50ug	   of	   venom,	   because	   Schiff’s	   stain	   is	   less	   sensitive	   than	  Coomassie.	   After	   completion	   of	   electrophoresis,	   SDS-­‐PAGE	   gels	   were	   immediately	  incubated	   in	   fixative	   solution	   containing	   Ascetic	   acid,	   Methanol	   and	   H2O	   (10:35:25)	  with	  constant	  rocking	  during	  15	  min.	  Three	  washes	  of	  5	  minutes	  each	  with	  H2O	  were	  subsequently	   done	   to	   remove	   all	   the	   excess	   fixative.	   Gels	   were	   then	   incubated	   in	  oxidative	  solution	  (1%	  NaIO	  in	  3%	  Ascetic	  acid)	  for	  a	  total	  of	  30	  min.	  Another	  wash	  of	  5	  min	  in	  H2O	  was	  done	  before	  the	  incubation	  in	  Schiff’s	  reagent	  (Sigma,	  UK)	  for	  1	  hour	  in	  the	   dark.	   Gel	   was	   immediately	   incubated	   in	   reducing	   solution	   (1%	   Na2S2O5)	   for	   30	  minutes	  and	  then	  washed	  every	  10	  minutes	  in	  H2O	  for	  a	  total	  of	  one	  hour.	  Gel	  was	  left	  in	  H2O	  overnight	  and	  visualized	  at	  the	  following	  day.	  	  
	  
6.2.3. Determination	  of	  IgG	  antisera	  binding	  to	  deglycosylated	  venom	  proteins	  	  Immunoblotting	  was	  performed	  to	  determine	  the	  binding	  of	  antibodies	  against	  the	  pre-­‐digested	   venom	   samples	   from	   E.	   ocellatus,	   E.	   pyramidum	   leakeyi,	   E.	   coloratus	   and	   E.	  
carinatus	   sochureki	   with	   the	   glycosidases	   under	   reduced	   or	   native	   conditions	   (as	  described	   in	   Chapter	   2,	   section	  2.4.1).	   Incubation	   in	   test	   antisera	  was	   done	   at	   1/500	  dilution.	   To	   calculate	   the	   titre	   of	   the	   antibodies	   against	   the	   native	   de-­‐glycosylated	  venom	  proteins,	  venoms	  were	  pre-­‐treated	  as	  described	  above	  and	  an	  indirect	  ELISA	  as	  described	  in	  Chapter	  2,	  Section	  2.4.3.	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6.3. RESULTS	  	  
	  
6.3.1. Echis	  venoms	  contain	  N-­‐linked	  glycosylation	  of	  complex-­‐type	  structures	  We	   first	   treated	   venom	   proteins	   from	  Echis	   ocellatus,	   Echis	   pyramidum	   leakeyi,	  Echis	  
coloratus	  and	   Echis	   carinatus	   sochureki	   with	   the	   glycosidades	   PNGase	   F	   and	   Endo	   H	  under	  denaturing	  conditions,	  which	  specifically	  cleave	  Asn-­‐linked	  glycans	  (Figure	  6.3).	  	  	  
	  
	  
Figure	  6.3:	  Coomassie	  stained	  SDS-­‐PAGE	  gels	  of	  deglycosylated	  Echis	  venoms	  	  (marked	  with	  +)	  with	  PNGaseF	  (left)	  and	  EndoH	  (right).	  Ea:	  Egg	  albumin	  (positive	  control),	  ECO:	  Echis	  ocellatus,	  EPL:	  Echis	  pyramidum	  leakey,	  ECO:	  Echis	  coloratus,	  ECS:	  
Echis	  carinatus	  sochureki	  (10μg	  of	  venom/well).	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venom	  glycoproteins.	  In	  addition,	  glycans	  present	  in	  the	  venom	  samples	  were	  shown	  to	  be	  of	  a	  complex-­‐type	  structure,	  on	  the	  basis	  that	  Endo	  H	  is	  capable	  of	  cleaving	  only	  high	  mannose	   and	   hybrid	   types	   of	   N-­‐linked	   carbohydrates.	   Furthermore,	   experiments	  carried	   out	   under	   the	   same	   conditions	   but	   using	   a	   special	   glycoprotein	   stain	   (Schiff)	  (Figure	   6.4)	   showed	   that	   a	   complete	   deglycosylation	   of	   the	   venom	   proteins	   was	  	  accomplished	   by	   PNGase	   F	   (which	   therefore	   excluded	   the	   presence	   of	   O-­‐linked	  glycosylation	  in	  the	  samples),	  as	  evidenced	  by	  the	  lack	  of	  visible	  bands	  in	  the	  samples	  pre-­‐incubated	   with	   this	   glycosidase.	   Results	   additionally	   extended	   the	   range	   of	  molecular	  weights	  in	  which	  glycosylation	  seems	  to	  be	  present,	  to	  35	  -­‐	  150	  kDa.	  	  
	  
	  
Figure	  6.4:	  Schiff	  stained	  SDS-­‐PAGE	  gels	  of	  deglycosylated	  Echis	  venoms	  	  (marked	  with	  +)	  with	  PNGaseF	  (left)	  and	  EndoH	  (right).	  Ea:	  Egg	  albumin	  (positive	  control),	  ECO:	  Echis	  ocellatus,	  EPL:	  Echis	  pyramidum	  leakey,	  ECO:	  Echis	  coloratus,	  ECS:	  
Echis	  carinatus	  sochureki	  (50μg	  of	  venom/well).	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assembled	   as	   N-­‐linked,	   complex-­‐type	   glycan	   conformations	   (Gowda	   and	   Davidson	  1992;	   Soares	   and	   Oliveira	   2009),	   with	   the	   important	   exception	   that	   glycosylation	   of	  
Echis	  venoms	  appears	  to	  be	  restricted	  the	  venoms	  of	  75	  –	  150	  kDa.	  	  
	  
6.3.2. Reactivity	  of	  whole	  venom	  IgG	  antisera	  (EchiTabG)	  against	  de-­‐
glycosylated	  Echis	  venom	  proteins	  	  To	   compare	   the	   binding	   of	   antibodies	   raised	   using	   native	   venom	   immunisation	  protocols,	  we	  probed	  immunoblots	  of	  Echis	  venoms	  with	  PNGase	  F	  under	  reduced	  and	  native	  conditions	  with	  EchiTAbG	  antivenom	  (Figure	  6.5).	  
	  
	  
Figure	  6.5:	  Immunoblot	  of	  SDS-­‐PAGE	  gels	  of	  Echis	  venoms,	  either	  treated	  with	  PNGaseF	  (+)	  or	  untreated	  (-­‐)	  	  In	  either	  reduced	  (a)	  and	  native	  conditions	  (b)	  probed	  with	  EchitabG	  (1:5000).	  Ea:	  Egg	  albumin	  (positive	  control),	  ECO:	  Echis	  ocellatus,	  EPL:	  Echis	  pyramidum	  leakey,	  ECO:	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Results	   showed	   that	   antivenom	   IgGs	   are	   capable	   of	   binding	   extensively	   to	  deglycosylated	   venom	   proteins	   under	   reduced	   conditions.	   Moreover,	   some	   bands	  between	   30	   –	   75	   kDa	   appeared	   to	   react	  with	  more	   intensity	  when	   the	   venoms	  were	  pre-­‐treated	   with	   the	   glycosidase.	   For	   immunoblots	   with	   venom	   under	   native	  conditions,	   a	   very	   unexpected	   decrease	   in	   antivenom	   IgG	   binding	   was	   observed.	  Importantly,	  there	  was	  no	  evident	  sign	  of	  changes	  in	  the	  molecular	  weight	  of	  the	  native	  venom	  proteins	  pre-­‐treated	  with	  PNGase	  F,	  which	  suggested	  limitations	  of	  the	  method	  for	  the	  venom	  proteins	  in	  a	  native	  state.	  A	  possible	  failure	  of	  the	  enzyme	  to	  remove	  the	  glycan	   groups	  when	   the	   venom	   proteins	   conserve	   their	   three-­‐dimensional	   structure,	  added	  to	  an	  unusual	  migration	  of	  the	  proteins	  under	  native	  conditions	  in	  the	  SDS-­‐PAGE	  gel	  was	   further	   supported	  by	  Schiff	   and	  Coomassie	   stain	  of	   the	  native	  SDS-­‐PAGE	  gels	  (not	  shown)	  before	  the	  blotting	  respectively.	  	  	  
	  
The	  next	  experiment	  used	  a	  distinct	  method	  (ELISA)	   to	  present	  E.	  ocellatus	   venom	   in	  non-­‐denaturing	  conditions	   to	  antivenom,	  with	   the	  objective	  of	  comparing	   the	  binding	  of	   antivenom	   antibodies	   to	   glycosylated	   and	   de-­‐glycosylated	   venom	  proteins	   in	   their	  natural	  	  three-­‐dimensional	  configuration	  (Figure	  6.6).	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Figure	  6.6:	  Venom	  from	  E.	  ocellatus	  (50	  μg)	  in	  native	  state	  (blue	  bars)	  and	  pre-­‐treated	  with	  PNGase	  F	  (red	  bars)	  	  Incubated	  with	  serial	  dilutions	  (horizontal	  axis)	  of	  EchiTabG	  IgG	  antisera.	  Optical	  density	  determined	  is	  located	  on	  the	  vertical	  axis.	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6.3.3. Reactivity	  of	  toxin-­‐specific	  IgG	  antisera	  against	  de-­‐glycosylated	  Echis	  
venom	  proteins	  	  The	  above	  experiments	  were	  conducted	  with	   IgG	  raised	  by	   immunisation	  with	  native	  venom	  proteins.	  The	  next	   experiment	  was	  performed	  with	   IgG	   raised	   to	   the	   epitope-­‐string	   immunogens	   because	   they	   are	   linear	   and	   non-­‐glycosylated.	   An	   immunoblot	   of	  reduced	  or	  native	  Echis	  venom	  proteins	  was	  probed	  with	  mixed-­‐monospecific	  affinity	  purified	  sheep-­‐IgG	  antisera	  (Chapter	  5)	  (Figure	  6.7).	  	  
	  
	  
Figure	  6.7:	  Immunoblot	  of	  SDS-­‐PAGE	  gels	  of	  deglycosylated	  Echis	  venoms	  	  With	  PNGaseF	  (marked	  with	  +)	  in	  reduced	  (left)	  and	  in	  native	  conditions	  (right)	  against	  mixed	  monospecific	  sheep-­‐IgG	  antisera	  (1:500).	  Ea:	  Egg	  albumin	  (positive	  control),	  ECO:	  Echis	  ocellatus,	  EPL:	  Echis	  pyramidum	  leakey,	  ECO:	  Echis	  coloratus,	  ECS:	  Echis	  
carinatus	  sochureki	  (10μg	  of	  venom/well).	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venom	  proteins	   –	   an	  observation	  not	   so	   apparent	  when	   the	   same	   immunoblots	  were	  probed	  with	  antivenom.	  	  
	  
When	  venom	  was	  under	  native	  conditions,	   the	  binding	  of	  antibodies	  was	  stronger	   (i)	  when	   compared	   to	   results	   previously	   obtained	   when	   proteins	   had	   not	   been	   treated	  with	  the	  glycosidase	  (Chapter	  5)	  and	  (ii)	  than	  the	  antivenom	  EchiTAbG	  under	  the	  same	  conditions	  (Figure	  6.5).	  Furthermore,	  native	  results	  showed	  that	  there	  was	  only	  a	  slight	  evidence	  of	  changes	  in	  the	  molecular	  weight	  of	  de-­‐glycosylated	  native	  venom	  proteins,	  which	   agrees	   with	   results	   previously	   obtained	   during	   native	   immunoblot	   with	  antivenom	   under	   the	   same	   conditions	   and	   further	   confirms	   that	   digestion	   with	   the	  enzyme	  is	  problematic	  when	  proteins	  retain	  their	  three-­‐dimensional	  structure.	  Results	  suggest	  that	  is	  necessary	  to	  evaluate	  other	  systems	  in	  order	  to	  evaluate	  the	  reactivity	  of	  toxin-­‐specific	  antibodies	  against	  native	  de-­‐glycosylated	  venom	  proteins.	  	  
	  
6.4. DISCUSSION	  	  
In	   the	   current	   study	   we	   have	   successfully	   demonstrated	   the	   presence	   of	   N-­‐linked	  glycans	  of	   the	  complex-­‐type	  structure	  attached	  to	   the	  venoms	  of	  Echis	  ocellatus,	  Echis	  
pyramidum	  leakeyi,	  Echis	  coloratus	  and	  Echis	  carinatus	  sochureki,	  which	  is	  in	  agreement	  with	   previous	   studies	   reporting	   the	   presence	   of	   this	   type	   of	   sugars	   in	   snake	   venom	  proteins	   (Gowda	   and	   Davidson	   1992;	   Soares	   and	   Oliveira	   2009).	   Although	   previous	  bioinformatic	   examination	   of	   the	   venom	   proteins	   under	   study	   (Phospholipase	   A2,	  Serine	   proteases,	   C-­‐Type	   lectins,	   Snake	   Venom	   Metalloproteinases	   and	   Disintegrins)	  showed	   a	   number	   of	   sites	   available	   within	   all	   of	   the	   sequences	   for	   the	   N-­‐linked	  attachment	  of	  glycans	  (Chapter	  3),	  we	  observed	  that	  glycosylation	  in	  Echis	  venoms	  was	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consistently	   restricted	   to	   proteins	   that	   range	   from	   35	   to	   150	   kDa.	   Furthermore,	   de-­‐glycosylation	   of	   venom	  proteins	  was	   shown	   to	   decrease	   the	  molecular	  mass	   of	   some	  toxin	  groups	  by	  at	   least	  10	  kDa,	   suggesting	   that	   the	  sugar	  composition	  of	   this	  venom	  proteins	  accounts	  for	  a	  considerable	  part	  of	  their	  structure.	  	  
	  
While	  glycosylation	  in	  snake	  venom	  proteins	  has	  been	  reported	  to	  represent	  from	  5	  to	  sometimes	  90%	  of	  the	  molecular	  mass	  of	  venom	  proteins	  (Gowda	  and	  Davidson	  1992;	  Murayama	  et	  al.	   2003),	   and	   to	   impact	   significantly	   upon	   the	  biological	   activity	   of	   the	  toxins	  (Gowda	  and	  Davidson	  1992;	  Pfeiffer	  et	  al.	  1992;	  Gowda	  et	  al.	  1996;	  Veiga	  et	  al.	  1999;	   Chen	   et	   al.	   2000;	   Lai	   and	   Her	   2000;	   Murayama	   et	   al.	   2003;	   Valdez-­‐Cruz	   et	   al.	  2004;	  Ande	  et	  al.	  2006;	  Silva-­‐Junior	  et	  al.	  2007;	  Soares	  and	  Oliveira	  2009),	  no	  studies	  have	  focused	  upon	  the	  impact	  that	  glycosylation	  of	  venom	  proteins	  could	  have	  on	  the	  development	  of	   antivenom	   therapy.	  Non-­‐venom	  studies	  have	   reported	   that	   this	  post-­‐translational	   modification	   can	   affect	   the	   antibody	   interaction	   with	   the	   underlying	  peptide	  sequence	  (Gribben	  et	  al.	  1990;	  Huang	  et	  al.	  1997;	  Hermeling	  et	  al.	  2004;	  Wei	  et	  
al.	   2010),	   thus	   implying	   that	   is	   an	   important	   factor	   to	   take	   into	   consideration	   for	   the	  design	  of	  antibody-­‐based	  therapies	  against	  the	  damaging	  effects	  of	  the	  venoms	  (Sinclair	  and	  Elliott	  2005).	  
	  
Cognisant	  of	  the	  above,	  the	  bioinformatic	  design	  of	  the	  epitope-­‐string	  immunogens	  that	  preceded	  the	  current	  study	  carefully	  excluded	  antigenic	  domains	  containing	  predicted	  N-­‐linked	  glycosylation	  sites	  (Chapter	  3).	  Results	  obtained	  during	  this	  study	  were	  able	  to	  demonstrate	   through	   immunoblot	   that	   some	  venom	  proteins	  become	  more	  visible	  when	   Echis	   venom	   pre-­‐treated	   with	   the	   glycosidase	   PNGaseF	   is	   incubated	   under	  reduced	   conditions	   with	   antivenom	   EchiTAbG	   and	   with	   toxin-­‐specific	   IgG	   antisera	   -­‐	  suggesting	   perhaps	   the	   presence	   of	   some	   epitopes	   that	   could	   be	   hidden	   by	   this	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modification.	  However,	   the	  apparent	   low	  reactivity	  of	   the	  glycosidase	  when	  removing	  the	  glycan	  groups	  in	  venom	  proteins	  under	  native	  state	  made	  it	  difficult	  to	  further	  test	  if	   the	   post-­‐translational	   modification	   (i)	   interferes	   with	   the	   underlying	   peptide	  epitopes	  when	   antibodies	   are	   raised	   to	   synthetic	   toxin-­‐specific	   immunogens	   (mixed-­‐monospecific	   IgG	   antisera)	   or	   if	   perhaps	   (ii)	   has	   an	   impact	   upon	   the	   reactivity	   of	  antibodies	  raised	  to	  whole	  venom	  (EchiTAbG).	  	  	  
	  
Some	   non-­‐venom	   studies	   have	   previously	   shown	   that	   N-­‐linked	   glycosylation	   can	  influence	   the	   proteolytic	   processing	   of	   antigens	   by	   sterically	   blocking	   the	   action	   of	  proteases	   required	   for	   antigen	   presentation	   and	   cytotoxic	   T-­‐cell	   priming	   (Doe	   et	   al.	  1994;	   Li	   et	   al.	   2009;	   Wolfert	   and	   Boons	   2013).	   Regarding	   conventional	   antivenom	  formulation,	  the	  presence	  of	  glycosylation	  in	  snake	  venom	  proteins	  highlights	  the	  need	  to	   further	   examine	   if	   this	  modification	   perhaps	   reduces	   the	   immune	   response	   of	   the	  host	   during	   immunisation	   protocols,	   which	   could	   further	   explain	   the	   if	   the	   low	  immunogenicity	   seen	   of	   some	   pathologically	   relevant	   venom	   toxins	   (which	   is	  necessarily	   translated	   to	   a	   decrease	   in	   the	   effectiveness	   of	   antivenoms	   during	   the	  treatment	  of	  envenomation	  cases)	  is	  due	  to	  the	  presence	  of	  glycan	  groups.	  	  
	  
Within	  a	  different	  point	  of	  view,	  the	  little	  of	  knowledge	  on	  the	  molecular	  interaction	  of	  antibodies	   raised	  during	  conventional	  antivenom	  protocols	   to	  venom	  proteins	  during	  envenomations	  has	  additionally	  lead	  to	  ignore	  if	  the	  glycans	  attached	  to	  the	  toxins	  are	  perhaps	  immunologically	  relevant	  and	  can	  elicit	  a	  response	  that	  leads	  to	  the	  generation	  of	  anti-­‐sugar	  antibodies.	  Recent	  studies	  have	  demonstrated	  the	  presence	  of	  a	  CD4+	  T-­‐cell	  population,	  termed	  as	  Tcarbs,	  which	  can	  recognize	  polysaccharides,	  are	  relevant	  for	  eliciting	  optimal	  immune	  responses	  against	  glyco-­‐conjugate	  vaccines	  (Avci	  et	  al.	  2011;	  Wolfert	   and	  Boons	  2013).	  On	   the	  other	  hand,	   the	  highly	   conserved	  nature	  of	   glycans	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across	   eukaryotes	   (Lehle	   et	   al.	   2006),	   which	   could	   be	   predicted	   to	   overcome	   the	  commonly	   found	   peptide	   differences	   in	   Elapids	   and	   Viperids,	   might	   account	   for	   a	  promising	   approach	   in	   the	   attempt	   to	   generate	   of	   a	   polyspecific	   antivenom	   that	  neutralizes	  despite	  phylogenetic	  or	  geographical	  variation	  of	  the	  venomous	  species.	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7.	  	  GENERAL	  DISCUSSION	  
	  Snakebite	  is	  estimated	  to	  cause	  as	  many	  as	  94,000	  deaths	  worldwide	  per	  year,	  with	  a	  considerable	  proportion	  occurring	  in	  sub-­‐Saharan	  Africa	  and	  South	  Asia	  (Kasturiratne	  
et	  al.	  2008;	  Chippaux	  2011)	  mainly	  by	  members	  of	  the	  Echis	  genus	  (family	  Viperidae).	  	  Also	  referred	  to	  as	  the	  saw	  scaled	  vipers,	  the	  Echis	  genus	  has	  been	  reported	  to	  account	  more	   deaths	   than	   any	   other	   single	   snake	   genus	   (Warrell	   et	   al.	   1977;	   Pugh	   and	  Theakston	   1987;	   Laing	   et	   al.	   1995;	   Theakston	   and	  Warrell	   2000;	   Habib	   et	   al.	   2001;	  Chippaux	  2002;	  Stock	  et	  al.	  2007),	  due	  to	  a	  number	  of	  factors	  that	  arise	  from	  their	  wide	  distribution	  and	  abundance	  in	  areas	  of	  poor	  health	  facilities,	  and	  necessarily	  conclude	  in	   the	   consistent	   low	  effectiveness	  and	   low	  cross-­‐reactivity	  of	   the	   treatment	   (Warrell	  and	  Arnett	  1976;	  Benbassat	  and	  Shalev	  1993;	  Habib	  et	  al.	  2008;	  Visser	  et	  al.	  2008).	  	  
	  
Snake	   venoms	   have	   more	   than	   a	   hundred	   proteins	   and	   peptides	   that	   exhibit	   a	  significant	  (inter	  e	  intraspecific)	  diversity	  in	  terms	  of	  isoform	  complexity,	  toxicity	  and	  immunogenicity	   (Calvete	   et	   al.	   2007;	   Harrison	   et	   al.	   2011).	   While	   antivenom	  (formulated	  as	  purified	   IgGs	   from	   the	   sera	  of	  horses	  or	   sheep	  hyper-­‐immunised	  with	  increasing	   doses	   of	   venom)	   is	   life-­‐saving,	   it	   doesn’t	   take	   into	   account	   the	   individual	  variation	   and	   representation	   of	   the	   venom	   toxins	   and	   frequently	   contains	  therapeutically	   redundant	   IgGs	   to	   non-­‐toxic	   venom	   components,	   as	   well	   as	   a	   lack	   of	  high	   titre	   IgGs	   to	  highly	   toxic,	   but	  weakly	   immunogenic	   components	   (Harrison	  2004;	  Wagstaff	  et	  al.	  2009;	  Harrison	  et	  al.	  2011).	  	  
	  
The	  Alistair	  Reid	  Venom	  Research	  Unit	  has	  been	  pioneering	  a	  new	  approach	  to	  address	  the	   current	   antivenom	   challenges	   by	   using	   the	   rationale	   of	   generating	   venom	   toxin-­‐
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specific	  antibodies.	  Based	  on	  preliminary	  work	  illustrating	  extensive	  cross-­‐specific	  and	  cross-­‐generic	   reactivity	  of	   a	   toxin-­‐specific	   antibody	   (Harrison	  et	  al.	   2000;	  Harrison	  et	  
al.	  2002;	  Harrison	  et	  al.	  2003b;	  Harrison	  2004;	  Wagstaff	  and	  Harrison	  2006;	  Azofeifa-­‐Cordero	  et	  al.	   2008;	   Casewell	  et	  al.	   2010).	   In	   this	   PhD	  project,	  we	  have	   extended	   the	  previous	   efforts	   in	   the	   development	   of	   a	   toxin-­‐specific	   antivenom	   with	   a	   view	   to	  ultimately	   generate	   an	   effective	   therapy	   against	   all	   the	   African	   species	   of	   the	   Echis	  genus	   (Harrison	   et	   al.	   2011).	   According	   to	   pathogenicity	   and	   representation	   in	   the	  Expressed	  Sequence	  Tag	  (EST)	  data	  of	  the	  medically	  important	  species	  Echis	  ocellatus,	  
Echis	  pyramidum	  leakeyi	  and	  Echis	  coloratus,	  five	  major	  toxin	  groups	  were	  selected	  as	  a	  target	   for	   the	  design	  of	  epitope-­‐string	   immunogens:	  Phospholipases	  A2	   (PLA2),	  Serine	  proteases	   (SP)	   C-­‐type	   lectins	   (CTLs),	   Metalloproteinases	   (SVMPs)	   and	   Disintegrins	  (Casewell	  et	  al.	  2009),	  based	  on	  the	  hypothesis	  that	  the	  raised	  toxin-­‐specific	  antibodies	  would	  ultimately	  be	  capable	  of	  neutralizing	  the	  toxic	  effect	  of	  the	  venoms.	  	  
	  
Although	  the	  molecular	  interaction	  between	  antivenom	  antibodies	  and	  venom	  proteins	  remains	   largely	   understood,	   and	   only	   a	   few	   attempts	   have	   been	   made	   in	   order	   to	  elucidate	  neutralizing	  epitopes	   (Tanjoni	  et	  al.	   2003b;	  Fernandes	  et	  al.	   2010;	  Lomonte	  2012)	   that	   can	   give	   valuable	   information	   in	   the	   design	   of	   toxin-­‐specific	   antivenoms.	  The	   bioinformatic	   interrogation	   of	   the	   venom	   gland	   transcriptomes	   (Chapter	   3)	  revealed	   significant	   sequence	   diversity	   in	   Echis	   transcripts,	   known	   as	   driven	   by	  evolutionary	   forces	   that	   are	   necessarily	   based	   on	   the	   divergence	   of	   the	   species	   into	  different	   preys	   (Casewell	   et	  al.	   2009).	   In	   agreement	  with	   previous	   studies	   predicting	  the	  translation	  of	  conserved	  areas	  of	  antigenicity	  into	  possible	  target	  areas	  for	  antibody	  binding	   (Wagstaff	   et	   al.	   2006),	   we	   successfully	   identified	   epitopes	   on	   Echis	   venom	  transctipts	  the	  basis	  of	  i)	  sequence	  conservation,	  ii)	  antigenicity,	  (iii)	  surface	  exposure	  and	  (iv)	  coverage	  across	  the	  EST	  data.	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The	   delivery	   of	   toxin-­‐specific	   immunogens	   as	   DNA	   constructs	   (generally	   with	   the	  implementation	   of	   biolistics)	   has	   been	   a	   successful	   strategy	   in	   the	   improvement	   of	  antivenoms	  to	  treat	  snakebite	  (Harrison	  et	  al.	  2000;	  Harrison	  et	  al.	  2002;	  Harrison	  et	  al.	  2003a;	   Harrison	   et	   al.	   2003b;	   Harrison	   2004;	   Azofeifa-­‐Cordero	   et	   al.	   2008;	   Arce-­‐Estrada	   et	   al.	   2009).	   Nevertheless,	   we	   were	   not	   able	   to	   replicate	   its	   success	   in	   the	  current	   study	   (Chapter	   4).	   Our	   results	   showed	   a	   disappointingly	   low,	   and	   in	   some	  epitope-­‐string	   immunised	  mice,	   even	  absence	  of	   IgG	   reactivity	   to	  DNA	   immunisation,	  particularly	   in	   comparison	   with	   results	   obtained	   using	   the	   same	   methodology	  (Wagstaff	  et	  al.	   2006).	  We	   currently	  have	  no	   compelling	   evidence	   to	   suggest	   that	   the	  lack	   of	   seroconversion	   was	   due	   to	   (i)	   an	   insufficient	   amount	   of	   DNA	   delivered	   to	  transfect	  cells	  (Dendritic	  cells	  –	  Langerhans,	  myocites	  or	  keratinocytes)	  (Lu	  et	  al.	  1996;	  Porgador	  et	  al.	   1998;	  Watts	   and	  Kennedy	  1999)	  or	   if	   (ii)	   transfected	   cells	   expressing	  the	  immunogenic	  peptide	  were	  a	  target	  for	  removal	  by	  immune-­‐mediated	  mechanisms	  (Payette	   et	   al.	   2001;	   Moreno	   and	   Timón	   2004).	   Results	   lead	   to	   the	   need	   of	  implementing	  a	  different	  strategy	   for	   the	  synthesis	  of	   the	  epitope-­‐string	   immunogens	  that	   overcomes	   the	   possible	   redundancy	   that	   can	   commonly	   arise	   from	   DNA	  immunisation	   protocols,	   as	   well	   as	   to	   ultimately	   give	   us	   the	   possibility	   to	   immunise	  higher	  order	  animals	  -­‐	  which	  has	  additionally	  been	  reported	  as	  problematic	  with	  DNA	  immunisation	   (Babiuk	   et	   al.	   2003).	   Consequently,	   we	   implemented	   a	   different	  methodology	   for	   the	   synthesis	   of	   the	   epitope-­‐string	   immunogens,	   this	   time	   as	  recombinant	  proteins.	  
	  
Synthesis	   of	   recombinant	   proteins	   has	   been	   widely	   used	   for	   immunogenic	   peptides	  	  (Pereira-­‐Chioccola	   et	   al.	   1999;	   Wang	   et	   al.	   2004;	   Wagstaff	   et	   al.	   2006).	   However,	  constructs	   that	   are	   likely	   to	  be	  devoid	  of	   a	  biological	   function	   to	   the	  host	  usually	   fall	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into	  the	  category	  of	  exogenous	  and	  can	  be	  sometimes	  problematic	  to	  express	  and	  scale-­‐up	   (Rozkov	   2001;	   Baneyx	   and	   Mujacic	   2004).	   In	   agreement,	   the	   synthesis	   of	   the	  epitope-­‐string	  immunogens	  as	  recombinant	  protein	  products	  of	  different	  E.	  coli	  strains	  (Chapter	  5)	   showed	   that	   some	  of	   the	   construct	   immunogens	  were	  highly	   toxic	   to	   the	  bacterial	  host	  after	  induction,	  therefore	  requiring	  significant	  amount	  of	  media	  volumes	  to	   obtain	   the	   quantities	   needed	   for	   immunisation	   and	  making	   it	   a	   complex	   task.	   The	  unknown	  behaviour	  of	  the	  immunogens	  inside	  the	  transfected	  host,	  together	  with	  their	  unknown	   structural	   characteristics	   (i.e.	   their	   folding	   after	   purification)	   that	   were	  revealed	   by	   the	   impossibility	   to	   remove	   the	   purification	   tags	   from	   the	   proteins	   of	  interest,	   highlighted	   the	   need	   to	   further	   study	   the	   protein	   immunogens	   in	   order	   to	  implement	  the	  synthesis	  of	  recombinant	  protein	  immunogens	  as	  a	  strategy	  in	  a	  large-­‐scale	   production	   that	   would	   be	   necessarily	   required	   during	   antivenom	  manufacture	  (Calvete	  et	  al.	  2009).	  	  
	  
The	  delivery	  of	  immunogens	  as	  recombinant	  proteins	  has	  been	  previously	  shown	  to	  be	  a	   successful	   strategy	   for	   vaccine	   delivery	   (Pereira-­‐Chioccola	   et	   al.	   1999;	  Wang	   et	   al.	  2004;	   Wagstaff	   et	   al.	   2006).	   Initial	   testing	   of	   the	   purified	   recombinant	   protein	  constructs	  by	  immunisation	  of	  mice	  (Chapter	  5),	  showed	  it	  as	  a	  promising	  strategy	  for	  the	   delivery	   of	   toxin-­‐specific	   immunogens	   by	   revealing	   the	   capability	   of	   the	   raised	  antibodies	   to	  bind,	  with	   a	  high	  degree	  of	   specificity	   to	   reduced	  proteins	  belonging	   to	  certain	   molecular	   weight	   areas	   when	   compared	   to	   the	   polyspecific	   binding	   of	   the	  antivenom	   (EchiTAbG)	   positive	   control.	   In	   addition,	   molecular	   weight	   of	  immunoreactive	   bands	   showed	   to	   be	   conserved	   across	   the	   venoms	   of	   that	   the	  immunogens	   were	   initially	   designed	   to	   target	   (E.	   ocellatus,	   E.	   pyramidum	   leakeyi,	   E.	  
coloratus	   and	   E.	   carinatus	   sochureki)	   as	   well	   as	   to	   other	   phylogenetically	   and	  geographically	  distant	  viper	  species	  (Echis	  leucogaster	  –	  Mali,	  Echis	  coloratus	   -­‐	  Eygipt,	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Echis	   carinatus	   sochureki	   -­‐	   United	   Arab	   Emirates,	   Cerastes	   cerastes	   -­‐	   Eygipt,	   Bitis	  
arietans	   -­‐	  Ghana,	  Bitis	  arietans	   -­‐	   Zimbabwe,	  Bitis	  gabonica	   -­‐	  West	  Africa).	  Taking	   into	  account	   that	   variation	   in	   the	   composition	   of	   venoms	   is	   known	   to	   be	   one	   of	   the	   key	  factors	   in	   toxinological	   research	   that	   commonly	   complicate	   the	   design	   and	   use	   of	  antivenoms	   (Warrell	   1997;	   Fry	   et	   al.	   2003a),	   and	   that	   several	   studies	   have	  demonstrated	   the	   consistent	   lack/low	   cross	   reactivity	   of	   antivenoms	   raised	   against	  venoms	  of	  the	  Echis	  genus	  (i.e.	  clinical	  management	  of	  envenomations	  by	  of	  E.	  coloratus	  has	   shown	   to	   be	   problematic	   when	   patients	   are	   treated	   with	   the	   monospecific	  antivenom	  EchiTAbG,	  which	  is	  raised	  against	  the	  venom	  of	  E.	  ocellatus)	  (Gillissen	  et	  al.	  1994;	   Visser	   et	  al.	   2008;	   Pook	   et	  al.	   2009;	   Casewell	   et	  al.	   2010).	  We	   believe	   that	   the	  cross-­‐reactive	   nature	   of	   the	   antibodies	   raised	   to	   recombinant	   protein	   epitope-­‐string	  constructs	   as	   immunogens	   successfully	  demonstrates	   that	   the	   sequence	   conservation	  of	  the	  transcripts	  used	  during	  the	  bioinformatic	  design	  of	  the	  immunogens	  (Chapter	  3),	  predicted	   to	   be	   under	   high	   evolutionary	   pressures	   (perhaps	   due	   to	   their	   biological	  significance	  related	  directly	  or	  indirectly	  to	  toxin-­‐induced	  pathologies)	  provide	  support	  for	  the	  development	  of	  serotherapies	  that	  are	  based	  on	  the	  design	  of	  cross-­‐taxa	  toxin-­‐specific	  immunogens.	  	  
	  
Whilst	   preliminary	   results	   of	  murine	   toxin-­‐specific	   antisera	   provided	   an	   encouraging	  and	  comprehensive	  immunological	  profile	  against	  reduced	  venom	  proteins	  of	  different	  viperid	  venoms,	  the	  analysis	  on	  reduced	  proteins	  is	  known	  to	  expose	  the	  epitopes	  that	  not	  necessarily	  are	  available	   for	  antibody	  binding	  when	  the	  protein	   is	  maintaining	   its	  tree-­‐dimensional	  structure	  (native	  state),	  which	  is	  the	  essential	  scenario	  to	  predict	  the	  pre-­‐clinical	  and	  clinical	  efficacy	  of	  the	  therapy	  (Casewell	  et	  al.	  2010;	  Cook	  et	  al.	  2010a;	  b).	   Accordingly,	   subsequent	   experimental	   data	   on	   serum	   from	  mice	   immunised	  with	  toxin-­‐specific	   recombinant	   protein	   constructs	   revealed	   that	   toxin-­‐specific	   antibodies	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bound	  with	  a	  significantly	   lower	  efficacy	  to	  native	  venom	  proteins	  when	  compared	  to	  antivenom	   EchiTAbG.	   Results	   suggested	   an	   interaction	   of	   low	   affinity	   and	   avidity	  between	  the	  target	  venom	  proteins	  (in	  a	  native	  state)	  and	  the	  antibodies	  raised	  against	  the	   previously	   predicted	   surface-­‐exposed	   linear	   epitopes.	   While	   this	   outcome	   was	  attributed	   in	   first	   instance,	   to	   the	   possible	   low	   accuracy	   in	   the	   location	   of	   promising	  epitopes	   that	   arises	   from	   the	   mapping	   of	   antigenic	   domains	   during	   bioinformatic	  analysis,	  onto	  previously	  elucidated	  venom	  protein	  structures	  that	  were	  in	  most	  of	  the	  cases,	  from	  distant	  relatives	  to	  the	  species	  under	  study,	  it	  also	  emphasised	  the	  need	  to	  include	   proteomic	   data	   in	   the	   design	   of	   toxin	   epitopes	   as	   immunogens	   to	   be	  incorporated	  into	  a	  string	  for	  immunisations.	  	  
	  
Subsequent	  immunisation	  of	  a	  higher	  order	  animal	  (8	  sheeps)	  with	  a	  pool	  toxin-­‐specific	  recombinant	  protein	  constructs	  (Chapter	  5)	  by	  Ig-­‐Innovations	  (Wales,	  UK)	  allowed	  us	  to	   purify	   toxin-­‐specific	   IgG	   in	   a	   similar	   manner	   to	   that	   of	   current	   antivenom	  manufacture,	   but	   it	  was	  difficult	   to	   compare	   their	  neutralizing	   capacity	   to	   that	  of	   the	  antivenom	   EchiTAbG.	   Results	   of	   the	   purification	   with	   caprylic	   acid	   of	   sheep	   serum	  previously	  immunised	  with	  recombinant	  protein	  toxin-­‐specific	  constructs	  revealed	  the	  existence	   of	   IgG	   in	   the	   pre-­‐immune	   sera,	   thus	   confirming	   the	   presence	   of	  immunoglobulins	   to	   components	   different	   to	   the	   ones	   raised	   to	   the	   toxin-­‐specific	  immunogens.	   Furthermore,	   immunological	   experiments	   showed	   a	   disappointingly	  unspecific	   binding	   to	   reduced	   venom	   proteins	   as	   well	   as	   a	   low	   reactivity	   of	   the	  antibodies	   to	   native	   venom	   proteins.	   Purified	   IgG	   from	   immunized	   animals	   during	  conventional	   antivenom	  manufacture	   is	  widely	  known	   to	   contain	  not	  only	   antibodies	  against	   the	   immunogen	  of	   interest,	  which	   is	  why	  a	   series	  of	  key	  secondary	  processes	  have	   been	   carried	   out	   in	   the	   past	   years	   in	   order	   to,	   through	   affinity	   purification,	  identify	   and	   quantify	   the	   specific	   venom	   toxins	   exhibiting	   immunoreactivity	   towards	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immobilized	   antivenom	   IgG	  molecules,	   and	   the	   set	   of	   toxins	   lacking	   immunoreactive	  epitopes	   (Calvete	  et	  al.	   2009;	  Pla	  et	  al.	   2012).	  Consequently,	   in	  an	  attempt	   to	   identify	  the	   neutralizing	   capacity	   of	   the	   sheep	   toxin-­‐specific	   IgGs,	   subsequent	   affinity	  purification	   revealed	   that	   although	   there	   was	   minimal/trace	   specific	   binding	   to	   the	  
Echis	   venom	  proteins	   (suggesting	  strongly	   that	   the	  presence	  of	   tag-­‐protein	   inside	   the	  immunisation	   samples	   could	   have	   diluted	   the	   amount	   of	   toxin-­‐specific	   protein	  delivered	  to	  the	  sheep),	  purified	  antibodies	  showed	  to	  be	  able	  to	  bind,	  through	  western	  blot,	  in	  a	  higher	  capacity	  to	  native	  venom	  proteins	  when	  compared	  to	  results	  obtained	  during	  immunisation	  of	  mice.	  
	  
In	   consideration	   to	   our	   evidence	   demonstrating	   that	   antibodies	   raised	   against	   linear	  epitopes	   of	   the	   most	   pathogenic	   groups	   of	   Echis	   venom	   toxins	   consistently	   shows	   a	  considerably	  lower	  binding	  to	  native,	  rather	  than	  reduced	  venom	  proteins	  (Chapter	  5),	  the	   hypothesis	   of	   glycans	   interfering	  with	   the	   binding	   of	   antibodies	   to	   native	   venom	  proteins	  arose	  based	  on	   the	   substantial	   evidence	   from	  non-­‐venom	  studies	   suggesting	  that	   glycosylation	   can	   affect	   the	   antibody	   interaction	   with	   the	   underlying	   peptide	  sequence	   (Gribben	   et	   al.	   1990;	   Huang	   et	   al.	   1997;	   Hermeling	   et	   al.	   2004;	   Wei	   et	   al.	  2010).	   While	   experiments	   on	   glycosylation	   demonstrated	   the	   presence	   of	   N-­‐linked	  glycans	  of	   the	  complex-­‐type	  structure	  attached	  to	   the	  venoms	  of	  Echis	  ocellatus,	  Echis	  
pyramidum	   leakeyi,	   Echis	   coloratus	   and	   Echis	   carinatus	   sochureki,	   which	   was	   in	  agreement	  with	  previous	  studies	  reporting	  the	  presence	  of	  this	  type	  of	  sugars	  in	  snake	  venom	  proteins	  (Gowda	  and	  Davidson	  1992;	  Soares	  and	  Oliveira	  2009),	   results	  could	  not	  be	  translated	  to	  the	  evaluation	  of	   the	  previously	  undertaken	  bioinformatic	  design	  of	   immunogens	   for	   the	   venom	   proteins	   under	   study	   (Phospholipase	   A2,	   Serine	  proteases,	  C-­‐Type	  lectins,	  Snake	  Venom	  Metalloproteinases	  and	  Disintegrins),	  where	  a	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number	   of	   predicted	   N-­‐linked	   glycosylation	   sites	   were	   carefully	   excluded	   from	   the	  antigenic	  domains.	  	  
	  
Within	  a	  different	  point	  of	  view,	  the	  little	  of	  knowledge	  on	  the	  molecular	  interaction	  of	  antibodies	   raised	  during	  conventional	  antivenom	  protocols	   to	  venom	  proteins	  during	  envenomations	  has	  additionally	  lead	  to	  ignore	  if	  the	  glycans	  attached	  to	  the	  toxins	  are	  perhaps	  immunologically	  relevant	  and	  can	  elicit	  a	  response	  that	  leads	  to	  the	  generation	  of	  anti-­‐sugar	  antibodies.	  Recent	  studies	  have	  demonstrated	  the	  presence	  of	  a	  CD4+	  T-­‐cell	  population,	  termed	  as	  Tcarbs,	  which	  can	  recognize	  polysaccharides,	  are	  relevant	  for	  eliciting	  optimal	  immune	  responses	  against	  glyco-­‐conjugate	  vaccines	  (Avci	  et	  al.	  2011;	  Wolfert	  and	  Boons	  2013),	   in	  addition,	  neutralizing	  antibodies	  have	  been	  shown	  to	  be	  successfully	  raised	  against	  carbohydrate	  groups	  (Kieliszewski	  and	  Lamport	  1986;	  Wei	  
et	  al.	   2010;	  Wolfert	   and	  Boons	  2013).	   The	  highly	   conserved	  nature	   of	   glycans	   across	  eukaryotes	  (Lehle	  et	  al.	  2006)	  might	  account	  for	  a	  promising	  approach	  in	  the	  attempt	  to	   generate	   of	   a	   polyspecific	   antivenom	   that	   neutralizes	   despite	   phylogenetic	   or	  geographical	   variation	   of	   the	   venomous	   species.	   We	   additionally	   believe	   that	   the	  further	  exploration	  on	   this	   field	   is	  of	   importance	   to	  perhaps,	   find	  antigens	   that	   could	  additionally	   enrich	   antivenom	   therapies	   that	   fail	   to	   neutralize	   low	   immunogenic	   and	  pathogenically-­‐relevant	  toxin	  groups.	  
	  
We	   strongly	   suggest	   that	   glycosylation	   of	   venom	   proteins	   is	   a	   promising	   field	   to	  incorporate	  in	  the	  design	  of	  antivenom	  therapies	  and	  additionally	  highlight	  the	  need	  to	  elucidate	  the	  structural	  types	  of	  the	  glycans	  attached	  to	  the	  venom	  proteins,	  as	  well	  as	  to	   add	   venomic	   and	   antivenomic	   approaches	   in	   order	   to	   have	   a	   more	   accurate	  approach	   to	   the	   molecular	   interactions	   of	   the	   molecules	   with	   the	   antibodies	   during	  therapy.	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A. APPENDIX:	  
General	  stock	  solutions	  and	  buffers	  	  	  
Solutions	  for	  sodium	  dodecyl	  sulphate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐
PAGE)	  and	  staining	  of	  the	  gels:	  
• 10X	  Phosphate-­‐buffered	  saline	  (PBS)	  80g	  NaCl	  2g	  KCl	  14.4g	  Na2HPO4	  2g	  KH2PO4	  Up	  to	  1L	  with	  dH2O	  	  
• Non-­‐reduced	  2X	  protein	  loading	  buffer	  (2X	  PLOB)	  10ml	  0.5M	  Tris-­‐base	  pH	  8.5	  	  6ml	  20%	  SDS	  30ml	  glycerol	  1.8mg	  bromophenol	  blue	  Up	  to	  100ml	  with	  dH2O	  
	  
• 1.5M	  Tris	  solution,	  pH	  8.8	  181.71g	  Tris-­‐base	  	  Up	  to	  1L	  with	  dH2O	  	  
• 0.5M	  Tris	  solution,	  pH	  6.8	  60.57g	  Tris-­‐base	  Up	  to	  1L	  with	  dH2O	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• 5X	  Tris-­‐glycine-­‐SDS	  (TGS)	  running	  buffer	  151g	  Tris-­‐base	  720g	  glycine	  50g	  SDS	  Up	  to	  10L	  with	  dH2O	  	  
• Coomassie	  blue	  stain	  2.5g	  Coomassie	  Blue	  R-­‐250	  500ml	  Methanol	  400ml	  dH2O	  100ml	  glacial	  Ascetic	  acid	  
	  
• Coomassie	  blue	  de-­‐stain	  4.5L	  Methanol	  1L	  Ascetic	  acid	  Up	  to	  10L	  with	  dH2O	  	  	  
Solutions	  for	  Western	  blotting:	  
• Immunotransfer	  buffer	  6g	  Tris-­‐base	  28.8g	  glycine	  400ml	  methanol	  Up	  to	  2L	  ice	  cold	  dH2O	  	  
• 1X	  Tris-­‐buffered	  saline-­‐Tween	  (TBST)	  10ml	  Tween-­‐20	  50ml	  2M	  Tris-­‐base	  (pH	  8.5)	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300ml	  5M	  NaCl	  Up	  to	  10L	  with	  dH2O	  
	  
• 1	  X	  Ponceau	  S	  dye	  2g	  Ponceau	  S	  30g	  trichloroacetic	  acid	  30g	  sulfosalicylic	  acid	  Up	  to	  100ml	  dH2O	  	  
• Blocking	  buffer	  5%	  skimmed	  milk	  (Marvel)	  in	  1	  x	  PBS.	  	  	  
• DAB	  peroxidase	  developing	  solution	  100mg	  DAB	  50µl	  hydrogen	  peroxide	  200ml	  1	  x	  PBS	  
	  
Solutions	  for	  DNA	  electrophoresis:	  	  
• 50X	  Tris-­‐Acetate	  EDTA	  (TAE)	  Buffer	  242g	  Tris-­‐base	  100ml	  0.5M	  Na2EDTA	  pH	  8	  57.1ml	  glacial	  Ascetic	  acid	  Up	  to	  1L	  with	  dH2O	  	  
• 6X	  DNA	  loading	  buffer	  1X	  TAE	  20%	  (v/w)	  glycerol	  1mg/ml	  Bromophenol	  blue	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Solutions	  for	  Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA):	  
• ABTS	  solution	  1	  Tablet	  of	  ABTS	  670µL	  H2O	  	  
• Citrate	  buffer	  525mg	  Citric	  acid	  50ml	  H2O	  	  
• Coating	  buffer	  1.59g	  Na2CO3	  2.93g	  NaHCO3	  0.2g	  NaN3	  1L	  dH2O	  	  
Solutions	  for	  bacterial	  cell	  culture:	  
• LB	  Broth	  (Lennox)	  Media	  –	  Sigma	  Aldrich	  10g/L	  Tryptone	  5	  g/L	  Yeast	  Extract	  	  5	  g/L	  NaCl	  Stir	  to	  suspend	  20g	  powder	  in	  1L	  water.	  Autoclave	  for	  15	  minutes	  at	  121°C	  to	  sterilize.	  Allow	  to	  cool	  before	  making	  additions,	  such	  as	  antibiotics	  (if	  desired).	  
	  
• LB	  Broth	  (Lennox)	  with	  Agar	  –	  Sigma	  Aldrich	  15g/L	  Agar	  	  10g/L	  Tryptone	  	  5	  g/L	  Yeast	  Extract	  	  5	  g/L	  NaCl	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Add	  35g	  powder	  in	  1L	  water.	  Heat	  to	  boiling	  while	  stirring	  to	  dissolve	  powder.	  Autoclave	   for	   15	   minutes	   at	   121C	   to	   sterilize.	   Allow	   to	   cool	   slightly	   before	  making	   additions,	   such	   as	   antibiotics	   (if	   desired).	   Pour	   into	   petri	   dishes	   and	  allow	  to	  solidify.	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